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Abstract 
 
Angiogenesis is the development of new blood vessels from existing vessels. Anti-angiogenic 
agents target the endothelial cells (ECs; the cells that line blood vessels) and have shown 
efficacy in solid tumours. However, current therapies are limited by their side effects. The 
goal of this project was to define new molecular targets for anti-angiogenic therapy using a 
mutational approach. Sleeping Beauty (SB) is a random insertional mutagenesis system for 
genetically modifying cellular behaviour. Endothelial-specific SB activation was achieved 
using angiopoietin receptor (Tie-2) promoter/enhancer sequences to drive Cre-recombinase 
expression. 
All SBxTie2-Cre (n=147) and no WT (n=89) mice became moribund within 1 year and were 
sacrificed. At necropsy, SBxTie2-Cre mice showed peripheral leukocytosis and elevated T-
cell and/or myeloid cells in spleen and bone marrow by flow cytometry and 
immunohistochemistry. The leukaemic phenotype in SBxTie2-Cre mice was confirmed in 
vitro using colony forming unit assays which identified the endothelium, and not 
haematopoietic stem cells (HSCs), as the source of leukaemia. Further, when segregated into 
vascular endothelium (CD45-/CD31+/CD144+/CD73+) and haemogenic endothelium (HECs; 
CD45-/CD31+/CD144+/CD73-), the HECs gave rise to the leukaemic populations. This 
proves HECs initiated leukaemia in SBxTie2-Cre mice and is the first report of functional 
contributions of HECs to haematopoiesis and/or leukemogenesis in adult organisms. Targeted 
deep sequencing of DNA from spleens and thymus of SBxTie2-Cre mice identified genes 
know to be molecular drivers of leukaemia in humans (e.g. Notch1, Ets1, Erg), suggesting 
that human leukaemia may also have origins in “badly behaved” endothelial populations. This 
validates the SB model as a therapeutic platform for drug development for leukaemia and 
provides further, previously unrecognised genes that contribute to leukaemia offering new 
therapeutic targets to treat this disease. 
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1.1 The Circulatory System 
1.1.1 The Vascular System 
The vascular system is comprised of the heart, lungs and vessels that carry blood and lymph 
through the body. The purpose of this system is cell homeostasis, which is maintained by a 
network of arteries, capillaries, and veins (Figure 1.1) to allow cellular function (growth and 
development), absorption of essential nutrients (such as vitamins and minerals), and 
elimination of cellular and metabolic waste products (Pugsley and Tabrizchi 2000). As such, 
the system has a critical role in the maintenance of all tissues and adjusts to both the 
physiological and pathological demands of tissues (Pugsley and Tabrizchi 2000).  
 
Arteries are the vessels that carry oxygenated blood from the heart and are adapted for high 
capacity transport with large radii and low resistance (Figure 1.1). The high elasticity of 
arteries acts as a pressure reservoir that absorbs elevated pressures from the heart during 
systole. The recoil during diastole provides additional pressure to keep blood flowing 
(Pugsley and Tabrizchi 2000). The thicker tunica media (along with the internal elastic 
lamina) is the basis for these properties (Figure 1.1). Smooth muscle cells (SMCs) also offer 
vessel stability and paracrine / juxtacrine signals to the underlying endothelial cells (ECs) 
(Pugsley and Tabrizchi 2000). The high pressures associated with arterial transport are too 
great to provide adequate nutrient delivery. This pressure is abated by arterioles (second order 
arteries) that have small enough luminal diameters to offer significant resistance to flow and 
normalise the pressures to provide a non-fluctuating blood flow through the capillary network 
(Pugsley and Tabrizchi 2000). The less elastic properties of the arteriolar wall help to absorb 
these changes in pressure to deliver constant flow through the capillary bed.  
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Figure 1.1: Structure of the vascular system (adapted from Yin, 2011) (Yin 2011). The 
figure shows the layers of arteries and veins. The venous system completes the circulation of 
blood back to the heart. Blood from the capillary bed enters venules that collect blood into 
progressively fewer but large capacity veins. Veins have thinner walls than arteries due to 
smaller numbers of VSMC in the tunica media (Hanahan and Folkman 1996). Venous return 
is aided by activity of skeletal muscle and the internal valves that prevent back-flow of blood 
in these low-pressure vessels. The one thing all vessels have in common are the ECs of the 
tunica intima which are the interface with the blood and play important roles in tissue 
homeostasis (Hanahan and Folkman 1996). 
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Downstream of the resistance arterioles is the capillary bed, the site of all exchange between 
blood and tissues. The capillaries (4-9 Pm diameter) are comprised of a single layer of ECs 
enveloped in a basement membrane (composed largely of collagen IV) and a single layer of 
support cells (such as pericytes) that lend stability to the structure (Figure 1.1) (Hirschi and 
D'Amore 1996, Dudley 2012). The capillary network is specialised to the needs of the tissues 
they serve. Continuous capillaries with their tight inter-endothelial junctions and resistance to 
fluid leak are mostly found in tissues such as fat, muscle and the central nervous system 
(CNS; Figure 1.1) (Cines, Pollak et al. 1998). This is especially important for the CNS where 
vascular leak into the brain would increase intracranial pressure or the swelling of the brain 
tissues would cause damage. It is also part of the reason why the cerebral vessels are 
intransigent to pharmacotherapy.  
 
Fenestrated capillaries are found in the intestinal villi, renal glomeruli and endocrine glands 
(Figure 1.1) (Cines, Pollak et al. 1998). The fenestrations (small membrane covered pores) 
provide a semipermeable barrier for the selective entry and/or removal of chemicals from the 
blood. Conversely, sinusoidal capillaries have large gaps between ECs and vascular 
structures, such as the basement membrane, which aids the function of organs in which they 
are found, such as the liver, bone marrow and spleen (Figure 1.1) (Cines, Pollak et al. 1998). 
The sinusoids allow for greater movement of cells and materials in these organs that are 
primarily involved in immune response and decontamination of toxins (Cines, Pollak et al. 
1998).   
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1.1.2 The Lymphatic System 
The lymphatic system is a network of blind-ended vessels, lined by ECs, found in almost all 
tissues. Lymphatic capillaries are lined with a continuous single-cell layer of ECs with a 
disjointed basement membrane and, in contrast to blood vessels, are not surrounded by 
pericytes or smooth muscle cells. The lymphatic vasculature begins with thin-walled 
capillaries that originate in the peripheral tissues and accumulate extravasated fluid from 
tissues (Butler, Isogai et al. 2009). The lymph fluid then drains into pre-collecting lymphatics, 
situated in the deep dermis, which in turn drain into the larger collecting vessels (enclosed by 
a basement membrane and lymph flow–promoting smooth muscle cells) that contain one-way 
valves that block backward flow of lymph (Schmid-Schonbein 1990, Aukland and Reed 
1993). Lymph fluid trafficked through collecting lymphatic vessels is channelled through 
multiple lymph nodes prior to collection in the thoracic duct and consequent return to the 
venous circulation at the junction of the jugular and subclavian veins (Christiansen and 
Detmar 2011). Growth of the lymphatic system originates with budding of lymphatic 
endothelial precursor cells from the cardinal vein, enabling formation of the lymph sacs, 
during embryogenesis. Growth of lymphatic ECs from these sacs form the primary lymphatic 
plexus, which is remodelled and expanded to produce the lymphatic network (Sabin 1902). 
Aside from the one anastomosis where the thoracic duct returns fluid to the jugular vein the 
lymphatic system is anatomically discrete from the blood vascular system, although lymphatic 
vessels are regularly located in close association to veins and arteries (Butler, Isogai et al. 
2009).   
 
The lymphatic vasculature is essential for regulation of tissue fluid homeostasis, and 
relocation of immune cells (such as antigen-presenting dendritic cells) from the periphery to 
lymph nodes (Swartz and Skobe 2001, Cueni and Detmar 2006, Tammela and Alitalo 2010, 
Wang and Oliver 2010). Unlike blood vessels, lymphatic vessels lack a central pump in the 
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transport system, relying instead on skeletal muscle contraction and respiratory movement for 
the transportation of lymph. The absence of a central driving force allows insignificant shear 
stress and optimal cell survival within the lymphatic transport network (Ran, Volk et al. 
2010).  
 
1.2 The Endothelium 
The first depiction of circulating blood was by William Harvey in 1628. Soon afterwards, the 
studies of Malphigi portrayed the presence of a network of vessels, and explained the physical 
separation between blood and tissue (Fishman 1982). In the 1800s, von Reckingausen 
recognised that vessels were not simply tunnels worn through tissues but were lined by cells. 
In 1896, Starling proposed his law of capillary exchange where the endothelium was 
predominantly a selective but inert physical barrier. The endothelium lines the entire vascular 
system and comprises of a single layer of ECs (Figure 1.1). In an adult, the endothelium 
consists of ~1-6×1013 cells establishing essentially a 1 kg “organ” and covers a surface area 
~1-7m2 (Augustin, Kozian et al. 1994).  
 
ECs play diverse roles in the vasculature. The initial concept of the endothelium was one of a 
passive container in which blood flowed. However, electron microscopy of the vessel wall by 
Palade in 1953 and physiological analyses by Gowan in 1959 defined the interaction between 
lymphocytes and endothelium of post-capillary venules, which encouraged several 
investigations suggesting that this is not the case. Starting in the 1980s, this perception began 
to radically change and the endothelium is now considered a vigorous, heterogeneous, 
dispersed organ that acquires vital secretory, synthetic, metabolic, and immunologic functions 
(Fishman 1982). ECs are characteristically “quiescent,” meaning that they are not actively 
proliferating (the average lifespan of an EC is more than one year). Indeed, EC turnover is as 
low as 0.1% of cells per day, due mostly to contact inhibition of proliferation through 
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intercellular junctions. However, in cases of need (such as the phases of ovulation and in 
response to injury) the proliferation of endothelium in the local environment can be as high as 
10% suggesting exquisitely sensitive regulatory pathways are at work (Martelli, Berardinelli 
et al. 2006). 
 
ECs regulate flow of nutrient substances, diverse biologically active molecules and the blood 
cells themselves (Augustin, Kozian et al. 1994). This gate-keeping role of the endothelium is 
stimulated by the manifestation of membrane-bound receptors for several molecules including 
proteins (e.g. growth factors, coagulant, and anticoagulant proteins), lipid transporting particle 
(e.g. low-density lipoprotein), metabolites (e.g. nitrous oxide and serotonin), and hormones 
(e.g. endothelin-1), as well as through specific junctional proteins and receptors that control 
cell-cell and cell-matrix interactions (Augustin, Kozian et al. 1994). The structure and 
functional integrity of ECs are significant in the maintenance of vessel wall and circulatory 
function (Sumpio, Riley et al. 2002). As a barrier, the endothelium is semi-permeable and 
controls the transfer of small and large molecules. ECs are versatile and efficient having many 
synthetic and metabolic assets, including the regulation of thrombosis and thrombolysis, 
platelet adherence, modulation of vascular tone and blood flow, and regulation of immune 
and inflammatory responses by controlling leukocyte, monocyte and lymphocyte interactions 
with the vessel wall (Sumpio, Riley et al. 2002).  
 
Dysfunction of endothelial structure and endothelial function is implicated in the pathogenesis 
of disease. Atherosclerosis, haemostatic dysfunction, and altered inflammatory and immune 
response are examples of situations where the EC plays a critical role (Sumpio, Riley et al. 
2002). It is currently thought that the endothelium must persist in a quiescent state to ensure 
an anti-coagulant lining of vessels to inhibit thrombus formation. However, the endothelium 
is a dynamic organ that reacts to an array of agonists and environmental stimuli by becoming 
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activated, which results in the loss of anticoagulant properties and/or acquisition of pro-
coagulant function (Cines, Pollak et al. 1998). Such environmental influences also result in 
perturbation of the normal “quiescent” state of the endothelium and result in 
neovascularisation, which is a hallmark of malignant disorders.  
 
1.3 Neovascularisation – Blood Vessel Development 
It is perhaps this last function of the endothelium that has received the most attention in the 
last 45 years. It was the initial report by Judah Folkman in 1971 that suggested that growth of 
tumours (and by extension tissues) required an increased blood supply and that molecular 
mediators from injured and/or malignant tissues would mediate this process (Folkman 1971).  
Over the intervening period, knowledge of the processes and mediators of neovascularisation 
has expanded rapidly (Ribatti, Vacca et al. 2000). Primarily the mechanisms of new vessel 
development fall into two main categories, vasculogenesis and angiogenesis. 
 
1.3.1 Vasculogenesis 
Vasculogenesis: is the de novo formation of new blood vessels when there are no pre-existing 
vessels (Risau and Flamme 1995). In the embryo the endothelial progenitors for this process 
are derived from mesoderm which proliferate and assemble to form a primitive network of 
vessels, the primary vascular plexus (Rafii, Lyden et al. 2002). In the adult the same process 
occurs at sites of injury and inflammation; however, the mobilisation, recruitment and 
differentiation of endothelial progenitor cells occurs from the bone marrow (Figure 1.2) 
(Balaji, King et al. 2013). The key molecular drivers of this process are VEGF-A165 and SDF-
1 (Reddy, Zhou et al. 2008). Both factors are able to enhance mobilisation of endothelial 
precursors from the bone marrow and target extravasation of the cells at sites of tissue repair 
and inflammation (Figure 1.2) (Reddy, Zhou et al. 2008). Once the cells extravasate at the 
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sites of injury there is debate about whether they differentiate into ECs and form part of the 
vessel wall or act as sources of factors that drive the angiogenic response from mature ECs 
(Reddy, Zhou et al. 2008). Certainly in the embryo the former is true but studies in adult 
organisms are less conclusive (Balaji, King et al. 2013). 
 
 
Figure 1.2:  Mechanism of the vasculogenic response in post-natal organisms (adapted 
from Kumar and Arbab, 2013) (Kumar and Arbab 2013). 
 
 
1.3.2 Angiogenesis 
Angiogenesis is the development of new capillaries from pre-existing blood vessels, occurs in 
both the developing embryo and post-natal life (Risau and Flamme 1995, Asahara, Murohara 
et al. 1997). It occurs via two mechanisms (Ribatti, Vacca et al. 2000): sprouting and 
intussusception.  
 
 
1.3.2.1 Sprouting Angiogenesis 
Sprouting angiogenesis is the growth of new vessels by the directed migration of existing ECs 
along a chemotactic gradient of factors released by the tissue (Gerhardt, Golding et al. 2003). 
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This mechanism begins with the binding of factors from damaged and/or inflamed tissues to 
the ECs (Figure 1.3-1/2/3), which initiate a series of events including perivascular cell 
detachment, vessel dilation, and “activation” of the endothelium from its quiescent state to a 
highly motile state (Gerhardt, Golding et al. 2003) (Figure 1.3-4).  
 
 
 
 
Figure 1.3:  Schematic of the cascade of events that occurs in sprouting angiogenesis 
(image adapted from The Angiogenesis Foundation). The stages in sprouting angiogenesis 
include activation of the endothelium, migration along a chemotactic gradient (which involves 
chemotaxis, ECM remodelling and proliferation of ECs) and ultimately re-differentiation of 
the cord cells to form a lumen. Recruitment of perivascular cells stabilises the now patent 
vessel and enhances delivery of blood to tissues. 
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The responsive ECs adopt specific phenotypes called “tip” and “stalk” cells (Gerhardt, 
Golding et al. 2003, De Smet, Segura et al. 2009). Tip cells lead the emerging angiogenic 
sprout and are characterised by extensive filopodia development (which it uses to scan the 
environment for attractive (VEGF-A and PDGF-B) and repulsive (SLIT2-ROBO1 and 
Semaphorins) cues and enhanced planar cell polarity (which provides for directional motility) 
(Gerhardt, Golding et al. 2003, De Smet, Segura et al. 2009). They remodel the local ECM 
and to pave the way for the emerging sprout. Adjacent to the tip cell are additional “activated” 
ECs, termed stalk cells that proliferate during sprout extension and form the nascent vascular 
lumen (Figure 1.3-5&8). Stalk cells deposit a new basement membrane and attract pericytes 
and/or VSMC to stabilise the emerging vessel (Figure 1.3-10).  
 
Tip cell migration can occur without stalk proliferation and vice versa (Gerhardt, Golding et 
al. 2003, De Smet, Segura et al. 2009). However, only a regulated balance between both 
processes establishes adequately shaped and stable nascent sprouts. By contrast, the 
remaining ECs in the vessel that do not activate are termed “phalanx” cells and remain 
quiescent and unresponsive to the original stimulus (De Smet, Segura et al. 2009, Mazzone, 
Dettori et al. 2009). The selection process for which ECs become tip, stalk or remain phalanx 
cells is largely not understood but is an active area of research in the blood vessel field. 
Current pathways involved in tip cells formation are Notch/DLL4, VEGFR2-Neuropilin, 
Reck-GPCR124 and Wnt/E-catenin pathways (De Smet, Segura et al. 2009, Blanco and 
Gerhardt 2013, Vanhollebeke, Stone et al. 2015). 
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1.3.2.2 Intussusception 
Intussusception is a form of vascular remodelling that occurs by internal division of a pre-
existing vascular plexus without sprouting (Figure 1.4). The first step of intussusceptive 
angiogenesis is the insertion and expansion of numerous trans-capillary tissue pillars across 
the vessel lumen (Burri, Hlushchuk et al. 2004).  There are three kinds of pillars (Djonov, 
Schmid et al. 2000).: 
1. Kissing contacts: small, disk-like points of inter-endothelial contacts between opposite 
capillary walls where the membranes have joined. 
2. Pillars: are cores of connective tissue ensheathed by ECs (diameter ≤ 2.5 μm). The 
endothelium are joined by either end-to-end or interdigitating intercellular junctions. 
Some pillars traverse the lumen obliquely, causing protrusions of the capillary wall at 
the base of the post. 
3. Meshes (round) and septa (elongated): columns of connective tissue containing 
extensions of interstitial cells (generally pericytes and myofibroblasts) and collagen 
fibrils more complex ion structure than the other 2 types of contacts. 
The rows demark the patterning of future vessels. These pillars refine into narrow tissue septa 
through remodelling and fusion. Ultimately the septa merge and expand segregating the once 
coherent vessel into multiple vessels (Figure 1.4) (Patan, Munn et al. 1996). New branching 
results from successive generations of the process. Intussusceptive angiogenesis does not 
require intense local endothelial cell proliferation; it is implemented primarily by 
rearrangement of the endothelial cell plates (Djonov, Schmid et al. 2000). Little is known 
about the molecular regulation or initiation of trans-capillary pillar formation; however, data 
suggests that shear stress or oscillatory blood flow are requirements for pillar formation 
(Djonov, Schmid et al. 2000). 
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 Figure 1.4:  Vessel splitting by intussusception (adapted from Adams and Alitalo, 2007) 
(with permission from Nature Publishing Group) (Adams and Alitalo 2007). Schematic 
depicting the three key forms of intussusceptive growth of blood vessels. EC = endothelial 
cell and ECM = extracellular matrix.  
 
 
1.4 Lymphangiogenesis 
Lymphangiogenesis is the development of lymphatic vessels from pre-existing lymphatics in 
a parallel manner to angiogenesis (blood vessel development). Lymphangiogenesis is active 
during embryogenesis but is quiescent in normal physiological post-natal settings. 
Lymphangiogenesis in adults only occurs during specific pathological conditions including: 
inflammation and tumour growth (Cueni and Detmar 2006, Cueni and Detmar 2008, Wang 
and Oliver 2010). Furthermore, lymphangiogenesis is also a significant characteristic of tissue 
repair and inflammatory responses in many organs, and congenital or attained dysfunctions of 
the lymphatic system, ensuing in the formation of lymphoedema, are common and often 
accompany with weakened immune function (Witte, Bernas et al. 2001). Moreover, 
lymphangiogenesis is regularly involved in the pathogenesis of vascular abnormalities (Witte, 
Bernas et al. 2001). The lymphatic system is the main channel for malignant tumour 
distribution to regional lymph nodes and perhaps, through the thoracic duct and the blood 
circulation, to distant organs and has a role is the target of intratumoral and peritumoral 
lymphangiogenesis in malignancies (Oliver and Detmar 2002). Lymphangiogenesis is 
controlled by the vascular endothelial growth factor (VEGF) family — specifically, VEGF-C 
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and VEGF-D — which activate VEGFR-3 and stimulate lymphangiogenesis (Stacker, Achen 
et al. 2002). In tumours, the sources of pro-lymphangiogenic factors are the tumour itself, 
stromal cells, tumour-infiltrating macrophages, and activated platelets (Wartiovaara, Salven et 
al. 1998, Neuchrist, Erovic et al. 2003, Schoppmann, Fenzl et al. 2006, Mohammed, Green et 
al. 2007).  
 
1.5 Neovascularisation in Health and Disease 
1.5.1 New Blood Vessel formation in Physiologic Settings 
There are two types of angiogenesis (1) physiological and (2) pathological angiogenesis 
(Sholley, Ferguson et al. 1984). Most angiogenesis occurs during development where it is 
important for formation of the vascular tree and establishes adequate blood supply for 
growing and developing organs (Folkman 1995). In the adult, angiogenesis occurs during the 
ovarian cycle, organ growth and repair processes (such as wound healing in damaged tissues) 
and in the placenta during pregnancy (Klagsbrun and D'Amore 1991). As such, ECs are a 
stable and virtually quiescent population exhibiting limited turnover in the adult vasculature 
(Denekamp 1982). In the adult, most blood vessels are kept in a quiescent state under 
physiological conditions by a balanced microenvironment of pro- and anti-angiogenic factors 
(Carmeliet and Jain 2011). During normal conditions, angiogenesis is a highly ordered, tightly 
controlled response that necessitates stimulating quiescent ECs to divide and migrate to 
increase the vascular network to meet the metabolic demands of the surrounding tissues 
(Papetti and Herman 2002).  
 
1.5.2 Pathological Neovascularisation 
However, in several disorders vascular expansion is disproportionate and poorly functional 
and the ECs abnormal.  Such pathological angiogenesis is intimately linked to the progression 
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of cancer, arthritis, chronic inflammation, and infectious or autoimmune diseases (Carmeliet 
and Jain 2011). Conversely, some diseases manifest due to inadequate angiogenesis or vessel 
regression (such as preeclampsia, Alzheimer disease, diabetic neuropathy, osteoporosis and 
ischemic heart disease) (Carmeliet and Jain 2011). The focus of this thesis will be tumour 
angiogenesis (as such a more generalised discussion is beyond the scope of this thesis). 
 
1.5.2.1 Tumour Dormancy and Neovascularisation in Solid Tumours 
The concept of dormancy describes the capacity of tumour to remain in an inactive state, 
either temporarily or permanently, that precede the onset of rapid growth. Up to 70% of 
people carry microscopic pre-malignant lesions in multiple organs. These pre-malignant 
masses, also referred to as non-angiogenic tumours, may never develop into detectable lesions 
and are characterised by minimal micro-vessel density, due to an excess of anti-angiogenic 
factors (Naumov and Folkman 2007, Naumov, Folkman et al. 2008). Human tumours can 
remain dormant for years owing to a balance between cell proliferation and apoptosis (Almog, 
Henke et al. 2006, Naumov, Bender et al. 2006). These microscopic lesions are non-
metastatic and are quite innocuous until they recruit a blood supply (Naumov and Folkman 
2007, Naumov, Folkman et al. 2008). Most human solid tumours develop and persist in situ 
without angiogenesis for months to years before switching to an angiogenic phenotype. 
 
Tumour size in these pre-malignant lesions is limited to ≤ 1mm in diameter, which is the 
diffusion limit of oxygen and nutrients (required to sustain the tissue) (Naumov and Folkman 
2007, Naumov, Folkman et al. 2008) . The release from dormancy to fast-growing, potentially 
lethal, tumours relies on a series of events including a switch to the “angiogenic phenotype” 
(Figure 1.5) (Naumov, Bender et al. 2006). This initiates neovascularisation, which is 
essential for tumour growth beyond the size of 1mm3. It is imperative that all tumours attract 
a vasculature in order to grow. Neovascularisation enables rapid tumour growth and facilitates 
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metastasis. Similarly, the lymphatic vasculature is also affected with enhanced numbers of 
lymphatic vessels mediating local dissemination to lymph nodes, and beyond (Butler, Isogai 
et al. 2009). 
 
The change from a dormant avascular tumour to a fast growing vascularised tumour is termed 
the “angiogenic switch” (Bergers and Benjamin 2003). The switch commences with 
perivascular detachment and dilation of blood vessels, followed by angiogenic sprouting. 
These new vessels perfuse the tumour with blood, which transports nutrients and oxygen to 
the tumour and removes waste (Bergers and Benjamin 2003). All solid tumours (including but 
not limited to brain, breast, colorectal, prostate, lung, liver, pancreatic, melanoma and other 
skin cancers) require new vessels to thrive making neovascularisation a key process to the 
development of all solid tumours (Bergers and Benjamin 2003). 
 
 
Figure 1.5:  The progression of growth from pre-malignant lesion to tumour requires 
angiogenesis (adapted from Bergers and Benjamin, 2003 and Carmeliet, 2003) (Bergers 
and Benjamin 2003, Carmeliet 2003).  An increase in production of pro-angiogenic factors, 
or ablation of expression of anti-angiogenic factors, in the avascular tumour recruits a blood 
supply, which is required for sustained rapid growth. 
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1.5.2.2 Soft Tumours 
Haematological malignancies comprise of acute and chronic leukaemias, myeloproliferative 
disorders, and myelodysplastic syndromes. It is now well established that the growth of solid 
tumours requires robust neovascularisation; however, it was long thought that haematological 
malignancies do not depend on angiogenesis (Ribatti, Vacca et al. 2003). The role of 
angiogenesis in growth and perpetuation of hematopoietic neoplasms was first proposed in 
1994. It has been confirmed in numerous haematological cancers as evidenced by the 
association of the severity and prognosis of the cancer and the level of bone marrow 
angiogenesis (Bertolini, Mancuso et al. 2000, Mangi and Newland 2000). As in solid 
tumours, the bone marrow vessels of haematological malignancies are abnormal in 
comparison to normal physiological blood vessels (Aguayo, Kantarjian et al. 2000). Complex 
and as yet poorly characterised interactions occur between the vasculature and normal and 
malignant cells, the extracellular matrix, growth factors and cytokines, in the bone marrow. 
These interactions underlie the basis for anti-angiogenic therapy in haematological 
malignancies.  
 
1.6 The Onset of Neovascularisation – The “Angiogenic Switch”  
The shift phenotype from a dormant pre-vascular lesion to a fast growing vascularised tumour 
is termed the “angiogenic switch” (Naumov, Bender et al. 2006). In normal tissues, the switch 
is off and the effects of pro-angiogenic factors are balanced, or overwhelmed, by anti-
angiogenic factors (Figure 1.6B). Once initiated, there is an imbalance with either too few 
anti-angiogenic or too many pro-angiogenic molecules (Figure 1.6A) which promotes 
neovascularisation and enhances the nutrient delivery to fast growing tumours (Naumov, 
Bender et al. 2006). Thus, the angiogenic switch is perhaps the most significant mechanism 
enabling tumour cells to overcome the growth restrictions of their pre- malignant state 
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(Naumov, Bender et al. 2006).  Whilst this is a discrete change in the biology of the tumour 
the basis for the angiogenic switch is not fully elucidated. The events that turn on the 
angiogenic switch are varied and may include cellular stress (hypoxia, glucose deprivation, 
formation of reactive oxygen species, cellular acidosis and iron deficiency), the activation of 
oncogenes or inactivation of tumour suppressor genes (Stein, Neeman et al. 1995, Kerbel and 
Folkman 2002, Verheul, Voest et al. 2004, North, Moenner et al. 2005).  
 
Figure 1.6: The equilibrium hypothesis for the angiogenic switch (adapted from 
Hannahan and Folkman, 1996) (Hanahan and Folkman 1996). (A) When the switch is on, 
there is an imbalance with either too few anti-angiogenic factors or too many pro-angiogenic 
factors, (B) however when the switch is off the pro-angiogenic factors are overwhelmed by 
anti-angiogenic factors (Hanahan and Folkman 1996). 
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The tumour suppressor gene, p53, is functionally inactivated in more than 50% of human 
cancers and results in the loss of a major section of the DNA damage sensor that can stimulate 
the apoptotic effector cascade (Harris 1996). The inactivation of p53 results in rapidly 
growing tumours containing low numbers of apoptotic cells (Symonds, Krall et al. 1994) and 
the inability to counter the effects of hypoxia and activation of oncogenes through p53-
mediated apoptosis (Lingen, Polverini et al. 1998). It also diminishes the release of potent 
anti-angiogenic proteins, such as thrombospondin-1, that are dependent upon p53 for their 
expression (Levine 1997). These changes result in an imbalance of angio-regulatory factors 
producing the neovascularisation of the tumour. 
 
1.6.1 Pro-angiogenic Factors 
Angiogenesis is tightly controlled by a balance between pro- and anti-angiogenic factors. 
Expression of pro-angiogenic factors aid the progression of tumour growth by enhancing 
neovascularisation (Risau and Flamme 1995, Asahara, Murohara et al. 1997). Table 1.1 lists 
some well-known pro-angiogenic factors and describes their functions. The main sources of 
angiogenic factors are the tumour epithelium and tumour microenvironment (Wicki and 
Christofori 2008). Stromal constituents of the tumour microenvironment include: ECs, 
immune cells, inflammatory cells and fibroblasts. Cancer-associated fibroblasts enhance 
tumour growth and progression (Mueller and Fusenig 2004) by producing extra-cellular 
matrix (ECM) that is abundant in fibronectin and type I collagen, both of which are 
favourable in activating tumour angiogenesis (Leung, Cachianes et al. 1989, Brown, Guidi et 
al. 1999, Feng, Nagy et al. 2000).  In addition, fibroblasts and inflammatory cells produce 
growth factors and chemokines that assist the recruitment of ECs and pericytes (Fukumura, 
Xavier et al. 1998, Kalluri and Zeisberg 2006). Tumour associated fibroblasts and 
inflammatory cells are principle sources of tumour-derived VEGF (Fukumura, Xavier et al. 
1998). Platelets sequester angiogenic regulators (Klement, Yip et al. 2009) and modulate their 
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release at sites of angiogenesis (Banks, Forbes et al. 1998, Kim, Song et al. 2003). This has 
implications for processes involving platelet-endothelial cell interactions (e.g. wound healing 
and in tumour metastasis) when platelets release these regulators at points of adhesion to 
endothelium, leading to hyper-permeability and extravasation of cells (Banks, Forbes et al. 
1998) and comparative studies suggest a correlation between increasing platelet counts and 
tumour progression (Pinedo, Verheul et al. 1998).  
 
The role of the Notch pathway in angiogenesis has been a key focus over the last 10 years. In 
tumour models, VEGF and Notch signaling are interrelated and both essential for tumour 
neovascularisation. VEGF inhibition in the mouse Lewis lung carcinoma tumour model is 
associated with a reduced Dll4 expression in tumor vessels (Noguera-Troise, Daly et al. 
2006). Also, human neuroblastoma tumour xenografts in mice treated with VEGFR-2 
blocking antibodies had increased Jagged1 protein expression and revealed elevated Notch1 
activation (Zaghloul, Hernandez et al. 2009). With the above discoveries, coupling agents that 
impede the VEGF pathway with factors targeting the Notch pathway may lead to improved 
therapies. 
 
Another pathway inhibitor important for cancer research is the SLIT-ROBO pathway. In 
addition to its functions in foetal growth and the regulation of tumorigenesis in adult cells, the 
SLIT-ROBO pathway plays a vital role in angiogenesis (Ballard and Hinck 2012). 
Angiogenesis necessitates close interaction between tumour cells and ECs, and many reports 
support the SLIT-ROBO pathway (SLIT2 and ROBO1) in facilitating this crosstalk. 
Conversely, there is uncertainty in how SLIT-ROBO signalling affects tumour angiogenesis 
as studies have exhibited both pro-and anti-angiogenic roles in pathological conditions 
(Ballard and Hinck 2012). 
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Table 1.1: Summary of the different types of pro-angiogenic factors (adapted from Bouis et 
al. 2006) (Bouïs, Kusumanto et al. 2006). 
Stimulating 
Angiogenic 
Activity 
Pro-
angiogenic 
Factors 
Mechanism of Action References 
RTK-
binding 
factors 
VEGF family 
(VEGF-A or 
VEGF, P1GF, 
VGGF-B, 
VEGF-C, 
VEGF-D, orf 
virus VEGF or 
VEGF-E) 
Binding to VEGFR-2 starts a 
tyrosine kinase signalling cascade 
that initiate the generation of 
factors that stimulate vessel 
permeability (eNOS, producing 
NO), proliferation/survival (bFGF), 
migration (ICAMs/VCAMs/ 
MMPs) and finally differentiation 
into mature blood vessels 
(Prior, Yang et al. 
2004) 
 Fibroblast 
growth factor 
family (FGF-1, 
FGF-2, etc.) 
FGF-1 initiates the proliferation 
and differentiation of all cell types 
crucial for constructing an arterial 
vessel, including ECs and SMCs. 
FGF-2 increases the expression of 
VEGF and promotes EC 
proliferation and the physical 
organisation of ECs into tube-like 
structures 
(Ornitz and Itoh 
2001, Spinelli, 
Vitale et al. 2015) 
 PDGF Signals through 2 receptors α and β, 
of which the β-form is prevalent in 
fibroblasts, SMCs and micro-
vascular ECs and only identifies 
PDGF-BB. Signalling results in 
cellular proliferation and migration 
in interaction with TGFβ and EGF 
(Bouïs, Kusumanto 
et al. 2006) 
 EGF Discharged by platelets, 
macrophages and monocytes and in 
salivary, lacrimal and duodenal 
glands and also in the kidney. EGF 
has no direct effects on ECs but is 
still involved in tumour 
proliferation, metastasis, apoptosis, 
angiogenesis and wound healing 
(Bouïs, Kusumanto 
et al. 2006) 
 Ang1, Ang2, 
TIE2-mab 
Ang1 stimulates maturation and 
maintenance of vessels and is 
expressed widely throughout 
(Prior, Yang et al. 
2004) 
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tissues, while Ang2 competes with 
Ang1 by replacing it from initiating 
the Tie2 receptor and is expressed 
at sites of vascular remodelling. 
Therefore Ang1 dominance is 
linked with a stable vasculature, 
and Ang2 dominance is linked with 
active angiogenesis 
 SLIT-ROBO 
signalling 
Slit2 interacts with Robo1 to 
facilitate repellent signals in 
myogenesis, leukocyte chemotaxis, 
and endothelial cell migration. 
Communication between Slit2 and 
Robo1 stimulates tumour 
angiogenesis. 
(Kramer, Kidd et al. 
2001, Wu, Feng et 
al. 2001, Wang, 
Xiao et al. 2003) 
 
Coagulation TF TF elevates VEGF on ECs and is 
increased by hypoxia 
(Bouïs, Kusumanto 
et al. 2006) 
 Thrombin Stimulates endothelial Ang2-
expression and secretion, and also 
release of VEGF and Ang1 from 
platelets 
(Huang, Li et al. 
2002) 
 
Fibrinolysis uPA uPA binds to its receptor uPAR, 
mainly expressed on EC  and 
controls stimulation of plasminogen 
in tissues  
(Mignatti and Rifkin 
1996) 
 tPA Regulation of fibrinolytic activity 
in blood  
(Blasi 1997) 
 Plasmin Degradations of various ECM 
elements, including fibrin, 
fibronectin, laminin, and the protein 
core of proteoglycans. Activation 
of numerous MMPs (MMP-1, 
MMP-3, and MMP-9) 
(Mignatti and Rifkin 
1996, Murphy, 
Stanton et al. 1999) 
 
Proteolysis MMPs MMPs; taking different substrates 
according to MMPs; substrates can 
be collagen, gelatin, laminin, 
fibronectin, proteoglycans, and 
proMMPs 
(Yoo and Kwon 
2013) 
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Platelet-
derived 
regulators 
TP Stimulates EC chemotaxis and 
angiogenesis 
(Moghaddam, 
Zhang et al. 1995) 
 HGF HGF’s angiogenic function 
involves the Ets family of 
transcription factors, resulting in 
the expression of VEGF, MMPs 
and uPA and strong anti-apoptotic 
effects on ECs 
(Morishita, Aoki et 
al. 2004) 
 NPY Powerful mitogen for ECs and 
SMCs, stimulating EC adhesion, 
migration and differentiation into 
capillaries 
(Lee, Michalkiewicz 
et al. 2003) 
 
Cell-
associated 
ligands 
Class 3 
Semaphorins 
Controls EC adhesion, migration, 
proliferation and apoptosis. 
Modifies vascular permeability 
(Mecollari, 
Nieuwenhuis et al. 
2014) 
 Notch 
signalling 
ECs express the Notch ligands, 
Dll1, Dll4, and Jagged1. Notch 
coordinates VEGF-mediated 
angiogenesis. Notch signalling 
directly and indirectly regulates a 
cohort of genes involved in 
angiogenesis, including the VEGF 
receptors and EphrinB2 
(Zimrin, Pepper et 
al. 1996, Beckers, 
Clark et al. 1999, 
Shutter, Scully et al. 
2000, Mailhos, 
Modlich et al. 2001, 
Taylor, Henderson 
et al. 2002, 
Shawber, Das et al. 
2003, Duarte, 
Hirashima et al. 
2004, Carlson, Yan 
et al. 2005, Iso, 
Maeno et al. 2006, 
Shawber, Funahashi 
et al. 2007, 
Suchting, Freitas et 
al. 2007, Thurston, 
Noguera-Troise et 
al. 2007, Harrington, 
Sainson et al. 2008, 
Siekmann, Covassin 
et al. 2008, 
Trindade, Kumar et 
al. 2008, Phng, 
Potente et al. 2009, 
Funahashi, Shawber 
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et al. 2010, Outtz, 
Wu et al. 2010) 
 Ephrins Ephrin-B2 is spread in the ECs of 
primordial arterial vessels. EphB4 
marks ECs of primordial venous 
vessels in embryo and in adult, thus 
it may be control interactions 
between ECs and SMCs involved 
in the development of arterial 
muscle walls 
(Wang, Chen et al. 
1998, Adams, 
Wilkinson et al. 
1999, Gerety, Wang 
et al. 1999) 
 
 Integrins αvβ3, 
αvβ5, α5β1 
αvβ3 is almost untraceable on 
quiescent endothelium, but is 
greatly increased during cytokine- 
or tumour-induced angiogenesis 
(Liekensa, De 
Clercqa et al. 2001) 
 TNFα, TGFβ, 
IFNγ, IL-8, 
GM-CSF, and 
PAF 
Secreted by inflammatory cells 
including neutrophils, macrophages 
and lymphocytes of which many 
impact on angiogenesis 
(Coussens and Werb 
2002) 
 COX-2 Associated with increased VEGF 
production and angiogenesis 
(Toomey, Murphy et 
al. 2009) 
 
RTK = receptor tyrosine kinase; VEGF = vascular endothelial growth factor; eNOS = 
endothelial nitric oxide synthase; NO = nitric oxide; ICAMs = intracellular adhesion 
molecules; VCAMs = vascular cell adhesion molecules; MMP = matrix metalloproteinases; 
FGF = fibroblast growth factor; EC = endothelial cell; SMC = smooth muscle cell; PDGF = 
platelet-derived growth factor; TGF transforming growth factor; EGF = epidermal growth 
factor; Ang = angiopoietin; TIE = tyrosine kinase with immunoglobulin-like loop; TP = 
thymidine phosphorylase; uPA = urokinase receptor; uPAR = urokinase-type plasminogen 
activator receptor; tPA = tissue-type plasminogen activator; ECM = extracellular matrix; HGF 
= hepatocyte growth factor; NPY = neuropeptide Y; TNF = tumour necrosis factor; IFN = 
interferon; Il = interleukin; GM-CSF = granulocyte macrophage – colony stimulating factor; 
PAF = platelet-activating factor; robo = Roundabout and COX2 = cyclooxygenase-2.  
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1.6.2 Anti-Angiogenic Factors and Vascular Pruning 
Anti-angiogenic factors are produced primarily by stromal cells and cells of the immune 
system. Their function is to control the balance between initiation and termination of 
angiogenesis and to promote vascular remodelling and regression. The above mechanisms 
have focussed on how new vessels form; however, enhanced vessel density can also result 
from manipulating the rate of vascular remodelling (Bouïs, Kusumanto et al. 2006, Yoo and 
Kwon 2013). Multiple factors have now been identified (both endogenous and man-made) 
that promote vascular regression. These anti-angiogenic agents target (1) proteins and protein 
fragments of naturally occurring ECM and basement membrane components, and (2) growth 
factors, cytokines and other non-matrix-derived proteins that directly repress endothelial cell 
proliferation and migration (Table 1.2) (Bouïs, Kusumanto et al. 2006, Yoo and Kwon 2013). 
A number of extracellular proteins have been identified as anti-angiogenic factors (endostatin, 
TSP1/2, tumstatin, etc). They all inhibit tumour growth and metastasis when used in in vivo 
models (Oreilly, Holmgren et al. 1994, Oreilly, Boehm et al. 1997) and inhibit endothelial cell 
proliferation, migration, invasion and tube formation both in vitro and in vivo (Iruelaarispe, 
Bornstein et al. 1991, Oreilly, Boehm et al. 1997). Apart from this they share little in common 
acting on multiple targets to impair neovascularisation. A summary of the most significant 
anti-angiogenic factors is listed in Table 1.2. 
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Table 1.2: Summary of the different types of anti-angiogenic factors and their functions 
(adapted from Bouis et al., 2006 and Yoo and Kwon, 2013) (Bouïs, Kusumanto et al. 2006, 
Yoo and Kwon 2013). (Fan, Jagger et al. 1995, Gately, Twardowski et al. 1997, Oreilly, 
Boehm et al. 1997, Powell, Skotnicki et al. 1997, Balzarini, Gamboa et al. 1998, McNamara, 
Harmey et al. 1998, Brower 1999, Gasparini 1999, Hamby and Showalter 1999, Klagsbrun, 
Moses et al. 1999, Shiff and Rigas 1999, Stathakis, Lay et al. 1999, Ferreras, Felbor et al. 
2000, Hebbar, Peyrat et al. 2000, Funatsu, Yamashita et al. 2001, Short, Derrien et al. 2005, 
Bornstein 2009, Chen, Huynh et al. 2009). 
Pathway Targeted Anti-angiogenic Factors Mechanism of Action 
Inhibitors of ECM 
remodelling 
Batimastat, marimastat, 
AG3340, Neovastat, PEX, 
TIMP-1, -2, -3, -4 
MMP inhibitors, block 
endothelial and tumor cell 
invasion 
 PAI-1, -2, uPA Ab, uPAR Ab, 
Amiloride 
uPA inhibitors, block 
ECM breakdown 
 Minocycline, tetracyclines, 
cartilage-derived TIMP 
Collagenase inhibitors, 
disrupt collagen synthesis 
and deposition 
 IFN-α, IFN-γ, IL-12, nitric oxide 
synthase inhibitors, TSP-1 
Block EC migration and/or 
proliferation; reduce ECM 
remodelling/MMP9 
expression 
 TNP-470, Combretastatin A-4 Block EC proliferation 
 Thalidomide Inhibits angiogenesis in 
vivo 
 Linomide Inhibits EC migration 
   
Anti-angiogenic 
fragments/matrikines 
Angiostatin Angiostatin, a degradation 
product of plasmin 
consists of kringle units 1-
4 and the product of 
proteolytic cleavage. 
Inhibits EC proliferation, 
migration, and 
angiogenesis in vivo and 
in vitro, promotes EC 
apoptosis in vitro and 
limits tumour growth in 
vivo 
 Endostatin Endostatin, a proteolytic 
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product of collagen XVIII 
has similar effects to 
angiostatin. Endostatin 
decreases EC survival, 
motility and invasion by 
opposing VEGF signalling 
and inhibits MMPs 
 Thrombospondin (TSP) 1 and 
TSP2 
TSP1 and 2 alter EC 
adhesion, inhibits EC 
proliferation, migration 
and tube formation and 
increase EC specific 
apoptosis. TSP1 and 2 
contain a variety of 
domains that interact with 
CD36, integrins (D2E1, 
DvE3, D5E1 and DE), 
CD47 and heparan 
sulphates, to inhibit 
angiogenesis. 
 Collagen IV fragments 
(Arresten, Canstatin, tumstatin, 
Tetrastatin, lamstatin) 
Matrikines derived from 
the non-collagenous 
domain of the D-subunits 
of collagen 4 isoforms.  
Interact with α1β1, α3β1, 
ανβ3, ανβ5 and ανβ1 
integrins to inhibit EC 
proliferation and 
migration, enhance EC 
apoptosis in vitro and 
suppress tumour growth 
and angiogenesis in vivo 
   
Inhibitors of angiogenic 
mediators or their receptors 
IFN-α, PF-4, prolactin fragment Inhibit FGF-2, inhibit 
FGF-2-induced EC 
proliferation 
 Suramin and analogues Binds to various growth 
factors, including FGF-2, 
VEGF, PDGF, inhibit EC 
migration and proliferation 
 PPS, distamycin A analogues, 
FGF-2 Ab, antisense-FGF-2 
Inhibit FGF-2 activity 
 Protamine Binds heparin, inhibits EC 
migration and proliferation 
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 SU5416, soluble Flt-1, 
dominant-negative Flk-1, VEGF 
receptor ribosymes, VEGF Ab 
Block VEGF activity 
 Aspirin, NS-398 COX inhibitors 
 6AT, 6A5BU, 7-DX TP antagonists 
   
Inhibitors of EC 
intracellular signalling 
Genistein Tyrosine kinase inhibitor, 
blocks uPA, EC migration 
and proliferation 
 Lavendustin A Selective inhibitor of 
protein tyrosine kinase 
 Ang-2 Inhibits Tie-2 
 
ECM = extracellular matrix; TIMP = tissue inhibitors of metalloproteases; IFN = interferon; 
PF = platelet factor; EC = endothelial cell; uPA = urokinase receptor; ab = antibody; uPAR = 
urokinase-type plasminogen activator receptor; MMP = matrix metalloproteinases; PAI-1 = 
plasminogen activator inhibitor-1; FGF = fibroblast growth factor; VEGF = vascular 
endothelial growth factor; PDGF = platelet-derived growth factor; PPS = pentosan 
polysulphate; COX2 = cyclooxygenase-2; TP = thymidine phosphorylase; Ang = 
angiopoietin; and TIE = tyrosine kinase with immunoglobulin-like loop. 
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1.7 Differences between Normal and Tumour ECs 
The tumour vasculature is a vital component of the tumour microenvironment and is vastly 
different to blood vessels in normal tissues. The microarchitecture of the vascular tree of a 
“normal” tissue is an ordered hierarchically bifurcating arrangement of mature vessels (with 
intact mural cells and pericytes) with regular branching, diminishing lumen size and that 
allow for evenly distributed perfusion of oxygen and other nutrients to all cells (Figure 1.7) 
(Jain, 2005). Conversely, the overstimulation of the tumour vasculature by pro-angiogenic 
factors results in formation of immature (no pericytes or VSMC), tortuous, and 
hyperpermeable vessels (Figure 1.7). This disorganised labyrinth shows none of the normal 
vessel hierarchy (arterioles, capillaries, and venules are not clearly identifiable), vessels are of 
disproportionate diameter, with excessive branching, uneven shape (with abnormal bulges and 
blind ends), arteriolar–venous shunts and many vessels are devoid of blood cells indicating 
they do not participate in tissue perfusion (Figure 1.7) (Jain, 2005). The absence of peri-
vascular support cells, and abnormal basement membrane, makes tumour vessels leaky with 
the increased intra-tumoral osmotic pressure that also impairs nutrient delivery (Jain, 2005). 
Similarly, the accompanying lymphatic vessels are dilated, leaky and discontinuous leading to 
dilated fluid-engorged vessels. As such, the functionality of both the vascular and lymphatic 
systems is highly compromised in tumours, which is why regional hypoxia is a common 
feature. 
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Figure 1.7:  Tumour vasculature is structurally and functionally abnormal (image 
adapted from Jain, 2005) (Jain, 2005). On the left is a schematic, and accompanying two-
photon image (of skeletal muscle), depicting the normal vasculature composed of mature 
vessels and regulated by the balance of pro- and anti-angiogenic factors (Jain, 2005). The 
figure on the right represents the abnormal tumour vasculature with a two-photon image from 
a murine carcinoma. 
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While tumour blood vessels are obviously abnormal they are frequently referred to as a single 
entity. However, tumour blood vessels are highly heterogeneous and can be classified into at 
least four structurally and functionally discrete forms (Figure 1.8): mother vessels, capillaries, 
glomeruloid microvascular proliferations and vascular malformations. 
 
1.7.1 Mother Vessels (MV) 
MV are enlarged, thin-walled, serpentine, pericyte-poor, hyperpermeable, and strongly 
VEGFR-2-positive sinusoids that form quickly upon activation of the angiogenic switch 
(Pettersson, Nagy et al. 2000). Mother vessels arise from the enlargement of pre-existing 
vessels through a series of processes. Basement membrane degradation, the first process, is 
essential as the basement membrane restrains the expansion of vessels. Basement membrane 
degradation is mediated by pericyte cathepsins and loss of cysteine protease inhibitors (Nagy, 
Chang et al. 2009). Removal of the basement membrane allows for a 3-5 fold enlargement of 
the cross-sectional area and (Swayne, Smaje et al. 1989) and results in pericyte detachment 
removing all the constraints that normally limit vessel size. MV are maintained only as long 
as high concentrations of VEGF-A are present. Their thin walls, sluggish blood flow and a 
lack of pericyte and basement membrane support make them susceptible to thrombosis or 
collapse (Pettersson, Nagy et al. 2000). MV are transitional structures, present only for a 
limited time, and evolve into one or another type of stable daughter vessel (Figure 1.8). 
 
1.7.2 Capillaries  
Capillaries form from MV by intraluminal bridging, a VEGF-A driven process where EC 
extend cytoplasmic processes into and across MV lumens (Pettersson, Nagy et al. 2000, 
Nagy, Chang et al. 2009). These extensions divide blood flow into multiple smaller-sized 
channels that ultimately separate into discrete capillary-sized vessels that unlike MV are not 
hyperpermeable. 
                                                                                                      Chapter 1: Literature Review 
 
 32 
 
Figure 1.8: The different phenotypes of tumour vessels and their interrelationships 
(image taken from Nagy et al., 2009 with permission from Nature Publishing Group) 
(Nagy, Chang et al. 2009). The formation of mother vessels is rapid but transient. 
Remodelling the one of three daughter vessels prolongs the life of the vessels and ensures 
continued delivery of blood for tumour growth.  
 
1.7.3 Glomeruloid Microvascular Proliferations (GMPs) 
GMPs are found in a wide variety of VEGF-A-expressing human tumours (such as 
glioblastoma multiforme, stomach and breast cancer) and are associated with an unfavourable 
prognosis (Pettersson, Nagy et al. 2000, Sundberg, Nagy et al. 2001, Straume, Chappuis et al. 
2002). Like MV, GMPs require constant VEGF-A stimulation for their continued existence. 
They develop from the subdivision of MV and acquire pericyte support, which enshroud the 
vessels in layers of abnormal basement membrane. Despite this these vessels are 
hyperpermeable, although poorly perfused; and so do not contribute greatly to the elevated 
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intratumoral osmotic pressure (Pettersson, Nagy et al. 2000, Sundberg, Nagy et al. 2001).  
 
1.7.4 Vascular Malformations  
Other MVs evolve into vascular malformation (Dvorak, Weaver et al. 2011) by retaining their 
large size and acquiring a thinner, often asymmetric coating of smooth muscle-cells (Figure 
1.8) and closely resemble non-malignant vascular malformations in other tissues (such as the 
skin and brain) (McKee, 1996). Vascular malformations are not permeable and will persist 
indefinitely in a low VEGF-A environment. 
 
Given the differences in the structure of tumour vessels what are the characteristics of the ECs 
that compose them? In normal tissues the ECs form a continuous and uniform monolayer with 
limited cytoplasmic projections. Ultra-structurally, tumour vessels are abnormal with the ECs 
of irregular shape and size (Figure 1.9) (Benjamin, Golijanin et al. 1999). Tumour ECs have 
disrupted margins and long, fragile cytoplasmic projections spreading outward and across the 
vessel lumen. The endothelium grow on top of each other (whereas ECs in normal vessels 
form single cell layers) (Figure 1.9). The endothelial monolayer contains several ‘openings’ 
(endothelial fenestrae, vesicles and transcellular holes), enlarged inter-endothelial junctions 
and an abnormal or absent basement membrane (Figure 1.9) (Benjamin, Golijanin et al. 
1999). Moreover, the vessels lack perivascular cells (pericytes and vascular smooth muscle 
cells), which are scarce and loosely attached compared to normal vessels, that provide 
stability through stimulating vascular quiescence and supplying essential vasoactive control to 
accommodate metabolic need (Benjamin, Golijanin et al. 1999). The combined effects of an 
incomplete endothelial monolayer, absent basement membrane and supporting cells promote 
vascular permeability or “leakiness” in tumour vessels (Hobbs, Monsky et al. 1998, Dvorak, 
Nagy et al. 1999, Hashizume, Baluk et al. 2000). The obvious differences between tumour 
and normal ECs has sparked multiple efforts to identify the molecular drivers of the tumour 
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phenotype in the pursuit of therapeutic targets to attack this “Achilles heel” and provide new 
options for patients with cancer. 
 
 
Figure 1.9: Differences between “normal” and tumour-associated endothelial cells 
(image adapted from Carmeliet, 2003 and Jain, 2003) (Carmeliet 2003, Jain 2003). 
Phenotypic changes observed in tumour–associated vessels compared to those in “normal” 
tissues.   
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1.8 Phenotyping Tumour Vessels to Identify Novel Angiogenic Regulators 
Since the first reports of differences between tumour and normal vasculature there has been 
an effort to identify tumour-specific endothelial markers as novel targets for therapy that 
would not compromise endothelial function in normal tissues. Several mechanisms have 
allowed the genome wide discovery of variances in gene expression and have been effectively 
used to examine gene expression in tumour development. 
 
1.8.1 Differential Display  
The most utilised method in the 1990’s to assess gene expression variances between two cell 
populations was differential display, where 3′anchored oligo(dT) primers and short 5′arbitrary 
primers are used to amplify the transcriptome of a sample and the products analysed by 
electrophoresis (Peale and Gerritsen 2001). Numerous reports have utilised differential 
display to study vascular biology and angiogenesis (Peale and Gerritsen 2001). The effects of 
culturing bovine ECs in vitro for 5 days compared to their in situ counterparts in the intima of 
the aorta were first described using differential display (Shima, Saunders et al. 1995). 
Similarly, a role of the follistatin/activin mechanism in the autocrine control of the growth 
and differentiation of ECs (but not confluent ECs) in vitro was also identified (Kozian and 
Augustin 1995). Differential display also enabled the discovery of angiogenesis-related 
functions for known and novel genes alike including the Notch ligand Jagged. Jagged was 
upregulated in ECs grown in fibrin gels, comparative to ECs grown with collagen (Zimrin, 
Villeponteau et al. 1995). Inhibition of Jagged expression accelerated FGF-2-induced 
endothelial morphogenes in vitro (Zimrin, Pepper et al. 1996). These outcomes are consistent 
with a function for Jagged–Notch signalling in sustaining ECs in a proliferative but 
comparatively homogenous environment. The limitations of differential display were the 
failure to identify anything except the most highly expressed genes.  However, in an era prior 
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to sequencing of the genome and online repositories of sequencing data the differential 
display approach was a capable, albeit blunt, tool for getting the field started.  
 
1.8.2 Nucleic Acid Microarrays 
Microarray analysis can be divided into two key steps: probe production and target (cDNA) 
production (Govindarajan, Duraiyan et al. 2012). Detailed sequences are restrained to a 
surface and altered with labelled cDNA targets. A signal developing from hybridisation of the 
labelled target with the detailed immobilised probe distinguishes which RNAs are existent in 
the unidentified target sample (Govindarajan, Duraiyan et al. 2012). 
 
An example of the power of this technique was the identification of SENEX/ARHGAP18 in 
the late stages of tube formation.  SENEX is a novel gene found to regulate stress induced 
premature senescence pathways in ECs involving p16INK4a and retinoblastoma protein 
activation. RhoGAP and SENEX were identified in a DNA microarray screen of genes 
regulated during in vitro tube formation, as a mechanism of angiogenesis (Hahn, Su et al. 
2005, Coleman, Hahn et al. 2010). The authors were able to demonstrate the power of 
combining RNA amplification and suppression subtractive hybridisation with microarray and 
numerous widespread statistical methodologies to: (a) differentiate indistinct regulated genes 
that are recognised to be greatly biologically significant, (b) establish the significance of 
ontological alignment of genes to signify vital biological mechanisms, and (c) determine 
earlier unrecognised whole pathways that are regulated at the transcript level (Hahn, Su et al. 
2005). 
 
Microarrays were the gold standard for analysis but could only identify known genes. At a 
time of increasing knowledge about the genome this disadvantage was small; however, other 
technologies were able to provide answers where microarrays proved deficient. 
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1.8.3. Serial Analysis of Gene Expression (SAGE) 
SAGE is a gene-expressing profiling system that allows global, unbiased, quantitative 
identification of the transcriptome (Velculescu, Zhang et al. 1995, Polyak and Riggins 2001, 
Beauchamp, van Achterberg et al. 2003, Madden, Cook et al. 2004, Parker, Argani et al. 
2004, Porter, Yao et al. 2006). SAGE was first discovered by Velculescu (Velculescu, Zhang 
et al. 1995) and is based on the isolation of unique sequences (termed tags) from distinct 
positions at the 3-end of each mRNA. The excess of these 14-bp to 15-bp tags is recognised 
by large-scale sequencing and reveals the complete expression level of the corresponding 
gene (Hermeking 2003). These findings have led to the detection of tumour-specific markers, 
transcriptional pathways, or therapeutic targets. As SAGE does not require prior knowledge 
of the genes of interest, it can detect novel, un-named and unexpected transcripts. For these 
reasons, the SAGE system has been preferred as the optimal method to assess the level of 
gene expression from subpopulations of cells isolated from fresh biological samples (Polyak 
and Riggins 2001, Beauchamp, van Achterberg et al. 2003, Madden, Cook et al. 2004, Parker, 
Argani et al. 2004, Porter, Yao et al. 2006).  
 
The first studies of SAGE compared ECs of three tumour types: colon carcinoma, breast 
carcinoma and brain tumour, with normal tissues (Teicher 2008). However, most of the 
genes/mRNA expressed were similar between tumour ECs and the ECs of the corresponding 
normal tissue (Teicher 2008). Closer examination revealed highly differentially expressed 
genes that identified the tumour ECs as immature compared to the corresponding normal ECs. 
(Teicher 2008). There also seemed to be a high degree of organ and tissue specificity in the 
endothelium as well as a high degree of heterogeneity among the tumour endothelium 
(Teicher 2008). These findings, suggested that the tumour EC is quite heterogeneous and that 
targeting tissue-specific pathways (rather than universal mechanisms) would be of greater 
benefit for development of anti-angiogenic therapies (Teicher 2008). 
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St. Croix et al compared gene expression patterns of vascular ECs from normal and malignant 
colorectal tissues by SAGE (St Croix, Rago et al. 2000). They found nine tumour-specific 
endothelial markers (TEM1-9), absent in normal ECs some of which (TEM7 and TEM5) are 
promising therapeutic targets (St Croix, Rago et al. 2000). The discovered genes (TEM1-9) 
were present in multiple tumour types suggesting the universal nature of their findings.  
Normal and tumour endothelium were found to share many specific markers; however, the 
tumour endothelium is quantitatively different to normal endothelium.  As such, it was the 
degree of expression rather than qualitative differences that were most obvious.  Indeed, many 
of the differentially expressed genes in tumour endothelium were also expressed throughout 
physiological angiogenesis (e.g. wound healing) (St Croix, Rago et al. 2000). This is 
consistent with the notion that tumours may acquire vasculature by measures of identical 
signals developed during other physiological or pathological responses (St Croix, Rago et al. 
2000). Gerritsen et al assessed gene expression profiles from colon tumour cell lines, tumours 
and normal tissues (Gerritsen, Soriano et al. 2002) to identify genes, which could be possible 
markers for angiogenesis-related disease treatment (Gerritsen, Soriano et al. 2002). However, 
targets specific for tumour vessels that spare the normal endothelium are yet to be identified. 
 
In another study by Cimica et al., they focused on physiological angiogenesis in regards to 
SAGE analysis for rat liver regeneration (Cimica, Batusic et al. 2007). They discovered an 
important angiogenic factor: connective tissue growth factor as a signalling facilitator that 
may have a direct function in the method of liver regeneration initiation. The same authors 
discovered an important similarity between their SAGE data and microarray studies in the 
liver generation for various stimulated and repressed genes. This is noteworthy as it suggests 
the reproducibility of results and signifies the reliability of their models and the SAGE 
technique (Su, Guidotti et al. 2002, Fukuhara, Hirasawa et al. 2003, Togo, Makino et al. 
2004). 
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1.8.4. Phage Display 
Phage display was generated by G. Smith in 1985 as a means for expression of endogenous 
polypeptides on the surface of lysogenic filamentous bacteriophages (phage particles) (Smith 
1985). This technique has become one of the most efficient methods for creating large 
volumes of peptides, proteins and combinatorial peptide libraries. The foreign DNA fragment 
is incorporated into the genome of the filamentous phage and the encoded foreign peptide is 
expressed as a fusion to one of the coat proteins on the phage surface (Pandea, Szewczykb et 
al. 2010). A library of phage particles displaying a wide range of peptides is used to select 
those that bind the preferred target (Pandea, Szewczykb et al. 2010).  
 
The molecular diversity of the vascular endothelium has been illustrated using in vivo 
application of phage display libraries.  The in vivo selection processes involved injection of 
random phage libraries which home to specific vascular beds (based on expression of surface 
peptides) (Arap, Kolonin et al. 2002). The phage are isolated form the various organs, 
propagated and re-injected to enrich for the population of phage binding the vasculature in 
that organ. These data enabled separation of peptides homing to brain, kidney, lung, skin, 
adrenal gland, intestine, pancreas, retina, prostate, breast tissue and uterus (Arap, Haedicke et 
al. 2002, Essler and Ruoslahti 2002) which enabled tissue- and tumour-specific targeting of 
the vasculature. Indeed, some peptides blocked the communication between MMP and DVE3 
integrin (Boger, Goldberg et al. 2001) and blocked receptor-bound VEGF (Cooke, Boxer et 
al. 2001). Both peptides display strong anti-angiogenic and anti-tumour activity in vivo.  
Furthermore, this process also identified pro-apoptotic peptides capable of vascular regression 
and reformulation of binary compounds (with cytotoxic drugs, metalloprotease inhibitors and 
cytokines) to acquire more effective and less toxic therapeutics (Arap, Kolonin et al. 2002).   
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1.8.5. RNA Sequencing (RNA-Seq) 
Sequencing mRNA libraries by utilising second generation sequencing platforms (RNA-Seq) 
is emerging as technology of choice for genomic analysis of tumour vasculature (Wang, 
Gerstein et al. 2009). There are several key advantages of RNA sequencing over microarrays 
to measure and compare gene transcription levels, such as: increased sensitivity and dynamic 
range, the absence of probe effects. Sequence data can be utilised to identify mRNA 
quantification, gene sequence variants including splice isoforms and gene fusions, and 
somatic mutations (Wang, Gerstein et al. 2009). Another advantage of RNA-Seq is that it 
allows for unbiased quantification of all expressed genes and is not limited to loci targeted 
specifically by array probe-sets, therefore increasing the possibility of quantifying non-protein 
coding genes such as long non-coding RNA. RNA-Seq is emerging as a powerful system for 
transcriptome analyses that may ultimately take over the use of microarrays for gene 
expression analyses (Ramskold, Kavak et al. 2012). Enhancements in high-throughput 
sequencing and effective sample barcoding are enabling multiple samples to be analysed in an 
economical way, therefore rivalling with microarrays in price and outdoing in performance 
(Ramskold, Kavak et al. 2012). A recent study by Zhuang et al. utilised the RNA-Seq method 
to detect cell-surface tumour endothelial markers in lung cancer patients, which is of interest 
in therapeutic antibody and vaccine development (Zhuang, Herbert et al. 2015). Through 
comprehensive expression profiling, they discovered for the first time that STEAP1 
expression is upregulated in ECs in the vessels of human lung tumours (Zhuang, Herbert et al. 
2015). Further analysis of STEAP1 identified a function in EC migration and tube formation. 
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In pancreatic ductal adenocarcinoma (PDAC), VEGF-A immunoreactivity (by 
immunohistochemistry) and gene expression are very high (Itakura, Ishiwata et al. 1997, 
Ikeda, Adachi et al. 1999, Seo, Baba et al. 2000). This is in contrast to normal human 
pancreas samples and colon cancer cells (Itakura, Ishiwata et al. 1997, Ikeda, Adachi et al. 
1999). However, the use of the RNA-Seq has suggested that only 4% of human PDAC 
samples overexpress VEGFA, therefore indicating that this growth factor may not be as 
significant in PDAC as originally thought (Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013).  
 
 
The above analyses, along with high-throughput protein and gene arrays and miRNA screens, 
have uncovered unique molecular signatures in the tumour vasculature that potentially offer 
clinical promise. All of these reports together demonstrate the variety in gene expression from 
diverse tumour types and during phases of development. However, no exclusive marker or 
factor in the tumour vasculature has been demonstrated to be appropriate enough as a stable 
target for anti-angiogenic treatment. 
 
1.9 Angiogenic Therapies 
Neovascularisation is a key process in the development and progression of solid tumours. 
Stopping vascular proliferation would be a rational method in the treatment of cancer. 
However, tumour angiogenesis varies from normal angiogenesis in that the resulting blood 
vessels in the tumour are convoluted, disproportionately shaped, and hyper-permeable (Jain 
2005). These deformities lead to irregular blood flow and elevated interstitial fluid pressure 
within the tumour, which can damage the supply of oxygen and drugs to the tumour (Jain 
2005). Emerging evidence implies that anti-angiogenic therapy can reduce some tumour 
vessels and normalise the structure and function of the rest, thereby improving drug delivery 
and normalising the tumour microenvironment. This normalisation outcome may provide a 
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therapeutic advantage for combined anti-angiogenic and cytotoxic therapies (Jain 2005). The 
discovery of pro-angiogenic factors has resulted in a universal effort to identify novel 
antagonists as adjunct therapies to standard treatment programs. 
 
1.9.1 Anti-Angiogenic Therapy  
1.9.1.1 Endothelial Cell Inhibitors – Direct Inhibition 
Since ECs are crucial elements in tumour angiogenesis, one way anti-angiogenic agents have 
been used is to target the tumour endothelium directly. Angiostatin and endostatin are two 
endogenously expressed anti-angiogenic factors that restrict EC migration and stimulate 
apoptosis exclusively in ECs in vitro and obstruct tumour progression leading to regression of 
tumours in vivo (Oreilly, Holmgren et al. 1994, Oreilly, Boehm et al. 1997). Both endostatin 
and angiostatin are anti-angiogenic, anti-metastatic and active in ECs. Anti-angiogenic 
therapy with endostatin in animals requires constant administration of the protein, and 
angiostatin has only been examined in Phase I clinical trials for safety.  The extensive clinical 
assessment of both proteins has been hindered by lack of stability and inability to produce 
large quantities of these proteins. Gene therapy could offer an alternate method to constant 
local delivery of these anti-angiogenic factors in vivo but remains untrialled. Adenovirus-
mediated, intra-tumoral delivery of endostatin ablated murine mammary carcinoma 
development and reinforced the efficacy of endostatin for cancer therapy (Ding, Sun et al. 
2001, Wen, Bai et al. 2001). 
 
One promising group of anti-angiogenic agents is antibiotics (such as fumagillin and its 
synthetic analogue TNP-470), which are in clinical trials for treating a selection of cancers. 
TNP-470 is less toxic than fumagillin and is a more powerful angiogenic inhibitor (Ingber, 
Fujita et al. 1990). In clinical trials, TNP-470 has shown signs of anti-tumour activity when 
used as monotherapy with numerous partial responses observed with relapsed and refractory 
                                                                                                      Chapter 1: Literature Review 
 
 43 
tumours. When used in combination with chemotherapy, TNP-470 has shown more promise; 
however, many patients experienced side effects, such as neurotoxicity, at doses required for 
anti-tumour activity.  Subsequent trials have varied the dosing procedures, but these have 
been ineffective in controlling toxicity. Therefore, alterations in the formulation of TNP-470 
that maintain or increase anti-angiogenic activity while decreasing toxicity are essential for 
further clinical use (Herbst, Madden et al. 2002).  
 
1.9.1.2 Matrix Degradation and Remodelling-Targeted Therapy 
Matrix degradation and remodelling are initiated by tumours to alter the local 
microenvironment and increase angiogenic potential. Matrix metalloproteinases (MMPs) are a 
family of endopeptidases secreted by tumour, endothelial and inflammatory cells (Rundhaug 
2005). They facilitate the degradation of the basement membrane and remodelling of the 
ECM to allow EC migration and invasion into neighbouring tissues (Drevs, Laus et al. 2002). 
Whilst tightly controlled in normal tissues MMP production is stimulated by growth factors in 
diseased tissue resulting in the liberation of pro-angiogenic factors and matrikines from the 
ECM (Rundhaug 2005). Hence, numerous agents have been designed to prevent MMP 
activity (Table 1.2) thus inhibiting tumour angiogenesis (Rothenberg, Nelson et al. 1998). 
MMP-9 has been shown to have a significant function in tumour angiogenesis in the 
regulation of the bioavailability of VEGF. Inflammatory cells within pancreatic islet tumours 
secrete MMP-9 turning on the angiogenic switch by increasing the availability of VEGF for 
its receptor (VEGFR2) (Bergers, Brekken et al. 2000). MMP-14 is known to have a vital role 
in the regulation of vascular stability and permeability. This inhibitor facilitates the vascular 
reaction to tissue injury and tumour progression by triggering TGF-β (Sounni, K. et al. 2010). 
 
Pre-clinical studies with synthetic MMP inhibitors (MMPIs) have not successfully translated 
into human clinical trials. Poor bioavailability of first-generation MMPIs led to second-
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generation MMPIs that were practical but produced undesirable side effects with long-term 
administration: musculoskeletal pain and inflammation (Coussens, Fingleton et al. 2002, 
Overall and Lopez-Otin 2002). These side effects may be due to the concentration of the 
doses administered, based on the maximum accepted dose, which led to the inhibition of 
associated metalloproteinases, such as ADAMs (a disintegrin and metalloproteinase) and 
ADAMTSs (ADAMs with thrombospondin-type motifs), which have “sheddase” activity (the 
ability to shed functional inflammatory cytokines and growth factors from cell membranes) 
(Coussens, Fingleton et al. 2002, Overall and Lopez-Otin 2002).  
 
A Phase I clinical trial utilising BMS-275291 (originally manufactured to avoid the sheddase 
activity) failed to proceed to Phase III (Naglich, Jure-Kunkel et al. 2001, Coussens, Fingleton 
et al. 2002, Lockhart, Braun et al. 2003). From what is now known about the functions of 
MMPs in the angiogenic switch, tumour angiogenesis, and acquisition of the invasive 
phenotype, the administration of MMPIs to patients in earlier stages would be anticipated to 
have greater efficacy. Thus, future trials should account for the tumour stage and type when 
recruiting patients and a need exists for better biomarkers for defining effectiveness of dosing 
regimens (Coussens, Fingleton et al. 2002).  
 
1.9.1.3 Growth Factor Pathway Inhibitors 
In solid tumours, the VEGF and EGFR pathways appear to be associated, especially in 
regards to angiogenesis. EGF and TGF-α both stimulate VEGF expression via triggering 
EGFR in cell culture models and have pro-angiogenic properties (Perrotte, Matsumoto et al. 
1999, Ellis 2004). It has been reported that tumour-associated ECs express EGFR (Kim, 
Uehara et al. 2003) and that over-expression or constitutive activation of EGFR has a poor 
prognosis (Ellis 2004). It is possible that the EGFR pathway regulates angiogenesis by 
increasing VEGF in the angiogenic process (Perrotte, Matsumoto et al. 1999). Several 
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inhibitors of VEGF and EGFR are approved for clinical use. Some of these are antibodies 
(bevacizumab), which obstruct VEGFR2-VEGF interactions while small molecule inhibitors 
of VEGF, or EGF receptor tyrosine kinase activities have also shown promise (vatalanib 
(PTK787/ZK) or erlotinib (OSI-774) and gefitinib (ZD1839), respectively) (Tabernero 2007). 
However, systemic side effects are common with the use of these anti-angiogenic agents as 
they affect not only tumour vasculature, but also other tissues. Toxicities of angiogenic 
inhibitors include: decreased wound healing, hypertension and increased risk of thrombosis – 
therefore affecting normal physiological angiogenesis. Therefore, new therapies that target 
only the tumour vasculature would be beneficial.  
 
1.9.2 Vascular Normalisation Therapies 
Vascular normalisation involves re-establishing equilibrium between pro- and anti-angiogenic 
signalling: either via inhibition of angiogenic factors or augmentation of anti-angiogenic 
activity. Several reports analysing the outcomes of anti-angiogenic drugs have observed a 
“normalisation window” — a phase starting with the presence of a normalised vascular 
phenotype (usually within 1–2 days of commencing treatment), and finishing when 
characteristics of normalisation are gone (Tong, Boucher et al. 2004, Winkler, Kozin et al. 
2004, Jain 2005, Batchelor, Sorensen et al. 2007, Kamoun, Ley et al. 2009). The cessation of 
the normalisation window may be result from extremely high or extended dosing of anti-
angiogenic drugs (tilting the balance in support of anti-angiogenic factors and thus resulting 
in vascular regression), or because of the development of resistance to anti-angiogenic 
therapy, in which tumours recruit vessels via alternative means. Intriguingly, several genetic 
reports have not observed this normalisation window but instead illustrate extended 
continuance of vascular normalization (Mazzone, Dettori et al. 2009). Several important 
factors are involved in vascularisation normalisation.  
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Anti-angiogenic antibodies directed against VEGF were discovered to normalise tumour 
vasculature. The first evidence of vascular normalisation in response to VEGF blockade was 
in 1996 using A4.6.1 therapy (Yuan, Chen et al. 1996). The complexities and density of the 
vessels were both diminished after a single dose of A4.6.1, which was accompanied by a 
decline in permeability (Yuan, Chen et al. 1996). If therapy was prolonged, conversely, 
characteristics of normalisation were rapidly substituted by vascular regression, possibly due 
to extreme counterbalancing of VEGF activity. These discoveries offered initial indication 
that counterbalancing of tumour-cell-derived VEGF could reverse (although briefly) some of 
the aberrations of the tumour microvasculature (Yuan, Chen et al. 1996). Following this 
study, multiple reports have investigated modifications in vessel structure and functions in 
response to VEGF blockade (e.g. Bevacizumab, Ang-1, MMPs, Cediranib, Anginex, etc.).  
 
Physical alterations including decreased vessel density and increased vascular maturity have 
been observed with anti-VEGF therapies in several tumour models (Yuan, Chen et al. 1996, 
Hansen-Algenstaedt, Stoll et al. 2000, Lee, Heijn et al. 2000, Wildiers, Guetens et al. 2003, 
Inai, Mancuso et al. 2004, Tong, Boucher et al. 2004, Dickson, Hamner et al. 2007, Juan, 
Roffler et al. 2009). 
 
Anti-VEGF therapy has also been shown to normalise vessel function by decreasing vessel 
permeability, lowering intratumoral pressure and improving perfusion. This reduces tumour 
hypoxia, improves tumour radiosensitivity and (Gorski, Beckett et al. 1999, Lee, Heijn et al. 
2000, Winkler, Kozin et al. 2004, Dings, Loren et al. 2007) penetration of large molecules 
into the tumour interstitium (Tong, Boucher et al. 2004), and also increases distribution of 
chemotherapeutics into the tumours (Wildiers, Guetens et al. 2003, Dickson, Hamner et al. 
2007). 
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Pharmacological blockade of another pro-angiogenic agent, Ang-2 (but not Ang-1) 
normalised the tumour vessel phenotype by improving vascular perivascular cell coverage 
and tightening of EC junctions (Falcon, Hashizume et al. 2009). A dual pharmacological anti-
VEGF and angiopoietin inhibitor (termed the “double anti-angiogenic protein”) reduced the 
development of numerous murine tumours through normalisation of vessels in ovarian cancer 
(Koh, Kim et al. 2010). This is the first of several reports investigating the approach of 
inhibiting multiple pro-angiogenic agents to increase vessel normalisation. 
 
1.9.3 Vascular Disrupting Agents (VDA) 
VDAs target ECs and pericytes of the established tumour vasculature. Many VDAs stimulate 
modifications in the cytoskeletal structure and cell-to-cell junctions of ECs, which elevates 
permeability to proteins and increases interstation fluid pressure (which may be adequate to 
decrease vessel diameter) (Hinnen and Eskens 2007). The cessation of blood flow and the 
ensuing reduction of oxygen and nutrients stimulate necrosis in the tumour cells (Hinnen and 
Eskens 2007). The occurrences lead to vascular shutdown events occur in tumour ECs rather 
than normal ECs. In pre-clinical models, exposure to VDAs promotes necrosis of the tumour 
centre with a sustainable rim remaining in the periphery (which exists as it stems nutritional 
sustenance from nearby normal blood vessels that are normally less reactive to VDAs) 
(Hinnen and Eskens 2007). 
 
Tubulin-binding agents, such as combretastatin A4 phosphate (CA4P) (Table 1.2), are small 
molecule VDAs that bind E-tubulin are the same site as colchicine, depolymerising the 
microtubules and disrupting actin and tubulin. CAP also disturbs VE-cadherin/β-catenin 
signalling thus disrupting cell–cell contact (Vincent, Kermani et al. 2005). Disorganisation of 
the endothelial cytoskeleton and intercellular contacts leads to structural alterations resulting 
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in loss of blood flow (Hinnen and Eskens 2007), enhanced vascular permeability and 
increased interstitial pressure. Combinations of CA4P with other anti-cancer drugs, including 
5-fluorouracil (Grosios, Loadman et al. 2000), doxorubicin (Nelkin and Ball 2001), cisplatin, 
radiation, and hyperthermia (Horsman, Murata et al. 2000) all target the remaining viable rim 
and were discovered to generate increased tumour responses to therapy. 
 
As VDAs and other anti-angiogenic agents have been FDA approved for various cancers and 
as these drugs target ECs, which are genetically stable, drug resistance is unlikely to emerge 
(Kerbel and Folkman 2002). However, despite these positive advances, some concerns 
continue to linger including tumour resistance due to over dosage of anti-angiogenics and side 
effects, which can affect the normal vasculature. Efficient development of anti-angiogenic 
therapy in the future will necessitate a better understanding of how diverse cancers become 
vascularised and how they escape the outcomes of anti-angiogenic therapy. This will allow 
the expansion of novel anti-angiogenic methods tailored to specific cancers and disease 
situations. Furthermore, the growth of prognostic biomarkers that provide reliable measures 
of response to therapy and effectiveness of agents will be essential to personalise treatments 
to individual patients. 
 
The one key commonality to all the previous research into tumour biology is that it has been 
observational and after the fact. These “passive” approaches have provided many molecular 
targets which have been validated for their functional role in angiogenesis using cell- and 
animal-based approaches. However, few studies have taken an “active”, directed approach by 
changing the endothelium to provoke the response which will change neovascularisation rates 
and tumour growth. From other fields (such as cancer) we know these approaches to be 
powerful and often provide causal relationships between tumour growth and the genes 
identified.  Such an approach may yield the answers we need to reformulate anti-angiogenic 
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therapy to spare normal vessels any ill effects and extend the clinical range of this most 
promising therapeutic approach. 
 
1.10 Mutagenesis Strategies of the Mammalian Genome 
Sequencing of the human and mouse genomes enabled the increased understanding of how 
adult mammalian physiology and pathology features are encoded by DNA. The mouse model 
systems have been an instrumental genetic tool in cancer research and immunology. Forward 
genetic analysis in mouse models is one of the most powerful techniques to increase 
understanding of the genetic foundation of human disease (Moresco, Li et al. 2013). Recent 
enhancements in DNA sequencing technology have significantly improved the pace at which 
disease-causing mutations can be discovered in mutagenised mice. By coupling a high-
throughput, genome-wide mutagenesis method on a large scale, mouse genetics has become a 
vital approach of performing functional genomics research (Gondo 2008). Such methods 
include: site-specific gene targeting, alkylating agent N-ethyl-N-nitrosourea, insertional 
mutagenesis, retrovirus-based insertional mutagenesis and transposon-mediated insertional 
mutagenesis to name a few. 
 
1.10.1 Site-specific Gene Targeting 
Gene targeting is defined as the homologous recombination of DNA sequences inhabiting the 
chromosome with newly presented DNA sequences, which allows for the initiation of specific 
mutations into the mammalian genome (Thomas, Polger et al. 1986). These DNA sequences 
can: (1) delete or insert mutations into genes of interest to understand their functionality; (2) 
integrate human genes into the mammalian genome to construct animal models to analyse 
human diseases and genes; (3) integrate individual genes or genomes of pathogens (such as 
viruses) to study their functionality to the pathogenesis of the parent pathogens; and (4) 
integrate reporter genes that enable examining in vivo or ex vivo the expression of genes of 
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interest (Bouabe and Okkenhaug 2013). Gene targeting has been extensively utilised to study 
human genetic diseases by removing ("knocking out"), or adding ("knocking in"), specific 
mutations of interest to a variety of mouse models. Employing recombination systems 
including Cre/loxP or FRT/FLP allow for the conditional initiation or suppression of gene 
expression in a specific cell type / tissue of a mouse (Bouabe and Okkenhaug 2013). 
 
 
The original technique of gene targeting in mammals was accomplished through manipulation 
of the target cells own homologous recombination machinery (Capecchi 2005, Makarova, 
Haft et al. 2011, Qi, Larson et al. 2013). This was performed by microinjection of embryonic 
stem cells, and was initially the most effective and frequently used approach of generating 
gene-disrupted mice (Austin, Battey et al. 2004). The process of converting embryonic stem 
cells into mutant animals was technically challenging, expensive and time-consuming. Since 
2013, the current process for creating genetically modified organisms is the “clustered 
regulatory interspaced short palindromic repeats” or CRISPR/Cas9 system of gene-disruption. 
This technique is faster and more effective than the conventional use of embryonic stem cells 
(Capecchi 2005, Makarova, Haft et al. 2011, Qi, Larson et al. 2013, Wang, Yang et al. 2013). 
However, there are some instances in which using CRISPR/Cas9 cannot accomplish the 
anticipated genetic disruption. The CRISPR/Cas9 method has a drawback as it requires Cas9 
a Protospacer adjacent motif in close proximity to the target DNA sequence or it cannot 
effectually function, thus, limiting its ability for gene targeting to a minimum. 
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1.10.2 Random Mutagenesis 
1.10.2.1 Alkylating Agent N-Ethyl-N-Nitrosourea (ENU) 
Genetic and epigenetic modifications caused by chemical agents can lead to genomic 
instability, clonal expansion and neoplasia. Many chemical compounds are utilised to cause 
carcinogenic lesions that may parallel human diseases; including: heterocyclic amines, 
aromatic amines, alkilnitrosamide compounds and dimethylhydrazine and azoxymethane.  
 
The alkylating agent N-ethyl-N-nitrosourea (ENU) is a powerful germline mutagen that 
causes point mutations in a genome-wide process, which enables the generation of mouse 
models with mutations similar to those found in human cancers. Since the 1990s ENU has 
been utilised for generating mouse mutants for gene-driven (reverse genetics) and phenotype-
driven (forward genetics) research (Yates, McMurray et al. 2009). ENU can also be directed 
to precise genomic areas (Ching, Munroe et al. 2010). Increased mutation rates occur in the 
pre-meiotic spermatogenial stem cells after inoculation of ENU, which functions by assigning 
its ethyl group onto the bases causing mispairing and base-pair switch if not repaired (changes 
at A-T bases being the most frequent mutations) (Justice, Noveroske et al. 1999, Yates, 
McMurray et al. 2009). 
 
Screenings of phenotype-driven ENU have generated mouse models of several types of 
human cancers. An earlier study by Shoemaker and colleagues demonstrated that injection of 
ENU into genetically engineered mice led to the development of several adenomas throughout 
the entire intestinal tract thus causing colon cancer at a young age (Shoemaker, Moser et al. 
1995). Fenske et al. implemented a screen in genetically engineered mice to describe the 
influence of genetic variability to alkylator-induced cancer susceptibility by mutagenising 
mice with ENU (Fenske, McMahon et al. 2006). The most commonly discovered cancer 
phenotypes from this study were: lung adenocarcinoma and haematological malignancies of 
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both the lymphoid and myeloid lineages (Fenske, McMahon et al. 2006).  
 
Use of ENU has increased the knowledge of mouse physiology, pathology and genetics. 
However, ENU mutagenesis screen has numerous disadvantages including its strong bias 
towards A/T base pairs (87%) and a high level of background mutations (Justice, Noveroske 
et al. 1999). Furthermore, due to the absence of a molecular identifier, tracking the mutations 
initiated by ENU can be arduous and time-consuming, and thus ENU is frequently replaced 
by other mutagenesis strategies (Justice, Noveroske et al. 1999). 
 
1.10.3 Insertional Mutagenesis 
Insertional mutagenesis is when an exogenous DNA fragment (insertional mutagen) is 
introduced into the host cell genome (Ranzani, Annunziato et al. 2013). These insertional 
mutagens could either be a gene-trap vector, retrovirus DNA or transposon. Insertional 
mutagenesis can lead to loss-of-function or gain-of-function mutations, dependent on the 
presence of genetic components (Ranzani, Annunziato et al. 2013). These components offer 
substantial flexibility for alteration depending on the requirement of the experiment or screen. 
After the success of the first report of insertional mutagenesis, large-scale mutagenesis 
analyses in mammalian systems have become popular (Jaenisch 1976). In cancer research, 
insertional mutagens are mobilised within an animal model system and after a certain time, 
the development of cancer occurs (Ranzani, Annunziato et al. 2013). The detection of 
integration sites from the tumours and mapping them to the genome enables the 
documentation of genes that may have caused the cancer. Frequently targeted integration sites 
in tumours (common insertion sites; CIS) may be candidate cancer genes (Ranzani, 
Annunziato et al. 2013). Moreover, the integration site signifies both the cause of cellular 
alteration and a traceable molecular marker. 
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1.10.4 Retrovirus-Based Insertional Mutagenesis 
Retroviruses are a family of enveloped RNA viruses that replicate their genome via a DNA 
intermediate. The standard genes in the retroviral genome are: gag (encodes core proteins), 
pol (encodes reverse transcriptase) and env (encodes the protein envelop) (Coffin, Hughes et 
al. 1997, Ranzani, Annunziato et al. 2013). Both ends of the viral genome comprise long 
terminal repeats (LTRs), which include promoter and enhancer components in addition to 
other viral sequences for viral splicing and integration (Coffin, Hughes et al. 1997, Ranzani, 
Annunziato et al. 2013). Once the envelope glycoproteins make contact with cellular 
receptors, the virus is merged into the host cell plasma membrane, and the viral capsid 
comprising the RNA genome enters the cell (Coffin, Hughes et al. 1997, Ranzani, Annunziato 
et al. 2013). The retroviral genome is discharged into the cell cytoplasm and consequently 
retro-transcribed into a double-stranded proviral DNA. After achievement of reverse 
transcription, the proviral DNA is linked with viral proteins, and transfers to the cell nucleus, 
where the integration of the provirus into the host cell genome occurs (Coffin, Hughes et al. 
1997, Ranzani, Annunziato et al. 2013). 
 
Oncogenic retroviruses are categorised into two groups: acute- and slow-transforming. Acute-
transforming retroviruses stimulate the development of polyclonal cancers by highly 
expressing virus-encoded oncogenes with short latency (2 – 3 weeks). Slowly-transforming 
retroviruses stimulate the growth of oligoclonal tumours by incorporating into the host 
genome proximal to oncogenes with longer latency (3 – 12 months) (Coffin, Hughes et al. 
1997, Ranzani, Annunziato et al. 2013). 
 
There has been substantial advancement in the development of viral vectors for human gene 
therapy over the last 15 years. However, there are problems associated with these vectors such 
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as: their integration-site preferences which may increase possibilities of unfavourable 
outcomes; the requirement for widespread purification and quality control to avoid 
replication-competent virus and also the expense accompanying the manufacturing and 
handling of the virus (Chen, Reeves et al. 2001, Kohn, Sadelain et al. 2003, Hodges and 
Cheng 2006, Hackett, Geurts et al. 2007). 
 
1.10.5 Transposon-Mediated Insertional Mutagenesis 
Gene function may be investigated by altering the expression of the gene product or 
modifying the sequence of the gene (Izsvak and Ivics 2005). Indeed, the targeted loss (knock-
out) or mutation (knock-in) of genes in the mouse genome is a standard approach for the 
assessment of gene function. Transposons, mobile DNA elements or “jumping genes”, have 
the ability to produce mutations by inserting into genes and therefore can be also be used as 
markers or tags to seek out the mutated gene (Izsvak and Ivics 2005).  
 
1.10.5.1 piggyBack (PB) System of Insertional Mutagenesis 
Another system is the PB system which displays an integration pattern that is similar to that 
of integrating viral vectors (Wilson, Coates et al. 2007). Up to the present time, the only 
transposon that has been effectively utilised for discovery of cancer genes (as a substitute to 
SB) is the PB system, which is a DNA transposon developed from the moth Trichoplusia ni 
and has been established to be functional in mammalian cells (including mice) (Ding, Wu et 
al. 2005). The PB system differs from Sleeping Beauty as PB can effectively mobilise larger 
loads (hundreds of kb); PB integrates at a TTAA tetranucleotide sequence; after excision no 
footprints are left by PB, while inaccurate excision incidents may mutate the genome at the 
mobilisation site (Li, Pettitt et al. 2013). One setback of PB is that, unlike SB, which has no 
close relatives in the human genome, there are PB-like components scattered on various 
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human chromosomes (Feschotte 2006).  
 
A study by Rad et al. compared three different types of transposons:, each with different 
enhancer / promoters in the Sleeping Beauty and PB systems: MSCV, two composite 
promoters comprised of the cytomegalovirus enhancer, fragments of the chicken beta-actin 
promoter and the rabbit beta-globin gene (CAG); or the phosphoglycerate kinase (PGK) 
promoter with the (Rad, Rad et al. 2010). Rosa26-SB11 or Rosa26-PB transposase mice were 
crossed with 14 transposons lines Mobilisation of the MSCV transposon resulted in >90% 
haematopoietic malignancies; CAG transposon resulted mainly in solid tumours (comprising 
sarcomas and carcinomas) and the PGK transposon induced both (Rad, Rad et al. 2010). PB 
insertional mutagenesis identified 42% of the candidate cancer genes that were not discovered 
in earlier reports that utilised the retrovirus or the Sleeping Beauty system, thus implying that 
PB targets a distinctive range of loci (Rad, Rad et al. 2010). The Sleeping Beauty system 
displayed a higher rate of embryonic lethality in mouse strains with a high copy number of 
transposons, however, tumours formed with strains that had intermediate to low copy number 
transposons (Rad, Rad et al. 2010).  
 
1.10.5.2 Sleeping Beauty (SB) System  
These unique properties of transposons were harnessed for the next generation technology of 
the genetically engineered SB insertional mutagenesis system. In the past decades, a variety 
of transposable elements (including Tc1, Tol2, Minos, Himar1, Hsmar1, Mos1, Frog Prince, 
SB and piggyBack) have been established in vertebrate cells (Ivics, Hackett et al. 1997, 
Miskey, Izsvak et al. 2003, Meir and Wu 2011, Urschitz and Moisyadi 2013, Chitilian, 
Thillainadesan et al. 2014, Pflieger, Jaillet et al. 2014). Of those, the SB system has been most 
well described.  
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The SB system is a synthetic reconstruction of transposable elements that were originally 
dispersed in fish genomes (Ivics, Hackett et al. 1997). The system consists of two unlinked 
transgenes, a transposon (or mobile element) and a transposase enzyme, that are expressed 
simultaneously in the mouse genome (Dupuy 2010). The SB transposon is a derivative of the 
Tc1/mariner superfamily of DNA transposons prevalent among ancient vertebrate and 
invertebrate genomes (Geurts, Yang et al. 2003). The SB transposase catalyses the 
mobilisation of the transposon from the transgene and their reintegration elsewhere in the 
mouse genome (Dupuy 2010). If the reintegration site is within a gene then insertional 
mutagenesis leading to inappropriate activation or loss of that gene may occur. If the resulting 
mutations provide the cell with a selective advantage, such as an increased rate of 
proliferation or survival, then clonal populations of the mutated cells may arise (Dupuy 2010). 
Reintegration is site specific, requiring a TA sequence. As the number of potential sites 
surpasses the number of known genes, reintegration may still be effectively random. Each 
mutated gene is tagged with a transposon, enabling easy identification of these mutated genes 
by sequencing the regions adjacent to the re-integrated transposons. Some of these genes will 
be primary drivers of the observed phenotype. These valuable characteristics of the SB system 
have led to extensive use of the system with the generation of new genetic SB-induced mouse 
models of cancer.  
 
A drawback to the SB system is the ‘local hopping’ event where, during transposition, DNA 
transposons have a tendency to reintegrate near the original excision site. A certain amount of 
transposition incidents will be local and the remaining events would generally be dispersed 
evenly throughout the genome (Chew, Rad et al. 2011). The SB system is described to display 
local hopping in ~10-75% depending on the tissue and cellular nature (Vigdal, Kaufman et al. 
2002, Horie, Yusa et al. 2003, Collier, Carlson et al. 2005, Dupuy, Akagi et al. 2005). 
                                                                                                      Chapter 1: Literature Review 
 
 57 
However, the local hopping event considerably enhances the mutagenicity of SB in a 
controlled section of the genome. 
 
The SB system was originally utilised for germline mutagenesis in mice expressing the SB 
transposase (SB10 or SB11) and a mutagenic transposon line (T2/Onc or T2/Onc2) (Collier, 
Carlson et al. 2005, Dupuy, Akagi et al. 2005). Combining SB10 transposase with the 
CAGGS transgene with high copy T2/Onc mice was inadequate to stimulate tumours due to 
restricted transposase expression in normal adult tissues (possibly due to epigenetic silencing) 
(Collier, Adams et al. 2009). No sign of embryonic lethality was detected in these mice; 
however, no difference was observed in the survival rates of WT and CAGGS-SB10 mice, 
signifying that mutagenesis rate attained by mobilising T2/onc from a high copy line by 
CAGGS-SB10 is inadequate for tumour development (Collier, Adams et al. 2009). 
 
Dupuy et al. altered the transposase component of the SB system to a SB11 knock in to the 
Rosa26 locus (Rosa26-SB11) (Dupuy, Akagi et al. 2005). An advantage of Rosa26 is that 
genes targeted to this locus are broadly expressed during adulthood with no epigenetic 
silencing, which frequently ensues with traditional transgenes. This would drive SB11 
expression in virtually all somatic cells from embryonic phase throughout adulthood (Dupuy, 
Akagi et al. 2005). However, when Rosa26-SB11 mice were crossed with high copy T2/Onc2 
transgenic mice, 75% of the double transgenic mice had embryonic lethality possibly due to 
unrepaired DNA damage after transposition (Dupuy, Akagi et al. 2005). The surviving mice 
began to show signs of disease by 7 weeks of age all died by 120 days of primarily 
haematological malignancies (lymphocytic leukaemia/lymphoma), but also some solid 
tumours including medulloblastoma and other hyperplasias and neoplasias (Dupuy, Akagi et 
al. 2005).  
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In another study by Collier et al. where Rosa26-SB11 mice were crossed with low copy 
T2/Onc transgenic mice, no embryonic lethality was observed, due to the lower number of 
mobilising transposons in the transposon (Collier, Adams et al. 2009). Also, Mendelian 
inheritance of Rosa26-SB11 crossed with T2/Onc low transgenes signifies a mutagenic 
frequency adequate enough to stimulate tumour development, but inadequate to obstruct 
normal development. These mice had a latency of 6 – 8 months prior to the development of 
disease, primarily lymphomas / leukaemias but also gliomas (Collier, Adams et al. 2009). 
 
The composition of the T2/Onc2 transposon is shown in Figure 1.10 and includes the 5’ LTR 
from the murine stem cell virus (MSCV), which has preferential expression in haematopoietic 
tissues (Hawley, Fong et al. 1992, Dupuy, Akagi et al. 2005).  
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Figure 1.10: The SB transposon (image adapted from Collier and Largaespada, 2005 
and Howell, 2012) (Collier and Largaespada 2005, Howell 2012). The transposon is 
bidirectional with both loss- and gain-of-function features so that it can mutate both tumour 
suppressor genes and oncogenes upon reintegration in the mouse genome. Reintegration 
requires a TA site (blue) and is influenced by local structural features of the DNA. (A) and 
(B) display loss of function events through premature termination of the mRNA following 
insertion of the transposon in the forward (A) or reverse (B) orientation. The strong splice 
acceptor (SA) directed splicing from the upstream exon (purple) into the transposon. The 
downstream polyadenylation signal (pA) in the transposon begins premature termination of 
the transposon-trapped transcript. C represents commencement of an mRNA by the MSCV 
LTR promoter/enhancer component of the transposon. The strong splice donor (SD) of the 
transposon targets splicing from the transposon into downstream endogenous exons (pink). 
Figure adapted from Collier et al. (2005) and Howell, VM (2012) (Collier and Largaespada 
2005, Howell 2012).  
 
A significant alternative to the T2/Onc configuration was generated in version 3, T2/Onc3, in 
which the MSCV LTR was substituted by the CMV enhancer / chicken beta-actin (CAG) 
promoter (Karreth, Tay et al. 2011). This new CAG promoter reduced haematopoietic activity 
in tissues and increased activity in epithelial tissues (Karreth, Tay et al. 2011). Mice with 
T2/Onc3 and Rosa26-SB11 mice were slow to develop tumours with an average age at death 
of 55 weeks compared to 68 days for Rosa26-SB11;T2/Onc2 mice (Dupuy, Rogers et al. 
2009). The target of my study was the vascular endothelium. Given the developmental origins 
of the endothelium the T2/Onc2 system was used for the current study. 
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A study by Starr et al in 2009 used the SB system for generating insertional mutations to 
detect possible driver genes in human colorectal cancers (CRC) (Starr, Allaei et al. 2009). 
Mice with mutagenic SB transposons were crossed to mice with SB transposase in 
gastrointestinal tract epithelium. Many of the offspring acquired intestinal lesions comprising 
intraepithelial neoplasia, adenomas, and adenocarcinomas (Starr, Allaei et al. 2009). They 
examined over 16,000 transposon insertions and discovered 77 potential CRC genes, of which 
60 were found to be mutated and / or dysregulated in human CRC and therefore are almost 
certainly to drive tumorigenesis, and also discovered 17 novel potential genes that were not 
formerly associated with CRC (Table 1.3) (Starr, Allaei et al. 2009). 
 
Another study in 2009, by Keng et al. utilised the same SB system to model hepatocellular 
carcinoma (HCC) in mice by specifically restricting SB transposition to the liver (Keng, 
Villanueva et al. 2009). They discovered already known HCC genes (eg EGFR and MET) as 
well as novel genes (eg UBE2H). These novel genes may provide potential therapeutic targets 
for HCC (Table 1.3) (Keng, Villanueva et al. 2009). 
 
A report from 2010 discovered that SB-mediated somatic mutagenesis implicated colony-
stimulating factor-1 (CSF1) in the formation of high-grade astrocytomas (Bender, Collier et 
al. 2010). SB mutagenesis induced glioma formation, and sequencing of the transposon 
insertion sites in the tumour DNA identified Csf1 to be mutated in the majority of mouse 
tumours. Evaluation in human astrocytomas confirmed that CSF1 over-expression is a 
common feature in these tumours. This study provided the first forward mutagenesis evidence 
that inappropriate activation of Csf1 may contribute directly to astrocytoma formation (Table 
1.3) (Bender, Collier et al. 2010).   
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Mann et al. utilised the SB system in mice to detect novel potential cancer genes in pancreatic 
cancer. Combining the SB system with an oncogenic Kras allele led to a phenotype of highly 
metastatic pancreatic adenocarcinomas (Mann, Ward et al. 2012). They discovered 543 
candidate cancer genes that display major enhancement for transposon insertions in SB-driven 
pancreatic cancer (Mann, Ward et al. 2012). They identified 20 genes that were not formerly 
implicated in pancreatic cancer, which were importantly linked to poor patient prognosis 
(Mann, Ward et al. 2012). They concluded that SB mutagenesis delivers a vast array of 
mutations in candidate drivers of cancer for cross-comparative examinations with continuing 
sequencing analyses in human pancreatic adenocarcinoma (Table 1.3) (Mann, Ward et al. 
2012).  
 
A recent study by Heltemes-Harris et al. performed an unbiased SB transposon mutagenesis 
screen to distinguish genes and signalling pathways that cooperate with STAT5 activation to 
initiate progenitor B-ALL (Heltemes-Harris, Larson et al. 2016). Transposon insertions 
characteristically led to a modified expression of Sos1, Kdm2a, Jak1, Bmi1, Prdm14 or 
Ncoa2, Cdkn2a, Ikzf1, Caap1 and Klf3 (Heltemes-Harris, Larson et al. 2016). An interesting 
finding of this study was the expression of Sos1 and Kdm2a, and activation of p38, which 
were found to be associated with survival, proposes that inhibitors of these enzymes may be 
beneficial for B-ALL therapy (Table 1.3) (Heltemes-Harris, Larson et al. 2016). 
 
To date, over 300 commonly mutated genes have been identified in several SB-induced 
tumours (Dupuy 2010). Amongst these are previously validated human cancer-causing genes, 
providing proof-of-principle for the SB-approach for the identification of regulatory genes 
(Table 1.3). 
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Table 1.3: In vivo screening of SB system for cancer genes, which are published to date 
(adapted from Moriarity and Largaespada) (Moriarity and Largaespada 2015). 
Type of Cancer Gene Promoter Year Reference 
BCP-ALL Etv6 2011 (van der Weyden, Giotopoulos et 
al. 2011) 
BCP-ALL CD79a 2016 (Heltemes-Harris, Larson et al. 
2016) 
BCP-ALL Etv6 2016 (van der Weyden, Giotopoulos et 
al. 2016) 
Erythro-megakaryocytic 
leukaemia 
vav1 2013 (Tang, Carmichael et al. 2013) 
Chronic lymphocytic 
leukaemia 
CD19 2013 (Zanesi, Balatti et al. 2013) 
Leukaemia/lymphoma Germline 2005 (Dupuy, Akagi et al. 2005) 
Leukaemia/lymphoma Germline 2009 (Collier, Adams et al. 2009) 
Leukaemia/lymphoma Germline 2013 (van der Weyden, Rust et al. 2013) 
Lymphoma Vav 
Lck 
CD4 
2011 (Berquam-Vrieze, Nannapaneni et 
al. 2011) 
Lymphoma Germline 2011 (Koudijs, Klijn et al. 2011) 
Lymphomas Germline 2012 (van der Weyden, Arends et al. 
2012) 
Myeloid leukaemia Actb 2016 (Mann, Newberg et al. 2016) 
CRC Villin 2009 (Starr, Allaei et al. 2009) 
CRC CYP1A1 2011 (March, Rust et al. 2011) 
CRC Villin 2011 (Starr, Scott et al. 2011) 
CRC Villin 2015 (Takeda, Wei et al. 2015) 
CRC Germline 2016 (Morris, Davison et al. 2016) 
Gastrointestinal cancer Germline 2016 (Takeda, Rust et al. 2016) 
HCC Albumin 2009 (Keng, Villanueva et al. 2009) 
HCC LAPtTA 2012 (O'Donnell, Keng et al. 2012) 
HCC Albumin 2013 (Keng, Sia et al. 2013) 
HCC Albumin 2014 (Bard-Chapeau, Nguyen et al. 
2014) 
HCC K5 2016 (Kodama, Newberg et al. 2016) 
HCC Albumin 2016 (Kodama, Bard-Chapeau et al. 
2016) 
HCC Germline 2016 (Tao, Xu et al. 2016) 
Histiocytic sarcoma Lysozyme2 2014 (Been, Linden et al. 2014) 
GBM Nestin 2012 (Koso, Takeda et al. 2012) 
Glioma GFAP 2014 (Vyazunova, Maklakova et al. 
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2014) 
Glioma Germline 2010 (Bender, Collier et al. 2010) 
Malignant peripheral 
nerve sheath tumors 
Cnp 2013 (Rahrmann, Watson et al. 2013) 
Medulloblastoma Math1 2013 (Wu, Northcott et al. 2012) 
Medulloblastoma β-actin 2013 (Genovesi, Ng et al. 2013) 
Medulloblastoma Germline 2013 (Lastowska, Al-Afghani et al. 
2013) 
Medulloblastoma Nestin 2014 (Koso, Tsuhako et al. 2014) 
Melanoma Tyrosinase 2011 (Karreth, Tay et al. 2011) 
Melanoma Tyrosinase 2015 (Perna, Karreth et al. 2015) 
Melanoma Tyrosinase 2015 (Mann, Black et al. 2015) 
Non melanoma skin 
cancer 
K5 2013 (Quintana, Dupuy et al. 2013) 
Multiple – solid and soft Germline 2013 (Rogers, Olivier et al. 2013) 
Non-small cell lung 
cancer 
SPC 2015 (Dorr, Janik et al. 2015) 
Osteosarcoma Osterix 2015 (Moriarity, Otto et al. 2015) 
Osteosarcoma Osterix 2016 (Temiz, Moriarity et al. 2016) 
Sarcoma Germline 2005 (Collier, Carlson et al. 2005) 
PDAC Pdx1 2012 (Mann, Ward et al. 2012) 
PDAC Pdx1 2012 (Pérez-Mancera, Rust et al. 2012) 
Prostate cancer PB 2016 (Ahmad, Mui et al. 2016) 
 
BCP = B-cell precursor acute lymphoblastic leukaemia; CRC = colorectal carcinaoma; HCC 
= hepatocellular carcinoma; GBM = glioblastoma multiforme; PDAC= pancreatic ductal 
adenocarcinoma; PB = ARR2Probasin transgenic line; GFAP = glial fibrillary acid protein; 
LAPtTA = liver-specific tet-transactivator; K5 = keratin gene promoter; GFAP = glial 
fibrillary acidic protein promoter; SPC = surfactant protein C and Cnp = cyclic nucleotide 
phosphodiesterase. 
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1.11 Hypothesis and Aims 
This project is based on the hypothesis that changes to the endothelial cell genome will affect 
the angiogenic potential of the endothelium. We hypothesise that the alterations in the 
angiogenic potential will produce spontaneous tumour formation, altered growth rates or 
ischaemic disease (under supply of vessels). Some of the genes mutated by the SB random 
mutagenesis strategy will be novel regulatory genes important for angiogenesis, whether that 
be tumour-specific or physiologic angiogenesis. The chosen mutagenesis strategy has 
advantages over other similar systems (such as ENU mutagenesis) as the transposon leaves a 
signature “tag” at the site of insertion that can be used for subsequent identification and 
sequencing. Moreover, the changes caused by the SB mutagenesis system are independent of 
the microenvironment of the tumour and are more likely to be directly related to the 
regulation of angiogenesis than those identified by other means.  
 
There are three aims that will be assessed in this thesis: 
(1) To determine and characterise the phenotype of SB mice (Chapter 3), 
(2) To determine the contribution of multiple cell types to the phenotype in SB mice 
(Chapter 4), and 
(3) To identify the genes responsible for the phenotype in SB mice (Chapter 5). 
Collectively these aims will provide novel insight into the molecular regulation of 
neovascularisation and ultimately identify fertile new areas for therapeutic development with 
the goal of improving and refining anti-angiogenic therapies for tumours. 
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2.1 Introduction 
This chapter describes the common materials, general methods and instrumentation used for 
this project. Methodologies specific to individual aims are described in the relevant results 
Chapters 3-5. 
 
2.1.1 Materials 
The general reagents and equipment used are listed in Table 2.1. 
 
Table 2.1: Materials and equipment. 
Item Catalogue Number Manufacturer Details 
10% Neutral Buffered Formalin NBF5LT POCD Scientific, Artarmon, NSW, 
Australia 
6-well plate 353046 Corning, Clayton, VIC, Australia 
70 μm cell strainers 352350 Corning 
Acetic Acid 320099 POCD Scientific 
Agarose BIO-41025 Bioline, Alexandria, NSW, Australia 
Antibody Diluent, REAL S202230 DAKO 
autoMACS Pro Separator 130-092-545 Miltenyi Biotech Australia Pty. Ltd. 
Macquarie Park, NSW, Australia 
Autostainer Plus - DAKO, North Sydney, NSW, 
Australia 
BD FACSCalibur - BD Biosciences, North Ryde, NSW, 
Australia 
CD14 FITC 12-0141 eBioscience, Jomar Bioscience, 
Kensington, SA, Australia 
CD144 PerCP 46-1441 eBioscience 
CD19 PE 12-0913 eBioscience  
CD3 FITC 100204 BioLegend, Australian Biosearch, 
Karrinyup, WA, Australia 
CD31 Microbeads Mouse 130-097-418 Miltenyi Biotech 
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CD4 PE 100408 BioLegend 
CD45 Microbeads Mouse 130-052-301 Miltenyi Biotech  
CD73 PE 130-202-616 Miltenyi Biotech 
CD8 PE 100708 BioLegend 
Chloroform C2432 Sigma-Aldrich, Castle Hill, NSW, 
Australia 
Coulter Counter - Beckman Coulter, Lane Cove West, 
NSW, Australia 
DAKO Pascal Pressure Chamber S2800 DAKO 
Disodium hydrogen phosphate S9390 Sigma-Aldrich 
DNA engine dyad / Tetrad 
thermal cycler 
4375786 Applied Biosystems, Thermo Fisher 
Scientific, Taren Point, NSW, 
Australia 
dNTPs  Bioline 
Dynabeads Sheep Anti-Rat IgG 11035 Invitrogen, Life Technologies, 
Mulgrave, Victoria, Australia 
Envision FLEX Target Retrieval 
Solution, High pH (9) 
K8004 DAKO 
Envision+ System HRP Labelled 
Polymer Anti-Rabbit solution 
K8003 DAKO 
Eppendorf Microcentrifuge 5415 5415R Sigma-Aldrich 
Ethanol C2H5(OH) EA043-2.5L POCD Scientific 
Ethylenediaminetetraacetic acid E9884 Sigma-Aldrich 
Eukitt quick-hardening mounting 
medium 25608-33-7 
Sigma-Aldrich 
Excelsior AS Tissue Processor A82300001 Thermo Fisher Scientific, Taren 
Point, NSW, Australia 
Foetal Bovine Serum F9423 Sigma-Aldrich 
FORANE (isoflurane, USP) 1001936060 Baxter, Toongabbie, NSW, Australia 
Goat MACH 3 Probe and Polymer M3M530 Biocare Medical, Redcliffe, QLD, 
Australia 
Histosette M499-2 Sakura Finetek, Mount Waverley, 
Victoria, Australia 
HOT Firepol DNA Polymerase 01-02-01000 Solis BioDyine, Integrated Sciences 
PTY. LTD., Chatswood, NSW, 
Australia 
Hydrochloric acid 38280 Sigma-Aldrich 
Hydrogen Peroxidase 216763 Sigma-Aldrich 
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Hyperladder IV DNA Ladder BIO-33056 Bioline 
IHC Microscope Slides, FLEX K020 DAKO 
ImageQuant LAS 4000 
 
28-9558-10 GE Healthcare Life Sciences, 
Parramatta, NSW, Australia 
ImmPACT NovaRED SK-4805 Vector Labs, Abacus ALS, 
Waterford, QLD, Australia  
Lauryl Sulfate 161-0418 Bio-Rad, Gladesville, NSW, 
Australia 
Leica rotary microtome RM2245 Leica Biosystems, North Ryde, 
NSW, Australia 
Methylcellulose-Based Medium 
with Recombinant Cytokines (no 
EPO) for Mouse Cells 
3534 StemCell Technologies, Tullamarine, 
Victoria, Australia 
Nanodrop Spectrophotometer ND-1000 Thermo Fisher Scientific 
PCR-strip tubes 3926-550-000 Edwards Instruments Inc, Narellan, 
NSW, Australia 
Phosphate-buffered saline 18912014 Thermo Fisher Scientific 
Potassium Chloride 7447-40-7 Univar PTY Ltd., Ingleburn, NSW, 
Australia 
Potassium di-hydrogen phosphate P5655 Sigma-Aldrich 
Proteinase K 25530-015 Invitrogen 
QIAamp DNeasy Blood and 
Tissue Kit 
69504 QIAGEN, Chadstone, Victoria, 
Australia 
Rat MACH 3 Probe and Polymer M3R531 Biocare Medical 
Red blood cell lysing buffer 
Hybri-Max 
R7757 Sigma-Aldrich 
Rodent Decloaker (pH6) (target 
retrieval solution) 
RD913 Biocare Medical 
Sca1 Microbeads Mouse 130-092-529 Miltenyi Biotech 
Sodium chloride S7653 Univar 
Sulfuric acid 339741 Sigma-Aldrich 
Superfrost™ Ultra Plus Adhesion 
Slides 
1014356190 Menzel-Glasser, Thermo Fisher 
Scientific 
SYBr-Safe DNA Dye S33102 Invitrogen 
Trizma base, acetic acid and 
EDTA Nucleic Acid 
Electrophoresis Buffer 
1610743 Bio-Rad 
Trizma Base, Minimum 99.9% T1503 Sigma-Aldrich 
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Titration 
Wash Buffer 20X GC807 DAKO 
Xylene C8H10 XYLENEPL5LT POCD Scientific 
 
FITC = fluorescein isothiocyanate, PerCP = peridin chlorophyll, PE = phycoerythrin, dNTPs 
= deoxynucleotide, EPO = erythropoietin, PCR = polymerase chain reaction and DNA = 
deoxyribonucleic acid. 
 
2.2 Animal Model  
To investigate the genes that regulate endothelial cell proliferation we generated transgenic 
mice with mutations introduced randomly into the genome using the Sleeping Beauty 
transposon system (see Chapter 1, Section 1.10.5.1). Gene mutations were conditionally 
expressed in the endothelial cells of SB mice by inclusion of an endothelial specific promoter 
(Tie2) to control expression of the Cre recombinase.  
 
2.2.1 Parental Mouse Lines 
Experimental SBxTie2-Cre binary mice were derived from breeding three published parental 
knock-in and transgenic lines together to utilise the Cre-LoxP system for conditional 
activation. The background strain of all lines was C57Bl/6. All breeding colonies were housed 
in the Kearns Small Animal Facility at the Kolling Institute. Experimental mice were issued 
under North Sydney Local Health District Animal Care and Ethics (ACEC) protocols 0907-
008A and 1309-004A. The ethics protocol complied with NHMRC guidelines by conforming 
to the Australian Code for the Care and Use of Animals for Scientific Purposes (8th Edition). 
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The conditional SB Transposase Gt(ROSA)26Sortm2(sb11)Njen (Rosa26-LoxP-STOP-LoxP-
SB11) (Dupuy, Rogers et al. 2009) and high-copy SB transposon line 6113 TgTn(SB-
T2/Onc2)6113Njen (T2/Onc2) (Dupuy, Akagi et al. 2005) (abbreviated to SB), were obtained 
as double homozygotes from Drs Neal Copeland and Nancy Jenkins, A-STAR, Singapore 
(current address: The Methodist Hospital Research Institute, Houston, Texas, USA).  
 
Cre recombinase expression (Cre) was supplied by mouse line B6.Cg-Tg(Tek-cre)1Ywa/J 
(abbreviated to Tie-2-Cre receptor tyrosine kinase 2 with Cre: “Causes recombination") 
(Sternberg and Hamilton 1981) that was hemizygous for a transgene in which the Cre cDNA 
was under the control of the angiopoietin receptor (Tie-2; tyrosine kinase with 
immunoglobulin like and EGF like domains 2) promoter (Kisanuki, Hammer et al. 2001). The 
Tie-2-Cre mice were obtained from Dr Brian Duling (Cardiovascular Research Center, 
University of Virginia).  
 
The Cre-LoxP system of conditional transgenesis enables genetically engineered changes to 
be directed or limited to specific cell types or tissues (Kisanuki, Hammer et al. 2001). By 
using the Tie-2 receptor promoter, genetically engineered changes are directed to the 
endothelium. This permits analysis of the changes in specific cells or tissue and may avoid 
unwanted phenotypes such as early lethality, which may occur with ubiquitous expression of 
some transgenes. Cre, derived from bacteriophage, recognises genetically engineered LoxP 
sites that are specific 34-bp sequences not found in the normal mammalian genome (Kisanuki, 
Hammer et al. 2001). The enzyme cleaves the DNA at these engineered sites and ligates 
neighbouring sites to each other (Figure 2.1) removing the intervening DNA. In the 
conditional SB-transposase transgene, expression of Cre deletes the STOP codon and results 
in expression of the SB transposase (Figure 2.1).  
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Figure 2.1: Schematic for the generation of the SBxTie2-Cre binary mice. Breeding the 
Tie2-Cre transgenic mice with SB mice results in binary mice with deletion of the stop codon 
leading to activation of SB in the endothelium.  
 
2.2.2 Generation of Experimental SBxTie2-Cre Line 
To generate the SBxTie2-Cre binary mice, homozygous female SB mice were bred with 
hemizygous male Tie2-Cre mice. From Mendel’s law of inheritance all pups were predicted 
to be hemizygous for the two SB transgenes and 50% of the offspring predicted to be 
hemizygous for the Cre transgene. Litters were genotyped using a PCR-based approach to 
detect the Cre allele (Wang and Storm 2006) (see Section 2.3). This enabled identification of 
mice with Cre-mediated activation of SB (Cre) from those expressing the wild type allele 
(WT; no SB activation). Genotyping also confirmed the presence of the two SB transgenes 
(T2Onc2 and SB-transposase).  
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Genomic DNA (gDNA) served as the template for genotyping and was extracted from 2-3 
mm of mouse tail biopsied at approximately four weeks of age when pups are weaned from 
the dam. At the same time each pup was given a unique ID using numbered ear tags. The 
Kearns Small Animal Facility staff performed the tail biopsies and ear tagging. The tail 
biopsies were stored at -20qC until DNA extraction and genotyping was performed. 
Following genotyping, mice designated for experiments were moved into the experimental 
room in the Kearns Small Animal Facility at the Kolling Institute and monitored for any 
changes in condition including sickness and mortality. 
 
2.2.3 Monitoring and Euthanasia of Mice 
WT and SBxTie2-Cre mice were exposed to a 12-hour day/night cycle and fed normal chow 
and water ad libitum. Mice were weighed weekly and checked daily. SBxTie2-Cre mice were 
euthanised when one or more ethically defined endpoints were reached; weight loss (>10% of 
body weight over 1 week), lack of locomotion, dehydration, dishevelled external appearance 
(hunched, lack of grooming), and signs of pain and distress (such as vocalisation upon 
handling). WT mice were euthanised at the same time as SBxTie2-Cre mice for age-matched 
controls. Mice were euthanised by inhaled anaesthesia (2%{v/v} isoflurane, 1% {v/v} oxygen 
and 2% {v/v} nitric oxide in room air) followed by cervical dislocation. For vessel density 
studies in Chapter 3, a subset of mice (that were free of detectable disease) were euthanised at 
11 weeks of age. 
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2.3 DNA Experiments 
DNA was extracted from murine tissues for (i) genotyping for the three transgenes (Cre, 
T2Onc2 and SB-transposase), (ii) excision-PCR to confirm SB-activation via mobilisation of 
transposons from the T2Onc2 transgene, and (iii) targeted next generation sequencing for the 
identification of the SB transposon-mutated genes. One round of DNA extractions was 
performed and used for both excision-PCR and targeted next generation sequencing. These 
procedures are described below. 
 
2.3.1 DNA Extractions  
Genomic DNA was extracted from a 2-3 mm tail biopsies, or frozen spleen and thymus, of 
mice by previously established methods (Wang and Storm 2006). Tissue was placed in a 
labelled 1.8 mL micro-centrifuge tube with 300 PL of digestion buffer (100 mM Trizma Base 
{pH 8.0}; 200 mM sodium chloride; 0.2% {w/v} lauryl sulfate; 5 mM 
ethylenediaminetetraacetic acid {EDTA; pH 8.0}) containing 0.4 mg/mL Proteinase K and 
incubated at 55°C overnight to digest the tissue. The next morning the tubes were vortexed 
briefly and centrifuged at a 16000 g for 10 minutes in an Eppendorf Microcentrifuge to 
separate undigested tissue from the supernatant (containing gDNA). The supernatant was 
transferred into a clean labelled 1.8 mL tube and 1 mL of 100% (v/v) ethanol added to 
precipitate gDNA. The samples were centrifuged at 16000 g for 30 minutes to pellet the 
gDNA. The ethanol was discarded and pellet washed with 1 mL of 70% (v/v) ethanol. The 
samples were centrifuged at 16000 g for 20 minutes and the ethanol discarded. The gDNA 
pellets were dissolved in 300 μL of Trizma base-EDTA buffer (10 mM Trizma base-
hydrochloric acid and 1 mM EDTA, pH 7.5) and the samples placed in a 55°C heat block for 
2 hours with the lids open to evaporate residual ethanol. gDNA was then stored at 4qC until 
needed. 
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2.3.2 Determining DNA Concentration using Nanodrop Spectrophotometer 
gDNA was quantitated using the Nanodrop spectrophotometer as per manufacturer’s 
instructions. Prior to measuring DNA samples a blank measurement, using 2 μL PCR-grade 
deionised water, was initially performed to ensure the instrument was working well and 
remove any sample carryover from previous measurements. Each DNA sample (2 μL) was 
loaded onto the instrument and scanned in the range from 230 – 340 nm. The absorbance at 
260 nm is used to calculate the concentration of nucleic acids. For reliable spectrophotometric 
DNA quantification A260 readings should lie between 0.1 and 1.0. Phenol, protein and other 
contaminants absorb at 280 nm and can affect the readings at 260 nm. As such, the ratio of 
absorbance at 260 and 280 nm was used to assess the purity of the DNA. Uncontaminated 
nucleic acid preparations should have an A260/A280 ratio of 1.8.  Therefore, a ratio of ~1.8 
was accepted as “pure” for DNA. Lower A260/280 values indicated contamination by organic 
solvents, protein or salts and were re-purified by precipitation with ethanol. 
 
2.3.3 Polymerase Chain Reaction (PCR) 
gDNA was amplified using the primers and reagents listed in Tables 2.2 and 2.3. Expected 
amplicon sizes are also outlined in Tables 2.2 and 2.3 respectively.  All primers were bought 
from Sigma-Aldrich and 100-200ng gDNA was used. Each assay included gDNA samples 
with known genotypes as positive controls and a no template control (sterile water) to check 
for contamination of the reagents. PCR was performed in 25 μL volumes in PCR-strip tubes, 
in a DNA Engine Dyad or Tetrad thermal cycler (MJ Research, Bio-Rad, USA). The PCR 
program consisted of an initial denaturation at 95°C for 3 minutes (extended to 10 minutes for 
the HOT FirePol DNA Polymerase used for Cre genotyping), followed by cycling steps of 
denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds and extension at 72°C 
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for 1 minute. The 3 cycling steps were performed 40 times, followed by a final extension at 
72°C for 5 minutes and the tubes then cooled to 10 °C until removal from the thermal cycler. 
Amplicons were stored at 4°C until visualised by gel electrophoresis. 
 
 
Table 2.2: Primers and expected amplicon sizes for genotyping. 
Transgene Primer ID Sequence 5`-3` Expected size and genotype 
Cre Cre-1 ACCAGCCAGCTATCAACTCG 199 bp for Cre allele 
No band at 199 bp for 
WT allele  Cre-2 TTACATTGGTCCAGCCACC 
* IL-2-F CTAGGCCACAGAATTGAAAGATCT 324 bp Control band 
for both Cre allele 
and WT  IL-2-R GTAGGTGGAAATTCTAGCATCATCC 
T2/Onc2 T2B-F AACTCGTTTTTCAACTACTCCACA 165 bp band for 
transgene allele 
No band at 165 bp for 
WT allele  
 T2B-R CTGACCCACTGGAATTGTGA 
Sleeping 
Beauty 
Transposase 
RosaSB-3 AAGGAGCGAGGGCTCAGTTG 412 bp band for 
transgene allele 
(RosaSB-3+5) 
488 bp band for WT 
allele (RosaSB-3+4) 
 RosaSB-4 CGAGGCGGATCACAAGCAAT 
 RosaSB-5 GCCCAAGGCCATACAAGTGTTG 
*IL-2 primers are used as controls for amplification for Cre genotyping. 
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Table 2.3: PCR reagents. 
 
Master Mix 
component Cre T2/Onc2 Rosa26-LSL-SB11 Excision 
10xTop Taq PCR 
Buffer with MgCl2 
 1× 1× 1× 
10 x Coral load 
concentrate 
 1× 1× 1× 
5 x HOT Firepol 
Blend Master Mix 
Ready to load (12.5 
mM) 
1×   
 
dNTPs (Bioline) 200 μM 200 μM 200 μM 200 μM 
MgCl2 2.5 mM 1.5 mM 2.5 mM 2.5 mM 
Taq Polymerase 1 Unit* 1 Unit** 1 Unit** 1 Unit** 
Forward primer 1 Cre-1 (0.3 μM) T2B-F (0.6 μM) RosaSB-3 (0.5 μM) 
T2 excision –F 
(0.5 μM) 
Reverse primer 1 Cre-2 (0.3 μM) T2B-R (0.6 μM) RosaSB-4 (0.5 μM) 
T2 excision –R 
(0.5 μM) 
Forward primer 2 IL-2-F (0.3 μM)    
Reverse primer 2 IL-2-R (0.3 μM)  RosaSB-5 (0.5 μM)  
 
* = Hot Firepol DNA polymerase, ** = Qiagen Top Taq polymerase and MgCl2 = magnesium 
chloride. 
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2.3.4 Sleeping Beauty Excision PCR 
DNA was extracted from mouse splenic and thymic tissues using the method described in 
Section 2.3.1. The following primers were used to identify excision of the T2/Onc2 transgene, 
which provides efficacy of excision and confirmation of a SB transposition event:  
Forward:  5’- TGTGCTGCAAGGCGATTA-3’  
Reverse:  5’-ACCATGATTACGCCAAGC-3’.  
Excision of the T2/Onc2 transgene was visualised as an amplicon of 233 bp. The absence of 
the excision amplicon, or presence of the donor concatemer (2.4 kb) amplicon, denotes a lack 
of SB activation, which is expected in Cre-/WT mice. 
 
2.3.5 Gel Electrophoresis of Amplicons 
Amplicons were separated on a 2% (w/v) agarose gel prepared with 1× TAE electrophoresis 
buffer (40 mM Trizma base, 20 mM Acetic acid, 11 mM EDTA) and 1 x SYBR-Safe DNA 
dye. Amplicons (5-10 μL/lane) were loaded onto the gel next to a molecular weight marker 
(Hyperladder IV; 5 PL). Samples were electrophoresed in 1 × TAE electrophoresis buffer at 
120 volts for 20-40 minutes and bands were visualised in an ImageQuant LAS 4000.  
 
2.4 Histological Processing of Tissues 
Tissues (heart, lungs, spleen, liver, kidneys and thymus) were fixed in 10% (v/v) neutral 
buffered formalin overnight at 4qC. Fixed tissues were trimmed, placed into labelled 
histosettes and stored in 70% (v/v) ethanol until processed in an Excelsior AS tissue processor 
(see Table 2.1 for product details). Tissue processing was performed by the Kolling Histology 
Core Facility and involved dehydration through a series of graded ethanols (70% {v/v} 1 
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hour; 75% {v/v} 1 hour; 85% {v/v} 1 hour; 95% {v/v} 1 hour; 100 % {v/v} 3 changes of 1 
hour each) followed by clearing through 3 changes of chloroform (2 hours each), infiltration 
with paraffin wax (56qC, 2 changes, 1 hour each) and a final change of wax (2 hours). Excess 
paraffin wax was trimmed from embedded tissue blocks and 4 μm sections cut using a Leica 
rotary microtome (see Table 2.1 for product details) and floated on a water bath at 48°C. The 
sections were collected onto adhesive Superfrost™ Ultra Plus Adhesion Slides (see Table 2.1 
for product details) for Haematoxylin and Eosin (H AND E) staining and IHC microscope 
slides, FLEX, for immunohistochemical staining. Sections were dried at 60°C for 40 minutes 
in a fan forced slide drying oven. Sections were stored at room temperature until staining.   
 
 
2.5 Morphological Assessment 
For morphological assessment of tissues, sections were deparaffinised using 2 × 5 minute 
incubations in xylene and then rehydrated by immersing the sections though a series of graded 
alcohols (100%, 100%, 95% {v/v}, 70% {v/v} ethanol) for 3 minutes each (total 12 minutes), 
followed by rinsing the slides in running tap water for 30 seconds. 
 
 
2.5.1 May Grumwald Giemsa Staining for Haematological Assessment 
Blood smears were prepared from blood of WT and SBxTie2-Cre mice at time of euthanasia. 
Smears underwent May Grumwald Giemsa stain at PaLMS, Royal North Shore Hospital, St 
Leonards, in order to visualise leukocytes for differential counts. Microscopic assessments 
were performed by an independent assessor (Dr William Stevenson; Kolling Institute) and the 
PhD candidate. 
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2.5.2 Haematoxylin and Eosin (H and E) Staining for Histological 
Assessment 
For assessment of tissue morphology (heart, lungs, spleen, liver, kidneys and thymus), 1-2 
sections from each tissue were stained with H and E. Following deparaffinisation and 
rehydration, the sections were placed in running tap water for one minute and stained by 
immersion in Mayer’s Haematoxylin (0.1% {w/v} haematoxylin, 5% {w/v} ammonium, 
0.1% {w/v} citric acid, 5% {w/v} chloral hydrate, 0.02% {w/v} sodium iodate) for 5 minutes. 
Slides were washed under running tap water until all excess stain was removed, followed by 
immersion in Scott’s Blueing solution (2% {w/v} sodium bicarbonate, 0.34% {v/v} sulphuric 
acid) for 1 minute with agitation, and placed in running tap water for 1 minute. Slides were 
checked microscopically for the correct ratio of staining (blue, clearly defined nuclei with an 
almost clear background). If slides were under-stained, staining in Mayer’s Haematoxylin and 
Scott’s Blueing solution was repeated as above. If the slides were over-stained, they were 
immersed in acid alcohol (1% {v/v} of 100% hydrochloric acid in 70% {v/v} ethanol) to 
differentiate staining, followed by washing in running tap water for a few seconds before 
being immersed in Scott’s Blueing solution for 1 minute. The slides were immersed in Eosin 
solution (10 % {w/v} for 5 minutes with agitation followed by a quick rinse in running tap 
water. Stained slides were dehydrated using 100% ethanol for 10 seconds each after 4 
changes and finally 2 changes of xylene (20 seconds each). Sections were mounted using 
Eukitt quick-hardening mounting medium (1-2 drops per slide) and covered with a 22 × 50 
mm coverslip. Slides were lowered on to coverslips at an angle to prevent bubbles forming 
and were then left to dry in fume hood overnight to ensure complete polymerisation of 
mounting media. 
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2.6 Immunohistochemical Labelling 
Immunohistochemistry (IHC) was performed on deparaffinised and rehydrated tissue sections 
as described below. For the work described in this thesis the detection systems were biotin-
free and polymer based, either 1-step (Envision+) or 2-step (MACH 3).  
 
A. Heat-Induced Antigen Retrieval: Heat retrieval was performed using a DAKO Pascal 
pressure chamber. For each run, 2 sets of 20 slides were placed in slide racks in 2 Tissue Tek 
staining bucket with 200 mL target retrieval solution in each. The containers were placed in 
the pressure cooker with 500 mL distilled water and heated under pressure to 121ºC for 30 
seconds, then cooled to 90qC for 10 seconds. The containers were removed and the target 
retrieval solution slowly replaced with tap water to prevent thermal stress from breaking of 
the glass slides.  
 
B. Immunolabelling/Staining Method: The IHC performed in this thesis, utilised the 
automated staining platform (Autostainer Plus; DAKO) for immunohistochemial processing 
of the experimental sections. Once tagged with a bar code displaying a unique identification 
number the slides are positioned in the Autostainer and a pre-programmed set of parameters 
executed. All reagents including hydrogen peroxidase, primary and secondary antibodies and 
detection system solutions were loaded at the start of the run with procedures performed on 
the Autostainer. 
 
C.i.  1st Reagent – Hydrogen Peroxidase: After rehydration, using the Autostainer, slides 
were immersed in 0.3% (w/v) hydrogen peroxidase in water for 5 minutes to quench 
endogenous peroxidase activity and then washed with wash buffer 20X (diluted to 1X). 
 
C.ii. 2nd Reagent – Primary Antibodies: Properties of the primary antibodies used, and their 
isotype controls, are outlined in Table 2.4 (including name and function of the target protein 
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and antibody characteristics) and Table 2.5 (final concentrations and antigen retrieval). Using 
the Autostainer, the primary antibodies and their matched isotype controls were diluted with 
Antibody Diluent, REAL, and added to each slide (200 μL). The slides were incubated with 
the antibody for 1 hour at room temperature and then washed with wash buffer 20X (diluted 
to 1X). 
 
C.iii. 3rd Reagent – Secondary Antibodies: For primary antibodies raised in mouse and 
rabbit, 200 μL of the Envision+ detection reagent was added to each slide on the Autostainer 
and incubated for 30 minutes at room temperature. For primary antibodies raised in rat and 
goat, the 2-step MACH3 system (Biocare Medical) was used on the Autostainer. Firstly 200 
μL of anti-rat/goat M3 Probe was added to the slide and incubated for 15 minutes at room 
temperature. The probe was washed off with buffer, 200 μL of anti-rat/goat M3 Polymer 
applied and incubated for 15 minutes at room temperature. Reagents were washed off with 
wash buffer and then proceeded with detection of staining. 
 
C.iv. 4th Reagent – Detection System – ImmPACT NovaRED: The peroxidise substrate, 
ImmPACT NovaRED, was prepared according to the manufacturer’s instructions to yield 5 
mL of staining solution. Using the Autostainer, 200 μL of the ImmPACT NovaRED staining 
solution was added to each slide for 15 minutes at room temperature, and then washed with 
distilled water for 1 minute.  
 
D. Haematoxylin Counterstain for Tissue Morphology: Haematoxylin Counterstain for 
tissue morphology: Slides were counterstained using Mayer’s Haematoxylin, dehydrated and 
mounted as described above (section 2.5.1). Stained slides were imaged using a microscope 
(Olympus BX50).  
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Table 2.4: Details of antibodies used for immunohistochemistry. 
 
Antibody Alternative Name Species Catalogue 
Number 
Company 
IgG  Goat anti-mouse sc2028 Santa Cruz 
Biotechnology 
SB Anti-Sleeping Beauty 
Transposase  
Goat polyclonal 
anti-mouse 
AF2798 R&D Systems 
IgG2a  Rat anti-mouse 559073 BD 
Pharmingen 
CD45R B220, B cells Rat monoclonal 
anti-mouse 
550286 BD 
Pharmingen 
IgG  Rabbit anti-mouse Z0259 DAKO 
CD3 T cells, natural killer cells Rabbit polyclonal 
anti-mouse 
ab5690 Abcam 
MPO Myeloperoxidase Rabbit polyclonal 
anti-mouse 
ab9535 Abcam 
F4/80 EGF-like module-containing 
mucin-like hormone receptor-
like 1 (EMR1) 
Rabbit polyclonal 
anti-mouse 
sc-25830 Santa-Cruz 
CD31 Platelet / endothelial cell 
adhesion molecule (PECAM1) 
Rabbit polyclonal 
anti-mouse 
ab28364 Abcam 
LYVE-1 Lymphatic vessel endothelial 
hyaluronan receptor 1 
Rabbit polyclonal 
anti-mouse 
ab14917 Abcam 
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Table 2.5: Antibody conditions for immunohistochemistry. 
 
Antibody Mouse Tissue Concentration 
/ Dilution 
pH TRS Secondary 
SB Spleen 1 μg/mL 
1:200 
6 Goat MACH 3 Probe 
and Polymer 
SB Thymus 1 μg/mL 
1:200 
6 Goat MACH 3 Probe 
and Polymer 
SB Bone Marrow 2 μg/mL 
1:100 
6 Goat MACH 3 Probe 
and Polymer 
SB Heart 0.5 μg/mL 
1:400 
6 Goat MACH 3 Probe 
and Polymer 
CD3 Spleen 5 μg/mL 
1:100 
9 Envision+ System HRP 
Labelled Polymer Anti-
Rabbit solution 
CD45R Spleen 0.08 μg/mL 
1:400 
9 Rat MACH 3 Probe 
and Polymer 
MPO Spleen 2 μg/mL 
1:50 
9 Envision+ System HRP 
Labelled Polymer Anti-
Rabbit solution 
F4/80 Spleen 2 μg/mL 
1:50 
6 Envision+ System HRP 
Labelled Polymer Anti-
Rabbit solution 
CD31 Heart (used double 
concentration of sodium 
chloride in buffer to 
remove background 
staining) 
4 μg/mL 
1:200 
9 Envision+ System HRP 
Labelled Polymer Anti-
Rabbit solution 
LYVE-1 Heart (used double 
concentration of sodium 
chloride in buffer to 
remove background 
staining) 
4 μg/mL 
1:200 
9 Envision+ System HRP 
Labelled Polymer Anti-
Rabbit solution 
 
SB = Sleeping Beauty; TRS = target retrieval solution; HRP = horseradish peroxidase; MPO 
= myeloperoxidase and LYVE-1 = lymphatic vessel endothelial hyaluronan receptor 1. 
 
 
                                                                                              Chapter 2: Materials and Methods 
 125 
 
 
 
2.7 Statistical Analyses 
As each SBxTie2-Cre mouse is mutated differently to other SBxTie2-Cre mice (differences in 
degree of: mutagenesis, phenotypes and age), the SBxTie2-Cre mice were generally not 
assessed as a group but rather compared with control mice for which the results were 
expressed as mean + standard deviation (SD) or mean + standard error of mean (SEM) or 
mean + range as indicated in text and / or figure legends. Data were analysed using GraphPad 
Prism version 5.0 (GraphPad Software). Assessment of statistical significance of differences 
was performed by Mann-Whitney T-Tests or One-way ANOVA (Kruskal-Wallis Test) along 
with survival curves and indicated in figure legends. P values <0.05 were considered 
statistically significant or otherwise specified.  
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3.1 Introduction 
This chapter focused on the characterisation of mice with activation of SB mutagenesis 
restricted to the endothelium (SBxTie2-Cre). Mutating the endothelium was of interest in this 
thesis as while the contribution of neovascularisation in cancer is well documented, the 
molecular drivers that mediate the enhanced angiogenesis and the altered phenotypic 
characteristics of tumour vessel are far from fully characterised. The majority of the studies in 
this field have been “passive” reports, investigating retrospectively the molecular makeup of 
normal and pathological endothelium. To increase understanding of the endothelium in 
cancer, for this thesis an “active” or “forward” approach was taken by mutating the 
endothelium in vivo and characterising the resulting phenotype.  
 
3.1.1 The Endothelium 
ECs are important regulators of vascular homeostasis, as they communicate with circulating 
cells and also interact with mural cells of the vascular wall, such as smooth muscle cells 
(Michiels 2003). The physiological roles of the endothelium include: controlling blood 
clotting, helping the body's immune response, controlling the volume of fluid and the quantity 
of materials passing from the blood into the tissues, and generating dilation or constriction of 
the blood vessels (Rajendran, Rengarajan et al. 2013). Despite exhibiting a number of 
common functional and morphological phenotypes, a unique, and often underappreciated 
characteristic of the endothelium is the remarkable heterogeneity it represents. Organ-specific 
mediators encountered by the endothelium promote formation of continuous, fenestrated and 
discontinuous capillaries (See Figure 1.1) with different molecular characteristics. Even 
within the same organ, the endothelium of large and small vessels, veins, and arteries exhibit 
significant heterogeneity. Moreover, laminar blood flow versus (vs) turbulent flow (such as 
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experienced at points of vascular branching) changes the signatures of the endothelium 
greatly. Thus, despite being only one cell thick, the endothelium is far from being the “one-
dimensional” organ it appears to be. 
 
ECs border blood and tissue and are frequently predisposed to alterations in blood 
composition and flow. They immediately react to all these modifications and disruption of 
these functions can change the endothelium from anti-thrombotic, anti-inflammatory, and 
vasodilative tissue to one disposed to coagulation, inflammation and vasoconstriction 
(Michiels 2003). Such endothelial dysfunction plays a significant part in the pathogenesis of 
vascular disorders (Michiels 2003) including the cardiovascular diseases: stroke (which can 
cause damage to the blood brain barrier), hypertension, coronary artery disease, chronic heart 
failure, peripheral vascular disease, and also diabetes, chronic kidney failure, and severe viral 
infections (described in detail in Chapter 1, Section 1.2). 
 
To the author’s knowledge, there are no reports targeting SB mutagenesis exclusively to the 
endothelium. A potential outcome of mutating ECs is the generation of endothelial tumours, 
such as endotheliomas and angiosarcomas. These are extremely rare, reflecting the inherently 
stable genetic landscape of this cell type. It is currently unclear whether mutation of 
endothelial cell DNA using transposon-based approaches will initiate tumorigenesis, perturb 
the angiogenic potential of the endothelium or alter vascular reactivity to precipitate disease 
in mice (Rajendran, Rengarajan et al. 2013). However, the endothelium has been extensive 
targeted using genetic manipulation over the last 30 years and this has revealed multiple 
insights into disease. 
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3.1.2 Genetic Targeting to the Endothelium 
The size of the endothelium, the specialised functions it mediates and the inter-organ 
heterogeneity makes it a difficult organ to target. Moreover, an important and still 
incompletely solved question relates to what pathways of EC differentiation are active in 
different vascular beds. Given the heterogeneity of the endothelium several promoters have 
been assessed for endothelial specific activity both in in vitro (transient transfection) assays 
and in vivo transgenic mouse studies (Table 3.1).  
 
The most common transgene promoters are based on genes heavily implicated in the unique 
phenotypes of the endothelium, such as intercellular adhesion molecules (VE-cadherin) and 
growth factor receptors involved with angiogenesis (KDR/Flk1, Tie-1, ALK1), transcription 
factors directing endothelial specification in the embryo (Mef2c, SCL/TAL-1, c-mp1) and 
vascular homeostasis (eNOS, PPET1, vWF) (Table 3.1). These promoters have advantages 
and disadvantages regarding endothelial specificity.  
 
Not surprisingly, the c-mpl, SCL, Tie-1 and Mef-2c promoters (when driving enzymatic 
reporter constructs) have problems with sustained activation in the mouse post-partum given 
their role in endothelial specification in the embryo is no longer required (Table 3.1). 
Additionally, promoters like the KRD/Flk1 and some Tie-1 variants, are expressed poorly in 
aged mice vs young mice indicating that while promoter activity is sustained it ceases at some 
point after development is finished (Table 3.1).  
 
Other promoters (such as those for ALK1, Tie-1 and eNOS) have problems with uniform 
expression across all vascular beds with arterial and large vessel expression dominating the 
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pattern of reporter activation (Table 3.1). Some of these “silencing” events are likely the 
result of epigenetic silencing of the promoter (Ohtani, Vlachojannis et al. 2011). Moreover, 
some vascular beds (especially the blood brain barrier) have unique specialisations, such as 
enhanced intercellular junctions, pronounced cellular polarisation and low pinocytotic 
activity. As such, they may acquire specific markers but also lose, or express to a low degree, 
molecules that are otherwise present in other types of endothelium. As a consequence some 
promoters display organ specific preferences for the vasculature including the VE-cadherin 
and vWF promoters.  In addition to the promoters mentioned above (and in Table 3.1) there 
have been a number of inducible promoters adapted for targeting the endothelium, see 
Appendix 6 (Table A12) for discussion of the advantages/disadvantages of these.  
 
 
For the present study, the promoter used to drive SB activation was required to be: endothelial 
specific, active in mice cross a variety of ages, present in all organs and vascular beds at all 
levels (capacitance vessels, resistance vessels and capillaries). As all of the promoters listed in 
Table 3.1 could not meet one or more of these requirements, another well-characterised 
promoter, Tie2, was sought to perform these studies (Dumont, Yamaguchi et al. 1992, 
Schnurch and Risau 1993). 
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Table 3.1: Characteristics of endothelial-targeting constitutive promoters in transgenic mice. 
 
Gene Promoter Reporter 
Gene 
Expression in ECs Expression in 
Non-ECs 
Reference 
ALK1 9.2kb LacZ Arterial – in adults   (Seki, Hong et al. 2004) 
c-mp1 2kb Human 
placental 
alkaline 
phosphatase 
Some ECs in yolk sac; none in adult Megakaryocytes (Ziegler, Burki et al. 2002) 
eNOS 5.2kb LacZ ECs of large and medium blood vessels in 
various tissues  
Brain (Teichert, Miller et al. 
2000) 
EPCR -1080 to -1, -350 to -
1 
GFP Expression of ECs in various adult tissues, 
though cell type not described 
 (Gu, Fukudome et al. 
2000) 
KDR/Flk1 939bp promoter + 
510bp first intron 
fragment 
 
1640 - + 299 and 
510bp intronic 
enhancer 
 
4.5kb + 510bp 
intronic enhancer 
LacZ 
 
 
 
LacZ 
 
 
 
Luciferase 
Expression in most ECs, but lost with age 
 
 
WT promoter directs uniform expression 
in ECs of embryo 
 
 
Most tissues decreased expression with age 
 (Kappel, Ronicke et al. 
1999) 
 
 
(Wu, Moser et al. 2003) 
 
 
 
(Zhang, Fang et al. 2004) 
Mef2c 4.66kb LacZ Uniform expression of ECs in embryo; 
sporadic expression in adult 
Some circulating 
blood cells 
(De Val, Anderson et al. 
2004) 
PPET1  5.9kb Luc More expression of ECs of arteries and 
arterioles than in veins and capillaries 
VSMCs and 
certain epithelial 
cells 
(Harats, Kurihara et al. 
1995) 
SCL/TAL-1 5.5kb LaCZ Embryonic endothelium Blood cells (Sanchez, Gottgens et al. 
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ALK1 = activin receptor-like kinase 1; ECs = endothelial cells; bp = base pairs; kb = kilobase; mpl = myeloproliferative leukaemia; eNOS = endothelial 
nitric oxide synthase; EPCR = endothelial protein C receptor; GFP = green fluorescent protein; KDR = kinase insert domain receptor; Mef2c = 
myocyte enhancer factor 2c; PPET1 = pre-pro-endothelin; SCL/TAL-1 = stem cell leukaemia/T-cell acute lymphoblastic leukaemia 1; VSMCs = 
vascular smooth muscle cells; and vWF = von Willebrand factor. 
1999) 
Tie-1 0.74kb 
 
 
1.15kb 
 
 
 
0.54kb 
 
 
0.8kb 
 
 
 
1.1kb 
 
0.8kb 
LacZ 
 
 
Cre 
 
 
 
LacZ 
 
 
LacZ 
 
 
 
eGFP 
 
Growth 
hormone 
ECs in arterial segments at vascular 
junctions 
 
Sporadic expression of ECs in embryo 
 
 
 
Expression of ECs mainly in arterioles and 
capillaries in adult mice 
 
Expression of ECs throughout vasculature 
of embryo up to E11.5; reduced expression 
in adult 
 
 
 (Porat, Grunewald et al. 
2004) 
 
(Gustafsson, Brakebusch 
et al. 2001) 
 
(Boutet, Quertermous et 
al. 2001) 
 
(Korhonen, Lahtinen et al. 
1995) 
 
 
 
(Iljin, Petrova et al. 2002) 
 
(Iljin, Petrova et al. 2002) 
VE-
cadherin 
12486 to +24 CAT Expression of ECs in all vascular beds 
except brain capillaries in adult 
 (Gory, Vernet et al. 1999) 
vWF -2645 and the end of 
the first intron 
LacZ Expression of ECs in blood vessels in 
brain; micro-vessels in heart and skeletal 
muscle in adult 
 (Guan, Guillot et al. 1999) 
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3.1.3 Evolution of the Tie2-Cre Promoter / Enhancer 
A family of receptor tyrosine kinase genes specifically expressed in the mammalian 
endothelial lineage was cloned and characterised in the early 1990’s (Dumont, Yamaguchi et 
al. 1992, Partanen, Armstrong et al. 1992, Dumont, Gradwohl et al. 1993, Iwama, Hamaguchi 
et al. 1993, Maisonpierre, Goldfarb et al. 1993, Millauer, Wizigmann-Voos et al. 1993, 
Quinn, Peters et al. 1993, Sato, Qin et al. 1993, Schnurch and Risau 1993, Yamaguchi, 
Dumont et al. 1993, Ziegler, Bird et al. 1993). One of these genes includes the endothelial 
tyrosine receptor kinase, Tie2 (Tek), which was found to be exclusively expressed in the 
endothelial cell lineage, including endothelial precursors. Amongst all the available 
endothelial cell specific promoters the Tie2 promoters have undergone the most evolution as 
an endothelial-specific promoter. 
 
The first reported version of the vascular endothelial cell lineage-specific Tie-2 promoter 
consisted of a 1.2kb promoter. When this promoter was used to drive reporter expression 
transgenic mice showed sporadic LacZ expression in ECs in the embryo and lack of 
expression in all vessels except the liver sinusoids post-partum (Schlaeger, Qin et al. 1995). 
Expression was also lost under angiogenic stimuli. While there was no evidence of LacZ 
expression in haematopoietic lineage throughout embryonic development the promoter also 
targeted subsets of visceral mesenchymal cells, suggesting that these cells could be of the 
endothelial lineage (Schlaeger, Qin et al. 1995). It was unknown at the time whether these 
mesenchymal cells could be putative stem cells for the EC lineage (Sabin 1917, McClure 
1921, Murray 1932). However, it is clear that the 1.2kb Tie2 promoter used in this transgenic 
was unable to replicate the endogenous expression patterns in the mouse and that additional 
sequences were required for uniform expression of LacZ reporter gene in ECs of transgenic 
mice.  
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Table 3.2: Tie2 promoter analysis in transgenic mice. Italics = promoter used in this thesis. 
 
Promoter Reporter 
Gene 
Expression in ECs Expression 
in Non-ECs 
Reference 
1.2kb LacZ Sporadic EC expression in 
embryo, absent in adult 
 (Schlaeger, Qin 
et al. 1995) 
2.1kb promoter + 
1.7kb intron 1 
 
LacZ 
 
EC expression in embryos 
 
 (Schlaeger, 
Bartunkova et 
al. 1997) 
 
2.1kb promoter + 
10kb intron 1 
LacZ Uniform expression of 
ECs in embryo and adult 
 (Schlaeger, 
Bartunkova et 
al. 1997) 
2kb promoter + 
1.6kb intron 1 
GFP Uniform expression of 
ECs in embryos 
 (Motoike, 
Loughna et al. 
2000) 
2.1kb promoter + 
10kb intron 1 
Cre Bred with CAG-CAT-Z or 
R26R transgenic mice; 
expression of ECs in 
mesenchymal cells of 
antrioventricular canal 
(only embryos analysed) 
 (Kisanuki, 
Hammer et al. 
2001) 
 
2.1kb promoter + 
10kb intron 1 
Cre Uniform expression of 
ECs in embryo and adult 
 (Koni, Joshi et 
al. 2001) 
2.1kb promoter + 
10.5kb intron 1 
Cre Ubiquitous expression of 
ECs adult 
HSCs. (Constien, 
Forde et al. 
2001) 
2.1kb promoter + 
1.7kb intron 1 
t-TA 
 
In binary system (Tie-2-
tTA+TRE-βGal); near 
uniform expression of ECs 
in endothelium in adult 
 
 (Teng, Dichiara 
et al. 2002) 
 
0.72kb fragment 
containing 300bp 
intronic enhancer 
couples upstream 
to a 423bp core 
promoter 
LacZ Widespread expression of 
ECs in adult 
 (Minami, 
Kuivenhoven et 
al. 2003) 
2.1kb promoter + 
10kb intron 1 
Cre Widespread expression of 
ECs in embryo and adult 
HSCs (Tang, 
Harrington et 
al. 2010) 
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To identify the missing elements from the Tie2 promoter, another report also by Schaegler et 
al. undertook a comprehensive study to elucidate the transcription factors and/or genetic 
elements required for uniform EC expression (Schlaeger, Bartunkova et al. 1997). This 
second report discovered that the 2.1kb promoter in combination with a 10kb fragment from 
the first intron displayed uniform and EC-specific gene expression in both embryo and adult 
mice in vivo (Schlaeger, Bartunkova et al. 1997). The inclusion of the intronic fragment 
suppressed integration site dependency of LacZ expression and also protected the Tie2 
promoter from being ectopically activated. Schaegler et al. studied various intron fragments 
that suggest several transcriptional regulators present in the 10kb intronic fragment and 
determined the Ets-1 site was essential for promoter activity (Schlaeger, Bartunkova et al. 
1997).  
 
Subsequent reports using the same (2.1 + 10kb) promoter / enhancer combination validated 
Tie2 as an endothelial specific reporter of significant merit (Constien, Forde et al. 2001) 
(Kisanuki, Hammer et al. 2001). Eight independent Tie2-Cre lines were established and 
expression patterns assessed by LacZ / E-galactosidase staining following crosses with CAG-
CAT-Z (Araki, Araki et al. 1995) or R26R (Soriano 1999) transgenic mice. LacZ staining was 
first observed at E7.5 in the extra-embryonic mesoderm of the visceral yolk sac. At E8.5, 
positive staining was evident in the majority of endothelial cells in the blood islands, a portion 
of endothelial cells in the aorta and common atrial chamber, and no haematopoietic cells. By 
E9.5 LacZ staining was apparent in almost all endothelial and endocardial cells. These data 
indicate that the Tie2 promoter / enhancer regions used in the study accurately drove Cre 
transgene expression in a pan-endothelial-specific manner (Kisanuki, Hammer et al. 2001). 
The Tie2-Cre transgene designed by Kisanuki et al. comprised the 2.1 kb Tie2 promoter, 
(derived from pg50H1-2, Schlaeger et al., 1997), a 2.7 kb fragment of Cre cDNA with a 
metallothionein-1 (MT-1) polyA signal sequence, and the 10 kb intron 1 Tie2 enhancer 
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sequence (derived from pg50-2.11) (Schlaeger, Bartunkova et al. 1997). Indeed, some of the 
independent lines had weak staining reiterating the importance of integration-site on 
expression. The majority of lines, including the Tie2-Cre line B6.Cg-Tg(Tek-cre)1Ywa/J 
utilised for the present study (created using the Kisanuki construct), now include the 10kb 
region of intron 1 as an enhancer. Lines using the 10 kb enhancer have more uniform 
endothelial expression during embryogenesis and adulthood and B6.Cg-Tg(Tek-cre)1Ywa/J is 
the most widely used endothelial Cre line (Chen, Zhang et al. 2016). 
 
However, these latter studies also identified some “off target” expression. Certainly, variable 
and promiscuous expression remain issues for a number of lines using this Tie2 promotor. 
Kisanuki et al. showed strong LacZ staining in the mesenchymal cells of the atrio-ventricular 
canal in the Tie2-Cre embryos suggesting an endocardial origin for these cells which are now 
known to express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 
surface molecules (Kisanuki, Hammer et al. 2001, Dominici, Le Blanc et al. 2006). Moreover, 
rare circulating cells were positive for LacZ. As no haematopoietic cells were positive at any 
embryonic time-point, these were considered to be endothelial precursors but they may also 
represent endothelial cells that had detached from the vessel wall (Kisanuki, Hammer et al. 
2001).   
 
Despite consistent results in documenting the endothelial–specific nature of the (2.1 + 10kb) 
Tie2 promoter / enhancer it has been the identification of circulating cells that caused the 
biggest controversy and have been the most variable phenotype reported. A study by Constien 
and colleagues showed, in independent transgenic lines of Tie2-Cre mice, that LacZ 
expression was found in ECs and CD4/CD8 positive T-cells (Constien, Forde et al. 2001). 
This is in direct contrast to the original observations (Schlaeger, Bartunkova et al. 1997) yet 
the mice were created using the same (2.1kb + 10kb) promoter / enhancer combination. It was 
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found that second generation crosses of this Tie2-Cre and floxed lines resulted in progeny 
with germline Cre expression in one allele and endothelial-restricted Cre expression in the 
other allele. Another report also showed that 86% of CD45+ cells in mouse bone marrow 
were positive for the YFP reporter gene when using this promoter / enhancer construct (Tang, 
Harrington et al. 2010). However, when Tie2 expression was assessed by flow cytometry in 
bone marrow cells, only 2% were positive suggesting unlinking of Cre expression and Tie2 
expression. The controversy has yet to be solved but both these studies used the Tie2-Cre 
promoter / enhancer to drive reporter expression and may reflect more dysregulated Cre 
activity than aberrant promoter activation. A little known, but confounding, feature of the 
Kisanuki / Masashi Yanagisawa B6.Cg-Tg(Tek-cre)1Ywa/J (Tie2-Cre) line is that Cre is 
activated in the germline of the female Tie2-Cre mice (Ashton; unpublished data). For 
endothelial-exclusive expression, breeding strategies must only use male Tie2-Cre mice; 
using females will result in germline expression of Cre (Ashton; unpublished data). This effect 
was alluded to but not correctly resolved by Costien et al., and also affects the alternate 
commerically available Tie2-Cre mouse (B6.Cg-Tg(Tek-cre)12Flv/J) (Koni, Joshi et al. 
2001). Incorrect breeding strategies generate mice with ubiquitous Cre expression leading to 
the perception that this promoter has both endothelial and extra-endothelial activity.  
 
Other variants of the Tie2 promoter / enhancer have also been used to make transgenic mice.  
A shorter fragment of the Tie-2 gene was created by joining the 300-bp intronic enhancer to 
the 5′ end of the core promoter, which led to widespread expression in the endothelium 
(Minami, Kuivenhoven et al. 2003). Compared with the larger promoter, this short 723-bp 
fragment of the Tie-2 promoter was more active in the heart and less active in the lung 
(Minami, Kuivenhoven et al. 2003). An internal 1.7kb fragment of the 10 kb intronic 
enhancer was also identified as an autonomous EC-specific transcriptional enhancer that 
worked both in vitro and in vivo (Schlaeger, Bartunkova et al. 1997). The (2.1kb + 1.7kb) 
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Tie2 promoter / enhancer was sufficient to attain robust endothelial expression in both the 
adult and during embryonic development (Teng, Dichiara et al. 2002). Moreover, Motoike et 
al. compared the (2.1kb + 1.7kb) Tie2 promoter / enhancer to a (2kb + 1.6kb) element with 
similar expression in ECs in multiple lines of Tie2 transgenic mice (Schlaeger, Bartunkova et 
al. 1997, Motoike, Loughna et al. 2000). However, reporter activity of the (2.1kb + 1.7kb) 
Tie2 promoter / enhancer decreased over time in the animals that were backcrossed (Teng, 
Dichiara et al. 2002) and comparison of the (2.1kb + 10kb) and (2.1kb + 1.7kb) Tie2 promoter 
/ enhancer constructs indicated the latter displays increased sensitivity, a strong integration-
site-dependency and ectopic activation (Schlaeger, Bartunkova et al. 1997). Thus, the (2.1kb 
+ 1.7kb) Tie2 promoter / enhancer was less specific due to the broad spectrum of expression, 
although this could be due to increased integration-site-dependency. 
 
The Tie2 promoter has evolved extensively over the last 25 years; however, this evolution has 
produced a promoter among the most efficient for selective, directed expression of exogenous 
genes to the majority of ECs in vivo across a variety of ages, in all organs and vascular beds 
(Table 3.2) (Dumont, Yamaguchi et al. 1992, Schnurch and Risau 1993). Therefore the 
transgenic model described by Kisanuki et al (B6.Cg-Tg(Tek-cre)1Ywa/J) was chosen for the 
present study as it allows specific expression in ECs and the enhancer component of the Tie2 
promoter allows for continuous expression throughout adulthood, as it is unknown how long 
Sleeping Beauty will continue to operate, and when a developmental phenotype may be 
observed (Kisanuki, Hammer et al. 2001). 
 
3.1.4 Aim 
In this study, endothelial-specific SB activation was accomplished using the angiopoietin 
receptor (Tie-2) promoter / enhancer sequences to drive Cre-recombinase expression. Random 
mutagenesis of the endothelium was activated in mice that carry the Cre allele as well as the 
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SB transgenes (binary SBxTie2-Cre mice). The aim of this chapter was to determine and 
characterise the phenotype of SBxTie2-Cre mice. Littermates without the Cre allele were 
utilised as healthy controls. 
 
3.2 Methods 
For details about general methodologies pertaining to: animal models (Chapter 2, Section 2.2), 
genotyping methods (see Section 2.3); histological processing of tissues (see Section 2.4); 
morphological assessment using H and E staining, and May Grumwald Giemsa staining (see 
Section 2.5); and IHC (see Section 2.6), see the Sections indicated. For reagent and antibody 
details, see Table 2.1. 
 
3.2.1 Collection of Tissues 
During terminal anaesthesia of mice, the spleen, heart, liver, kidneys, lungs, thymus and 
femurs were excised and divided for histology, genetic studies and, or flow cytometry. Blood 
was collected by cardiac puncture into EDTA containing tubes (see Section 3.2.3). For 
histology, tissues were collected into specimen jars containing 10% (v/v) neutral buffered 
formalin for fixation overnight then transferred to 70% (v/v) ethanol. Prior to excision, the 
lungs were perfused by inserting a 23-gauge needle with a 3 mL syringe filled with neutral 
buffered formalin into the trachea for 45 seconds. The mass of each tissue was recorded, 
bisected longitudinally and placed into tissue processing cassettes and stored at room 
temperature in 70% (v/v) ethanol until needed for preparation for histological processing (see 
Section 2.4). For vessel density studies, heart was collected from a subset of mice at 11 weeks 
of age (see Section 3.2.5). For genetic studies (Chapter 5), approximately 1/3 of the spleen, 
liver and thymus were snap-frozen in liquid nitrogen. For flow cytometry, approximately 1/3 
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of spleen and bone marrow (flushed from femurs) was collected in 1 x phosphate-buffered 
saline with 2% (v/v) foetal bovine serum.  
 
3.2.2 Processing Blood in Coulter Counter 
At euthanasia, blood was collected via cardiac puncture (using a 1 mL syringe and 23-gauge 
needle) prior to removal of the heart. A small amount was used for 2 blood smears on glass 
slides (see Chapter 2, Table 2.1) and the remainder placed in EDTA blood collection tubes. 
EDTA anti-coagulated mouse blood was assessed using an automated differential particle 
counter (Coulter Counter, Beckman Coulter, see Table 2.1 for product details). This 
instrument allows the analysis of whole blood by measuring the concentration and counting 
different types of blood cells. This is achieved using electrical impedance to measure the 
volume of cells as they cross an opening of defined width and diameter. The tube was placed 
in the instrument, which automatically extracts and processes the blood, giving information 
on haemoglobin and counts for red blood cells, white blood cells (as a whole), lymphocytes, 
monocytes, granulocytes and platelets. 
 
3.2.3 Histopathological Assessment of Organs From WT and SBxTie2-Cre Mice 
Images of H and E stained spleens; livers; thymii, lungs, kidneys and hearts (10X and 40X 
magnification) were taken and scored manually (see Section 2.5.1 for complete H AND E 
staining method). Sections from SBxTie2-Cre mice were categorised as ‘SB Mild’ or ‘SB 
High’ by the degree of similarity they had to equivalent tissues from age-matched WT mice 
(normal growth and development). ‘SB Mild’ classification referred to animals with tissue 
architecture ranging from normal to mild pathological changes affecting < 30% of the cells. 
‘SB High’ nomenclature denotes presence of fulminant disease associated with moderate to 
complete loss of tissue architecture for each tissue examined (spleen, liver, thymus, lungs, 
heart and kidneys) affecting < 30% of the cells. A veterinary pathologist (Dr Rolfe Howlett; 
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Department of Pathology, University of New South Wales (UNSW)), performed 
histopathological assessment on a subset of tissues to validate the scorings by the PhD 
candidate and supervisors. 
 
3.2.4 Scoring Immunohistochemistry (IHC) 
IHC for CD45R, CD3, MPO and F4/80 (antigens which denote B-cells, T-cells, myeloid cells 
(mostly neutrophils) and macrophages) was performed on spleen tissue from a subset of 
SBxTie2-Cre and WT mice and the expression levels compared. “Mild” was defined as 
expression comparable to WT. “Low” was defined as expression at least 30% lower than WT 
and “high” as expression at least 30% higher than WT. Scoring was performed by the PhD 
candidate and supervisors.  
 
H and E staining of SBxTie2-Cre kidneys were scored to quantify leukocytic infiltration: 1+ = 
similar to WT (no infiltration of leukocytes, <10%); 2+ = little infiltration of leukocytes (10-
20%), 3+ = medium infiltration of leukocytes (20-40%) and 4+ = heavy infiltration of 
leukocytes (>40%). Scoring was performed by the PhD candidate 
 
Immunohistochemical staining was also performed for vessel density using CD31 and LYVE-
1 (lymphatic vessel endothelial hyaluronan receptor). The ImageJ software assisted in 
calculating vessel density following CD31 and LYVE-1 IHC of heart tissue. Overlapping 
images (20x magnification) were taken of consecutive areas across the sections to provide 
assessment of the entire heart, the background nuclear staining was removed, and then the 
images were loaded onto ImageJ for pixel counts (VectoRed staining denoting CD31+ and 
LYVE-1+ vessel). Results were exported to GraphPad Prism for statistical analysis.  
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3.2.5 Flow Cytometry Analysis in WT and SBxTie2-Cre Mice 
Flow cytometry cell staining and data acquisition were performed on splenic and bone marrow 
cells of WT and SBxTie2-Cre mice as described (Kim, Wiesner et al. 2007). Bone marrow 
cells were flushed from the femurs with 1 × ice-cold phosphate-buffered saline with 2% (v/v) 
foetal bovine serum with 5 mL syringe and 21G × 1½ needle, and washed with 1 × phosphate-
buffered saline with 2% (v/v) foetal bovine serum and centrifuged for 5 minutes at 500 g at 
4qC. Single-cell suspensions from spleen were prepared by grinding tissues with the back of a 
5 mL syringe in a 6-well plate and filtered with 70 μm cell strainers. Red blood cells (RBC) 
were lysed by suspending each pelleted cells in 1 mL RBC lysing buffer (contains 8.3 g/L 
ammonium chloride in 10 m M Tris-hydrochloric acid buffer) for 5 minutes. Nucleated cells 
were washed once in 2% (v/v) foetal bovine serum in 1 x phosphate-buffered saline. Cells from 
bone marrow and spleen were counted first by loading 10-20 μL onto a haemocytometer and   
1 × 107 cells/mL were stained with fluorochrome-conjugated antibodies (Table 3.3) and 
incubated at room temperature for 40 minutes, washed with 2% (v/v) foetal bovine serum in 1 
× phosphate-buffered saline and pelleted by centrifugation for 5 minutes at 500 g at 4qC. 
 
Table 3.3: Anti-mouse antibodies used for flow cytometry. 
Antibody Catalogue 
Number 
Manufacturer Details Conjugation Amount per 
Sample 
CD3 100204 BioLegend, Australian Biosearch, 
Karrinyup, WA, Australia 
FITC 5 μL 
CD4 100408 BioLegend PE 10 μL 
CD8 100708 BioLegend PE 10 μL 
CD14 12-0141 eBioscience, Jomar Bioscience, 
Kensington, SA, Australia 
FITC 10 μL 
CD19 12-0913 eBioscience  PE 5 μL 
FITC = fluorescein isothiocyanate and PE = phycoerythrin. 
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After centrifugation, cells were resuspended in 1 × phosphate-buffered saline with 2% (v/v) 
foetal bovine serum and 1% (w/v) paraformaldehyde and stored at 4 qC overnight and 
analysed the next day. All procedures were performed on ice or a centrifuge pre-chilled to 
4°C and protected from light. Flow cytometric data acquisition and analysis were performed 
on BD FACSCalibur with CellQuest software. Dead cell exclusion was performed using gates 
based on the forward and side scatter to remove debris and dead cells. The splenic and bone 
marrow flow cytometry data were analysed using total percentage numbers for CD3, CD14 
and CD19 to reflect mixed populations of cells; and also restrictions to the leukocyte subset 
for CD4 and CD8.  
 
3.2.6 Statistical Analyses 
The Frequency Distribution method was used to identify the nature of the data sets 
(parametric or non-parametric). Non-parametric Pearson’s and parametric Spearman’s 
correlations were used for normally distributed and skewed data, respectively. When data 
were a mixture of both parametric and non-parametric values, then parametric Spearman’s 
method was used. In order to assess the correlation between different variables, the Pearson’s 
and Spearman’s correlation coefficients (r and rs) were used. Pearson’s correlation coefficient 
(r) is a measure of the linear correlation between two parametric variables: X and Y. 
Spearman’s correlation coefficient (rs) is a statistical measure of the strength of a monotonic 
(non-linear) relationship between paired data (de Siqueira Santos, Takahashi et al. 2014). A 
monotonic function is one that either increases or decreases as its independent variable 
increases. In a simple statistic, it is interpreted as: -1 <  r / rs > 1. The closer r/rs is to +1, the 
stronger the monotonic relationship. Correlation is an effect size and can be described using a 
guide for the value of r/rs (Hinkle DE 2003, Mukaka 2012):  
- 0.00-0.30 = insignificant correlation 
- 0.30 to 0.50 (-0.30 to -0.50) = low positive (negative) correlation 
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- 0.50 to 0.70 (-0.50 to -0.70) = moderate positive (negative) correlation 
- 0.70 to 0.90 (-0.70 to -0.90) = high positive (negative) correlation 
- 0.90 to 1.0 (-0.90 to -1.0) = very high positive (negative) correlation 
For other statistical analyses in this chapter, see Chapter 2, Section 2.7. 
As mentioned in Chapter 2, Section 2.7, each SBxTie2-Cre mouse is mutated differently to 
other SBxTie2-Cre mice (differences in degree of: mutagenesis, phenotypes and age), the 
SBxTie2-Cre mice were generally not assessed as a group but rather compared with control 
mice (WT), hence why the SBxTie2-Cre data do not include a Mean + SD or Mean + SEM. 
 
3.3 Results 
3.3.1 Genotyping to Identify SBxTie2-Cre Mice 
Progeny from homozygous SB female mice and hemizygous male Tie-2-Cre mice (Section 
2.2) were genotyped for the Cre allele (Section 2.5). PCR for the IL-2 gene was used as a 
control for the gDNA isolations to ensure the integrity of the isolation was sufficient for PCR. 
A representative image of the Cre genotyping is shown in Figure 3.1. Mice were born in a 
ratio that reflected expected patterns of Mendelian inheritance (47% Cre+ {SBxTie2-Cre}) vs 
53% Cre- mice (controls, designated as wild type, WT) (n = 89). These data show that 
approximately half of the progeny have the desired endothelial-specific SB activation to 
enable “forward” investigation of the genes that regulate angiogenesis. 
 
Figure 3.1: Genotyping for the Cre allele. Amplicons for the Cre genotyping PCR were 
separated on a 2% (w/v) agarose gel using TAE electrophoresis. The primers for Cre (199bp 
band) were multiplexed with those for IL-2 (300 bp band), as a control for DNA quality. M: 
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molecular weight marker; 1-14: DNA samples from 14 mice; N: no template negative PCR 
control. DNA samples 1, 4, 6, 7, 9, and 13 do not carry the Cre allele (WT) and while samples 
2, 3, 5, 8, 10-12, and 14 were positive for the Cre transgene (SBxTie2-Cre). 
 
 
3.3.2 SB Immunostaining in Heart Tissues 
SB immunostaining (Section 2.6, Figure 3.2) of myocardium revealed that SB Transposase 
expression was restricted to the endothelial cells in coronary blood vessels in SBxTie2-Cre 
mice (brown staining, Figure 3.2C). No other cells in the myocardium of SBxTie2-Cre mice 
showed staining and staining was absent in WT mice (Figure 3.2B).  
 
 
 
Figure 3.2: Representative images of SB immunostaining in heart tissue. (A); Isotype 
control (IgG) (A) showed no positive staining. IHC for protein expression of SB transposase 
was performed on hearts of 8-10 week old WT (B) and SBxTie2-Cre (C) mice. Positive 
(brown) nuclear staining was observed in the endothelium SBxTie2-Cre mice but absent in 
WT vessels. Scale bar = 100 μm. All histology images taken by PhD candidate. 
 
 
 
                                                                    Chapter 3: Characterisation of SBxTie2-Cre Mice 
 147 
 
3.3.3 Survival and Growth of SBxTie2-Cre Mice 
The health and growth of SBxTie2-Cre mice (n=147) and their WT (n=89) littermates were 
monitored for one year. Over the course of the study no morbidity (as determined by ethically 
defined signs for endpoints described in Section 2.2.3) or mortality was observed in WT mice 
(Figure 3.3). Conversely, 100% of SBxTie2-Cre mice became ill and had to be euthanised 
during this time period (Figure 3.3A). Female (Figure 3.3B) and male (Figure 3.3C) mice 
succumbed to disease at a similar rate (T-Test, P = 0.858). After 100 days, 97% of SBxTie2-
Cre mice had become moribund. The remaining ~5% of male mice survived to ~350 days 
(Figure 3.3B and C). SBxTie2-Cre mice also tended to weigh less than WT mice at the same 
age (Figure 3.4). When assessed over time, the rates of growth for WT and SBxTie2-Cre mice 
were: 4 and 3 g/month in males and 2 and 1 g/month in females respectively. Overall, at 
death, median age of SBxTie2-Cre mice = 79 days and range = 34 – 351 days; male SBxTie2-
Cre mice = 64 days and range = 35 – 351 days; and median age of female SBxTie-2xCre mice 
= 82 days and range = 34 – 100 days (Figure 3.4C). Erythroderma (abnormal redness of the 
skin due to inflammation) was also observed in a subset (8%) of SBxTie2-Cre mice.  
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Figure 3.3: Survival of WT and SBxTie2-Cre mice over 350 days. (A) SBxTie2-Cre mice 
became ill and were euthanised between 35 and 530 days of age. (B) SBxTie2-Cre mice 
succumb to disease between 35 and 530 days of age in males (n=116) and (C) between 35 and 
100 in females (n=31).  WT (n=89);  SBxTie2-Cre (n=147). 
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Figure 3.4: Body weights of WT and SBxTie2-Cre mice. (A) Weight of WT and SBxTie2-
Cre mice females and males in relationship to age. Median body weight of WT mice = 27.8g 
and range = 21.3-37.7g. Median body weight of SBxTie-2xCre mice = 21.2g and range = 
12.6-30.23g. Black lines represent trend lines. (B) Body weights at euthanasia of WT and 
SBxTie2-Cre mice, and also shown in relation to sex (C). Bars represent mean ± SD for WT 
and SBxTie2-Cre mice. * Indicates P = 0.0294, and ***P = 0.0001 vs WT by T-Test (Mann-
Whitney). Median body weight of female WT mice = 24.9g and range = 23-32g. Median 
body weight of SBxTie-2-Cre mice = 16.4g and range = 12.6-18.5g. Median body weight of 
male WT mice = 27.99g and range = 21.3-37.7g. Median body weight of SBxTie-2xCre mice 
= 22.59g and range = 14.89-30.23g. 
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3.3.4 Examination of the Endothelium  
Necropsies were performed on all animals to identify endothelial changes associated with 
early morbidity. Initially, macroscopic examination for endothelial tumours 
(haemangiosarcomas) and other solid tumours was performed. None were observed. The heart 
is highly vascular and central to the circulatory system. As such, it was the perfect candidate 
in which to assess changes to the endothelium in SBxTie2-Cre mice. Heart weights and 
vascular density were determined and compared as the basis of this analysis.  
 
3.3.4.1 Heart Weights Comparison between WT and SBxTie2-Cre Mice 
SBxTie2-Cre mice were lighter in weight compared to WT littermates. To normalise for this 
weights of the heart and other organs were expressed as a percentage relative to the body 
weight of the individual mouse. This also accounted for the different ages at which the mice 
became ill and were euthanised.  
 
The normalised mean (± SD) heart weight in SBxTie2-Cre mice was 0.45r0.08 % body 
weight and significantly heavier than WT hearts (0.42r0.07 %) (Figure 3.5A). Normalised 
weights were similar in female (0.40r0.06 %) and male (0.42r0.08 %) WT mice (Figure 
3.5B). While in SBxTie2-Cre mice, relative heart weights were greater in female (0.46r0.07 
%) than male (0.44r0.09 %) mice and female SBxTie2-Cre mice had significantly heavier 
hearts than female WT mice.  Enlarged hearts are often the beginning of heart failure, which 
can be caused by endothelial dysfunction and compromised neovascularisation of the heart 
(Marti, Gheorghiade et al. 2012). To see if this was the case, vascular density was examined 
in the hearts of WT and SBxTie2-Cre mice. 
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Figure 3.5: Macroscopic characteristics of hearts in WT and SBxTie2-Cre mice. (A) 
Heart weights from WT (¡) and SBxTie2-Cre () mice are presented as percentage of total 
body weight (graphed in Log2 scale). (B) Normalised heart weight for WT ( and ) and 
SBxTie2-Cre (z and ) mice was stratified by gender. Mean + SD shown for WT mice. * 
Indicates P = 0.039 and P = 0.0228 respectively vs WT by T-Test (Mann-Whitney).  
WT SBxTie2-CRE
2-3
2-2
2-1
20
21
22
(B) **
(N=55) (N=101)
%
 B
od
y W
eig
ht
 fo
r L
un
gs
WT SBxTie2-CRE
2-3
2-2
2-1
20
(A)
*
(N=55) (N=101)
%
 B
od
y W
eig
ht
 fo
r H
ea
rt
2-3
2-2
2-1
20
21
22
MaleFemale
***
***(C)
(N=11) (N=22) (N=44) (N=79)
%
 B
od
y W
eig
ht
 fo
r L
un
gs
2-3
2-2
2-1
20
MaleFemale
*
(B)
(N=11) (N=22) (N=44) (N=79)
%
 B
od
y W
eig
ht
 fo
r H
ea
rt
WT SBxTie2-CRE
2-3
2-2
2-1
20
21
22
(B) **
(N=55) (N=101)
%
 B
od
y W
eig
ht
 fo
r L
un
gs
WT SBxTie2-CRE
2-3
2-2
2-1
20
(A)
*
(N=55) (N=101)
%
 B
od
y 
W
eig
ht
 fo
r H
ea
rt
2-3
2-2
2-1
20
21
22
MaleFemale
***
***(C)
(N=11) (N=22) (N=44) (N=79)
%
 B
od
y 
W
eig
ht
 fo
r L
un
gs
2-3
2-2
2-1
20
MaleFemale
*
(B)
(N=11) (N=22) (N=44) (N=79)
%
 B
od
y 
W
eig
ht
 fo
r H
ea
rt
                                                                    Chapter 3: Characterisation of SBxTie2-Cre Mice 
 152 
 
3.3.4.2 Assessment of Vessel Density in the Heart 
Vessel density was assessed on a subset of mice euthanised at 11 weeks of age specifically for 
this analysis. Vessels were visualised by immunohistochemical staining and quantified by 
pixel counts using ImageJ (represented as average pixel counts per mouse) (Figure 3.6). 
Immunohistchemical staining was performed with antibodies against the pan endothelial cell 
marker CD31 (Figure 3.6B). As CD31 labels both vascular and lymphatic endothelial cells 
immunohistchemical labelling for lymphatic endothelial marker LYVE-1 (hyaluronan 
receptor) was performed on consecutive sections to distinguish vascular and lymphatic 
vessels (Figure 3.6C).  
 
The procedure for quantifying vessel density using ImageJ (Figure 3.6) included thresholding 
the entire image to remove nuclear staining (which would otherwise be included in the pixel 
counts) (background subtraction; Figures 3.7B and C). Vessel density for both CD31 and 
LYVE-1 was determined for the entire cross-section of the heart for each mouse. Raw pixel 
counts (Figures 3.7B and C) and percentage body weights for heart are listed in Appendices 
(Tables A1 and A2). 
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Figure 3.6: Objective criteria for analysis of CD31 and LYVE-1 heart sections using 
ImageJ software. (A) Negative control (IgG2a). Scale bar = 200 μm. Method of analysis of 
CD31 (B) and LYVE-1 (C) stained WT and SBxTie2-Cre hearts with: original representative 
image taken of stained heart; image with nuclear background removed and measurement of 
pixel count (red) respectively. WT mouse #244: CD31 average raw pixel count =70,574 and 
LYVE-1 average raw pixel count = 30,376. SBxTie2-Cre mouse #231: CD31 average raw 
pixel count = 239,347 and LYVE-1 average raw pixel count = 58,951. Scale bar = 100 μm.  
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The ranges of values for vessel density in SBxTie2-Cre mice were greater than WT mice for 
both CD31 (average 239,347 pixels vs 70,574 pixels) and LYVE-1 (average 58,951 pixels vs 
30,376 pixels) (Figure 3.7A and B). This was due to a proportion of SBxTie2-Cre mice (26 % 
for CD31 and 7 % for LYVE-1) having markedly increased densities, although this reached 
significance only with CD31 (Figure 3.7A).  
 
To determine if perturbations in vasculature played a role in altered heart size, vessel density 
was expressed against normalised heart weight for each mouse (Figure 3.7C and D). To gauge 
alterations in heart weight and vessel density, “normal” was defined as < 2 SD from the mean, 
and “abnormal” as > 2 SD from the mean (Figure 3.7C and D) of WT mice. No correlations 
were found for either WT or SBxTie2-Cre mice (Table 3.4). For CD31 staining, the majority 
of SBxTie2-Cre mice had normal heart weight and vessel density (16/39); however, in many 
SBxTie2-Cre mice this relationship was perturbed and mice with normal vessel density had 
both significantly larger (5/39) or smaller (3/39) hearts. In addition, a large cohort of mice 
showed increased vessel density but normal heart weight (14/39) with one mouse having an 
enlarged heart with increased vessel density. These results generally support a perturbation of 
both tissue size and vascularity in SBxTie2-Cre mice (Figure 3.7C).  
 
There were also significant perturbations in the LYVE-1 stained lymphatic system (Figure 
3.7D). Normal lymphatic density and heart weight were observed in only 40% (10/28) of 
SBxTie2-Cre mice. Normal hearts with enhanced (3/28) and diminished (5/28) lymphatic 
counts were also observed. Large hearts with normal (3/28), diminished (1/28) and elevated 
(2/28) lymphatic density were recorded as were small hearts with normal lymphatic density 
(2/28). There was, however, a similar correlation between lymphatic (LYVE-1) and vascular 
(CD31) densities noted for WT (rs = 0.5147 and P = 0.0413) and SBxTie2-Cre mice (rs = 
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0.5082, P = 0.0095) (Figure 3.7E) (Table 3.4) suggesting that the vascular / lymphatic 
relationship did not change and that both systems were affected by the SB-mediated 
mutagenesis. These results demonstrate that SB-mediated mutagenesis altered the 
characteristics of the vasculature in some of the SBxTie2-Cre mice; however, the altered 
behaviours of the endothelium did not adequately explain the early lethality observed in 
SBxTie2-Cre mice. 
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Figure 3.7: Analysis of vessel density in WT and SBxTie2-Cre mice. (A) Average vessel 
densities of CD31 and (B) LYVE-1 in WT (; n = 22, 17) and SBxTie2-Cre mice ( n = 39, 
28) respectively. ** Indicates P = 0.005 vs WT by T-Test (Mann-Whitney). (C) Percentage 
body weight for heart vs. vessel density of CD31 in WT (; n = 22) and SBxTie2-Cre (; 
n=39) mice. (D) Percentage body weight for heart vs. vessel density of LYVE-1 in WT and 
SBxTie2-Cre mice. (; n = 17) and SBxTie2-Cre (; n = 28) mice. Black lines represent 2 
SD from mean of WT vessel density and green lines represent 2 SD from mean of WT heart 
weight. (E) CD31 vessel density vs. LYVE-1 vessel density in WT and SBxTie2-Cre mice. 
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Table 3.4: Correlation statistics for vessel density in WT and SBxTie2-Cre mice. 
 
 
# of 
XY 
Pairs 
Spearm
an r 
95% 
Confidence 
Intervals 
P value 
(two-
tailed) 
P value 
summary 
Exact or 
Approximate 
P value? 
Correlation 
significant? 
(alpha = 
0.05) 
CD31: 
       WT Heart 
VD Vs 
%BW 22 0.08978 
-0.3566 to 
0.5028 0.6911 ns 
Gaussian 
Approximation No 
SB Heart 
VD Vs 
%BW 39 -0.1812 
-0.4774 to 
0.1520 0.2697 ns 
Gaussian 
Approximation No 
LYVE-1: 
       WT Heart 
VD Vs 
%BW 17 -0.2132 
-0.6387 to 
0.3121 0.4112 ns 
Gaussian 
Approximation No 
SB Heart 
VD Vs 
%BW 28 -0.2228 
-0.5583 to 
0.1752 0.2544 ns 
Gaussian 
Approximation No 
CD31 Vs 
LYVE-1: 
       
WT 16 0.5147 
0.009305 
to 0.8106 0.0413 * 
Gaussian 
Approximation Yes 
SB 25 0.5082 
0.1292 to 
0.7576 0.0095 ** 
Gaussian 
Approximation Yes 
 
# = Number, VD = vessel density, %BW = percentage relative to body weight, ns = not 
significant and */** = significance. 
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3.3.5 Pathological Phenotype of SBxTie2-Cre Mice  
During necropsy, no definitive endothelial-specific causes of the lethality (endothelial or other 
solid tumours and no oedema) were discovered, and assessment of other tissues was 
performed. Significant splenomegaly, hepatomegaly, enlarged thymii and lungs with 
increased weight were detected in > 50% of SBxTie2-Cre mice. A summary of the organ-
related phenotypes is shown in Table 3.5 and the findings for individual mice are detailed in 
Table 3.6. Tables A3 and A4 (see Appendices) contain raw data of body and organ weights of 
WT and SBxTie2-Cre mice.  
 
Table 3.5: Summary of the organ phenotypes in SBxTie2-Cre mice based on mice with 
complete data (n=40).  
 
Phenotype Number Percentage (%) 
4 14 35 
3 15 37.5 
2 8 20 
1 3 7.5 
0 0 0 
 
Phenotypes = enlarged spleen, enlarged liver, enlarged thymus and enlarged lungs. 4 = 4 
phenotypes present, 3 = 3 phenotypes present, 2= 2 phenotypes present, 1 = 1 phenotype 
present, and 0 = 0 phenotype present.  
 
 
Histopathological changes accompanied the observed organ enlargement. Loss of normal 
tissue architecture was a common finding and ranged from normal to mild changes (‘SB 
Mild’), or moderate to complete loss (‘SB High’) as detailed in section 3.2.4. In the main, the 
SB high phenotype was associated with the largest increases in organ weight. The results for 
different organs are described below. 
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Table 3.6: Penetrance of phenotype in SBxTie2-Cre mice.  
 
Mouse  
ID 
×
Spleen
Spleen 
%BW 
×  
Liver
Liver 
%BW 
×
Thymus
Thymus 
%BW 
×
Lungs
Lungs 
%BW 
2362 ✔ 12.37 ✔ 16.51 ✔ 0.68 ✔ 1.72 
2365 ✔ 8.45 ✔ 14.98 ✔ 0.57 ✔ 2.76 
2366 ✔ 3.26 ✔ 22.05 ✔ 1.28 ✔ 2.44 
2367 ✔ 6.77 ✔ 8.16 ✔ 0.37 ✔ 2.46 
2368 ✔ 5.8 ✔ 13.22 ✔ 1.29 ✔ 2.09 
2376 ✔ 5.05 ✔ 8.36 ✔ 3.43 ✔ 1.64 
2379 ✔ 4.06 ✔ 11.38 ✔ 0.59 ✔ 1.39 
2383 ✔ 3.84 ✔ 9.54 ✔ 1.03 ✔ 1.28 
2386 ✔ 3.48 ✔ 9.41 ✔ 1.96 ✔ 1.41 
2420 ✔ 1.28 ✔ 6.22 ✔ 4.13 ✔ 1.53 
2422 ✔ 4.55 ✔ 15.61 ✔ 3.51 ✔ 1.46 
2334 ✔ 2.62 ✔ 9.8 ✔ 3.08 ✔ 1.07 
2524 ✔ 3.88 ✔ 7.66 ✔ 0.56 ✔ 1.68 
2361 ✔ 8.51 ✔ 14.87   0.15 ✔ 1.31 
2374 ✔ 4.95 ✔ 15.87   0.04 ✔ 1.1 
2387 ✔ 4.2 ✔ 8.51   0.16 ✔ 1.12 
2425 ✔ 3.84 ✔ 11.01 ✔ 0.96   0.78 
2424 ✔ 1.06   3.32 ✔ 0.36 ✔ 1.34 
2364 ✔ 1.16   5.42 ✔ 6.16 ✔ 1.58 
2427 ✔ 2.29   5.35 ✔ 1.62 ✔ 1.11 
197 ✔ 3.57 ✔ 16.64   N/A ✔ 1.41 
2518 ✔ 3.82 ✔ 12.65   0.04 ✔ 1.34 
2523 ✔ 4.62 ✔ 7.43   0.03 ✔ 1.74 
2340 ✔ 4 ✔ 9.35 ✔ 1   0.56 
2396 ✔ 4.91 ✔ 13.63 ✔ 3.45   0.6 
2401 ✔ 4.15 ✔ 8.29 ✔ 1.19   0.24 
2522 ✔ 5.51 ✔ 9 ✔ 0.69   0.81 
2519 ✔ 1.87   5.22 ✔ 4.53 ✔ 2.54 
2517 ✔ 2   4.93 ✔ 0.4 ✔ 1.69 
2421 ✔ 6.09 ✔ 10.67   0.11   1.03 
158 ✔ 8.12 ✔ 20.7   N/A   0.69 
184 ✔ 4.65 ✔ 11.81   N/A   0.73 
198 ✔ 4.52 ✔ 19.5   N/A   0.92 
203 ✔ 3.71 ✔ 6.28   N/A   0.73 
2345 ✔ 5.21 ✔ 12.44   N/A   0.94 
2354 ✔ 3.51 ✔ 8.28   N/A   0.87 
2402 ✔ 6.61 ✔ 12.02   0.27   0.59 
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2403 ✔ 4.03 ✔ 7.12   0.09   0.78 
2525 ✔ 3.48 ✔ 10.33   0.06   0.42 
2406 ✔ 1.11   4.45 ✔ 4.3   1 
2520 ✔ 2.43   4.98 ✔ 0.62   0.51 
2526 ✔ 0.88   3.42 ✔ 3.65   0.63 
245 ✔ 2.87   3.65   N/A ✔ 1.34 
247 ✔ 2.18   4.71   N/A ✔ 1.33 
2399 ✔ 3.97   6.08   N/A ✔ 1.11 
2393   0.69   4.16 ✔ 4.33 ✔ 1.44 
2372 ✔ 2.12   4.72   0.3   0.78 
2378 ✔ 3.01   5.03   N/A   0.97 
143 ✔ 1.03   2.65   N/A   0.87 
179 ✔ 3.84   0.95   N/A   0.56 
296 ✔ 1.26   3.88   N/A   0.82 
2389 ✔ 1.04   3.43   0.31   0.91 
2395   0.6   3.16 ✔ 2.6   0.82 
132   0.36   5.59   N/A ✔ 1.45 
256   0.33   3.24   N/A   0.96 
315   0.26   3.46   N/A   0.27 
 
×= enlarged. For liver and spleen: blue = male (n=35) and red = female (n=22). For 
thymus: Blue = male (n=19) and red = female (n=21). A tick indicates the presence of the 
phenotype, and no entry indicates that the phenotype was normal. N/A = not available. WT 
male (n=20 for thymus, n=21 for other organs) WT female (n=11), WT spleens: mean (as a 
percentage relative to body weight; %BW) = 0.42, range = 0.14-0.74; WT livers: mean = 
3.91, range = 2.88-6.09; WT thymus: mean = 0.12, range = 0.02-0.34; WT lungs: mean = 
0.77, range = 0.49-1.59. Organ weights were expressed as a percentage relative to the body 
weight of the individual mouse in order to normalise for the different ages at which the mice 
became sick and were euthanised. 
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3.3.5.1 Spleen 
Splenomegaly was detected in ~70% of all SBxTie2-Cre mice in comparison to WT 
littermates (Figure 3.8A). The average spleen weight in WT mice was 0.32r0.17 % body 
weight. This was significantly different between female (0.51r0.20 %) and male (0.28r0.13 
%) WT mice. The overall splenic weight difference between WT and SBxTie2-Cre mice was 
7.9-fold – 2.53r2.30 % body weight (Figure 3.8B). This difference displayed a gender bias 
with 4.62r2.71 % and 1.95r1.81 and body weight in female and male SBxTie2-Cre mice 
respectively (Figure 3.8C). 
 
    
 
Figure 3.8: Macroscopic characteristics of the spleen in WT and SBxTie2-Cre mice. (A) 
Representative macroscopic images of spleen from WT (i) and SBxTie2-Cre (ii) mice. Scale 
bar = 1cm. (B) Spleen weights from WT or SBxTie2-Cre mice and in relation to gender (C) 
are presented as a percentage relative to the total body weight (graphed in Log2 scale). Mean 
+ SD shown for WT mice and SBxTie2-Cre mice. *** Indicates P = 0.0009 (WT female vs 
WT male) and 0.0001 vs WT by T-Test (Mann-Whitney). All photos taken by the author. 
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Normal splenic architecture (Figure 3.9) was evident in all WT mice with well-defined areas 
of white pulp intermingled with comparable amounts of red pulp (Figure 3.10 A and D). A 
range in the severity of loss of normal splenic architecture was also noted. The majority 
(84%) of SBxTie2-Cre mice were classified into the ‘SB High’ group, which demonstrated 
complete ablation of splenic structure with integration of cellular populations into a 
homogenous mass (Figure 3.10C and F). The ‘SB Mild’ group maintained some distinction 
between red and white pulp but the average size of white pulp was larger and less well 
delineated from the red pulp (Figure 3.10B and E). This enlargement of the splenic white pulp 
could be reminiscent of either lymphoid hyperplasia, or lymphomas and other 
lymphoproliferative disorders including lymphocytic leukaemia. 
 
 
 
Figure 3.9: Schematic drawing of a section of normal mouse spleen. All figures generated 
by the author unless otherwise stated. 
                                                                    Chapter 3: Characterisation of SBxTie2-Cre Mice 
 165 
 
 
 
WT    SB (Mild)   SB (High) 
 
 
Figure 3.10: H and E staining of WT and SBxTie2-Cre spleens. Representative images are 
shown at two different magnifications. In the top panels, bar represents 200 μm and in the 
bottom panels, the bar represents 50 μm. (A,D) WT, (B,E) SB Mild (C,F) SB High. R = red 
pulp and W = white pulp. 
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3.3.5.2 Liver 
 
Significant hepatomegaly was detected in ~60% of all SBxTie2-Cre mice but not in any WT 
littermates (Figure 3.11). The average liver weight in WT mice was 3.83r0.53 % body weight 
(Figure 3.11B) and this was not significantly different between female (4.00r0.51 %) and 
male (3.80r0.54 %) WT mice (Figure 3.11C). In SBxTie2-Cre mice the overall liver weight 
difference between WT mice was 1.8-fold – 7.08r4.48 % body weight (Figure 3.11B). Again 
this difference in WT and SBxTie2-Cre mice displayed a gender bias with 10.63r4.79 and 
6.10r3.87 % body weight in female and male SBxTie2-Cre mice respectively (Figure 3.11C).   
 
 
 
 
 
 
Figure 3.11: Macroscopic characteristics of the liver in WT and SBxTie2-Cre mice. (A) 
Representative macroscopic images of liver from WT (i) and SBxTie2-Cre (ii) mice. Scale 
bar = 1cm. (B) Liver weights from WT or SBxTie2-Cre mice and in relation to gender (C) are 
presented as a percentage relative to the total body weight (graphed in Log2 scale). Mean + 
SD shown for WT mice and SBxTie2-Cre mice. *** Indicates P = 0.0001 vs WT and 
SBxTie2-Cre mice by T-Test (Mann-Whitney). 
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Normal liver architecture (Figure 3.12, Figure 3.13A and D) including a radial arrangement of 
liver parenchyma with a central portal tract and clear sinusoidal spaces was evident in all WT 
mice.  
 
 
Figure 3.12: Schematic of the histological structure of the mouse hepatic lobule. 
 
 
Normal to mildly altered architecture was observed in 23% of SBxTie2-Cre mice, and these 
were classified as ‘SB Mild’ (Figure 3.13B and E). Moderate to complete loss of this 
architecture was observed in 77% of SBxTie2-Cre mice, and these were classified as ‘SB 
High’ (Figure 3.13C and F). ‘SB High’ livers often displayed diffuse thinning of the liver 
parenchyma combined with extensive leukocytic infiltrate into the sinusoidal spaces. The 
remaining hepatocytes were mostly atrophic and the radial pattern of the hepatic parenchyma 
lost suggesting that infiltration of leucocytes into the hepatic parenchyma ultimately resulted 
in liver failure.  
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WT    SB (Mild)   SB (High) 
 
 
Figure 3.13: H and E staining of WT and SBxTie2-Cre livers. Representative images are 
shown at two different magnifications. In the top panels, bar represents 200 μm and in the 
bottom panels, the bar represents 50 μm. (A,D) WT, (B,E) SB Mild (C,F) SB High. 
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3.3.5.3 Thymus 
Enlarged thymii were observed in 75% of SBxTie2-Cre (Figure 3.14A). The average thymus 
weight in WT mice was 0.12r0.07 % body weight (Figure 3.14B). This was not significantly 
different between male (0.12r0.08 %) and female (0.12r0.05 %) WT mice (Figure 3.14C). In 
SBxTie2-Cre mice the overall thymic weight difference between WT mice was 13.7-fold – 
1.64r01.75 % body weight (Figure 3.14B); however, unlike the spleen and liver there was no 
gender bias in the weight difference between the two groups of mice (1.64r01.70 % and 
1.63r01.84 % - male and female respectively) (Figure 3.14C). 
 
 
 
 
Figure 3.14: Macroscopic characteristics of the thymus in WT and SBxTie2-Cre mice. 
(A) Representative macroscopic images of thymus from WT (i) and SBxTie2-Cre (ii) mice. 
Scale bar = 1cm. (B) Thymus weights from WT or SBxTie2-Cre mice and in relation to 
gender (C) are presented as a percentage relative to the total body weight (graphed in Log2 
scale). Mean + SD shown for WT mice and SBxTie2-Cre mice. *** Indicates P = 0.001, P = 
0.005, and P = 0.003 vs WT respectively by T-Test (Mann-Whitney). 
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The normal thymus is composed of two regions: the outer cortex and the inner medulla 
(Figure 3.15, Figure 3.16A and D). The cortex is densely populated by pre-T lymphocytes (or 
thymocytes while in the thymus), and the medulla is comprised of few, but fully mature, T 
lymphocytes. From the stem cells are derived pre-T cells that migrate from the cortex to the 
medulla, where they become functional CD4 and CD8 cells. Typical thymic architecture, with 
a normal medulla and cortex, was evident in 20% of SBxTie2-Cre mice (Figure 3.16B and E). 
The remaining 80% of SBxTie2-Cre mice were classified as ‘SB High’ with complete loss of 
normal thymic architecture with atypical hyperplasia resulting in loss of the normal cortico-
medullary demarcation. (Figure 3.16C and F). This is inverse of the normal histological 
picture, where the cortex has a higher cellular density than the medulla is indicative of thymic 
lymphomas or leukaemias.  
 
 
 
 
Figure 3.15: Schematic diagram of normal cross-section of mouse thymus. 
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WT    SB (Mild)   SB (High) 
 
 
Figure 3.16: H and E staining of WT and SBxTie2-Cre thymii. Representative images are 
shown at two different magnifications. In the top panels, bar represents 200 μm and in the 
bottom panels, the bar represents 50 μm. (A,D) WT, (B,E) SB Mild (C,F) SB High. C = 
cortex; M = medulla. 
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3.3.5.4 Lungs 
Heavy lungs were observed in 11% of SBxTie2-Cre (Figure 3.17A).  The average lung weight 
in WT mice was 0.76r0.22 % body weight (Figure 3.17B) and was the same in female 
(0.83r0.23 %) and male (0.75r0.21 %) WT mice (Figure 3.17C). In SBxTie2-Cre mice the 
weight of the lungs was increased 1.2-fold (1.01r0.51 % body weight), relative to WT mice 
(Figure 3.17B). Again, these differences were discordant between SBxTie2-Cre female and 
male (1.49r0.53 and 0.88r0.42, respectively) mice. 
 
  
Figure 3.17: Macroscopic characteristics of the lungs in WT and SBxTie2-Cre mice. (A) 
Representative macroscopic images of lungs from WT (i) and SBxTie2-Cre (ii) mice. Scale 
bar = 1cm. (B) Lungs weights from WT or SBxTie2-Cre mice and in relation to gender (C) 
are presented as a percentage relative to the total body weight (graphed in Log2 scale). Mean 
+ SD shown for WT mice and SBxTie2-Cre mice. ** Indicates P = 0.0008. *** Indicates P = 
0.0005 and P = 0.0001 vs WT respectively by T-Test (Mann-Whitney). 
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WT mice displayed normal pulmonary structures (Figure 3.18, Figure 3.19A and D). Alveolar 
spaces were clear and free of proteinaceous fluid. Alveoli were thin with little indication of 
deterioration. Normal to near normal lung architecture was also observed in 47% of SBxTie2-
Cre mice, (Figure 3.19B and E). In the remaining 53% of SBxTie2-Cre mice (‘SB High’), 
alveolar wall thickening was observed with overall smaller alveolar spaces; however, no 
proteinaceous accumulation was observed (Figure 3.19C and F). The bronchial tree was 
unobstructed and the vasculature well formed into tight bundles arteriovenous structures.  The 
alveolar space was occupied by infiltrating mononuclear cells and aggregates of mononuclear 
cells were observed (Figure 3.19C and F). These changes may have compromised gas 
exchange resulting in poor oxygenation of blood, leading to apparent respiratory distress. All 
of the SBxTie2-Cre mice had laboured breathing at euthanasia independent of the age of the 
mice suggesting this change was part of the lethal phenotype. 
 
 
Figure 3.18: Schematic diagram of normal cross-section of mouse lung. 
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WT    SB (Mild)   SB (High) 
 
 
Figure 3.19: H and E staining of WT and SBxTie2-Cre lungs. Representative images are 
shown at two different magnifications. In the top panels, bar represents 200 μm and in the 
bottom panels, the bar represents 50 μm. (A,D) WT, (B,E) SB Mild (C,F) SB High. 
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3.3.5.5 Heart 
For completeness, in addition to heart weights and vessel density (detailed in Section 3.3.4), 
other morphological features were also assessed in the heart. Significant differences in 
percentage body weight were observed between WT and SBxTie2-Cre mice hearts (Figure 
3.5A). We had documented changes in vascular density in a proportion of hearts so we 
assessed the general morphology as well. WT mice displayed normal myocardial structure 
(Figure 3.20; Figure 3.21 A and D). The myocardium was of uniform appearance with tightly 
interwoven syncytium of cardiac myocytes and stromal support cells (such as fibroblasts) 
with evenly distributed blood vessels throughout. Histological but not gross morphological 
changes were observed in the hearts of SBxTie2-Cre mice in comparison to WT mice (Figure 
3.21E and F). In 91% of SB-Tie2-Cre mice, the hearts showed similar features to WT mice 
with no lesions of significance (Figure 3.21E) and were classified as “SB Mild”. However, 
9% of SBxTie2-Cre mice (classified as “SB High”) showed cardiac hypertrophy with a sheath 
of mononuclear cells in the epicardium (characteristic of lymphoid aggregation) and 
basophilic debris scattered through the myocardium. This could be a result from anaemia, 
which is intrinsic to leukaemia (Paplanus, Zbar et al. 1958).  
 
Figure 3.20: Schematic diagram of normal cross-section of mouse heart. 
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   WT    SB (Mild)      SB (High) 
 
Figure 3.21: H and E staining of WT and SBxTie2-Cre hearts. Representative images are 
shown at two different magnifications. In the top panels, bar represents 200 μm and in the 
bottom panels, the bar represents 50 μm. (A,D) WT, (B,E) SB Mild (C,F) SB High. EP = 
epicardium, MC = myocardium and EN = endocardium. 
 
H and E staining of mouse heart showed no oedema, and therefore no baseline change to 
vascular permeability. To thoroughly assess permeability, the mouse B16-F10 melanoma 
allograft model was used (which have been shown to have increased permeability) and 
stained for albumin (see Appendix 9). However, no significant differences were seen between 
WT and SBxTie2-Cre mice and thus, mutating the endothelium does not affect vascular 
permeability (see Appendix 9, Tables A16-17). Thus, the WT and SBxTie2-Cre melanoma 
tumours were of the same size, and the plasma leakage were also the same suggesting minor 
changes to the basal endothelial phenotype by SB-mediated mutagenesis. 
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3.3.5.6 Kidneys 
No significant differences in kidney weights between WT and SBxTie2-Cre mice (Figure 
3.22). The average kidney weight in WT mice was 1.19r0.14 % body weight (left and right 
kidneys weighed separately, Figure 3.22A) and was the same in female (1.15r0.06 %) and 
male (1.20r0.15 %) WT mice (Figure 3.22B). In SBxTie2-Cre mice the weight of the kidneys 
was similar (1.24r0.51 % body weight) to WT mice (Figure 3.22B). These similarities were 
observed between SBxTie2-Cre female and male (1.19r0.42 and 1.25r0.53, respectively) 
mice. 
 
 
 
Figure 3.22: Macroscopic characteristics of kidneys in WT and SBxTie2-Cre mice. (A) 
Weight of kidneys from WT or SBxTie2-Cre mice are presented as a percentage of total body 
weight (graphed in Log2 scale). T-Test (Mann-Whitney). Mean + SD shown for WT mice and 
SBxTie2-Cre mice. 
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Figure 3.23 represents schematic drawing of normal kidney. Normal kidney has three 
functional zones, the cortex, medulla and pelvis. The cortex contains the glomerulus (tightly 
coiled network of anastomosing capillaries and podocytes) proximal and distal collecting 
tubules. The medulla is a mixture of the loop of Henle and the collecting ducts, which filter 
down into the renal pyramids and ultimately into the pelvis.   
 
 
 
Figure 3.23: Schematic drawing of normal mouse kidney. 
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WT mice displayed normal structure (Figure 3.24A) with classical glomeruli (with intact 
basement membranes; Figure 3.24D), medullary rays and renal pyramids (Figure 3.24G). In 
66% of SBxTie2-Cre mice, the kidneys demonstrated normal structures of the cortex, 
medullar and pelvis with tightly packed tubules and normal looking glomeruli (Figure 3.24B, 
E and H). In 34% of SBxTie2-Cre mice, kidneys displayed large amounts of inflammation 
with swollen glomeruli and collecting tubules with compromised lumens, and were classified 
as ‘SB High’ (Figure 3.24C, F and I). These kidneys also showed large sub-capsular 
aggregates of lymphocytic cells with occasional foci of lymphocytic cells in the renal cortex. 
The medulla displayed a very thick band of malignant cells (mononuclear monomorphic cells) 
enclosing the kidney, which had also invaded the pelvic zone. 
 
Due to the increased kidney weight observed in Figure 3.22 and differences in cell count 
between WT and SBxTie2-Cre mice in Figure 3.24, a semi-quantitative histological score was 
performed on the H and E staining of SBxTie2-Cre kidney sections to quantify the leukocyte 
infiltrates (as outlined in section 3.2.4) (see Appendix 8 for results). ALL WT mice had a 
score of: 1+. Most of the SBxTie2-Cre kidneys were similar to WT (1+, 44.5%) with the 
remaining SBxTie2-Cre sections being: 2+ at 25%; 3+ at 18% and 4+ at 12.5% (see Appendix 
8 Table A14). 
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WT        SB (Mild)   SB (High) 
 
Figure 3.24: H and E staining of WT and SBxTie2-Cre kidneys. The top panel bars 
represent 500 μm and the bottom 2 panels, the bars represent 50 μm. (A,D,G) WT, (B,E,H) 
SB Mild (C,F,I) SB High. 
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3.3.6 Comparative Analyses of SBxTie2-Cre Organs 
To determine relationships between organs, the relative weight of each organ (spleen, liver, 
thymus lungs, heart and kidneys) was compared to each other organ. The results are described 
below. See Tables A5-A8 and Figures A2-A7 in Appendices for complete statistical data for 
this section. The higher the rs value (positive or negative), the higher the correlation (see 
Section 3.2.7 for statistical analyses). 
 
 
3.3.6.1 Organ weight correlations: Spleen vs Liver, Thymus, Lungs, Heart 
and Kidneys 
Normalised spleen weights were plotted against the other organs for both WT and SBxTie2-
Cre mice (Figure 3.25). No correlations were observed between any organs in any of the WT 
mice assessed (Figure 3.25). A significant positive correlation was found between spleen and 
liver weights for SBxTie2-Cre mice confirming that mice with splenomegaly generally also 
had hepatomegaly, as suggested in Tables 3.6 and 3.7 (Figure 3.25A). All SBxTie2-Cre mice 
that had enlarged thymii had enlarged spleen, but not all SBxTie2-Cre mice with enlarged 
spleens had large thymii (Figure 3.25B), which indicates that the two phenotypes are not 
always linked. No correlations were observed between the weight of the spleen and heart, 
lungs or kidneys.  
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Figure 3.25: Relationship between weights of spleen and other organs (expressed as % 
body weight of mice). (A) Spleen vs. liver, (B) spleen vs. thymus, (C) spleen vs lung, (D) 
spleen vs heart, (E) spleen vs kidneys (Graphed in Log2 scale). Spearman’s Test = rs, F = 
female and M = male. ¡ = WT female (n=11);  = WT male (n=44);  = SB female  
(n=22);  = SB male (n=79) – unless otherwise stated. 
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3.3.6.2 Liver vs Thymus, Lungs, Heart and Kidneys 
The weights of WT and SBxTie2-Cre mouse livers were plotted against other organs (thymus, 
lungs, heart and kidneys) (Figure 3.26). No significant correlations were observed.  
 
 
 
Figure 3.26: Relationship between weights of liver and other organs (expressed as % 
body weight of mice). (A) Liver vs thymus, (B) liver vs lung, (C) liver vs. heart, (D) liver vs 
kidneys (graphed in Log2 scale). Spearman’s Test = rs, F = female and M = male. ¡ = WT 
female (n=11),  = WT male (n=44),  = SB female  (n=22) and  = SB male (n=79) – 
unless otherwise stated.  
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3.3.6.3 Thymus vs Lungs, Heart and Kidneys 
Weights for WT and SBxTie2-Cre mouse thymii were plotted against other organs with no 
significant correlations observed except between thymus and heart in WT mice (Figure 3.27).  
 
 
Figure 3.27: Relationship between weights of thymus and other organs (expressed as % 
body weight of mice). (A) Thymus vs lung, (B) Thymus vs heart, (C) Thymus vs kidneys 
(graphed in Log2 scale).   Spearman’s Test = rs, F = female and M = male. ¡ = WT female 
(n=11),  = WT male (n=20),  = SB female  (n=21) and  = SB male (n=19).  
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3.3.6.4 Lungs vs Heart and Kidneys; and Heart vs Kidneys 
Weights for WT and SBxTie2-Cre mouse lungs were plotted against weights for hearts and 
kidneys; and heart weights were plotted against kidney weights. No significant correlations 
were observed (Figure 3.28). 
 
 
Figure 3.28: Relationship between weights of lung, heart and kidneys (expressed as % 
body weight of mice). (A) Heart vs lung, (B) kidney vs lung (C) heart vs kidney (graphed in 
Log2 scale). Spearman’s Test = rs, F = female and M = male. ¡ = WT female (n=11),  = 
WT male (n=44),  = SB female  (n=22) and  = SB male (n=79).   
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3.3.7 Blood Analysis  
The presence of hepato-splenomegaly and enlarged thymii, along with the profound 
inflammatory response in other organs, suggested a haematological basis for the observed 
early lethality in SBxTie2-Cre mice. To investigate this we assessed peripheral blood from 
WT and SBxTie2-Cre mice. Preliminary analysis of blood smears indicated increased 
leukocyte numbers in the blood of symptomatic SBxTie2-Cre mice (Figure 3.29A). Analysis 
of whole blood (Figure 3.29B) indicated that the number of red blood cells (RBC) (Figure 
3.29B); platelets (Figure 3.29C) and haemoglobin content (Figure 3.29D) were similar 
between SBxTie2-Cre mice and WT littermates.  Markedly elevated white blood cell counts 
were observed in 70% of SBxTie2-Cre mice (Figure 3.29B) consistent with findings from 
blood films (Figure 3.29A). Differential counts of the white blood cells (WBC) showed 
elevation in three different leukocyte cell lineages (Figure 3.29E) and microscopic 
examination of blood smears identified that the majority of lymphocytes in SBxTie2-Cre mice 
were immature lymphocytes or blast cells (Figure 3.29A, F). Smudge cells were also detected 
in the blood smears for SBxTie2-Cre mice (Figure 3.29A,F). These are artefacts produced by 
the rupture of fragile WBCs during blood smear preparation. They are rarely observed in 
normal blood smears but are a common finding in leukaemia.  
 
Collectively, the results from organ size, organ histology and white blood cell counts 
(especially the increase in blasts and smudge cells) suggest that the cause of the early lethality 
in SBxTie2-Cre mice was due to development of acute leukaemia. To further characterise the 
type of leukaemia, IHC and flow cytometric analyses were performed. 
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Figure 3.29: Blood analysis of WT and SBxTie2-Cre mice. Whole blood from mice was 
analysed using microscope and coulter counter. (A) Blood smears stained with May-
Grünwald Giemsa-Wright. SBxTie2-CRE mice (ii) display a marked increase in leukocytosis 
when compared to WT (i). (B) White blood cell (WBC), red blood cell (RBC) and (C) platelet 
(PLT) count and (D) haemoglobin (HGB) content on peripheral blood. (E) Lymphocyte (LY), 
monocyte (MO) and granulocyte (GR) counts from peripheral blood of WT and SBxTie2-Cre 
mice:  = WT (n=23) and  = SBxTie2-Cre (n=9). Cells are expressed per litre (L) of blood. 
(F) Percentage (%) of blast (n=16) and smudge (n=7) cells in the lymphocytic cell count (D) 
from SBxTie2-Cre mice. T-test (Mann-Whitney). Mean + SD shown for WT mice. * 
Indicates P = 0.0119, 0.0112 and P = 0.0275 vs WT mice respectively. ** Indicates P = 
0.0088 vs WT. 
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3.3.8 Immunohistochemical Labelling of Splenic Tissue   
To further characterise the possible leukaemic populations, immunohistochemistry for 
leukocyte markers was performed on splenic tissue from WT and SBxTie2-Cre mice (see 
Section 2.6). Using the European group for the immunological classification of leukaemias 
(EGIL) scoring guidelines (Table 3.7), a score of two or more is required for an unambiguous 
diagnosis of a leukaemic lineage (Catovsky, Matutes et al. 1991, Bene, Castoldi et al. 1995, 
Bene 2009, Wolach and Stone 2015). In the EGIL system the number of points awarded to a 
particular lineage marker is a reflection of the specificity and the degree of expression of the 
marker for that lineage. A marker is considered positive if more than 20% of cells stain for 
that epitope. The most specific markers (CD3, CD22, CD79a, IgM, myeloperoxidase 
(Casasnovas, Slimane et al.) and T-cell receptor {TCR}) are assigned a score of 2, the least 
specific, a score or 0.5 (Bene, Castoldi et al. 1995, Wolach and Stone 2015). Accordingly, 
immunohistochemistry was performed on splenic tissue using MPO/F4/80 and CD3 as 
markers for myeloid and T-cell lineages, respectively. For completeness, a B-cell marker, 
CD45R, was also included in the analysis.  
Table 3.7: EGIL scoring system for acute leukaemia (adapted from Bene, 2009) (Bene 
2009). 
 B-Lineage T-Lineage Myeloid Lineage 
2 Points CD79 
IgM 
cCD22 
CD3 
Anti-TCR 
MPO (Lysozyme) 
1 Point CD19 
CD10 
CD20 
CD2 
CD5 
CD8 
CD10 
CD13 
CD33 
CDw65 
0.5 Point TdT 
CD24 
TdT                  CD1a 
CD17 
CD117          CD64 
CD14           CD 15 
TdT= terminal deoxynucleotidyl transferase (or DNA nucleotidylexotransferase), MPO = 
myeloperoxidase; Ig = immunoglobulin; and TCR = T cell receptor. 
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Immunostaining WT spleens (Figure 3.30) revealed normal distribution of these cell types in 
the spleen. CD3 immunostaining was strongly positive in the white pulp (T-cell zones) with 
sporadic positivity in the germinal centres (B-cell follicles) and red pulp (refer to Figure 3.9 
for splenic architecture). CD45R immunostaining for B cells was strongly positive in the 
germinal centres (B-cell follicles) with less dense positivity in the red pulp. MPO 
immunostaining for myeloid cells and F4/80 immunostaining for macrophages were restricted 
to sporadic positivity in the red pulp.  
 
Consistent with the H and E staining of these sections (Figure 3.10) the immunostaining for 
leukocyte subsets in the spleens of SBxTie2-Cre mice revealed a very different pattern of 
staining. To categorise these changes we established a scoring system where the criteria for 
‘Low’, ‘Mild’ and ‘High’ stemmed from the degree of difference between WT and SBxTie2-
Cre mice (see Section 3.2.4 for criteria).  Three phenotypic immunophenotypes emerged from 
the analysis of SBxTie2-Cre mice (Figure 3.30):  
Phenotype 1: (equivalent of T-ALL) was characterised by increased CD3 T cell 
immunostaining and reduced MPO myeloid and F4/80 macrophage 
immunostaining (Figure 3.30 G-J). The CD3 staining pattern became diffusely 
positive with increasing loss of splenic architecture.  This was the most common 
phenotype observed, found in 44% of mice assessed. 
Phenotype 2: (equivalent of AML) was characterised by increased MPO and F4/80, and 
decreased CD3 immunostaining (Figure 3.30 K-N) The MPO staining remained 
sporadic or patchy. This pattern of immunostaining was observed in 14% of 
mice assessed. 
Phenotype 3: (equivalent of MPAL) was characterised by both diffuse positive CD3 
immunostaining and increased sporadic MPO and F4/80 immunostaining 
(Figure 3.30 L-N) and was observed in 21% of mice. 
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Collectively the three identifiable phenotypes accounted for 79% of all SBxTie2-Cre mice.  
The other 21% of mice did not conform to these phenotypes; however, only 3 mice show a 
‘High’ phenotype for CD45R staining suggesting B-cell lymphomas comprised a small 
proportion of the disease cohort (Table 3.8 and summarised in Table 3.9). The 21% mice with 
no specific phenotype could have been a non-T-cell, non-myeloid or B-cell malignancy.  
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Figure 3.30: IHC of splenic tissues shows WT and 3 different patterns of leukaemia in 
SBxTie2-Cre mice. Isotype controls IgG2a (A; CD45R) and IgG1 (B; MPO and CD3) 
showed no staining. Splenic sections were stained for B-cells (CD45R, C,G,K,O), T-cells 
(CD3;F, J, N, R), and myeloid cells (MPO; D, H, L, P and F4/80; E, I, M, Q). Bars represent 
200μm. 
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Table 3.8: IHC analysis of SBxTie2-Cre mice spleens with spleen and thymus weights.  
Subtype Mouse ID IHC: CD3 IHC: MPO 
IHC: 
CD45R 
Spleen 
%BW 
Thymus 
%BW 
T-ALL 197 High Mild Low 3.57 N/A 
T-ALL 203 High Mild Mild 3.71 N/A 
T-ALL 245 High Mild Low 2.87 N/A 
T-ALL 315 High Mild Mild 0.26 N/A 
T-ALL 2334 High Low Mild 2.62 3.08 
T-ALL 2340 High Low Mild 4 1 
T-ALL 2345 High Low Mild 5.21 N/A 
T-ALL 2395 High Mild Mild 0.6 2.6 
T-ALL 2401 High Mild Low 4.15 1.19 
T-ALL 2403 Mild/High Low Low/Mild 4.03 0.09 
T-ALL 2517 Mild/High Mild Mild 2 0.4 
T-ALL 2523 Mild/High Low Low 4.62 0.03 
T-ALL 2364 High Mild Mild 1.16 6.16 
T-ALL 2368 High Low Low 5.8 1.29 
T-ALL 2372 High Mild Mild 2.12 0.3 
T-ALL 2376 High Low Mild 5.05 3.43 
T-ALL 2378 High Low Low 3.01 N/A 
T-ALL 2379 High Low Mild 4.06 0.59 
T-ALL 2383 High Low High 3.84 1.03 
T-ALL 2386 High Mild Mild 3.48 1.96 
T-ALL 2420 High Mild Mild 1.28 4.13 
T-ALL 2421 High Mild Mild 6.09 0.11 
T-ALL 2422 High Mild Mild 4.55 3.51 
T-ALL 2424 High Mild Mild 1.06 0.36 
T-ALL 2425 Mild/High Mild Mild 3.84 0.96 
AML 158 Mild High Low 8.12 N/A 
AML 179 Mild High High 3.84 N/A 
AML 184 Mild High Mild 4.65 N/A 
AML 296 Low High Mild 1.26 N/A 
AML 2399 Mild High Mild 3.97 N/A 
AML 2367 Low High Mild 6.77 0.37 
AML 2387 Mild High Mild 4.2 0.16 
AML 2427 Mild High Mild 2.29 1.62 
MPAL 2389 High High Mild 1.04 0.31 
MPAL 2393 High High Mild 0.69 4.33 
MPAL 2396 High High Mild 4.91 3.45 
MPAL 2406 High High Mild 1.11 4.3 
MPAL 2518 High High Mild 3.82 0.04 
MPAL 2519 High High Mild 1.87 4.53 
MPAL 2520 Mild/High High Mild 2.43 0.62 
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MPAL 2524 High High Mild 3.88 0.56 
MPAL 2525 High High Mild 3.48 0.06 
MPAL 2526 High Mild/High High 0.88 3.65 
MPAL 2365 High High Mild 8.45 0.57 
MPAL 2366 High Mild/High Mild 3.26 1.28 
Other 132 Mild Mild Mild 0.36 N/A 
Other 143 Mild Mild Mild 1.03 N/A 
Other 198 Low/Mild Mild Low 4.52 N/A 
Other 247 Mild Mild Mild 2.18 N/A 
Other 256 Mild Mild Mild 0.33 N/A 
Other 2354 Mild Mild Mild 3.51 N/A 
Other 2402 Mild Low Low 6.61 0.27 
Other 2522 Mild Mild Mild 5.51 0.69 
Other 2357 Mild Low Low 5.43 5.57 
Other 2361 Mild Low Low 8.51 0.15 
Other 2362 Mild Mild Low/Mild 12.37 0.68 
Other 2374 Low Mild Low/Mild 4.95 0.04 
 
Immunohistochemistry (IHC) analysis of spleens stained for CD45R (B-Cell); CD3 (T-Cell) 
and MPO (myeloid cells).  = mice with T-ALL (T-cell acute lymphoblastic leukaemia);  
= mice with AML (acute myeloid leukaemia);  = mice with MPAL (mixed phenotype acute 
leukaemia).  = High CD45R result. Blue = male (n=35); red = female (n=22). N/A = not 
available and ID = identification. Spleen and thymus weight as a percentage of total body 
weight (BW) for each mouse is shown if available. WT spleens: mean = 0.42, range = 0.14-
0.74; WT thymus: mean = 0.12, range = 0.02-0.34.  = Organ weights within the normal 
range for the WT. High = elevations in leukaemic cells; Mild = normal volume of leukaemic 
cells and Low = decreased leukaemic cells. 
 
Table 3.9: Summary of IHC analysis of SBxTie2-Cre mice spleens. SBxTie2-Cre mice were 
categorised into leukaemia subtypes. 
Subtype Number (N=57) Percentage (%) 
T-ALL 25 44 
AML 8 14 
MPAL 12 21 
Other 12 21 
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The increased splenic and/or thymic weights showed no clear correlation with any phenotype 
as the majority of SBxTie2-Cre mice had enlarged spleens and thymii (Figures 3.11 and 
3.17). Moreover, the age at euthanasia was plotted for each immune-subtype of leukaemia in 
SBxTie2-Cre mice (stratified by gender). No significant differences were observed (Figure 
3.31) although the one mouse that lived past 250 days was classified as T-ALL. The ‘Other’ 
category are non-T-cell and non-myeloid leukaemias. 
 
 
 
Figure 3.31: Classification of age and subtype of leukaemia in SBxTie2-Cre mice. The 
age of death for each leukaemic subtype was plotted. T-ALL = T-cell acute lymphoblastic 
leukaemia (n=25), AML = acute myeloid leukaemia (n=8) and MPAL = mixed phenotype 
acute leukaemia (n=12) and Other (n=12).  = male and  = female. P = 0.4747 by One-way 
ANOVA (Kruskal-Wallis Test). Mean + SD shown for SBxTie2-Cre mice. 
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3.3.9 Flow Cytometry Analysis of WT and SBxTie2-Cre Mice 
To enumerate the changes observed by IHC and to investigate the origins of the leukaemia 
further, flow cytometry on both splenic and bone marrow cells was performed (see Section 
3.2.6). Thymic tissue was not analysed due to the difficulty in obtaining sufficient cells from  
 
WT thymus, which was too small to divide between IHC and flow analysis. CD14 was used 
to identify monocytes, as it is a surface marker amenable to flow cytometry while the myeloid 
marker used for IHC (MPO) is not. For similar reasons CD19 was used for as the B-cell 
marker for flow cytometry. 
 
Forward scatter light (FSC) and side scatter light (SSC) were used to differentiate cell types in 
the heterogeneous cell population of the spleen and marrow. The resulting 2D dot plot 
(logarithmic scale) was use to define populations for subsequent analysis (Figure 3.32A). 
Regions positive for CD3, CD14 and CD19 were defined by comparison to staining with 
negative control IgGs (Figure 3.32A). The CD3 positive population was used as the base 
population for CD4 and CD8 analysis and all data displayed as CD4/CD3 and CD8/CD3 
double positive populations (Figure 3.32B). Upper left and bottom right quadrants display 
single positive (only one marker) while the upper right quadrant identifies cells positive for 
both markers (CD4/CD3 or CD8/CD3). The bottom left quadrant show cells negative for both 
markers. The flow cytometry results on spleen cells and bone marrow for both WT and 
SBxTie2-Cre mice are listed in Table 3.10.  
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Figure 3.32: Panels showing representative staining of splenic cell populations by flow 
cytometry. (A) SBxTie2-Cre mice are characterised by increased T-cells (CD3), increased 
myeloid (CD14) cells, and loss of B-cells (CD19), in the spleen. R2 (green) = positive 
populations from the marker. (CD3, CD14 and CD19). R1 (red) = mixed cell populations. (B) 
SBxTie2-Cre mice showing increased CD3 population with similar CD4 and CD8 results to 
WT mice. Black populations = debris. 
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Table 3.10: Flow cytometry analysis of spleen and bone marrow (BM) from WT and SBxTie2-Cre mice. 
Mouse ID CD3% CD14% CD19% Other %   CD4% CD8% 
  Spleen BM Spleen BM Spleen BM Spleen BM   Spleen BM Spleen BM 
WT1 23.39 25.07 24.36 19.81 27.72 25.85 24.53 29.27   17.84 2.24 8.55 1.34 
WT2 19.11 20.00 20.07 25.36 20.00 16.53 40.82 38.11   18.10 1.71 14.20 2.14 
WT3 21.74 25.97 22.21 22.73 28.73 19.53 27.32 31.77   16.57 2.06 10.35 1.99 
WT4 22.04 19.43 14.90 20.04 18.83 25.76 44.23 34.77   14.97 4.88 9.59 2.82 
WT5 22.17 20.77 18.07 18.77 19.53 20.00 40.23 40.46   25.35 2.10 29.35 2.20 
           
    2389 55.52 45.44 30.75 29.40 11.16 22.08 2.57 3.08   4.10 5.90 3.93 3.98 
2401 49.61 56.46 21.48 24.84 9.13 5.58 33.40 13.12   9.68 15.62 36.66 32.36 
2403 54.37 57.59 10.88 14.86 4.66 14.98 30.09 12.57   5.51 9.07 1.74 2.44 
2406 54.97 53.52 26.57 25.89 12.28 10.67 6.18 34.80   0.14 10.42 42.94 25.17 
2517 42.82 39.60 15.39 40.88 15.42 18.76 26.37 0.76   7.11 15.60 4.20 15.04 
2519 51.20 50.64 32.84 30.25 14.79 8.87 1.17 10.24   4.58 2.33 36.31 19.23 
2523 54.46 54.09 7.15 24.26 6.53 9.05 31.86 23.02   2.19 1.01 8.33 8.81 
2524 44.20 39.40 29.40 26.66 20.76 22.55 5.64 18.49   3.60 6.10 10.04 1.72 
2525 31.15 46.55 25.26 39.91 9.32 12.97 34.27 0.57   20.77 14.41 17.89 13.54 
2526 48.50 41.21 25.77 36.07 18.50 16.46 7.23 12.63   15.00 5.32 20.75 31.29 
2520 36.61 14.61 25.34 25.38 16.75 59.51 21.30 0.50   9.92 7.48 5.52 2.63 
2362 44.08 45.91 32.03 38.64 18.90 14.29 11.42 1.16   21.48 19.26 6.84 8.48 
2376 47.46 58.14 14.44 13.55 12.33 8.69 29.32 19.62   6.95 13.31 37.82 35.40 
2378 60.71 50.94 9.54 23.53 10.53 22.07 19.22 3.46   2.81 2.51 1.19 1.31 
2383 56.51 38.52 21.71 21.23 18.79 40.03 2.99 0.22   9.91 22.70 12.43 2.24 
2422 50.24 52.20 21.32 19.54 11.01 25.23 17.43 3.03   3.33 13.00 1.06 4.63 
2424 48.36 41.90 23.18 23.45 26.26 18.34 2.20 30.59   31.13 12.50 4.51 4.36 
2425 64.50 63.87 14.14 24.09 20.70 7.66 22.96 4.38   1.44 14.89 1.80 6.11 
2427 30.07 33.06 24.72 27.57 28.23 36.35 16.98 3.02   2.10 1.20 5.48 1.78 
Blue = male mice and red = female mice.  = Abnormally high results and  = abnormally low results based on WT range. Total of CD3, CD14, 
CD19 and Other = ~100%. The ‘Other’ cells are non-T, B and myeloid cells.
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By flow cytometry, the average percentage for WT mice for CD3+ T-cells in spleen and bone 
marrow was 21.69 and 22.25 (Table 3.10). For CD14+ myeloid cells it was 19.92 and 21.34 
while CD19+ B cells were 22.96 and 21.53 in spleen and bone marrow, respectively (Table 
3.10). When compared to the published values (TheJacksonLaboratory 2007) for spleens of 
age-matched (8-10 weeks) WT C57Bl/6J mice (24.9% CD3 T-cells; 5.07% MAC1 myeloid 
cells; and 56.97% B220 B-cells) the values for T-cells compared favourably; however, the 
differences to the published values for myeloid and B-cell populations may be due to different 
markers and gating strategies used. In this study, the WT mice show fewer CD19 B cells and 
more CD14 monocytes than published data. 
 
Using the WT data as the comparator, elevated T cell (CD3) counts were found in all spleens 
and 95% of bone marrow aspirates from SBxTie2-Cre mice (Tables 3.10 and 3.11). The 
average increase was 2-fold compared to WT mice (Table 3.10). In spleens with elevated T-
cell (CD3) counts there was often a concomitant increase in CD14 counts (Tables 3.10 and 
3.11); 47% of mice had elevations in both CD3 and CD14 counts vs 53% of mice with 
elevation in CD3 alone (Table 3.11). A similar pattern was observed in bone marrow with 
elevations of CD3 or CD3 and CD14 in 47% of mice (Table 3.11). The “Other” category in 
bone marrow as seen in Table 3.11 depicts one mouse that had elevation of CD19 and CD14. 
 
Table 3.11: Summary of flow cytometry analysis of spleen and bone marrow from SBxTie2-
Cre mice based on WT range. 
 Spleen Bone Marrow 
Subtype Number (N=19) Percentage (%) Number (N=19) Percentage (%) 
T-ALL 10 53 9 47 
AML 0 0 0 0 
MPAL 9 47 9 47 
Other 0 0 1 6 
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The altered relationships for CD3, CD14 and CD19 cells between spleen and bone marrow in 
SBxTie2-Cre mice are evident in Figure 3.33. The similarity of the relationship between CD3 
and CD14 counts in spleen and bone marrow in WT and SBxTie2-Cre mice suggests 
involvement of both the spleen and the bone marrow in the T-ALL phenotype (Figure 3.33A 
and B). CD19 counts in WT mice suggest a far greater involvement of spleen than bone 
marrow (Figure 3.33C). This relationship was perturbed in the SBxTie2-Cre mice, most likely 
because the competing T-cell and myeloid leukaemic populations lowered the relative 
percentage of B-cells (Figure 3.33C). Therefore, there are multiple sites of initiation 
depending on the leukaemia in question.    
 
 
Figure 3.33: Flow cytometry analysis of SBxTie2-Cre mice spleens and bone marrow. 
(A) CD3% (T cell population); (B) CD14% (myeloid population) and (C) CD19% (B cell 
population) of spleens vs bone marrow of WT (n=5) and SBxTie2-Cre mice (n=19). 
Spearman’s Test = rs and * and ** Indicates significance vs SBxTie2-Cre.  
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The observed erythroderma in some SBxTie2-Cre mice (Section 3.2.2) suggested that the T-
cell sub-populations might be further dysregulated as a consequence of enhanced numbers of 
CD8 T-cells (Hashizume, Nakayama et al. 1992). Sub-classification of the CD3 T-cell 
populations in WT mice indicated that 1.48r0.45 and 1.24r0.43 were the normal ratios for  
CD4:CD8 T-cells in spleens and bone marrow respectively (Table 3.10, Figure 3.34). 
According to The Jackson Laboratory, the normal ratio for CD4:CD8 T-cells in C57BL/6 
spleen is 1.56 at 8 weeks of age, which is similar to the WT results (TheJacksonLaboratory 
2007). In SBxTie2-Cre mice a broad range of CD4:CD8 ratios were identified in both spleens 
and bone marrow (Table 3.10, Figure 3.34). Some mice had extremely elevated CD8 levels 
that decreased the ratio significantly. However, the majority of the deviations in CD4:CD8 
ratios can be accounted for by decreases in either the CD4 or CD8 subset without elevation of 
the opposing lineage. This happened even in SBxTie2-Cre mice with fulminant T-cell ALL 
suggesting that the majority of cells were uncommitted T-cells which perhaps reflects the 
increased numbers of blast cells originally observed in blood films (Figure 3.29A). 
 
 
Figure 3.34: Splenic (A) and bone marrow (B; BM) CD4:CD8 ratio of WT (n=5) and 
SBxTie2-Cre (n=19) mice. SBxTie2-Cre mice with high CD3, ; high CD3 and CD14, ; 
and high CD19, . T-test (Mann-Whitney). Mean + SEM. 
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Comparison of the flow cytometry and IHC data showed good concordance for CD3 (Table 
3.12). All mice with high CD3 by IHC (diagnosed with T-ALL or MPAL) also revealed high 
CD3 by flow cytometry for spleen, and in all but one case (#2520) for bone marrow and two 
cases (#2362 and #2427) for spleen. Further, all mice diagnosed with MPAL by splenic IHC 
(high CD3 + high MPO) were also diagnosed with MPAL by splenic and bone marrow flow 
cytometry (high CD3 + high CD14) except for one case (#2517) in bone marrow. The EGIL 
scoring system acknowledges MPO as the more stringent marker and MPO is used to verify 
blast cells belonging to the myeloid lineage as a diagnostic in AML (Casasnovas, Slimane et 
al. 2003).  
 
The one mouse (#2427) that was classed as AML by IHC also showed elevated CD14+ cells 
in spleen and bone morrow; however, was classified as MPAL using flow cytometry because 
of elevated T-cell counts. The incidence of AML was lower than ALL and MPAL by IHC 
(only 16%).  The low occurrence restricted sample numbers for flow analysis and the current 
result may not be truly representative of a larger cohort (just as sporadic mice were not a 
perfect match between IHC and flow data for ALL and MPAL).  
 
Three mice were found to have elevated B-cells by spleen IHC and 1 of these were confirmed 
by bone marrow (but not spleen) flow cytometry, which also identified an additional 2 cases 
not found by spleen IHC. Overall, the flow cytometry results for CD14 and MPO were 
matched between spleen and bone marrow.  
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Table 3.12: Cross analysis of SBxTie2-Cre spleen IHC and flow cytometry, bone marrow 
flow cytometry, % body weight of thymus and abnormal organs. 
Mouse ID IHC-Spleen Flow-Spleen Flow-BM Thymus %BW Abn organs 
2401 T-ALL 
↑CD8 ↑CD8 
+ SLLu T-ALL T-ALL 
2403 T-ALL T-ALL T-ALL Normal SL 
2523 T-ALL T-ALL ↑CD8 Normal SLLu 
T-ALL 
2517 T-ALL T-ALL ↑CD8 +/- SLu 
MPAL 
2376 T-ALL ↑CD8 ↑CD8 ++ SLLu 
T-ALL T-ALL 
2378 T-ALL T-ALL T-ALL N/A S 
2383 T-ALL T-ALL 
↑B cells 
+ SLLu 
T-ALL 
2422 
↑B cells 
T-ALL T-ALL +++ SLLu 
T-ALL 
2424 T-ALL T-ALL ↑CD8 +/- SLu 
T-ALL 
2425 T-ALL T-ALL ↑CD8 + SL 
T-ALL 
2406 MPAL 
↑CD8 ↑CD8 
+++ SLu 
MPAL MPAL 
2519 MPAL 
↑CD8 (↑CD8) 
+++ SLu 
MPAL MPAL 
2524 MPAL MPAL MPAL + SLLu 
2525 MPAL MPAL ↑CD8 Normal SL MPAL 
2389 MPAL MPAL MPAL Normal S 
2526 ↑B cells MPAL MPAL +++ S 
MPAL 
2520 ↑B cells MPAL ↑B cells + S 
MPAL Other 
2362 MPAL MPAL ↑CD8 + SLLu 
MPAL 
2427 AML MPAL ↑B cells ++ SLu 
MPAL 
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Total ALL 10 10 (+ 3 
CD8↑) 9   
Total 
MPAL 8 9 9   
Total AML 1 0 0 
  Other 0 0 1   
↑ B cells 3 0 3   
 
Blue = male mice and red = female mice. S = spleen, L = liver, Lu = lungs, ↑ = increased, ID 
= identification, N/A = not available, IHC = immunohistochemistry, %BW = percentage 
relative to body weight, Abn = abnormal, T-ALL = T-cell acute lymphoblastic leukaemia; 
AML = acute myeloid leukaemia, MPAL = mixed phenotype acute leukaemia, --- = normal, -
/+ = medium, + = large, ++ = extra large and +++ = gigantic. 
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3.4 Discussion 
The work presented in this chapter characterised the phenotype of SBxTie2-Cre mice. An 
early lethality developed in the SBxTie2-Cre mice, which was the result of acute leukaemia, 
starting as early as 5 weeks of age. The acute leukaemia was associated with alterations to 
blood and lymphatic vessel density (in the hearts of mice at 11 weeks of age) which, while it 
did not explain the lethality, it does confirm data from human trials suggesting enhanced 
angiogenic density in patients suffering with leukaemia (Jothilingam, Basu et al. 2014). 
Despite not being examined further, it would be interesting to use the SBxTie2-Cre system in 
a tumour model or cardiovascular model or any disease that has perturbations of the vessel, to 
observe what occurs when the endothelium is mutated in these settings. 
 
Although no evidence of endothelial or solid tumours was seen in SBxTie2-Cre mice, perhaps 
the endothelium was inflamed as fulminant inflammation was observed in spleens, livers, 
thymus and lungs. ALL (T-cell), AML and MPAL were identified in the mice. It is known 
that in lymphoid leukaemia, the white pulp of the spleen hypertrophies and the red pulp 
decreases in size and in certain occasions the white pulp can expand up to 50% of the total 
volume of the spleen (Pochedly 1989). In myeloid leukaemia, the opposite occurs where the 
white pulp atrophies and the red pulp inflates (Pochedly 1989). Similar to human disease, the 
presentation of leukaemia in the SBxTie2-Cre mice was accompanied by enlargement of the 
thymus (Craver 1932), spleen and liver (Rai, Sawitsky et al. 1975). Pulmonary complications 
were seen in 53% of SBxTie2-Cre mice and up to 80% of human leukaemias have pulmonary 
symptoms primarily due to pulmonary leukaemic infiltration (Kakihana K 2010).  
 
ALL is the most common childhood cancer and while it can occur at any age, is more common 
in children (0-14 years), accounting for 60% of all cases. This is perhaps reflective of the 
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young age (5 weeks) at which the SBxTie2-Cre mice develop clinically detectable ALL.  
Although ALL does occur in aged populations (1% of all adult cancers) (Pui, Carroll et al. 
2011) it is AML that predominates, with an incidence that increases with age. Results for 
2006–2010 indicate that individuals with acute myeloid leukaemia had a 5-year survival rate 
of ~21% (Pulte, Gondos et al. 2009). Acute leukaemia with a mixed phenotype is a rare 
disease and comprises 2–5% of all acute leukaemias (Weinberg and Arber 2010), with the 
overall survival rate for children to be ~75% (Al-Seraihy, Owaidah et al. 2009).  
 
Interestingly, the model used in this project is unusual, as it does not fit the generally accepted 
paradigm for the origins of leukaemia (Bonnet and Dick 1997, Zuckerman and Rowe 2014). 
The Cre transgene, used for SB activation in this study, is driven from the Tie2 promoter / 
enhancer. This promoter consists of a 2.1-kb 5’ fragment of the TEK/Tie2 promoter upstream 
of the Cre transgene with an SV40 poly(A) tail and a 10 kb enhancer region downstream of 
the transgene (Kisanuki, Hammer et al. 2001). It ensures uniform and ubiquitous transgene 
expression in the vascular endothelium throughout development and into adulthood (see 
Table 3.2). Typically, acute leukaemia is thought to originate from the malignant proliferation 
of cells of the myeloid (AML) or lymphoid (ALL) progeny. However, in these mice, the 
endothelium was targeted, indicating a non-traditional model for the development of 
leukaemia. Links between angiogenesis and leukaemia have been proposed previously: In 
1997, Perez-Atayde et al. first showed that increased vascularity was detected in bone marrow 
specimens from patients with childhood ALL (Perez-Atayde, Sallan et al. 1997). In 1997, 
Fiedler et al. observed that AML cells expressed VEGF, arguably the most prominent pro-
angiogenic factor responsible for generating a neovascularisation response in solid tumours 
(Fiedler, Graeven et al. 1997). These initial studies provide a foundation for this project and 
prompt further exploration of the non-traditional pathway of leukaemogenesis. 
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The rapid development of the lethality (5 weeks) in the SBxTie2-Cre mice suggested that the 
endothelium likely played a critical role at an early stage in the development of leukaemia. A 
study by Tang et al. used the same SB line as in this study crossed with a transgenic line with 
Cre under the control of the haematopoietic-selective vav 1 oncogene (vav1) promoter (SBvav) 
and an additional cohort harbouring the oncogenic JAK2 V617F mutation, which predisposes 
individuals to myeloproliferative cancer (Jak2SBvav) (Tang, Carmichael et al. 2013). (Tang, 
Carmichael et al. 2013). Diverse lineages of leukaemias were discovered, with lymphoid, 
myeloid, megakaryocytic, and erythroid disease in SBvav mice while several of the mice 
succumbed to lymphoid malignancy, erythroleukaemic pathology, or both (Figure 3.35) 
(Tang, Carmichael et al. 2013). On the other hand, the Jak2SBvav mice developed 
erythroleukaemia, sporadically concurrent with lymphoid disease (Figure 3.35) (Tang, 
Carmichael et al. 2013). SBxTie2-Cre mice (SBTie2) differed from these other two transgenic 
lines studied by Tang et al. in that they showed no elevation in erythrocytes nor any 
development of either erythroleukaemia or megakaryocytic leukaemia. The SBxTie2-Cre 
mice did develop three main types of leukaemia: lymphoid, myeloid and both (ALL and 
AML; classified as MPAL in the present study), with lymphoid disease being more 
predominant (Figure 3.35).  
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Figure 3.35: Range of leukaemias ensuing in SBvav, JAK2SBvav and SBTie2 mice (adapted 
from Tang et al. 2013 (with permission from Proceedings of the National Academy of 
Sciences) (Tang, Carmichael et al. 2013). Based on histopathological examination the 
dimension of each region in the pie charts characterise the measure of mice that succumbed to 
a specific type of leukaemia. In certain mice, two different leukaemia phenotypes were 
identified. SBTie2 = mice generated in this study. 
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Germline expression of SB using the same T2Onc2 transgene as utilised for the SBxTie2-Cre 
mice (in the present study) resulted in death from haematological malignancies predominantly 
but not exclusively of T-cell lineage between 7 and 17 weeks of age (Dupuy, Mouly et al. 
2005). To define the cell of origin targeted by SB for the T-cell lineage malignancy Berquam-
Vrieze et al. used different promoters to drive SB expression during different stages in T-cell 
differentiation (Berquam-Vrieze, Nannapaneni et al. 2011).  
 
When activated in haematopoietic stem cells (HSCs) (using Vav-Cre) leukaemia developed 
and resulted in death between 10 – 20 weeks of age (Figure 3.36) (Berquam-Vrieze, 
Nannapaneni et al. 2011). SB activation in immature thymocytes lacking CD4/CD8 
expression, using Lck-Cre (lymphocyte protein tyrosine kinase) slowed leukaemia 
development with average survival of 11 months (Figure 3.36). Targeting mature (CD4/CD8 
positive) T-cells using CD4-Cre further slowed leukaemia development with most mice 
surviving to 12 months of age (Figure 3.36) (Berquam-Vrieze, Nannapaneni et al. 2011). To 
put this project into context, the SBxTie2-Cre mouse model follows closely to the Vav-Cre 
mice, which suggests that endothelial control over haematopoiesis occurs at an early stage of 
differentiation (Figure 3.36). 
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Figure 3.36: Sleeping Beauty induced models of T-cell leukaemia that initiate at 
different developmental time points (adapted from Berquam-Vriez et al. 2011) 
(Berquam-Vrieze, Nannapaneni et al. 2011). Four different Cre-transgenic strains were 
used to induce SB transposase expression, and thus transposon mutagenesis, at various stages 
of differentiation.  WT,  SBxTie2-Cre,  Vav-SB,  Lck-SB and  CD4-SB mice. 
  
 
The earliest prenatal Vav expression was believed to be in HSC-derived progenitors, rather 
than in intra-embryonic or extra-embryonic HSCs themselves (Bustelo, Rubin et al. 1993, 
Okada, Watanabe et al. 1998, Ohmura, Kawamoto et al. 1999). It was interesting to find that 
two models of Vav-SB provide an early lethal phenotype. An underappreciated aspect of Vav-
Cre transgenic mice is that Cre expression is driven in both ECs and HSCs but rarely in other 
cell types (Figure 3.38) (Georgiades, Ogilvy et al. 2002, Croker, Metcalf et al. 2004).  
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Figure 3.37: Adult mesenteric lymph node medulla from Cre-mediated mutagenesis of 
vavCre8/R26R double heterozygous mice stained with X-gal (image taken from 
Georgiades et al. 2002) (with permission from John Wiley and Sons) (Georgiades, Ogilvy 
et al. 2002). Arrows point to blood vessels. 
  
 
Blood vessels in a lymph node from Vav-Cre x Rose 26 Tg mice expressed β-Gal signifying 
expression and Cre-mediate recombination in ECs (Figure 3.37). Recombination in ECs by 
the Vav-Cre construct was unpredicted as neither endogenous Vav or Vav-regulated 
transgenes were detected in adult endothelium (Ogilvy, Metcalf et al. 1999, Ogilvy, Metcalf 
et al. 1999). This could be due to Vav-regulated genes being transiently expressed in the 
endothelium at early stages of development.  
 
It is interesting to consider whether the Cre-mediated recombination in ECs, and not HSCs, 
was the reason for the increased mortality and the production of the ALL, AML and both 
(ALL and AML) phenotypes that are pervasive in this model.  If so, it would mean that the 
direct endothelial contribution to leukaemogenesis observed directly in our model has been 
confirmed, but not acknowledged, in 2 previous studies and explains why the results of the 
Vav-Cre and Tie2-Cre models of SB share such similarities in phenotype and disease 
progression.   
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Further, the timing of the early lethal phenotype observed in our SBxTie2-Cre mice suggests 
targeting of a population of early stage cells prior to haematopoietic stem cells.  These data 
are consistent with an endothelial cell population contributing to the early progenitor cells that 
form the basis for the leukemic populations. Moreover, an attractive hypothesis is that a 
population of primordial endothelial cells is capable of giving rise to lymphoid and myeloid 
precursors (Lancrin, Sroczynska et al. 2010). In the described model Tie-2-directed SB-
mediated mutagenesis may have been initiated in endothelial precursor cells resulting in the 
leukaemic phenotypes observed. This hypothesis will be further explored in Chapter 4.  
 
The most pronounced micro-environmental changes observed in the bone marrow of 
leukaemia patients are: endothelial proliferation and angiogenesis. The role of endothelial 
cells has not been investigated properly; therefore, in this study, the SB model was utilised to 
understand this role as it is shown to lead to leukaemia. Endothelial function may explain why 
anti-angiogenic agents are effective treatments for leukaemia. 
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4.1 Introduction 
Activation of the SB mutagenesis system in the endothelium produced a lethal phenotype 
where the pathological basis was one of three different phenotypes of leukaemia. The Tie-2 
promoter / enhancer used in this model is only activated in ECs, allowing uniform and 
ubiquitous transgene expression in the vascular endothelium throughout development and into 
adulthood (Section 3.1.3). However, the notion that ECs have a direct contribution to the 
pathogenesis of leukaemia challenges the traditional view of haematopoiesis. Under the 
prevailing model the HSCs and lineage committed progenitors that proliferate aberrantly in 
leukaemia should not have expressed the Cre transgene and therefore, the SBxTie2-Cre mice 
should not have developed leukaemia. This prompts the question: “did the leukaemia arise 
from the ECs or HSCs? This chapter sought to resolve this question by determining the 
contribution of ECs and HSCs to the leukaemia phenotype. To do this; however, the role of 
ECs and HSCs must first be appreciated in the context of the process of haematopoiesis and 
the derivation of leukocytic subsets. 
 
4.1.1 Traditional View of Haematopoiesis 
Haematopoiesis, the development of blood cells, comprises two phases in vertebrates: the 
primitive and definitive phase (Galloway and Zon 2003). The primitive phase includes the 
erythroid progenitor, which gives rise to erythrocytes and macrophages throughout early 
embryonic development in the mouse (E7.0 – 7.25) (Palis and Yoder 2001). Primitive 
haematopoiesis is largely regulated by the transcription factors GATA1 and PU.1 (now 
known as SFPI1 in mouse; SPI1B in zebrafish) that regulate primitive erythroid and myeloid 
fate decisions through reciprocal inhibition. GATA1 is a master regulator of erythrocyte 
development (Cantor and Orkin 2002) and suppresses the myeloid lineage. The reverse is true 
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for PU.1 (Scott, Simon et al. 1994). The direct interaction of the two proteins, assumed to be 
the basis for this regulation, is based on competition for target genes (Cantor and Orkin 2002). 
The main role of the primitive phase is to generate erythrocytes that can accelerate tissue 
oxygenation as the embryo undertakes rapid development (Orkin and Zon 2008). During early 
development, the erythroid progenitor cells initially emerge in blood islands in the extra-
embryonic yolk sac in mammals and avians (Paik and Zon 2010). The primitive wave is 
temporary and the erythroid progenitor cells are not pluripotent and do not have regenerative 
capability.  
 
Definitive haematopoiesis follows later in development and also at different time points in 
different organisms. It occurs in blood islands and generates erythroid-myeloid progenitors 
(Krevvata, Silva et al.) in most species (Bertrand, Kim et al. 2007, McGrath, Frame et al. 
2011). Definitive haematopoiesis later comprises HSCs, which are multipotent and are 
capable of giving rise to all blood lineages of the adult organism. During mouse 
embryogenesis, definitive haematopoiesis commences in the extra-embryonic yolk sac (~E8.0 
– E8.5) and placenta (~E9.5), and then within the aorta-gonad-mesonephros (AGM) region of 
the developing embryo (~E10). As development proceeds, the foetal liver becomes the main 
site of definitive haematopoiesis (~ E11 to E12), after which haematopoiesis is mainly 
restricted to the bone marrow and thymus (Muller, Medvinsky et al. 1994, Medvinsky and 
Dzierzak 1996, Sanchez, Holmes et al. 1996, Palis, Robertson et al. 1999, Gekas, Dieterlen-
Lievre et al. 2005, Ottersbach and Dzierzak 2005, Cumano and Godin 2007, Lucitti, Jones et 
al. 2007). A key driver of definitive haematopoiesis is RUNX1 (Wang, Stacy et al. 1996). 
Deletion of Runx1 in mice and zebrafish results in loss of definitive erythroid, myeloid and 
lymphoid cells. The loss of Runx1 decreases expression of the putative proto-oncogene cmyb 
which is also important for definitive erythropoiesis (Mucenski, McLain et al. 1991).  
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During childhood, blood cells are produced in all bones of the body, but with increasing age, 
the peripheral parts of the bones are replaced with inactive marrow (yellow marrow); in the 
adult, blood cells only develop in the central parts of the skeleton (skull, ossicles of the 
middle ear, hyoid, rib cage, sternum and vertebral column) (Jandl 1987). Traditionally, 
haematopoiesis in adult organisms is portrayed as a hierarchal development in which the HSC 
lies at the top of the order (Figure 4.1). Upon activation, the HSC is capable of differentiating 
into clonal progenitors that can multiply exponentially and continue the system of 
differentiation and self-replication (Figure 4.1). 
 
 
 
 
Figure 4.1: Broad schematic illustrating the development of different blood cells from 
haematopoietic stem cells to mature cells (image adapted from Motifolio). B = basophilic, 
N = neutrophilic and E = eosinophilic. 
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HSCs give rise to committed progenitors in both the lymphoid and myeloid cells (Figure 4.1). 
Lymphoid cells are involved in humoral and acquired immunity (including T cells, B cells, 
natural killer cells and dendritic cells). Myeloid cells include red blood cells, platelets and 
cells responsible for innate immunity including monocytes / macrophages and granulocytes as 
well as other cell type such as eosinophils, mast cells and basophils.  
 
4.1.2 Linking Haematopoietic and Endothelial Lineages  
The period of primitive and definitive haematopoiesis in development exists parallel with 
foundation of the primary vascular formation and patterning (Figure 4.2).  
 
  
Figure 4.2: Timeline of development of blood and endothelium in the developing mouse 
embryo (image adapted from Sills and Hirschi, 2011) (Sills and Hirschi 2011). The two 
waves of haematopoiesis (primitive and definitive) and formation or expansion of the primary 
vascular plexus (EC differentiation, vasculogenesis and plexus remodelling and angiogenesis) 
are shown along with the sites of haematopoiesis and initiation of cardiac function (arrows). 
AGM = aorta-gonad-mesonephros; and E = embryonic day. 
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These data clearly show the tight developmental relationship between endothelial and blood 
cell specification. However, how closely the two systems are linked and whether there is 
convergence in the developmental pathways that might yield an explanation for the results in 
Chapter 3 has not been fully explored. 
 
4.1.2.1 The Haemangioblast Concept 
Several theories postulate that HSCs originate from the haemangioblast, defined as a bi-
potential mesodermal precursor able to transiently give rise to both ECs and blood cells 
(Figure 4.3). The concept of the haemangioblast was proposed in the early 20th century 
following observations of the close temporal and spatial association between the development 
of blood cells and vascular structures (Bautch 2011). The observed ECs were able to 
asymmetrically divide such that an endothelial daughter cell and another cell (that “projects 
into the lumen, becomes filled with haemoglobin and breaks free from the vessel wall”) were 
formed. Many studies have suggested that during embryonic growth, HSCs develop from this 
mesodermal progenitor (Sabin 1920, Murray 1932).  
 
 
Figure 4.3: The concept of the “haemangioblast” giving rise to HSCs sand ECs.  
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Support for the haemangioblast theory came from the identification during embryonic stem 
cell differentiation of a clonal precursor, the blast colony-forming cell (BL-CFC), which 
generates colonies that contain both endothelial and haematopoietic elements (Kennedy, Firpo 
et al. 1997, Choi, Kennedy et al. 1998). Further support for a bi-potential haemangioblast 
derives from the fact that haematopoietic and endothelial lineages share core cell surface 
markers (e.g. CD34, bone morphogenic protein 4 {BMP4}, and vascular endothelial growth 
factor 2 {VEGFR2 or FLK-1}) and transcription factors important during differentiation (e.g. 
mesodermal markers: Brachyury {BRY}, RUNX1 and GATA2) (Gritz and Hirschi 2016). 
Unquestionably, the haemangioblast is reportedly double positive for BRY and VEGFR2 
(Huber, Kouskoff et al. 2004). However, fate-tracing studies with these cells identified the 
daughter progeny to include not only endothelial and blood cells but also vascular smooth 
muscle, cardiac and skeletal muscle cells (Motoike, Markham et al. 2003, Huber, Kouskoff et 
al. 2004) indicating that the cells are multipotent with perhaps only a subset functioning as 
dedicated haemangioblasts. Considerable evidence exists to support the notion that 
endothelial and blood cell development is independently fated during development (Kinder, 
Tsang et al. 1999, Vogeli, Jin et al. 2006). 
 
While recent reports have verified the existence of this bipotential precursor in vivo, the exact 
process of the development of HSCs from the haemangioblast remains unclear (Huber, 
Kouskoff et al. 2004, Vogeli, Jin et al. 2006). However, the contribution of the 
“haemangioblasts” to haematopoiesis in vivo remains controversial. Whilst few would 
disagree with the concept that at some point in the linage, vascular cells and blood cells likely 
have a common precursor, there is no definitive evidence in any in vivo models of blood or 
vessel development (either mouse, chicken or zebrafish) to support the existence of such cells 
as significant contributors to HSC production. If the haemangioblast does indeed contribute to 
blood cell development its role is unlikely to exist outside of primitive haematopoiesis during 
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development. Nevertheless, research in this area from the present study has delineated a close 
relationship between the haematopoietic and endothelial lineages that would be required for 
an endothelial origin of the leukaemia in the SBxTie2-Cre mice. 
 
4.1.2.2 Haemogenic Endothelium 
The leading theory of haematopoiesis is that everyone is born with all the HSCs that are 
needed and they are replenished through self-renewal. Support for this theory derives from 
cell transplantation studies in animal models, in which serial transplantation of HSCs or bone 
marrow ultimately leads to collapse of the HSC pool (Siminovitch, Till et al. 1964, Harrison, 
Astle et al. 1978). An alternate concept suggests that the first HSC is associated with a 
phenotypically differentiated EC with haematopoietic potential, termed the haemogenic 
endothelium (Jaffredo, Gautier et al. 1998, North, de Bruijn et al. 2002). The concept of the 
haemogenic endothelium was put forward to explain the close connection between 
haematopoiesis and the endothelium. Haemogenic endothelium is a subset of vascular 
endothelium that is transiently specialised with haematopoietic potential to give rise to multi-
lineage HSCs during definitive haematopoiesis (Figure 4.4). Indeed, results from Flk-1 null 
mice suggest that the progression of definitive haematopoiesis cannot take place in the 
absence of endothelial cell differentiation (Shalaby, Rossant et al. 1995, Shalaby, Ho et al. 
1997). 
 
The outcomes of a number of phenotypic and genetic findings in mammalian embryos, 
reinforced by rigorous in vivo transplantation studies of enhanced cell fractions, support HSCs 
originating from haemogenic endothelium (de Bruijn, Ma et al. 2002, North, de Bruijn et al. 
2002, Zovein, Hofmann et al. 2008, Chen, Yokomizo et al. 2009). This process, restricted to 
E10.0 – E11.5 during development is termed endothelial to haematopoietic cell transition 
(EHT) and represents the embryonic pathway that gives rise to the haemogenic endothelium 
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(Figure 4.4). 
 
  
Figure 4.4: The endothelium giving rise to both the haemogenic endothelial cell and the 
haematopoietic stem cell. 
 
The prominent role of the haemogenic endothelium at this stage in development has prompted 
speculation that the “haemangioblast” generates HSCs through a haemogenic endothelium 
stage (Lancrin, Sroczynska et al. 2009). Whereas haemogenic endothelium contributes to 
blood cell development in the dorsal aorta, yolk sac and placenta there is less evidence of a 
role for the haemogenic endothelium at other sites of definitive haematopoiesis (such as foetal 
liver and bone marrow) during development although this has not been entirely ruled out as 
neovascularisation of these tissues precedes the onset of their haematopoietic function 
(reviewed in Crivellato, 2011) (Crivellato 2011) (Figure 4.2). 
 
The haemogenic endothelium is a rare form of endothelium, comprising < 2% of the total 
endothelial complement of the yolk sac and dorsal aorta of the embryo at days E8.5 – E10.5 
(Nadin, Goodell et al. 2003, Goldie, Lucitti et al. 2008). In the embryo, the haemogenic 
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endothelial cells (HECs) are thought to be FLK1+/c-KIT+/CD45− and give rise to FLK1−/c-
KIT+/CD45+ HSCs with multi-lineage colony forming activity (Jackson, Majka et al. 2001, 
Nadin, Goodell et al. 2003, Goldie, Lucitti et al. 2008). Indeed, transplantation of haemogenic 
endothelium from the dorsal aorta can repopulate the multilineage precursors in neonatal and 
adult recipients where they have been rendered inert (Medvinsky and Dzierzak 1996) 
suggesting these are actually the source of HSCs during development. 
 
Choi et al. recently published a major advance in the identification of the haemogenic 
endothelium. They showed that haemogenic endothelial progenitors are produced from 
haematopoietic progenitor stem cells and accurately detected based on VE-cadherin (CD144) 
expression, absence of CD73 and absence of CD235a or CD43 expression (Choi, Vodyanik et 
al. 2012). They also noted that a specific subset of endothelial progenitors was identified by 
the low expression of CD73 and high expression of CD117 (Choi, Vodyanik et al. 2012). In 
the present study, CD73 was used to differentiate haemogenic endothelium and non-
haemogenic endothelium (endothelial cells). CD73 was initially thought to be a lymphocyte 
differentiation antigen, and is now considered to function as a co-signalling molecule on T-
cells and also as an adhesion molecule that is vital for lymphocyte attachment to the 
endothelium. Many reports have outlined that CD73 is involved in physiological functions 
including epithelial ion and fluid transport, ischemic pre-conditioning, inflammation, platelet 
function, hypoxia and vascular leak (Resta, Yamashita et al. 1998, Colgan, Eltzschig et al. 
2006). 
 
Although haemogenic endothelium has been identified in the embryo, its existence, and 
contribution to HSC production in situ, in the adult bone marrow, remains highly speculative 
and is not a well-accepted concept. Clearly the rarity of the population has hampered efforts 
to isolate and characterise this population in post-natal settings. However, a number of fate 
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tracing studies provide evidence for the existence of the haemogenic endothelium post-natally 
(Jaffredo, Gautier et al. 1998, Kiel, Yilmaz et al. 2005, Kopp, Avecilla et al. 2005, Zovein, 
Hofmann et al. 2008). For example, introduction of Dil-Acetylated low-density lipoprotein 
labelled ECs into the circulation of mice produces labelled circulating blood cells (HSCs) 
(Jaffredo, Gautier et al. 1998). Genetic labelling of HECs prior to definitive haematopoiesis, 
and following their progeny HSCs through adulthood, showed that while embryonic HSCs 
continue to function in the adult, they do not account for all HSCs produced post-natally 
suggesting an endothelial origin for HSCs (Zovein, Hofmann et al. 2008). Another 
consideration is that in adult bone marrow, HSCs are known to exist in close physical 
proximity with sinusoidal ECs, and the vasculature provides an essential niche for HSC 
survival and function (Kiel, Yilmaz et al. 2005, Kopp, Avecilla et al. 2005). Whether adult 
HSCs also originate from HECs still remains a mystery. However, several studies of 
leukaemia have shown that the same chromosomal translocations and mutations found in 
HSCs are also present in ECs of the bone marrow (Gunsilius, Duba et al. 2000, Streubel, 
Chott et al. 2004, Rigolin, Fraulini et al. 2005, Della Porta, Malcovati et al. 2008, Wu, Huang 
et al. 2009) suggesting derivation of one from the other. Moreover, genetic or environmental 
factors that ablate the HSCs in bone marrow (such as irradiation) may also kill the resident 
HECs suggesting that while the haemogenic endothelium may not account for all post-natal 
production of HSCs, it cannot currently be ruled out as a contributing factor. 
 
4.1.3 Hypothesis & Aims 
Dysregulation of HSCs is believed to be the principal cause of leukaemia. However, the 
results from Chapter 3 of the present study suggest that leukaemia may also have an 
endothelial origin. The aim of this chapter was to determine the contribution of the ECs, 
HSCs and HECs to the leukaemic phenotype in SBxTie2-Cre mice. ECs, HSCs and HECs 
were isolated from bone marrow and their abilities to proliferate and differentiate were 
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assessed by in vitro colony-forming unit (CFU) assays.  
 
From reviewing the literature above, the aim tested two different hypotheses for the role of 
ECs in the leukaemic process in the SBxTie2-Cre mice (Figure 4.5). In one scenario, 
haematopoietic growth factors are secreted by ECs to accelerate HSC differentiation and 
proliferation. Support for this hypothesis would be the finding of significantly greater 
expansion of HSCs over ECs following CFU assays. In a second scenario, ECs proliferate and 
transdifferentiate into early precursors of the leukocytic lineage. Greater expansion of ECs 
over HSCs following CFU assays would support this hypothesis. 
 
 
 
Figure 4.5: Two potential ways in which endothelial cell-directed haematopoiesis may 
occur. HSC = haematopoietic stem cell and EC = endothelial cell.  
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4.2 Methods 
For details about the animal model, DNA extraction and amplification, 
immunohistochemistry and statistical analyses, see Chapter 2, Sections 2.2, 2.3, 2.6 and 2.7. 
For consumables, see Table 2.1. Cell counting is described in Chapter 3, Section 3.2.5. 
 
4.2.1 Isolation of EC and HSC populations for CFU assays  
Moribund or age-matched healthy control animals were euthanised (as described in Section 
3.2.1) and the cells from the bone marrow cavity of both femurs removed by flushing with 2% 
(v/v) foetal bovine serum in 1 x phosphate-buffered saline using a 2.5mL syringe and 21-
gauge needle. Bone marrow cells were washed three times with 2% (v/v) foetal bovine serum 
in 1 x phosphate-buffered saline followed by RBC depletion using RBC lysing buffer for five 
minutes at room temperature. This was followed by selection using magnetic beads coated 
with antibodies against CD45 (depletion), CD31 (selection of adherent cells), Sca1 
(selection), CD144 (selection) and CD73 (selection). Separation was performed using the 
autoMACS Pro Separator, which allows for automated isolation of purified cells from the 
bone marrow (Figure 4.6). A similar cell counting technique was used as in Chapter 3, 
Section 3.2.3.  
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Figure 4.6: Schematic detailing the selection strategy for the in vitro Colony Forming 
Unit (CFU) assay to study HSCs. Bone marrow cells were retrieved from WT and SBxTie2-
Cre mice, and then labelled with anti-CD45 beads in order to deplete the white blood cells. 
The non-labelled CD45- cells were labelled with anti-CD31 beads to select for the endothelial 
cells (ECs). Some of the labelled CD31+ cells were also labelled with CD144 and CD73 (to 
select for ECs). The non-labelled CD31- cells were labelled with anti-Sca1 beads to select for 
haematopoietic stem cells (HSCs) present in the bone marrow. The cells were plated for CFU 
assays for 2 weeks and then cell counts and flow cytometry were performed. 
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4.2.2 In Vitro Colony Forming Unit (CFU) Assays 
The CFU assay is an in vitro functional assay for detecting and quantifying multi-potential 
and lineage-committed haematopoietic progenitor cells in blood and bone marrow 
(STEMCELLTechnologies 2015). It is performed in a semi-solid methylcellulose-based 
medium containing growth factors and supplements specific for the growth and differentiation 
of particular colonies of cells such as myeloid and/or erythroid progenitor cells, including: 
granulocyte/macrophage, erythroid and multi-lineage progenitors (STEMCELLTechnologies 
2015). CFU assays require a culture period of at least 14 days to facilitate optimum outgrowth 
and differentiation of the optimal number of CFUs in a cell preparation. To examine colony 
formation the different populations and cell numbers were plated accordingly (Table 4.1). As 
the majority of SBxTie2-Cre mice developed lymphoproliferative disorders, MethoCult was 
utilised in this project. Given that some mice developed AML, the CFU-GM assay was 
chosen to be used as it is an established cocktail for myeloid differentiation. The number of 
seeded cells are different between the cell types due to lower yield in the bone marrow, of 
endothelial cell compared to HSC, and thus assays were standardised based on available 
populations of cells. 
 
Table 4.1: Different populations plated for CFU formation. 
Number and Population of Cells: Type of Cells: 
1x103 CD45-/CD31-/Sca1+ Haematopoietic stem cells 
1x104 CD45-/CD31+ Endothelial cells 
1x102 CD45-/CD31+/CD144+/CD73+ Non-haemogenic endothelial ells 
1x102 CD45-/CD31+/CD144+/CD73- Haemogenic endothelial cells 
 
These cells were cultured in Methocult supplemented with 15% (v/v) foetal bovine serum, 1% 
(w/v) bovine serum albumin, 2 mM L-glutamine and 50 μM 2-mercaptoethanol and cytokines 
including stem cell factor (50 ng/mL, expressed in sites of haematopoiesis), IL-3 (10 ng / mL, 
stimulates myeloid differentiation) and IL-6 (10 ng/mL, secreted by macrophages) – which 
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allow for the expansion and differentiation of myeloid cells. The cultures were incubated at 
37°C in a humidified chamber under 5% (v/v) carbon dioxide for 14 days. After 2 weeks, 
cells were washed twice with 2% (v/v) foetal bovine serum in 1 x phosphate-buffered saline 
to remove residual methylcellulose, counted (Section 3.2.5), and the resulting cell populations 
(1 x 107) prepared for flow cytometry (CD3, CD4, CD8, CD14, and CD19; see Section 3.2.5 
for method of staining) (Figure 4.6). Similar flow cytometry gating strategies from 3.2.5 were 
used with CD3, CD14 and CD19 data gated on all cells. Dead cell exclusion was performed 
using gates based on the forward and side scatter to remove debris and dead cells. Further 
information about CD markers used in this chapter is seen in Appendix 7, Table A13. 
 
4.3 Results 
4.3.1 SB Transposase Expression in SBxTie2-Cre Mice 
To confirm that the SB system was active in the bone marrow of SBxTie2-Cre mice, 
immunostaining for the SB transposase was performed. Bone marrow from SBxTie2-Cre 
mice demonstrated strong SB transposase expression in situ in the expanded leukaemic 
populations (Figure 4.7). No positive staining was seen in bone marrow from WT mice. These 
data gave the first evidence that the leukaemic populations were directly derived from cells 
expressing the Cre transgene (i.e. ECs), supporting the second hypothesis for the source of the 
leukaemic cells. 
 
Figure 4.7: Sleeping Beauty expression in the bone marrow. IHC staining for anti-
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Sleeping Beauty transposase antibody in bone marrow of WT (A) and SBxTie2-Cre (B) mice. 
Scale = 50 μm. 
4.3.2 In Vitro CFU Assays 
With confirmation of SB activity in the leukaemic cells of the bone marrow of SBxTie2-Cre 
mice, the next step was to determine the relative contributions of the ECs and HSCs to the 
leukaemic process in the bone marrow. To do this, the differentiation of each cell type was 
assessed following CFU assays. 
 
 
4.3.2.1 Assessing Differences in Proliferation of CD45-/CD31-/Sca1+ and 
CD45-/CD31+ Cells  
Following magnetic selection of CD45-/CD31+ ECs and CD45-/CD31-/Sca1+ HSCs, (Figure 
4.6) cell counts were performed and 1 x 103 Sca1+ HSCs and 1 x 104 CD31+ ECs from WT 
and SBxTie2-Cre mice were plated in CFU assays (Section 4.2.1). After culture for two 
weeks, manual cell counts were performed on the resulting cell populations (Figure 4.8). The 
cell counts after CFU assays showed no significant differences in counts for Sca1+ cells 
between the WT and SBxTie2-Cre mice (Figure 4.8A). A significant increase in the CD31+ 
cells from the SBxTie2-Cre mice compared with WT mice was evident (Figure 4.8B). These 
data suggested that the CD31+ cells had greater proliferation and may be the source of the 
leukaemic cells. However, the source of the cells was unclear and so the phenotype of the 
lineages present in the CFU assays was sought from HSCs and ECs. 
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Figure 4.8: Cell count after CFU assay of CD45-/CD31-/Sca1+ and CD45-/CD31+ cells. 
No significant differences were seen in Sca1+ cell counts for the WT and SBxTie2-Cre mice 
(A); and significantly higher counts were found for CD31+ cells (B) derived from SBxTie2-
Cre cells in relation to WT mice. Mean + SEM. * Indicates P = 0.04 (WT vs SBxTie2-Cre) by 
T-Test (Mann-Whitney). 
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4.3.2.2 Transdifferentiation Analysis of Progenitor CD45-/CD31-/Sca1+ and 
CD45-/CD31+ Cells 
Following culture, flow cytometry analysis was also performed on the CD45-/CD31-/Sca1+ 
and CD45-/CD31+ subsets for CD3, CD14 and CD19. Isolated CD45-/CD31-/Sca1+ cells 
(HSCs) gave rise to predominantly CD14+ myeloid cells with minor populations of CD3+ T-
cells, with no significant differences observed between HSCs derived from WT and SBxTie2-
Cre mice (Figure 4.9A). No differences were seen in CD19+ cell numbers from HSCs 
isolated from either genotype.  
 
Conversely, CD45-/CD31+ ECs isolated from SBxTie2-Cre mice had a significant increase in 
CD14+ cells and a relative decrease in CD19+ cells (Figure 4.9B) when compared to ECs 
from WT mice. The CD3+ T-cells counts were also elevated in the EC cultures of SBxTie2-
Cre mice although they ultimately did not reach significance due to the variability of the 
response.  
 
The variability is likely due to the development of different leukaemic phenotypes in the 
SBxTie2-Cre mice some of which would have produced “normal” levels of T-cells (such as 
the AML phenotype). This result is still noteworthy as the cytokine milieu provided in the 
CFU assays was primarily focussed on supporting myeloid differentiation and not that of 
lymphoid lineages. As such, the enhanced levels of lymphoid progeny in the CFU assays of 
SBxTie2-Cre mice are highly significant.  
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Figure 4.9: Percentage populations in CD45-/CD31-/Sca1+ HSCs and CD45-/CD31+ 
ECs from WT and SBxTie2-Cre mouse bone marrow. Cells were magnetically selected 
using the indicated strategies and plated into methylcellulose media for 2 weeks. (A) No 
differences were seen in Sca1+ haematopoietic stem cells (HSCs) between CD3 (T-cell), 
CD14 (monocyte) and CD19 (B-cell) populations in wild type and SBxTie2-Cre mice. (B) 
Significant differences were observed in CD31+ endothelial cells (ECs) between CD14 and 
CD19 populations in WT and SB mouse BM, but not in CD3 populations. Mean + SEM. ** 
Indicates P = 0.0082 and 0.0023 respectively (WT vs SBxTie2-Cre mice) by T-Test (Mann-
Whitney). 
  
-1 -1 -1 -1 -1 -1
0
20
40
60
80
100
CD3 CD14 CD19
WT (N=7)
SBxTie2-Cre (N=6)
(A)
%
 S
C
A
-1
+ 
H
SC
s
0
20
40
60
80
100
*
CD3 CD14 CD19
(A)
WT High/Low (N=7)
SB High (N=3)
SB Low (N=3)
%
 S
C
A
1+
 H
SC
s
-1 -1 -1 -1 -1 -1
0
20
40
60
80
100
** **
CD3 CD14 CD19
WT (N=7)
SBxTie2-Cre (N=6)
(B)
%
 C
D
31
+ 
E
C
s
-1 -1 -1 -1 -1 -1 -1 -1 -1
0
20
40
60
80
100
* * *
**
CD3 CD14 CD19
(B) WT High/Low (N=7)
SB High (N=3)
SB Low (N=3)
%
 C
D
31
+ 
E
C
s
                                                             Chapter 4: In Vitro Analysis of Leukaemic Precursors 
 
 243 
 
4.3.2.3 Matching the Leukaemic Phenotype to the Arising Leukocyte 
Subsets Strongly Suggests an Endothelial Basis for Leukaemia in SBxTie2-
Cre Mice  
As different phenotypes of leukaemia were identified in the SB model (ALL, AML and 
MPAL), the CFU data for the arising CD3, CD14 and CD19 subsets from the CD31-/Sca1+ 
HSCs and CD31+ ECs shown in Figure 4.9 were also graphed for the individual mice to 
understand the contribution of the different phenotypes on these results (Figure 4.10).  
 
The SBxTie2-Cre mice were separated into two groups based on CD3 and CD14 (CD3 
High and CD14 High) relative to WT mice, which are suggestive of ALL and AML 
respectively. In the CD45-/CD31-/Sca1+ population (Figure 4.10A, C, E) no distinct patterns 
were observed between the WT () and SBxTie2-Cre (CD3 High and CD14 High) mice 
with the exception that CD3 High SBxTie2-Cre mice had low CD19 counts, although this 
did not reach significance.  
 
However, in the CD45-/CD31+ population, the CFU data segregated tightly for SBxTie2-Cre 
mice when the individual phenotypes of mice were considered (Figure 4.10B, D, F). Low 
numbers of B-cells for both ALL and AML phenotypes were identified from the CFU assays  
(Figure 4.10D). This was consistent with the IHC and flow cytometry data from spleens of 
SBxTie2-Cre mice (see Chapter 3). These results indicate that there were significant 
expansions in T-cell or myeloid populations arising from the CD45-/CD31+ cells, but not the 
CD45-/CD31-/Sca1+ cells, in SBxTie2-Cre mice. These results provide support for an 
endothelial rather than HSC origin for the leukaemia in the SBxTie2-Cre mice, validating the 
second hypothesis that was proposed in this chapter. 
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CD45-/CD31-/Sca-1+     CD45-/CD31+ 
 
Figure 4.10: CD3, CD14 and CD19 populations in CD31-/Sca1+ HSCs and CD31+ ECs. 
 WT (n = 7), SBxTie2-Cre – CD3 High (n = 3) and SBxTie2-Cre – CD14 High (n = 3) 
(with representing circle colours). In Sca1+ haematopoietic stem cells (HSCs), (A) CD3 vs 
CD14, (C) CD3 vs CD19 and (E) CD14 vs CD19 populations are variable in WT and 
SBxTie2-Cre mice. (B) In CD31+ endothelial cells (ECs) distinct segregations were seen in 
(B) CD3 vs CD14, (D) CD3 vs CD19 and (F) CD14 vs CD19 populations in SBxTie2-Cre 
mice, whereas WT mice showed variable populations.  
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4.3.2.4 CD73 Analysis of Progenitor SBxTie2-Cre CD31+ Cells for the 
Haemogenic Endothelium Confirmed  
The CFU assays have confirmed the basis of ECs for the leukaemia in SBxTie2-Cre mice; 
however, the nature of EC populations giving rise to these populations was uncertain. The 
existence of the haemogenic endothelium in post-natal organisms has not been conclusively 
proven. To determine the presence and contribution of the haemogenic endothelium to the 
leukaemic phenotype in the SBxTie2-Cre mice, the CD45-/CD31+ population was stratified 
for CD73 expression.  
 
From embryonic work it is known that CD73 is a marker for mature vascular endothelium 
with the molecular signature of the haemogenic endothelium being CD45-
/CD31+/CD144+/CD73- (Choi, Vodyanik et al. 2012). Bone marrow from SBxTie2-Cre mice 
was prepared as described previously (Section 4.2.1) and CD45-/CD31+/CD144+ cells 
selected (Figure 4.5). Following magnetic separation for CD73, 1 x 102 CD73+ and 1 x 102 
CD73- cells were plated in CFU assays. The cells were cultured for 2 weeks and cell counts 
were performed to determine the proliferative capacity of the haemogenic (CD73-) and non-
haemogenic (CD73+) cells (Figure 4.6).  
 
Mature vascular (non-haemogenic) endothelial cells (CD45-/ CD31+/CD144+/CD73+) did 
not expand significantly in the CFU assays (Figure 4.11) and were therefore unlikely to be the 
population responsible for the leukaemia in SBxTie2-Cre mice. Conversely, the haemogenic 
endothelial fraction (CD45-/CD31+/CD144+/CD73-) expanded significantly and formed 
colonies of leukocytes in the CFU assays (Figure 4.11) suggesting SB-mutagenesis of these 
cells was responsible for the leukaemic phenotype. Therefore the Tie2 specific promoter / 
enhancer targeted the HECs. 
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Figure 4.11: Cell count after CFU assay of CD73+ and CD73- cells from bone marrow of 
SBxTie2-Cre mice. Significant difference was seen between non-haemogenic endothelial 
cells (CD45-/CD31+/CD144+/CD73+) and haemogenic endothelial cells (CD45-
/CD31+/CD144+/CD73-) from SBxTie2-Cre mice (). Mean + SEM from n = 4 experiments. 
* Indicates P = 0.04 vs SBxTie2-Cre by T-Test (Mann-Whitney). 
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4.4 Discussion 
Chapter 3 identified acute leukaemic phenotypes in SBxTie2-Cre mice that have SB 
mutagenesis restricted to EC populations by Tie2-Cre. In this chapter, EC populations (CD45-
/CD31+) isolated from the bone marrow of SBxTie2-Cre mice were shown to give rise to 
significantly expanded populations of lymphoid and myeloid cells. Furthermore, these EC 
populations were significantly enriched for HECs (CD45-/CD31+/CD144+/CD73-). These 
data collectively support that the endothelium, and in particular the haemogenic endothelium, 
was the origin of the leukaemia in the SBxTie2-Cre mice and provide evidence for the 
hypothesis that proliferating ECs transdifferentiated into early precursors of leukocytic 
lineage (hypothesis 2, Figure 4.5). However, hypothesis 1, haematopoietic growth factors 
secreted by ECs accelerate HSC differentiation along the HSC pathway, has not been 
excluded.  
 
From the IHC results in Chapter 3, it was observed that 21% of SBxTie2-Cre mice developed 
MPAL. This could have been due to a secondary influx of myeloid cells (monocytes), in order 
to clear out the lymphocytes in the leukaemia, suggesting that the leukaemia in these 
SBxTie2-Cre mice should be classified as ALL and not MPAL (as the monocytes are actually 
not determining the leukaemia type in this case). However, results from this chapter clearly 
identify significant elevations of myeloid subsets in CFU assays derived from CD31+ cell 
populations, which disprove that the MPAL phenotype observed in the present study is a 
secondary influx of monocytes and represents a true manifestation of MPAL. What cannot be 
confirmed is whether the MPAL leukaemia manifests from a single bi-potential precursor or 
whether individual EC clones with lymphocyte and myeloid tendencies both contribute to the 
phenotype. The nature of the mouse model is that each endothelial cell in the SBxTie2-Cre 
mice mutates differently to the one beside it so it is possible that both circumstances are 
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correct. However, it would require lineage-tracing studies (beyond the scope of this thesis) of 
the individual cells from the CFU assays to determine which of the two hypotheses are 
correct.  
 
In the present study, the Tie2-Cre line is the same one used in the Kisanuki et al. study 
(Schlaeger, Bartunkova et al. 1997, Kisanuki, Hammer et al. 2001). An interesting finding in 
the Kisanuki et al. study is the discovery of mesenchymal cells in the atrio-ventricular canal 
in the Tie2-Cre embryos at E10.5 (Kisanuki, Hammer et al. 2001) (Figure 4.12). This finding 
was originally thought to represent aberrant expression of the Tie-2 promoter in non-
endothelial populations.  
 
However; approximately five years later, Mikkola and Orkin discovered mesenchymal cells in 
the dorsal aorta of the AGM (E10) capable of giving rise to haematopoietic lineages (Mikkola 
and Orkin 2006). Based on the findings in the present study, it is believed that the 
mesenchymal cells identified by Kisanuki are misdiagnosed as mesenchymal cells and are 
more likely to be Tie2-positive HECs of the dorsal aorta (Figure 4.12). This conclusion is 
directly supported by the results from the CFU assays using CD45-/CD31+/CD114+/CD73- 
cells from bone marrow of SBxTie2-Cre mice.  
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Figure 4.12: LacZ staining observed in the aorta-gonad-mesenephros region of mouse 
embryo (images taken from Kisanuki, Hammer et al., 2001 {A} and Mikkola and Orkin, 
2006 {B}) (with permission from Elsevier and Company of Biologists respectively) 
(Kisanuki, Hammer et al. 2001, Mikkola and Orkin 2006). (A) LacZ staining of 
endothelial cells lining the endocardium. Arrows represent LacZ staining of mesenchymal 
cells in the outflow tract (Kisanuki, Hammer et al. 2001). (B) LacZ staining of mesenchymal 
cells in the dorsal aorta (Mikkola and Orkin 2006). 
 
The results in this chapter also validate the endothelial specificity of the Tie2 promoter / 
enhancer used to drive Cre expression in the SBxTie2-Cre mice. Any endothelial Cre that is 
turned on before the transient generation of haemogenic endothelium will result in a 
population of HSCs arising from the haemogenic endothelium. Using a LacZ reporter system, 
the promoter / enhancer in the Tie2-Cre mouse is active by E7.5, and at E8.5 promoter 
activity is present in the majority of ECs in the blood islands of the yolk sac but not in HSCs 
(Kisanuki, Hammer et al. 2001) thus supporting the present study. However, following 
development of the circulation, occasional circulating LacZ positive cells were observed. 
These cells likely arose from the bone-marrow resident haemogenic endothelium and 
subsequent production of a minor population of HSCs. Indeed, other “endothelial-specific” 
promoters (such as SCL/TAL-1) have been noted to result in formation of haematopoietic 
subsets as part of their activity. These results now seem appropriate and a recent study has 
                                                             Chapter 4: In Vitro Analysis of Leukaemic Precursors 
 
 250 
characterised the haemogenic endothelium as having much higher expression of Tie2, VE-
cadherin (marker used in the present study), Flk1, and c-KIT than mature endothelium (Gritz 
and Hirschi 2016). These results finally remove the confusion about the specificity of the 
promoters originally used ECs and provide multiple lines of evidence not only for the 
existence of haemogenic endothelium in adult organisms but also its contribution to post-natal 
blood cell production. 
 
A recent paper by Kartalaei et al. utilised an extremely sensitive RNAseq technique to study 
the whole transcriptome of enriched aortic HSCs, HECs and ECs (Kartalaei, Yamada-
Inagawa et al. 2015). Examination of transcriptional profiles of HEC and EC shows positive 
labelling of blood cells in transgenic mice. In HECs there is 3.7 and 2.5 fold higher 
expression of Tie1 and Tie 2 compared to ECs (Kartalaei, Yamada-Inagawa et al. 2015), 
consistent with reporter activation in blood cells from these mice (Chapter 3, Tables 3.1 and 
3.2). Similarly, SCL/Tal1 expression is also higher in HECs compared to ECs and this 
correlates with expression in blood cells (Sanchez, Gottgens et al. 1999). Moreover, c-mpl 
expression is higher in ECs than HECs. c-mpl reporters are active in blood and endothelial 
cells (Ziegler, Burki et al. 2002) and the higher expression in ECs may mean it plays a role in 
directing EC-regulation or prevents HEC-regulation. Interestingly, Kartalaei et al. discovered 
numerous HSC gene sets that were significantly enriched in HECs when compared to ECs; 
however, no significant up-regulation of these genes were established in HSCs when 
compared to HECs, signifying that haematopoietic activity is already initiated in HECs 
(Kartalaei, Yamada-Inagawa et al. 2015). 
 
The cell sorting strategy utilised in this chapter was central to the novel finding of an 
endothelial basis for the leukaemia in the SBxTie2-Cre mice. The strategy focused on 
selecting ECs (CD45-/CD31+) from non-leukocyte, non-ECs (CD45-/CD31-) which were 
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then positively selected with Sca1 for HSCs. The ECs were not further segregated by Sca1 
expression. Therefore these cells may have been a mix of both Sca1 negative and positive 
populations. Differentiated ECs in the embryo are CD31+/Sca1- (Figure 4.13). Consistent 
with the present study, there is a close relationship between HSCs, HECs and ECs in the bone 
marrow as seen in Figure 4.13. The Sca1 positive CD31+ cells were likely to represent the 
haemogenic endothelium (Kartalaei, Yamada-Inagawa et al. 2015) (Figure 4.13) and the 
existence of these cells in this population was confirmed by negative selection with CD73 in 
the present study. It would be logical and feasible that in adult organisms the HECs may 
express stem cell like markers (such as c-KIT) as they do during development [Goldie et al., 
2008; Jackson et al., 2001; Nadin et al., 2003].  
 
 
Figure 4.13: Phenotype of EC and HECs in the embryonic vasculature at E10 (image 
taken from Kartalaei et al., 2015) (with permission from Rockefeller University Press) 
(Kartalaei, Yamada-Inagawa et al. 2015). Whole-mount image showing CD31 (magenta), 
c-KIT (red), and Lys6c/Sca1 (GFP, green) staining. Taken from Kartalaei et al., 2015 
(Kartalaei, Yamada-Inagawa et al. 2015). HC = haematopoietic cell (magenta and red, 
CD31+/c-KIT+/GFP-); HSC – haematopoietic stem cell (magenta, red and green, CD31+/ c-
KIT +/GFP+); EC = endothelial cell (magenta, CD31+/c-KIT-/-GFP-) and HEC = 
haemogenic endothelial cell (magenta and green, CD31+/c-KIT-/GFP+). 
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If the cell sorting strategy had relied on segregation by Sca1, rather than CD31, expression the 
Sca1+ and CD31+ cells would have been included in the HSC population, leading to a 
different conclusion for cell of origin of the leukaemia in these mice. Indeed, use of SCA1 and 
c-KIT as markers of HSCs is a common sorting strategy adopted in many publications and the 
results from the present study suggest that many of the previous findings should be re-
analysed as the active population of haematopoietic progenitors are likely to be HECs and not 
HSCs (Choi, Kennedy et al. 1998, Lancrin, Sroczynska et al. 2010, Hirschi 2012). If one were 
to undertake such an endeavour it would make a strong case for the post-natal existence of the 
haemogenic endothelium and alter the current perceptions on the basis of leukaemia. 
 
During embryonic development, the haemogenic endothelium is present within the yolk sac, 
placenta, and aorta, and is known to give rise to HSCs (Zape and Zovein 2011, Swiers, Rode 
et al. 2013). However, there is scant evidence of the haemogenic endothelium occurring post-
natally and although adult haemogenic endothelium has been identified, its exact role is 
unclear (Hirschi 2012). This chapter provides evidence that the haemogenic endothelium 
continues to function post-natally, and may provide a niche for haematopoiesis in bone 
marrow. The location of the haemogenic endothelium in the post-natal bone marrow is not yet 
defined. However, a new type of blind-ended specialised blood vessel, the H vessel, was 
recently identified in the bone marrow (Kusumbe, Ramasamy et al. 2016).  
 
The H vessel is a capillary-sized vessel where the endothelium has a high expression of CD31 
and endomucin. H vessels have been identified in the bone marrow of young mice, secrete 
stem cell factor and are intimately associated with HSC populations (Kusumbe, Ramasamy et 
al. 2016). Activation of Notch signalling in these populations results in expansion of HSC 
niches in bone marrow (North, de Bruijn et al. 2002). Certainly, attenuation of Notch 
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signalling attenuates definitive phase haematopoiesis and prevents the development of the 
haemogenic endothelium (Robert-Moreno, Guiu et al. 2008). It is appealing to speculate that 
haemogenic endothelium may reside in these vessels as depicted in Figure 4.14 and continue 
to provide self-renewing HSCs and ECs throughout an individual’s life. In the present study, 
given that the haemogenic endothelium has been identified as the precursor to all cells, it 
seems appropriate that therefore, the HECs lead to leukaemia.  
 
The proportion of H vessels to L vessels (which have low expression of both CD31 and 
endomucin and are not associated with expansion of HSC niches) in the bone marrow 
decreases in bone with increasing age (similar to the age-related decline in haematopoiesis 
observed in mice). However, restoration of Notch signalling in the endothelium of H vessels 
reinstates the blood vessel number, increases the number of HSCs and promotes 
haematopoiesis (Kusumbe, Ramasamy et al. 2016). From embryology it is known that the 
haemogenic endothelium is capable of giving rise to committed precursors for the myeloid 
and lymphoid lineages (Chen, Li et al. 2011). It would seem that the ability of H vessels to 
restore HSC pools to bone marrow might derive from the presence of haemogenic 
endothelium in these structures. 
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Figure 4.14: Unified schematic and stained image showing how the haemogenic 
endothelium functions (image taken from Kusumbe et al. 2016) (with permission from 
Nature Publishing Group) (Kusumbe, Ramasamy et al. 2016). The stained confocal image 
on the left shows: stem cell factor (green) staining in arteries, endomucin+ (stained in red) 
staining capillaries and type H vessels (arrows; stained in yellow) from 3-week-old mouse 
tibia. Confocal image sourced from Kusumbe et al., 2016 (Kusumbe, Ramasamy et al. 2016). 
The schematic on the right represents a cycle of events in the blood vessel: (Hammersen F 
1985) (1) the endothelial cells giving rise to the HECs, thus leading to HSCs, and going back 
to the ECs to repeat the cycle; and (Fox, Gatter et al.) (2) the HECs can give rise to HSCs and 
vice versa, with perivascular HSCs leading to daughter lineages (lymphoid and myeloid 
cells). HSCs = haematopoietic stem cells, ECs = endothelial cells, HECs = haemogenic 
endothelial cells, and H vessel = high CD31 and endomucin. 
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Combining the evidence from this chapter along with current knowledge of haematopoiesis in 
the literature, it is likely that lymphoid and myeloid progenitors can be derived not only from 
HSCs but also haemogenic endothelium (Figure 4.15). The markers acquired by the 
haemogenic endothelium upon differentiation are Tie2, Kit, VE-Cadherin, CD31, and Flk-1 
(Lancrin, Sroczynska et al. 2010). The Tie2 promoter / enhancer used to drive SB in the 
mouse model of the present study and the Tie2 positive HECs are capable of giving rise to 
lymphoid or myeloid progenitors (Figure 4.15). These findings collectively establish a link 
between ECs and the rise of leukaemia through the haemogenic endothelium.  
 
 
 Figure 4.15: Multiple pathways for differentiation of leukocytes (image adapted from 
Lancrin et al. 2010) (Lancrin, Sroczynska et al. 2010).  
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The murine AGM region is considered as the primary site of intra-embryonic definitive 
haematopoiesis, which is important for the haemogenic endothelium. Lineage tracing models 
using VE-Cadherin-Cre have revealed that multi-lineage HSCs have an endothelial origin. In 
these models, RUNX1 transcription factor was demonstrated to play a vital role in facilitating 
EHT (Figure 4.16) (Zovein, Hofmann et al. 2008, Chen, Yokomizo et al. 2009). Other models 
have utilised SCA1-GFP and CD41-YFP mice to display the development of phenotypically 
defined HSCs (SCA1+, c-KIT+ and CD41+) directly from murine ventral aortic HECs 
(Figure 4.16) (Boisset, van Cappellen et al. 2010). Importantly, HECs acquire CD41 
(haematopoietic marker) in order to yield primitive and definitive HSCs, demonstrating that 
they relate to the haemogenic endothelium (Lancrin, Sroczynska et al. 2009). These 
discoveries support a model of the development of the haemangioblast in which it gives rise 
to HSCs through an intermediate precursor: the haemogenic endothelium (Figures 4.15 and 
4.16).  
 
SCL (stem cell leukaemia transcription factor) is known to be a significant transcription factor 
in haematopoiesis and plays a critical role in the generation of the haemogenic endothelium 
(Lancrin, Sroczynska et al. 2010). When SCL is absent, HSCs, HECs and ECs are also absent 
and the embryos die before E9.5, and there is a complete deficiency of yolk sac primitive 
erythrocytes and myeloid progenitors (Shivdasani, Mayer et al. 1995). In addition, several 
reports indicate that SCL is crucial for the generation of VE-cadherin+ (marker for ECs) cells 
from FLK-1+ (marker for endothelial precursors) cells, signifying that SCL is not essential to 
give rise to the haemangioblast but is vital for the generation of endothelial and 
haematopoietic lineages from the precursor (Endoh, Ogawa et al. 2002, D’Souza, Elefanty et 
al. 2005). These findings propose that SCL is essential for haematopoiesis before the 
generation of Tie2+ cells (as removal of SCL in these cells does not disturb blood cell 
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production) (Schlaeger, Mikkola et al. 2005). These studies reiterate the importance of the 
haemogenic endothelium in haematopoiesis. Figure 4.16 displays a summary of published 
murine markers of ECs, HECs and HSCs of yolk sac and AGM regions.  
 
 
  
Figure 4.16: Schematic of primitive haematopoiesis with endothelium, haemogenic 
endothelium, haematopoietic progenitors and differentiated blood cells at E10.5 in 
mouse aorta (adapted from Sills and Hirschi 2011) (Sills and Hirschi 2011). Columns are 
colour-matched with the different cell types, which display murine phenotypic markers: EC 
(endothelial cell) = orange, HEC (haemogenic endothelial cells) = green and orange, HSC 
(haematopoietic stem cell) = pink and green, and BC (blood cell) = pink. RUNX1 = 
transcription factor located at arrow where this signalling applies its effect in requirement of 
HEC and HSC. VE-cadherin = vascular endothelial cadherin and VEGFR2 = vascular 
endothelial growth factor 2. 
 
The overlap in cell surface marker expression on HECs and HSCs has further confounded 
attempts to isolate the haemogenic endothelium in adults (Section 4.1.2.2) (Gritz and Hirschi 
2016). The collective knowledge from the present study and also current literature (Figure 
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4.15) has signified the separation of HSCs from HECs and ECs in adult organisms through 
combinations of cell surface markers (Table 4.2). 
 
Table 4.2: Cell surface markers for haemogenic endothelial cells, haematopoietic stem cells 
and endothelial cells. 
Type of Cell Cell Surface Markers 
Haemogenic endothelial cells CD45-/CD41-/CD31+/CD144+/FLK-1+/BRY-/c-KIT+/CD73- 
Haematopoietic stem cells CD45-/CD41+/CD31-/CD144-/FLK-1-/BRY+/c-KIT+/SCA1+ 
Endothelial cells CD45-/CD41-/CD31+/CD144+/FLK-1+/BRY-/c-KIT+/CD73+ 
 
 
With the discovery of these populations, the question arises as to whether these differences 
can be exploited for novel therapeutic applications. In particular, is it possible to adapt the 
plasticity between HSCs, HECs and adult ECs for therapeutic benefit? The relationship 
defined above between haemogenic endothelium and the development of haematopoietic 
progenitor cells has been harnessed for engineering autologous haematopoietic grafts that 
hold potential for the treatment of various blood disorders (Sandler, Lis et al. 2014). Sandler, 
Lis et al reported that adult dermal micro-vascular ECs could be reprogrammed by 
transduction with four transcription factors (FOSB, GFI1, RUNX1 and SPI1) into multi-potent 
progenitor cells capable of producing myeloid and lymphoid cells. Indeed, grafts of adult 
thoracic aorta or inferior vena cava when transplanted under the kidney capsule of lethally 
irradiated mice prevent onset of anaemia and show persistent activation for up to 12 months 
(van Montfort, Slingsby et al. 2002). Theoretically, these data show the potential for adult 
derived haemogenic endothelium to repopulate bone marrow niches and suggest an 
alternative pathway for transplants when bone marrow is in such short supply. 
Unquestionably, transplantation of the haemogenic endothelium from the dorsal aorta can 
repopulate the multi-lineage precursors in neonatal and adult recipients where they have been 
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rendered inert (Medvinsky and Dzierzak 1996). However, it is possible that not all HECs are 
created equally and cells from different anatomical sources may not all renew HSCs niches to 
the same degree. As such, more work is required to define the precise phenotype of those with 
blood-forming capabilities and differentiate this from other endothelial cell types and HSCs in 
order to capitalise on their remarkable therapeutic potential. 
 
The above data suggest that depletion of HSCs as a result of certain genetic states or 
cytotoxicities, such as irradiation of bone marrow, may be due to loss of HECs. It is known 
that irradiation of the bone marrow destroys the resident blood vessels (Cao, Wu et al. 2011) 
along with the HSCs. It was previously assumed that the ensuing hypoxia created a 
microenvironment difficult to repopulate with HSCs; however, if the HECs were also 
destroyed then they would be unable to regenerate new HSCs and restore health to the 
irradiated bone marrow. Donor HSCs have been shown to give rise to endothelial precursors 
after transplantation (Bailey, Jiang et al. 2004) indicating that plasticity in the HSC-HEC 
lineage is crucial for repopulation of bone marrow after transplant. Adopting adjunct therapies 
that protect the bone marrow endothelium from irradiation injury or that encourage plasticity 
in the formation of HECs from HSCs would seem likely to support the success for bone 
marrow transplantion and offer alternative avenues for therapy.   
 
In summary, the work in this chapter has contributed to increasing the understanding of the 
cellular mechanisms of haematopoiesis. Specifically, in vitro differentiation of HECs allowed 
access to numerous cells at an early phase of development and in so doing provided further 
support for the existence of haemogenic endothelium in post-natal development. This is a 
growing area of research and, comprehensive temporal, spatial and functional characterisation 
of the haemogenic endothelium in the adult may lead to better understanding of current and 
new therapeutic targets for leukaemia and other diseases.   
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5.1 Introduction 
In Chapter 3, a leukaemia phenotype was discovered in the SBxTie2-Cre mice. In this 
chapter, the genes affected by SB-mediated random mutagenesis of the endothelial genome 
were identified. The SB system involves two components: (1) a transposon or DNA mobile 
element and; (2) the SB transposase enzyme that recognises sequences within the transposon 
and mobilises them. The co-occurrence of both these elements leads to a “cut-and-paste” 
mechanism where excision of the transposon occurs and is subsequently re-integrated at a 
new site elsewhere within the genome. While the mobilisation is random, it has the tendency 
for “local hopping” where transposons re-insert at sites close to the donor locus. Local 
hopping is a common element of 'cut and paste' transposons (Keng, Yae et al. 2005, Ivics and 
Izsvak 2010).  
 
A significant feature of the SB system is its ability to reliably reiterate the course of 
tumorigenesis as it arises in humans (Riordan, Drury et al. 2014). Somatic mutations 
accumulate in a stepwise approach, driving a micro-evolution within the developing tumour 
wherein those mutations that present a selective advantage to cells are favourably sustained 
(Riordan, Drury et al. 2014). Positive selection for these mutation events leads to selective 
clonal expansion of the cells harbouring them. Clonal expansion of transposon insertions can 
be measured by examining the comparative sections of sequence reads acquired from 
insertions in individual tumours (Friedel, Friedel et al. 2013, Riordan, Drury et al. 2014). 
 
T2/Onc2 is a transposon that was synthesised to initiate both gene loss- and gain-of-function 
insertional mutations (Chapter 1, Figure 10). These mutations would be evident by the unique 
transposon sequences and may be utilised later to detect driver genes and/or mutations. When 
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the T2/Onc2 transgene was combined with ubiquitous expression of SB transposase in wild-
type or cancer predisposed mice, mice developed sarcoma and T-cell leukaemia (Collier, 
Carlson et al. 2005, Dupuy, Akagi et al. 2005). In both of these cancers, the tumours induced 
by SB were characterised by somatic, transposon insertions that occurred at frequently 
mutated known and novel cancer genes (Collier, Carlson et al. 2005, Dupuy, Akagi et al. 
2005). 
 
Next generation sequencing was performed in this chapter to discover transposon insertion 
sites. Sites altered by insertions considerably more often than expected by random 
coincidence are termed: common insertion sites (CIS) and are postulated to identify potential 
driver mutations in the tumours. Many reports have compared CIS from SB screens with 
human tumour mutations, and have identified CIS in genes linked to mutations and/or 
amplifications in human cancers such as: colorectal cancer, pancreatic cancer, 
medulloblastoma, and malignant peripheral nerve sheath tumours (March, Rust et al. 2011, 
Mann, Ward et al. 2012, Perez-Mancera, Rust et al. 2012, Wu, Northcott et al. 2012, 
Rahrmann, Watson et al. 2013). 
 
 
5.1.1 Aim 
As SBxTie2-Cre mice displayed leukaemia, the next step was to identify the genes 
responsible for the different subsets of acute leukaemias. The aim of this chapter was to 
identify the genes responsible in SBxTie2-Cre leukaemic mice. 
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5.2 Methods 
For animal model and details of DNA analysis (including excision PCR on spleen and 
thymus) see Chapter 2, Sections 2.2 and 2.3 respectively. For IHC experiments, see Section 
2.6. For consumables, see Table 2.1. 
 
5.2.1 DNA Purification 
After extraction, DNA from spleens and thymii from SBxTie2-Cre mice were purified using 
the QIAamp DNeasy Blood and Tissue Kit as per manufacturer’s protocol. Frozen SBxTie2-
Cre spleens and thymii were cut into small pieces on a petri dish over dry ice and then placed 
into a 1.5 mL microcentrifuge tube with appropriate buffer and proteinase K. The samples 
were vortexed briefly and incubated at 56°C overnight until the tissues were completely 
lysed. Appropriate buffer and 96-100% ethanol were then added and the sample briefly 
vortexed again. The mixture was transferred into a DNeasy Mini spin column, centrifuged at 
6,000 g for 1 minute and the flow-through discarded. The DNeasy Mini spin column was 
placed in a new collection tube with appropriate buffer added and centrifuged at 6,000 g for 1 
minute, with the flow-through discarded again. The DNeasy Mini spin column was placed in 
a new collection tube with appropriate buffer, centrifuged at 20,000 g for 3 minutes and the 
flow-through discarded. These steps remove residual ethanol that may interfere with 
subsequent reactions. The gDNA was finally eluted by addition of buffer to the DNeasy Mini 
spin column, incubation at room temperature for 1 minute and centrifugation at 6,000 g for 1 
minute. The elution step was repeated to increase overall gDNA yield. The gDNA samples 
were adjusted to 100ng/µL with 4µg of DNA sent for targeted deep sequencing. 
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5.2.2 Targeted Deep Sequencing 
Targeted deep sequencing was performed by Associate Professor Adam Dupuy (University of 
Iowa) on an Illumina platform as a paid service (Rogers, Olivier et al. 2013, Bard-Chapeau, 
Nguyen et al. 2014). Mutations occur by insertion of a transposon within the gene. If the 
sequence flanking each mobilised transposon can be determined, the genes affected by CIS 
can be identified by simple blast alignment (Figure 5.1).  
 
The Illumina sequencing technology functions in three phases: amplify, sequence, and 
analyse. In order to identify mutations, tumour DNA is firstly digested with two restriction 
enzymes that have known sites at each end of the transposon (Janik and Starr 2013). Both 
enzymes are 4-bp cutters so restriction sites are relatively frequent and the fragments 
containing the ends of the transposons to be relatively small, and easily amplified (Figure 
5.1). After digestion, adaptors are ligated to the fragments enabling their amplification by 
PCR. Illumina library preparation was completed through ligation-mediated PCR (LM-PCR).  
 
A second round of PCR is performed with nested primers that are “barcoded” – contain 
unique sequences to identify the tumour from which it was amplified (Janik and Starr 2013). 
The purified, nested and barcoded products from up to 200 tumours are combined and then 
deep sequenced using the generic primers (Figure 5.1). Bioinformatic algorithms map the 
reads to the mouse genome to identify the chromosomal regions and genes that harbour the 
transposon insertions. To remove bias due to “local hopping”, insertions sites near the 
location of the transposon transgene (part of chromosome 1) were removed from the 
downstream analysis. Of the genes mutated and identified, the genes most often targeted are 
the most likely drivers of the phenotype.  
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Figure 5.1: Identification of Sleeping Beauty mutated genes. T2 = transposon; IR = 
inverted repeats and DR = direct repeats. Adapted from (Janik and Starr 2013) 
 
5.2.3 In Silico Analysis of Gene Expression in Human Cancers 
The Cell Line Encyclopedia project (http://portals.broadinstitute.org/ccle/home) is a 
collaboration (between the Broad Institute, the Novartis Institutes for Biomedical Research 
and Genomics) to conduct a detailed genetic characterization of a large panel of human cancer 
cell lines. It offers public access to genomic data, analysis and visualisation of DNA copy 
number, mRNA expression, and mutation data for 1000 cancer cell lines. 
 
The data is represented in Robust Multi-Array Average (RMA) Log 2. RMA is the most 
commonly utilised pre-processing algorithm for Affymetrix gene expression microarrays 
(McCall, Jaffee et al. 2012). The raw intensity values are background corrected, log2 
transformed and then quantile normalised. Log 2 is used for convenient comparison of gene 
expression rates, e.g. a doubled expression rate can be defined by a log ratio of 1, a halved 
expression rate can be defined by a log ratio of −1, and an unchanged expression rate can be 
defined by a log ratio of 0 (Causton, Quackenbush et al. 2009). 
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The Database for Annotation, Visualization and Integrated Discovery (DAVID; v6.7) 
(https://david.ncifcrf.gov/) provides a complete set of functional annotation tools for 
researchers to recognise biological significance behind various genes.  
 
The cBioPortal for Cancer Genomics (http://www.cbioportal.org/) was originally developed 
at Memorial Sloan Kettering Cancer Center. The public cBioPortal site is hosted by the 
Center for Molecular Oncology at MSK. It provides visualisation, analysis and download of 
large-scale cancer genomics data sets.  
 
5.3 Results 
5.3.1 Confirmation of Sleeping Beauty Transposase Activity in Spleens and 
Thymii of SBxTie2-Cre Mice 
The leukaemic phenotype observed in SBxTie2-Cre mice was assumed to result from SB-
mediated insertional mutagenesis. Prior to identification of the SB mutated genes responsible 
for the leukaemia it was important to confirm the activity of SB in the tissues to be sequenced.  
Immunohistochemical assessment of spleens and thymii from SBxTie2-Cre mice revealed 
extensive Sleeping Beauty transposase expression. Representative results are shown in Figure 
5.2A. WT mice were negative for expression as expected. 
 
5.3.2 Identification of Tissues with Transposon Mobilisation 
Activity of Sleeping Beauty insertional mutagenesis requires transposase enzyme expression 
(Figure 5.2A) and mobilisation of transposons. Whilst IHC can display transposase 
expression in tissues, it does not provide direct confirmation of transposon mobilisation. This 
was determined by PCR. For this analysis, DNA was extracted from thymus and spleen of 
SBxTie2-Cre mice. Using PCR, an excised transposon has an amplicon length of 233 bp, 
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whilst the unmobilised transposon has a PCR product of 2.4 kb (Figure 5.2B). The majority of 
tissues assessed were positive for excision PCR (Figure 5.2B and Table 5.1) as denoted by the 
233 bp band. Three spleens showed no result (such as lane 2) and were excluded from further 
analyses (Table 5.1). One of these was not significantly larger than WT and was diagnosed as 
MPAL. The other two spleens were significantly larger than WT with one classified as ALL 
and the other as AML.  
(A)                                    
 
(B) 
 
Figure 5.2: Sleeping Beauty expression and activity in the spleen and thymus.  
(A) Immunohistochemistry staining for anti-Sleeping Beauty transposase antibody in WT: (i) 
spleen and (ii) thymus. Scale bar = 500μm. (B) 2% agarose gel electrophoresis of T2ONC2 
excision PCR. Excised transposon: 233 bp (base pair) band, or non-excised transposon 2.4 kb 
(kilo-base). M: molecular weight marker; Lane 2: template WT control showing the non-
excised transposon band; Lanes 3,5 – 7,9: DNA samples from spleens of SBxTie2-Cre mice; 
Lanes 1,4,8,10: DNA samples from thymus of SBxTie2-Cre mice; Lane N: no template 
negative PCR control. 
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Table 5.1: Details of excision PCR results and specimens sent for targeted deep sequencing. 
Leukaemia 
Subtype ID 
Spleen 
DNA 
Spleen 
Excision 
PCR 
Thymus 
DNA 
Thymus 
Excision 
PCR 
Sequencing Data 
ALL 2334 Yes + Yes + No overlap 
ALL 2340 Yes + Yes + No overlap 
ALL 2389 Yes + Yes + No overlap 
ALL 2401 Yes + Yes + No overlap 
ALL 2522 Yes * Yes + Thymus only 
ALL 2357 Yes + Yes + Overlapping mutations 
ALL 2366 Yes + Yes + Overlapping mutations 
ALL 2368 Yes + Yes + Thymus only 
ALL 2376 Yes + Yes + No overlap 
ALL 2383 Yes + Yes + No overlap 
ALL 2422 Yes + Yes + No overlap 
ALL 2345 Yes + No N/A Spleen only 
ALL 2354 Yes + No N/A Spleen only 
ALL 2403 Yes + No N/A Spleen only 
ALL 2523 Yes + No N/A Spleen only 
ALL 2361 Yes + No N/A Spleen only 
ALL 2378 Yes + No N/A Spleen only 
ALL 2421 Yes + No N/A Spleen only 
ALL 2517 Yes + Yes + No overlap 
ALL 2420 Yes + Yes + No overlap 
ALL 2425 Yes + Yes + No overlap 
ALL 2395 Yes + Yes + No overlap 
ALL 2364 Yes + Yes + Overlapping mutations 
ALL 2386 Yes + Yes + Overlapping mutations 
ALL 2424 Yes + Yes + Overlapping mutations 
ALL 2372 Yes + No N/A Spleen only 
AML 2367 Yes + No N/A Spleen only 
AML 2427 Yes + Yes + No overlap 
AML 2399 Yes + No N/A Spleen only 
MPAL 2520 Yes + Yes + No overlap 
MPAL 2526 Yes * Yes + Thymus only 
MPAL 2518 Yes + No N/A Spleen only 
MPAL 2393 Yes * Yes + Thymus only 
MPAL 2396 Yes + Yes + No overlap 
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MPAL 2406 Yes + Yes + Overlapping mutations 
MPAL 2519 Yes + Yes + Overlapping mutations 
MPAL 2524 Yes + Yes + Overlapping mutations 
MPAL 2365 Yes + Yes + No overlap 
MPAL 2525 Yes + No N/A Spleen only 
N/A 2374 Yes + No N/A Spleen only 
N/A 2362 Yes + Yes + No overlap 
 
Blue = male (n=21); red = female (n=20). ALL = acute lymphoblastic leukaemia; AML = 
acute myeloid leukaemia; and MPAL = mixed phenotype acute leukaemia. * = No result. N/A 
= not available. Green highlighted regions = no mutation results for spleen, and yellow 
highlighted regions = no mutation results for thymus (regardless of positivity for excision 
PCR). 
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5.3.3 Overview of Sequencing Results 
In total, 66 DNA samples (38 = spleen; 28 = thymus) from 41 mice were sent for deep 
sequencing for identification of Sleeping Beauty mutated genes (Table 5.1; see Appendices 
Table A9). Of these, 25 SBxTie2-Cre mice had matched gDNA from both spleen and thymus 
(n=50) and 16 mice had gDNA from either spleen (n=13) or thymus (n=3) sent for sequencing 
(Table 5.1). The subtype of leukaemia was based on spleen IHC data of SBxTie2-Cre mice 
from Chapter 4 with 26 mice having ALL, 3 having AML, 10 having MPAL and 2 with 
indeterminate results (Table 5.1). 
Due to local hopping, insertions close to the donor transposon on chromosome 1 were 
removed, as these insertions are not considered random. Following removal of these 
insertions, a total of 5286 insertion sites were found in the 66 samples (see Appendices, Table 
A10). The average number per sample was 80 and the number of insertions ranged from 13 to 
196. The highest number of insertions was found in the thymus from mouse #2344 and the 
lowest number in spleen from mouse #2523 and thymus from mouse #2424. There was no 
relationship between the number of insertions and either leukaemia subtype or tissue type.  
 
The number of times a gene needed to be identified in the cohort to be recognised as a CIS 
was 3 (minimum pattern which are unlikely to occur by chance) (Dupuy, Akagi et al. 2005). 
This was determined from Monte Carlo simulations on randomly generated TA-insertion 
sites.  When the genes were filtered for 3 or more insertions across all samples, 206 CIS were 
identified (see Appendices, Table A11). Following this filtering, 1 spleen sample contained 
none of the CIS and was removed from analysis (highlighted in green in Table 5.1). Of the 25 
mice with matched spleen and thymus DNA, significant overlaps in CIS were noted for 8 
mice (5 with ALL and 3 with MPAL). In 4 cases, thymus DNA contained only CIS 
overlapping with the spleen DNA and these thymus samples were removed from the analysis 
(highlighted in yellow in Table 5.1). 
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5.3.4 Commonly Mutated Genes 
In the combined CIS results, 3 genes were mutated in at least one third (≥ 20) of DNA 
samples. These were Erg (mutated in 29 samples) Notch1 (23 samples) and Ets1 (20 
samples). In the cohort of splenic DNA samples (n = 37) 134 CIS were identified with Ets1, 
Erg and Ncoa2 insertions in at least one third (≥ 12) of these samples. Similarly, 39 CIS were 
found in the cohort of thymic DNA isolates (n = 24) and insertions in the Erg, Notch1 and 
Zmiz1 genes were present in at least one third (≥ 8) of the samples. It was beyond the scope of 
this thesis to determine the consequence of each mutation – whether it is activating, loss of 
function or neutral. However, the fact that a gene is mutated more commonly that expected by 
chance (i.e. a CIS), means the mutation is likely functional. Indeed, all 5 genes listed above 
are described as mutated or altered at the chromosomal level in human leukaemia, providing 
proof of principle for the relevance of the identified CIS to human leukaemia. 
 
5.3.4.1 Gene Ontology 
The genes with insertion sites in at least 10% of samples in a leukaemia subtype are listed in 
Table 5.2. Of these, 25% (18/70) have known associations with human cancers, 
predominantly mutations or chromosomal aberrations. To identify pathways, biological 
processes and molecular functions enriched in this gene set DAVID bioinformatics database 
V6.7 was utilised. Following high stringency functional annotation clustering, AML, CML 
and Pathways in Cancer were identified as the most highly enriched cluster for KEGG 
pathways (Enrichment Score 6.95; KEGG, Table 5.2). The top Gene Ontology (GO) 
Biological Processes cluster (Enrichment Score 6.8) comprised regulation of myeloid cell 
differentiation, and positive regulation of cell differentiation and developmental processes 
(GO-BP in Table 5.2). The top GO molecular function cluster (Enrichment Score 3.99) 
comprised transcription factor or regulator activity and DNA binding (GO-MF in Table 5.2). 
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Table 5.2: Commonly mutated genes.  
The percentage of cases with an insertion site in each gene is listed for each leukaemia 
subtype. Only genes with insertion sites in at least 10% of cases are included. Associations 
with cancer are limited to chromosomal changes and mutations unless otherwise noted; * = 
significant difference (P < 0.05, Fisher’s exact test), the subtypes with significantly increased 
insertion sites are highlighted by grey shading; NHL = non-Hodgkin’s lymphoma; AML = 
acute myeloid leukaemia; CML = chronic myeloid leukaemia; CMML = chronic 
myelomonocytic leukaemia; DLBCL = diffuse large b-cell lymphoma; CRC = colorectal 
carcinoma; APL = acute promyelocytic leukaemia; APLL = anaplastic large cell lymphoma;  
(a): epigenetic silencing; and (b): aberrant expression co-operates with NOTCH1 mutations in 
ALL (acute lymphoblastic leukaemia). 
 
% Insertion/Leukaemia Subtype Associations of human gene with cancer 
Murine Gene 
ALL 
(n=29) 
AML 
(n=3) 
MPAL 
(n=17) 
 
Erg 48 0 47 
AML, prostate cancer, sarcoma, GO-MF-
TF, TR, DNA 
Notch1 41 0 47 
T-ALL, CLL, CMML, multiple solid 
cancers, GO-BP-diff, GO-MF-TF, TR, 
DNA 
Ets1 31 33 53 
AML, ALL, lymphoma, GO-BP-diff, 
GO-MF-TF, TR, DNA 
Ghr* 31 0 0 
 
Ikzf1* 31 0 0 
ALL, DLBCL, GO-BP-diff, GO-MF-TF, 
TR, DNA 
Ncoa2 31 67 24 
AML, CRC, chondrosarcoma, GO-MF- 
TR, DNA 
Pard3b 31 0 29 
 Sos1 31 33 18 KEGG-AML, CML, CA, GO-MF-DNA 
Tmeff2 31 0 24 Multiple solid cancers (a) 
Dis3l2* 28 0 0 Wilms tumour 
Stat5b* 28 0 0 
APL, APLL, basal cell skin cancer, 
KEGG-AML, CML, CA, GO-BP-diff, 
GO-MF-TF, TR, DNA 
Smap1* 24 0 0 GO-BP-diff 
Zmiz1 24 0 35 ALL 
Aff3 21 33 18 Lymphoma, GO-MF-TF, TR, DNA 
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Cntnap5a 21 67 0 
 Myo1b 21 0 0 
 Otop3 21 0 0 
 Sik3 21 0 0 
 
Akt2 17 0 0 
Breast, pancreatic cancer, KEGG-AML, 
CML, CA 
Ankrd44 17 0 0 
 
Bcl2 17 0 18 
B-cell Leukaemia, NHL, KEGG-CA, GO-
BP-diff, GO-MF-TR 
Ptpn4 17 67 0 
 Rasgrp1 * 17 0 47 (b) 
Rpe 17 0 0 
 Sdccag8 17 0 18 
 Trip12 17 0 18 
 Atf3 14 0 18 GO-MF-TF, TR, DNA 
Fam71a 14 0 0 
 Gls 14 0 0 
 Kcnq5 14 33 0 Colorectal cancer (a) 
Rasgrf1 14 33 0 
 
Runx1 14 0 18 
T-ALL, AML, preB-ALL, KEGG-AML, 
CML, CA, GO-BP-diff, GO-MF-TF, TR, 
DNA 
Srgap2 14 0 18 
 Agfg1 10 0 0 GO-MF-DNA 
Asb3 10 0 0 
 Bend5 10 0 0 
 
Braf 10 0 0 
NHL, multiple solid cancers, KEGG-
AML, CML, CA 
C1qtnf6 10 0 0 
 Col4a3 10 33 0 
 Dyrk1a 10 0 0 
 Erlec1 10 0 0 
 Gigyf1 10 0 0 
 Gigyf2 10 0 0 
 Gm13476 10 33 0 
 Gulp1 10 33 0 
 
Kras 10 33 0 
Multiple solid cancers, KEGG-AML, 
CML, CA 
Phlpp1 10 0 0 
 Plag1 10 0 0 GO-MF-DNA 
Pop7 10 0 0 
 Prdm14 10 33 0 
 Rere 10 0 0 GO-MF-TF, TR, DNA 
Rnf149 10 0 0 
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Slc39a10 10 0 0 
 
Stat5a 10 0 24 
KEGG-AML, CML, CA, GO-BP-diff, 
GO-MF-TF, TR, DNA 
Zeb2 10 33 0 GO-MF-TF, TR, DNA 
Cyp20a1 0 33 0 
 Dennd1b 0 33 0 
 Fam117b 0 33 0 
 Fam126b 0 33 0 
 Fli1 0 33 0 GO-MF-TF, TR, DNA 
Flt3 0 33 0 AML, ALL, KEGG-AML,CA 
Il1r1* 0 67 0 
 Il3 0 33 0 GO-BP-diff 
Lmbrd1 0 33 0 
 Mff 0 33 0 
 Mir30c-2 0 33 0 
 Pcmtd1 0 33 0 
 Satb2 0 33 0 GO-MF-TF,TR, DNA 
Stat4 0 33 0 GO-MF-TF, TR, DNA 
Trerf1* 0 0 18 GO-MF-DNA 
KEGG-AML, CML, CA: genes annotated in the KEGG pathways for AML, CML and cancer 
(DAVID database); GO-BP-Diff: genes annotated in DAVID for the gene ontology biological 
processes of Regulation of myeloid cell differentiation (GO:0045637; NB Notch1 and Bcl2 
are not included in this process) and positive regulation of cell differentiation (GO:0045597) 
and developmental processes (GO:0051094); GO-MF-TF, TR, DNA: Genes annotated in 
DAVID for the gene ontology molecular functions of transcription factor activity (TF; 
GO:0003700), transcription regulator activity (TR: GO:0030528) and DNA binding (DNA: 
GO:0003677).  Erg = (erythroblast transformation-specific (Kusumbe, Ramasamy et al.) 
transcription factor); Ets1 = (E26 avian leukaemia oncogene 1, 5' domain); Ghr = Growth 
hormone receptor; Ikzf1 = Ikaros family zinc finger protein 1; Ncoa2 = nuclear receptor 
coactivator 2; Pard3b = Partitioning defective 3 homolog B; Sos1 = Son of sevenless 
homolog 1; Tmeff2 = transmembrane protein with EGF-like and two follistatin-like domains 
2; Dis3l2 = DIS3 like 3'-5' exoribonuclease 2; Stat5 = signal transducer and activator of 
transcription 5; Smap1 = stromal membrane-associated protein 1; Zmiz1 = zinc finger MIZ-
type containing 1; Aff3 = AF4/FMR2 family member 3; Cntnap5a = contactin associated 
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protein-like 5A; Myo1b = myosin IB; Otop3 = otopetrin 3; Sik3 = serine/threonine-protein 
kinase 3; Ankrd44 = ankyrin repeat domain 44; Bcl2 = B-cell lymphoma 2; Ptpn4 = protein 
tyrosine phosphatase, non-receptor type 4; Rasgrp1 = ras guanyl nucleotide-releasing protein 
1; Rpe = ribulose-5-phosphate-3-epimerase; Sdccag8 = serologically defined colon cancer 
antigen 8; Trip12 = thyroid hormone receptor interactor 12; Atf3 = activating transcription 
factor 3; Fam71a = family with sequence similarity 71 member a; Gls = glutaminase 2; 
Kcnq5 = potassium voltage-gated channel, subfamily Q, member 5; Rasgrf1 = ras protein 
specific guanine nucleotide releasing factor 1; Runx1 = runt related transcription factor 1; 
Srgap2 = SLIT-ROBO Rho GTPase activating protein 2; Agfg1 = ArfGAP with FG repeats 1; 
Asb3 = ankyrin repeat and SOCS box-containing 3; Bend5 = BEN domain containing 5; 
C1qtnf6 = C1q and tumour necrosis factor related protein 6; Col4a3 = collagen, type IV, 
alpha 3; Dyrk1a = dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a; Erlec1 = 
endoplasmic reticulum lectin 1; Gigyf = GRB10 interacting GYF protein; Gulp1 = engulfment 
adaptor PTB domain containing 1; Kras = v-ki-ras2 kirsten rat sarcoma viral oncogene 
homolog; Phlpp1 = ph domain and leucine rich repeat protein phosphatase 1; Plag1 = 
pleomorphic adenoma gene 1; Prdm14 = pr domain containing 14; Rere = arginine-glutamic 
acid dipeptide repeats; Rnf149 = ring finger protein 149; Slc39a10 = solute carrier family 39 
member 10; Zeb2 = zinc finger E-box binding homeobox 2; Cyp20a1 = cytochrome P450 
family 20 subfamily A member 1; Dennd1b = DENN domain containing 1B; Fam117b = 
family with sequence similarity 117 member B; Fam126b = family with sequence similarity 
126 member B; Fli1 = friend leukaemia integration 1 transcription factor; Flt3 = fms like 
tyrosine kinase 3; Ili1r = interleukin 1 receptor, type I; Il3 = interleukin 3; Lmbrd1 = LMBR1 
domain containing 1; Mff = mitochondrial fission factor; Mir30c-2 = microRNA 30c-2; 
Pcmtd1 = protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1; 
Satb2 = special AT-rich sequence binding protein 2; Stat4 = signal transducer and activator of 
transcription 4 and Trerf1 = transcriptional-regulating factor 1.       
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5.3.5 Differences in CIS across the Leukaemia Subtypes 
To identify whether specific patterns of CIS exist for each leukaemic subtype, the percentage 
of samples of each subtype containing each CIS was determined. The results are shown in 
Table 5.2. The 3 most commonly mutated genes (Erg, Notch1 and Ets1) were found in both 
ALL and MPAL samples, with only Ets1 also found in AML. Assessment of mice with paired 
thymic and splenic DNA samples showed that every ALL mouse (Figure 5.3, n = 11) and 
80% of MPAL mice (Figure 5.3, n = 5) had an Erg mutation. Ets1 mutations were found in 
70% (8/11) of ALL mice and 60% (3/5) of MPAL mice, and in only one of these cases an 
Ets1 mutation was not found in spleen. Notch1 mutations were found in 60% of cases from 
both subtypes and in MPAL mice these mutations were found in both thymus and spleen.  
 
A signature of genes indicative of leukaemia, without reference to subtype, emerged (Ets1, 
Ncoa2, Sos1, Aff3, Cntnap5a, Ptpn4, Kcnq5, Rasgrf1, Col4a3, Gm13476, Gulp1, Kras, 
Prdm14 and Zeb2). These genes were present in ALL, AML and MPAL, although mostly the 
ALL and AML groups, and reveal the common phenotype in all the leukaemias in the 
SBxTie2-Cre mice. When considering acute lymphoblastic leukaemia, a common signature 
for ALL and MPAL (Erg, Notch, Pard3b, Tmeff2, Zmiz1, Bcl2, Sdccag8, Trip12, Atf3, Runx1, 
Srgap2 and Stat5a) and ALL-specific genes (Ghr, Ikzf1, Dis3l2, Stat5b, Smap1, Myo1b, 
Otop3, Sik3, Akt2, Ankrd44, Rpe, Fam71a, Gls, Agfg1, Asb3, Bend5, Braf, C1qtnf6, Dyrk1a, 
Erlec1, Gigyf1, Gigyf2, Phlpp1, Plag1, Pop7, Rere, Rnf149 and Slc39a10) both arose. The 
ALL-specific genes were not mutated in AML or MPAL indicating their unique signature.  
Similarly, an AML specific signature (Cyp20a1, Dennd1b, Fam117b, Fam126b, Fli1, Flt3, 
Il1r1, Il3, Lmbrd1, Mff, Mir30c-2, Pcmtd1, Satb2 and Stat4) was identified and this was 
exclusive of ALL and MPAL whilst only 3 genes (Trerf1, Rasgrp1 and Stat5a) were mutated 
more frequently in MPAL that in ALL or AML (Table 5.2). 
      Chapter 5: Identification of Genetic Alterations in Leukaemic SBxTie2-Cre Mice 
 
 287 
When gene changes were assessed in mice with matched splenic and thymic gDNA samples, 
ALL samples were found to show a higher mutational load in spleen than thymus (Figure 5.3) 
while this was not evident for MPAL (Figure 5.3), suggesting greater splenic involvement in 
the pathogenesis of ALL then MPAL. This is supported by data in Figure 3.35A suggesting 
greater involvement of spleen than bone marrow in the CD3 positive leukaemias in SBxTie2-
Cre mice compared to WT. Indeed, splenic and thymic CIS for MPAL samples agreed far 
more often than those for ALL (Figure 5.3) although the sample sizes for this analysis (11 vs 
5 samples) may have affected the associations observed. 
 
For this data set, it is easier to consider if the CIS was found in a large number of samples (> 
24% of mice) and signatures associated with each of the leukaemic subtypes (Table 5.3).  
 
Table 5.3: Genes commonly found in different subsets of leukaemia in > 24% of SBxTie2-
Cre mice. 
Subsets of Leukaemia: Genes: 
All leukaemia Ets1, Ncoa2, Sos1, Aff3, Cntnap5a 
All lymphoid leukaemia Erg, Notch1, Pard3b, Tmeff2, Zmiz1 
Acute lymphoblastic leukaemia Ghr, Ikzf1, Dis3l2, Stat5b, Smap1 
Acute myeloid leukaemia Cyp20a1, Dennd1b, Fam117b, Fam126b, Fli1, Flt3, 
Il1r1, Il3, Lmbrd1, Mff, Mir30c-2, Pcmtd1, Satb2, 
Stat4 
Mixed phenotypic acute leukaemia Rasgrp1, Stat5a 
 
Whilst genes targeted in less than 24% of tumours are still prominent drivers of disease in 
human leukaemias (indeed ETS1 is mutated in only 33% and 31% of AML and ALL 
respectively, and is a significant driver of disease in humans) for simplicity more robust 
associations were focused on for further analysis. 
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            (A)                        (B) 
 
Figure 5.3: Mutated genes identified in spleen and thymus of SBxTie2-Cre mice 
classified as ALL (A) and MPAL (B). Mouse IDs are shown at the top of each column. 
Coloured boxes indicate presence of mutations for the listed gene for that mouse. = 
mutations present in spleen and thymus; = spleen only and = thymus only. Paired samples 
of spleen and thymus only.  
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5.3.6 Mutation Profile for all Forms of Leukaemia in SBxTie2-Cre Mice 
with Associations to Human Leukaemia 
Five genes were identified to be to be present in > 24% of tumours with mutations in all 
leukaemias (ALL, AML and MPAL). 
 
5.3.6.1 Ets1 (E26 avian leukaemia oncogene 1, 5' domain) 
ETS1 is vital in the development of lymphoid tissues (Maroulakou and Bowe 2000). In adults 
ETS1 is expressed in B- and T-Cells at all stages of growth and development; and also natural 
killer cells (Barton, Muthusamy et al. 1998, Anderson, Hernandez-Hoyos et al. 1999).  
Endothelial and vascular smooth muscle cells rapidly produce ETS1 upon stimulation by 
angiogenic factors (e.g. VEGF, bFGF, TNFα, angiotensis II, endothelin-1) (Hultgardh-
Nilsson, Cercek et al. 1996, Naito, Shimizu et al. 1998, Tanaka, Oda et al. 1998, Yasuda, 
Ohzeki et al. 1999, Goetze, Kintscher et al. 2001). Increased ETS1 expression is common in 
T-ALLs (Sacchi, de Klein et al. 1988) and this is reflected in The Cell Line Encyclopedia data 
that shows highest expression in T-cell ALL followed by B-cell ALL with a relatively narrow 
range (Figure 5.4) although AML also had increased expression when compared with other 
leukaemias. The human data suggests that the Ets1 mutations are most likely to be activating 
mutations. In the SBxTie2-Cre mice Ets1 mutations occurred in all three leukaemia subtypes 
(Table 5.2) and paired sample analysis shows that they were commonly found in the spleen.  
 
For delineation of the Y-axis for Figures 5.4-5.10, see Section 5.2.3. 
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Figure 5.4: Analysis of ETS1, NCOA2, SOS1, and AFF3 genes using The Cell Line 
Encyclopedia showed enhanced mRNA expression level of each gene in all ALL and 
AML (compared between the subtypes). (Accessed – September 2016). B-Cell ALL 
(n=15); T-Cell ALL (n=16); AML (n=34); CML (n=15) and Leukaemia Other (n=1).  
 
 
5.3.6.2 Ncoa2 
The ETV6 gene was described to be fused with several genes in numerous haematological 
malignancies with 12p13 aberrations (Strehl, Nebral et al. 2008). Fusion between the 
transcriptional repressor ETV6 (TEL) and the transcriptional co-activator NCOA2 was 
identified. The ETV6-NCOA2 fusion gene may depict a unique subdivision of acute 
leukaemia with T-lymphoid and myeloid characteristics, which is associated with a high 
occurrence of NOTCH1 mutations (Strehl, Nebral et al. 2008, Van Vlierberghe, Ambesi-
Impiombato et al. 2011, Zhou, Gao et al. 2012). In ALL, Ncoa2 was mutated in 5 mice (3 in 
      Chapter 5: Identification of Genetic Alterations in Leukaemic SBxTie2-Cre Mice 
 
 291 
thymus, 1 in spleen and 1 in both) and in MPAL Ncoa2 was mutated in one mouse (both 
tissues) (Figure 5.3). Data from The Cell Line Encyclopedia (Figure 5.4) shows highly 
variable expression of NCOA2 in B-ALL, and similar expression in T-ALL, AML and CML.  
 
5.3.6.3 Sos1 (son of sevenless homolog 1) 
Son of sevenless homolog 1 is a protein that in humans is encoded by the SOS1 gene. SOS1 
encodes a protein that is a guanine nucleotide exchange factor for RAS proteins, membrane 
proteins that bind guanine nucleotides and partake in signal transduction pathways (Roberts, 
Araki et al. 2006). Mutations in this gene are associated with Noonan syndrome type 4. 
Noonan Syndrome patients are at increased risk of leukaemia and myeloproliferative diseases 
(Swanson, Winter et al. 2008). However, after sequencing a large series of primary 
malignancies, a study showed that missense SOS1 mutations were present in one pancreatic 
tumour, one lung adenocarcinoma, and one T-ALL cell line, therefore implying that SOS1 is 
not a significant human oncogene in leukaemia (Swanson, Winter et al. 2008). Sos1 mutations 
in ALL were identified in 6 mice (3 from thymus, 2 from spleen and 1 from both) and in 
MPAL; Sos1 was mutated in the thymus of two mice (Figure 5.3). Data from The Cell Line 
Encyclopedia (Figure 5.4) shows highly variable expression of SOS1 in AML, and similar 
expression in B-ALL and T-ALL.  
 
5.3.6.4 Aff3 (AF4/FMR2 family member 3) 
AFF3 (also known as LAF4, lymphoid nuclear protein related to AF4) encodes a tissue-
restricted nuclear transcriptional activator that is known to be specially expressed in lymphoid 
tissue (Ma and Staudt 1996). It was initially discovered from a subtracted cDNA library 
supplemented for lymphoid specific genes and shown to be expressed highly in pre-B cells 
and at lower levels in mature B cells (Ma and Staudt 1996). In several tissues including 
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plasma cells, LAF-4 mRNA levels were scarcely measurable or in numerous cases deficient 
(Ma and Staudt 1996). These studies implied that LAF-4 is a gene restricted to the lymphoid 
lineage. LAF-4 is one of an estimated 40 genes that can form fusions with MLL in infant ALL 
(von Bergh, Beverloo et al. 2002), and is also one of the few genes that is aberrantly 
translocated in both B- and T-cell derived leukaemias (Chinen, Taki et al. 2008). In the paired 
analysis (Figure 5.3) Aff3 was mutated in 4 mice for ALL (3 in thymus and 1 in spleen) and in 
3 mice with MPAL (2 in thymus and 1 in spleen). 
 
5.3.6.5 Cntnap5a (contactin-associated protein-like 5a) 
Cntnap5a is a gene only found in mice and therefore no data was found for this gene in The 
Cell Line Encyclopedia. From Figure 5.3, Cntnap5a mutations are only observed in the 
spleens of two SBxTie2-Cre mice with ALL. 
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5.3.7 Mutation Profile for all Lymphoid Leukaemias in SBxTie2-Cre Mice 
with Associations to Human Leukaemia 
Five genes were identified to be present in > 24% of tumours with mutations in all lymphoid 
leukaemias (ALL and MPAL). 
 
5.3.7.1 Novel Lymphoid Leukaemia Genes Identified in SBxTie2-Cre Mice 
Partitioning defective 3 homolog B is a protein that in humans is encoded by the PARD3B 
gene. Pard3b mutations in ALL were identified in 6 mice (2 from thymus, 2 from spleen and 
1 from both) and in MPAL; Pard3b was mutated in four mice (2 from thymus, 1 from spleen 
and 1 from both) (Figure 5.3). Data from The Cell Line Encyclopedia (Figure 5.5) shows 
highly variable expression of PARD3b in AML and CML, and similar expression in B-ALL 
and T-ALL. This is interesting to note, as Pard3b gene was predominantly found in lymphoid 
leukaemias in the present study. 
 
Tomoregulin-2 is a protein that in humans is encoded by the TMEFF2 gene. From Figure 5.3, 
Tmeff2 mutations are observed in 6 SBxTie2-Cre mice with ALL (4 in thymus and 2 in 
spleen) and 3 SBxTie2-Cre mice with MPAL (1 in thymus and 2 in spleen). Data from The 
Cell Line Encyclopedia (Figure 5.5) shows variable expression of TMEFF2 between the 
leukaemias implying that loss of expression is either rare or not exclusive to ALL (Figure 
5.7). 
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Figure 5.5: Analysis of PARD3B, TMEFF2, ERG, NOTCH1 and ZMIZ1 genes using The 
Cell Line Encyclopedia showed enhanced mRNA expression level of ERG, NOTCH1, 
and ZMIZ1 in human lymphoid and myeloid leukaemias (compared between the 
subtypes). (Accessed – September 2016). B-Cell ALL (n=15); T-Cell ALL (n=16); AML 
(n=34); CML (n=15) and Leukaemia Other (n=1). 
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5.3.7.2 Erg (erythroblast transformation-specific (Kusumbe, Ramasamy et 
al.) Related Gene) 
ERG is required for definitive haematopoiesis, adult haematopoietic stem cell function and 
the maintenance of normal peripheral blood platelet numbers (Loughran, Kruse et al. 2008). 
ERG is overexpressed in T-ALL and AML cells (Baldus, Liyanarachchi et al. 2004, Oram, 
Thoms et al. 2010). In the paired analysis (Figure 5.3) Erg was mutated in at least 1 of the 2 
tissues analysed for every mouse with ALL and all but one mouse with MPAL. Data from 
The Cell Line Encyclopedia (Figure 5.5) shows highly variable expression of ERG in T-ALL, 
AML and CML; however, B-ALL normally has higher expression in human disease. This 
makes the absence of B-cell ALL in the SBxTie2-Cre mice more curious and exemplifies the 
new disease correlations being produced by this model. 
 
5.3.7.3 Notch1 
NOTCH1 was initially recognised as pathogenic in human leukemogenesis through discovery 
of the chromosomal translocation t(7;9)(q34;q34.3) in a T-ALL patient (Ellisen, Bird et al. 
1991). While this translocation is uncommon in T-ALL patients (<1%), activating mutations 
in NOTCH1 are found in over 50% of T-ALL (Weng, Ferrando et al. 2004, Ferrando 2009). 
Indeed, of all the leukaemias present in The Cell Line Encyclopaedia (Figure 5.4) NOTCH1 
has the highest expression in T-ALL. In the SBxTie2-Cre cohort of mice with paired samples 
(Figure 5.3) 60% of the mice with ALL and MPAL had a CIS in the Notch1 gene. Notch1 was 
also the most highly targeted gene in both tissues from these mice. These observations in 
combination with the human data suggest that the Notch1 mutations are likely to be activating 
and driver mutations for the development of ALL. 
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5.3.7.4 Zmiz1 (zinc finger MIZ-type containing 1) 
Zinc finger MIZ-type containing 1 is a protein that in humans is encoded by the ZMIZ1gene.   
It encodes a PIAS (protein inhibitor of JAK-STAT)-like protein, also titled hZimp10, known 
to increase the transcriptional activity of the androgen receptor (Sharma, Li et al. 2003). In the 
paired analysis (Figure 5.3) Zmiz1 was mutated in 4 mice with ALL (1 in thymus, 2 in spleen 
and 1 in both) and in 3 mice with MPAL (1 in thymus and 2 in both). Data from The Cell 
Line Encyclopedia (Figure 5.5) shows highly variable expression of ZMIZ1 in T-ALL and 
AML. 
 
Many studies have recognised ZMIZ1 as a possible NOTCH1 collaborator in leukaemia 
development by utilising insertional mutagenesis in mice (Dupuy, Akagi et al. 2005, Uren, 
Kool et al. 2008, Berquam-Vrieze, Nannapaneni et al. 2011). A study by Rakowski et al 
showed that NOTCH1 and ZMIZ1 expression allowed stimulation of T-ALL in mice 
(Rakowski, Garagiola et al. 2013). They also showed that ZMIZ1 was overexpressed in a 
subset of human primary T-ALL samples and cell lines. Inhibition of ZMIZ1 impaired cell 
growth and sensitized cells to NOTCH inhibitors (Rakowski, Garagiola et al. 2013). 
Therefore, directing therapeutic approaches to the NOTCH1-ZMIZ1 interaction may fight 
leukaemic growth whilst circumventing the painful toxicities of NOTCH inhibitors (Pinnell, 
Yan et al. 2015). 
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5.3.8 Mutation Profile for ALL in SBxTie2-Cre Mice with Associations to 
Human Leukaemia 
Significant numbers of overlapping mutations in spleen and thymus were found in 30% (5/16) 
cases of ALL (Table 5.1). This suggests the presence of a common dominant tumour clone in 
these mice. The mutation profiles of the remaining mice with sequencing results for both 
spleen and thymus (Figure 5.3) show little overlap between the tissues within each mouse. 
This may indicate the presence of multiple independent tumour clones in these mice. Five 
genes were identified to be present in > 24% of tumours for mutations in ALL relative to the 
other leukaemia subtypes.    
 
5.3.8.1 Novel ALL Genes Identified in SBxTie2-Cre Mice 
Ghr and Dis3l2 are two novel genes that were discovered in SBxTie2-Cre mice (Table 5.2), 
which have not been reported in human leukaemia. From Figure 5.3A, 5 mice (3 from thymus 
and 2 from both) showed Ghr (growth hormone receptor) mutations. In human samples, the 
overall expression of GHR in leukaemic cells is low compared to other candidates identified 
by our screen but T-ALL shows the highest expression (Figure 5.6) of the subtypes of 
leukaemia assessed; however, these data suggest that altered expression in GHR may not be 
exclusive to T-ALL. DIS3 like 3'-5' exoribonuclease 2 (DIS3) is indispensable for RNA 
metabolism and the regulation of cell growth and division (Astuti, Morris et al. 2012). Dis3l2 
mutations were found in 3 mice (2 from thymus and 1 from both) (Figure 5.3A). Examination 
of the Cell line Encyclopaedia (Figure 5.6) shows DIS3 to have slightly higher expression in 
T-ALL than in other subtypes examined supporting the ALL-specific nature of the changes 
observed here. 
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Figure 5.6: Analysis of GHR, DIS3L2, IKZF1, STAT5B, and SMAP1 genes using The 
Cell Line Encyclopedia mostly show enhanced mRNA expression level of DIS3L2, 
IKZF1, STAT5B, and SMAP1 genes in human ALL (compared between the subtypes). 
(Accessed – September 2016). B-Cell ALL (n=15); T-Cell ALL (n=16); AML (n=34); CML 
(n=15) and Leukaemia Other (n=1).  
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5.3.8.2 Ikzf1 (ikaros family zinc finger protein 1) 
Deletion mutations of IKZF1 are found in approximately 15% of B-cell progenitor ALL 
(Georgopoulos, Moore et al. 1992, Hahm, Ernst et al. 1994, Kastner and Chan 2011). 
However, no association have been found with T-ALL. From Figure 5.3A, 6 mice (3 from 
thymus, 1 from spleen and 2 from both) showed Ikzf1 mutation. Ikzf1 is highly differentially 
expressed in T-ALL compared to AML (as we observed in SBxTie2-Cre mice) (Figure 5.6); 
however, the high expression in B-ALL prompts the question as to why more frequent B-cell 
ALL in the SBxTie2-Cre mice was not observed. 
 
A study by Clappier et al. described a subset of B cell precursor ALL classified by ERG 
deletions and a significant co-occurrence of IKZF1 deletions (Clappier, Auclerc et al. 2014).  
A relationship between ERG and IKZF1 in AML has also recently been reported. IKZF1 is a 
transcriptional regulator of ERG, with positively correlated transcript expression between 
these 2 genes in AML (Unnikrishnan, Guan et al. 2016). In this study, all ALL mice with 
Ikzf1 mutations (n=6) also had an Erg mutation and all but one of these had co-occurrence of 
the mutations in the same tissue (either spleen or thymus) (Figure 5.3A) suggestive of a co-
operative relationship between Ikzf1 and Erg. 
 
A study by Dail et al. documented a genetic pathway implicating Ikzf1, KrasG12D, and Notch1 
in T lineage leukaemogenesis (Dail, Li et al. 2010). In this study, while mutations were 
detected in all 3 genes, no mice had concurrent mutations in the 3 genes. However Ikzf1 and 
Notch1 mutations were found to co-occur in 5 mice (Figure 5.3). 
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5.3.8.3 Stat5b (signal transducer and activator of transcription 5b) 
STAT is a family of universal transcription factors (Kanai, Seki et al. 2014). STAT5 has 
important functions in the cellular response to numerous cytokines and hormones (Lin and 
Leonard 2000, Rochman, Spolski et al. 2009). It encompasses two highly related proteins, 
STAT5A and STAT5B. STAT5B-retinoic acid receptor-alpha (RARA) gene fusions have 
been reported in a small subset of acute promyelocytic leukaemias (Adams and Nassiri 2015) 
and both Stat5a and Stat5b mutations are found in lymphoid leukemias (Table 5.2), although 
only Stat5b mutations were enriched specifically in ALL, found in 6 of 11 mice (Figure 
5.3A). Analysis of the Cell line Encyclopaedia (Figure 5.6) showed highest expression of 
STAT in T-cell ALL supporting our observations in the SBxTie2-Cre model and providing 
further support for our model as representative of human disease. 
 
5.3.8.4 Smap1 (stromal membrane-associated protein 1)                        
SMAP1 is an ARF6 GTPase-activating protein that functions in clathrin-dependent 
endocytosis (Hongu, Yamauchi et al. 2016). In aged mice with loss of Smap1 approximately 
50% developed anaemia associated with erythroid-myeloid lineage dysplasia, suggestive of 
myelodysplastic syndrome (MDS) in humans, and a subset of these developed AML (Kon, 
Minegishi et al. 2013). While in the SBxTie2-Cre cohort Smap1 mutations were found only in 
ALL (Figure 5.3), the above report suggests the mutations are likely to result in loss of 
expression and function. Exploration of the Cell line Encyclopaedia (Figure 5.6) displayed 
highest expression of SMAP1 in B-ALL and CML and a comparatively narrow range in T-
ALL. 
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5.3.9 Mutation Profile for AML in SBxTie2-Cre Mice with Associations to 
Human Leukaemia 
Thirteen genes were identified to be present in > 24% of tumours with mutations in AML 
relative to the other leukaemia subtypes. Even though the sample size (n=3) was small, any 
gene that was present in 33% (n=1) or 67% (n=2) of samples or above from Table 5.2 was 
classified to be important drivers of disease in AML.    
 
5.3.9.1 Novel AML Genes Identified in SBxTie2-Cre Mice 
 Cyp20a1, Dennd1b, Fam117b, Fam126b, Lmbrd1, Statb2, Stat4, Pcmtd1 and Mff are novel 
genes that were discovered in SBxTie2-Cre mice (Table 5.2), and not reported to be 
associated with human leukaemia. CYP20A1 (cytochrome P450, family 20 subfamily A 
member 1) was found to have highest expression in T-ALL AML and CML in The Cell Line 
Encyclopedia (Figure 5.7). DENND1B (DENN/MADD domain containing 1b) was shown to 
have variable expression in leukaemia with highest expression in T-ALL (Figure 5.7). 
FAM117B (family with sequence similarity 117, member b) displayed highest expression in T-
ALL followed by B-ALL, AML and CML (Figure 5.7). FAM126B (family with sequence 
similarity 117, member b) demonstrated highest expression in T-ALL followed by B-ALL, 
AML and CML (Figure 5.7). FAM126B (family with sequence similarity 126, member b) 
revealed highest expression in T-ALL followed by AML, CML and B-ALL (Figure 5.7). The 
data from The Cell Line Encyclopedia for Cyp20a1, Dennd1b, Fam117b and Fam126b show 
high expression in T-ALL (Figure 5.7); however from Table 5.2, these genes were not found 
to be mutated in T-ALL.  
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Figure 5.7: Analysis of CYP20A1, DENND1B, FAM117B, and FAM126B genes using 
The Cell Line Encyclopedia showed enhanced mRNA expression level of each gene in 
human AML (compared between the subtypes). (Accessed – December 2016). B-Cell ALL 
(n=15); T-Cell ALL (n=16); AML (n=34); CML (n=15) and Leukaemia Other (n=1). 
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PCMTD1 (protein-L-isoaspartate {D-aspartate} O-methyltransferase domain containing 1) 
showed high variable expression in B-ALL, AML and CML (Figure 5.8). SATB2 (Satb 
homeobox 2) displayed high variable expression in AML and CML (Figure 5.8). STAT4 
(signal transducer and activator of transcription 4) revealed high variable expression in T-
ALL (Figure 5.8). This is interesting to note, as Stat4 was not found to be significant (0%) in 
Table 5.2. LMBRD1 (Lmbr1 domain containing 1) was found to be highly variably expressed 
mainly in CML and AML in The Cell Line Encyclopedia (Figure 5.8). MFF (mitochondrial 
fission factor) revealed highest expression of in AML followed by variable expression in T-
ALL and CML with narrow expression in B-ALL (Figure 5.8). The high expression level of 
MFF in AML is consistent with the findings of the present study (Table 5.2).  
 
The high expression level of LMRD1, MFF, PCMTD1 and SATB2 in AML (Figure 5.8) is 
consistent with the findings of the present study (Table 5.2). 
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Figure 5.8: Analysis of PCMTD1, SATB2, STAT4, LMBRD1 and MFF genes using The 
Cell Line Encyclopedia showed enhanced mRNA expression level of each gene in human 
AML (compared between the subtypes). (Accessed – December 2016). B-Cell ALL (n=15); 
T-Cell ALL (n=16); AML (n=34); CML (n=15) and Leukaemia Other (n=1). 
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5.3.9.2 Fli1 (friend leukaemia virus integration 1) 
The ETS gene superfamily members were found to program for various sequence specific 
transcriptional activators. The members include: C-ETS1, ETS2, ERG, ELK1, ELK2, 
PU.1/SPI1, E74, GABPα, SAP1, SAP2, ELF1, PEA3 and FLI1 (Prasad, Rao et al. 1992). 
Three of the ETS oncogene superfamily members V-ETS, SPI-1/PU.1 AND FLI-1, were 
found to be directly involved in retroviral-mediated acute erythroleukaemias (Rao, Ohno et al. 
1993). The FLI1 gene was shown to be rearranged in 75% of the erythroleukaemias 
stimulated by Friend murine leukaemia virus (F-MuLV), signifying a vital function in cellular 
transformation (Rao, Ohno et al. 1993). Data from The Cell Line Encyclopedia showed FLI1 
to be highly variably expressed mainly in B-ALL but also in AML (Figure 5.9). It is 
interesting to see that FLI1 is predominantly found in erythroleukaemias, which was not 
found in the present study. 
 
5.3.9.3 Flt3 (fms-like tyrosine kinase 3, CD135) 
FLT3 is a member of class III tyrosine kinase (RTKIII) receptor family and comprises c-FMS, 
c-KIT, and PDGFR (Adolfsson, Mansson et al. 2005). FLT3 expression is observed in 
immature haematopoietic stem cells, placenta, gonads, brain, and also in the lympho-
haematopoietic organs such as the liver, spleen and the thymus. In the normal bone marrow, 
FLT3 expression is limited to early progenitors, such as CD34+ cells with increased 
expression of CD117 (c-KIT), and committed myeloid and lymphoid progenitors with 
variable expression in the more mature monocytic lineage (Adolfsson, Mansson et al. 2005). 
Elevated FLT3 expression is observed in several haematological malignancies involving 
mainly AML subtypes, B-precursor cell acute lymphoblastic leukaemia (B-ALL), some T-cell 
ALLs, and CML in blast crisis (Turner, Lin et al. 1996, Stirewalt and Radich 2003). FLT3 
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mutations have significant clinical relevance in AML as they generally direct treatment 
assessments as independent markers of poor prognosis (Schlenk, Dohner et al. 2008, Patel, 
Gonen et al. 2012). FLT3 mutations account for most of the frequent molecular mutations in 
human AML with approximately 30 to 35% of AML patients having either internal tandem 
duplications (ITDs) or mutations in the activating loop of FLT3 (Gilliland and Griffin 2002, 
Levis and Small 2003). Indeed, of all the leukaemias present in The Cell Line Encyclopaedia 
(Figure 5.9) FLT3 has the highest expression in AML and B-ALL. 
 
 
 
 
Figure 5.9: Analysis of FLI1, FLT3, IL1R1, and IL3 genes using The Cell Line 
Encyclopedia showed enhanced mRNA expression level of FLI1, FLT3, and IL3 genes in 
human AML (compared between the subtypes). (Accessed – December 2016). B-Cell ALL 
(n=15); T-Cell ALL (n=16); AML (n=34); CML (n=15) and Leukaemia Other (n=1). 
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5.3.9.4 Ili1r (interleukin 1 receptor, type I) 
From Table 5.2, only Il1r1 showed a significantly higher percentage of insertion sites for 
AML than other subtypes. Interleukin 1 receptor, type I (IL1R1) also known as CD121a, is an 
interleukin receptor. Using Il1r1 knockout mice it has recently been shown that loss or 
inhibition of IL-1R signalling enhanced myeloid leukemogenesis through inactivation of the 
inflammasome (Hockendorf, Yabal et al. 2016). This suggests that the Il1r1 mutations found 
in this study are most likely to be loss of function mutations. Interrogation of IL1R1 mRNA 
expression from The Cell Line Encyclopedia, found comparable expression across the 
different subtypes of leukaemia implying that loss of expression is either rare or not exclusive 
to AML (Figure 5.9).  
 
5.3.9.5 Il3 (interleukin 3 {colony-stimulating factor, multiple}) 
IL-3 functions to influence the survival and proliferation of multipotent cells from normal 
bone marrow, and also haematopoietic precursors (limited to the granulocytic and monocytic 
lineages) (Miyajima, Mui et al. 1993, Bagley, Woodcock et al. 1997). Original reports centred 
on the examination of biological responses provoked in vitro by IL-3 addition and on the 
analysis of IL-3 to membrane receptors revealed that most human AML blasts proliferate in 
response to IL-3 and express IL-3 receptors (IL-3Rs) (Vellenga, Ostapovicz et al. 1987, 
Delwel, Salem et al. 1988, Budel, Touw et al. 1989, Budel, Elbaz et al. 1990). Specifically, in 
more than 85% of AML cases, IL-3 stimulated thymidine combination and as a stimulatory 
element, was significantly more effective than other haematopoietic growth factors (Vellenga, 
Ostapovicz et al. 1987, Delwel, Salem et al. 1988). Likewise, the examination of IL-3 binding 
to AML blasts indicated that >80% of AMLs display high-affinity IL-3 receptors (Budel, 
Touw et al. 1989, Budel, Elbaz et al. 1990). Indeed, data from The Cell Line Encyclopaedia 
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(Figure 5.9) showed expression in AML and T-ALL but interestingly higher expression in 
CML. 
 
5.3.9.6 Mir30c-2 (microRNA 30c-2) 
A report identified that MIR30C has a vital function in the regulation of myeloid 
differentiation stimulated by C/EBPa (Katzerke, Madan et al. 2013). They have also shown 
that MIR30C directly controls NOTCH1 to promote granulocytic differentiation. In AML, loss 
of function of C/EBPa results in a MIR30C deficiency, which leads to a loss of Notch1 
inhibition (Katzerke, Madan et al. 2013). No data were found for MIR30C2 in The Cell Line 
Encyclopedia. 
 
5.3.10 Mutation Profile for MPAL in SBxTie2-Cre Mice with Associations 
to Human Leukaemia 
Significant numbers of overlapping mutations in spleen and thymus were found in 50% (3/6) 
cases of MPAL, once again suggesting the presence of a common dominant tumour clone in 
these mice (Table 5.1). Mutations in Rasgrp1 and Stat5a were more frequently found in 
MPAL than the other subtypes (Table 5.2).  
 
5.3.10.1 Rasgrp1 (ras guanyl nucleotide-releasing protein 1) 
RasGRP1 is an activator of Ras that in T cells is a 2-step process that includes Son of 
sevenless homolog 1 (SOS1) (Buday and Downward 2008). Increased RasGRP1 expression is 
found in many paediatric T-ALL patients and contributes to leukemogenesis. Interestingly, 
Rasgrp1 is also commonly mutated by insertional mutagenesis in mouse leukaemia virus 
screens (Hartzell, Ksionda et al. 2013). Mutations in Rasgrp1 occurred in several mice with 
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MPAL and in 2 cases were accompanied by mutations in Sos1 (Figure 5.3) Rasgrp1 and Sos1 
mutations were also found in ALL mice; however, mutations in both genes did not co-occur.  
 
Although aberrant Ras signalling is common in leukaemia, mutations in K-RAS are 
uncommon. However, when they occur RasGRP1 expression appears to be decreased, 
suggesting that K-RAS mutations and increased RasGRP1 expression may be mutually 
exclusive events (Hartzell, Ksionda et al. 2013). Conversely, co-occurrence of NOTCH1 
mutations and increased RasGRP1 expression is reported to be a common event (Oki, Kitaura 
et al. 2012). In the SB-Tie2-Cre mice, K-ras mutations were found in 2 mice from the ALL 
cohort, and did not co-occur with Rasgrp1 mutations. Notch1 mutations were common in both 
MPAL and ALL mice, and co-occurrence with Rasgrp1 mutations was a frequent event. 
 
In agreement with the above reports of increased RasGRP1 expression in T-ALL, 
interrogation of data from Cell Line Encyclopedia showed highest RasGRP1 expression for 
T-ALL (Figure 5.10). Collectively, these data strongly suggest that the Rasgrp1 mutations 
identified in the SBxTie2-Cre mice are gain of function mutations that result in increased 
expression.  
 
5.3.10.2 Stat5a (signal transducer and activator of transcription 5a) 
See Section 5.3.7.1.4. From Figure 5.3, Stat5a mutations are only observed in the spleens of 
two SBxTie2-Cre mice with ALL. Examination of The Cell line Encyclopaedia (Figure 5.10) 
displayed high variable expression of STAT5A in T-ALL, AML and CML. 
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Figure 5.10: Analysis of RasGRP1 and STAT5A gene using The Cell Line Encyclopedia 
showed enhanced mRNA expression level of RasGRP1 in human ALL and STAT5A in 
human T-ALL, AML and CML (compared between the subtypes). (Accessed – 
September 2016). B-Cell ALL (n=15); T-Cell ALL (n=16); AML (n=34); CML (n=15) and 
Leukaemia Other (n=1). 
 
 
5.3.11 Associations Between Survival and the Mutational Status of ALL 
and MPAL in SBxTie2-Cre Mice 
The age at euthanasia was plotted for the absence and presence of genetic mutations in 
unpaired samples of spleen and thymus in 30 SBxTie2-Cre mice (stratified by ALL or MPAL 
– as sample number for AML was too small). Erg, Ets1, Ncoa2, Notch1, Pard3b, Rasgrp1, 
and Sos1 genes were selected as they show presence in ~ 30 – 70% of SBxTie2-Cre mice and 
show importance in ALL and MPAL (Table 5.2). Significance was observed in Erg and Ets1, 
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which indicate that alteration of the endothelium has a role in the mutation pattern of these 
two genes (Figure 5.11). No significant differences were observed in the other five genes 
analysed (Figure 5.11). SBxTie2-Cre mice that harbour Erg and Ets1 mutations have a 
survival advantage (Figure 5.12). In accordance with these results, from Chapter 3, SBxTie2-
Cre mice were shown to have similar survival rates to Vav-Cre mice, which are known to 
harbour ERG, ETS1, NOTCH1, and RASGRP1 mutations (Berquam-Vrieze, Nannapaneni et 
al. 2011) of which the first two show significance in Figure 5.11. Although Erg was mutated 
more frequently (twice) than Ets1 in the Vav-Cre mice, this suggests that this could be due to 
the endothelial and HSC nature of the promoter.  
 
 
Figure 5.11: Associations between survival (age at euthanasia) and mutational status in 
leukaemia subtypes of SBxTie2-Cre mice (n = 30). Age is classified with absence (-) and 
presence (+) of genetic mutations. Leukaemic subtypes include ALL (n = 18) and MPAL (n = 
12). * Indicates P = 0.0125, and **P = 0.0017. T-test (Mann-Whitney). S= ALL (-); 
U=MPAL (-); z= ALL (+); |= MPAL (+).  Mean + SD shown for SBxTie2-Cre mice. 
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Figure 5.12: Survival of SBxTie2-Cre mice (n = 30) with (+) and without (-) Erg and Ets1 
mutations. Age is classified with absence (-) and presence (+) of genetic mutations.  
 
 
 
The two significant genes (Erg and Ets1) from Figure 5.11 were plotted against age at 
euthanasia SBxTie2-Cre mice. Four groups were analysed: mutant for Erg but wild type for 
Ets (Erg {+} / Ets1 {-}), mutant for Ets but wild type for Erg (Erg {-} / Ets1 {+}), wild type 
for both Erg and Ets (Erg {-} / Ets1 {-}), and mutant for both Erg and Ets (Erg {+} / Ets1 
{+}), with the groups showing significance compared to each other (P = 0.0044) (Figure 
5.13). 
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Figure 5.13: Analysis of survival (age at euthanasia) and mutational status (Erg and 
Ets1) of SBxTie2-Cre mice (n = 30). Age is classified with absence (-) and presence (+) of 
genetic mutations. P = 0.0044 all 4 groups). One-way ANOVA Test (Kruskal-Wallis). Mean 
+ SD shown for SBxTie2-Cre mice. 
 
 
The relationship between mutations in Erg and Ets1 and survival was also assessed in human 
AML using cBioPortal. Analysis was restricted to AML, as the repositories forming the basis 
of the analysis had limited sample numbers for ALL and no available data for MPAL. 
Interestingly, the data (Figure 5.14) for AML shows decreased survival in patients harbouring 
mutations in either gene. The limited sample size for patients with ERG and ETS1 mutations 
prevented these trends from reaching significance; however, the trend to decreased overall 
and disease free survival for patients with these mutations is clear. These data are opposite to 
what was identified in the SBxTie2-Cre model where a survival advantage was identified 
when both genes were mutated (Figure 5.12). This may reflect the differing impact that these 
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mutations have in different leukaemia subtypes (ie lymphoid {in the mice} versus myeloid) in 
the human dataset. 
 
 
    (A)     Disease Free Survival (ERG)          (B)          Overall Survival (ERG) 
       
 
    (C)     Disease Free Survival (ETS1)          (D)          Overall Survival (ETS1) 
         
 
Figure 5.14: Survival analysis of patients with ERG and ETS1 mutations using 
cBioportal to understand the CNA expression level of each gene in human AML. 
(Accessed – November 2016). CNA = circulating nucleic acid and AML = acute myeloid 
leukaemia.  
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5.4 Discussion 
The SB system of insertional mutagenesis enables not only the accelerated induction of cancer 
through its generation of randomly mutated genes, but also the easy identification of the 
mutated genes driving the cancer. In Chapter 3, directing SB transposase activity to the 
endothelium using Tie2-Cre resulted in mice with leukaemia; classified as ALL, AML or 
MPAL. In Chapter 4, it was shown that the leukaemia in these mice originated in the 
haemogenic endothelium. In this chapter, the genes that were mutated by SB and led to the 
different subtypes of leukaemia were identified. 
 
The human homologues of the most commonly mutated genes in the SBxTie2-Cre mice (Erg, 
Ets1 and Notch1) have known associations with human leukaemias, being dysregulated either 
by mutation or enhanced transcription. A number of other genes identified in this study also 
have strong associations with human leukaemia, e.g. Ikzf1 and Runx1. Gene Ontology 
analysis of the entire CIS list similarly highlighted leukaemic and cancer pathways as the 
most highly enriched in the gene-set. These findings provide proof of principle for the 
relevance of the SBxTie2-Cre model of leukaemia to human disease.  
 
Some differences in the mutational profiles of the different leukaemia sub-types were found. 
The top 5 mutated genes that were present in > 24% of SBxTie2-Cre mice in all forms of 
acute leukaemia were: Ets1, Ncoa2, Sos1, Aff3, and Cntnap5a, and in all lymphoid 
leukaemias were: Erg, Notch1, Pard3b, Tmeff2, and Zmiz1. The top mutated genes present in 
> 24% of mice for ALL were Ghr, Ikzf1, Dis3l2, Stat5b, and Smap1 and for MPAL were: 
Rasgrp1, and Stat5a. The gene list was quite different for the AML mice with the top genes 
present in > 24% of SBxTie2-Cre mice being Cyp20a1, Dennd1b, Fam117b, Fam126b, Fli1, 
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Flt3, Il1r1, Il3, Lmbrd1, Mff, Mir30c-2, Pcmtd1, Satb2 and Stat4. These differences may 
simply relate to the fact that only 3 mice were included in the AML cohort for sequencing.  
 
The finding of a mutated gene-set exclusive to MPAL would have provided further evidence 
for this being a subtype distinct from both ALL and AML. However, only two genes, 
Rasgrp1 and Stat5a1 were found to be uniquely mutated in > 24% of samples in this subtype. 
Therefore, whether MPAL is a bone fide classification in the SBxTie2-Cre mice, or whether it 
indicates two different clones (the presence of both ALL and AML) remains to be 
determined. Tang et al. classified MPAL loosely as both lymphoid and myeloid leukaemias 
(Tang, Carmichael et al. 2013). Overall, the mutational profile for MPAL was found to be 
similar to ALL. As such, if MPAL is a distinct entity, the findings from the SBxTie2-Cre 
mice suggest ALL could be used as a clinical platform for testing treatments for this rare 
subtype, as currently there are no effective therapies for MPAL.  
 
Five of 16 (30%) ALL mice and 2 of 4 (50%) MPAL mice with sequencing results for both 
spleen and thymus had significantly overlapping mutations between these tissues indicating 
the same clone in both tissues. For the remainder of the mice, different mutational patterns 
were present suggesting the presence of several clonal leukaemic populations as has been 
previously reported in SB mice (Dupuy, Akagi et al. 2005).  
 
Mutations in NOTCH1 were the most common mutations observed in both tissues from the 
paired analysis suggesting these were driver mutations. Links to Notch signalling were also 
evident in the finding of mutations in the tumour suppressor IKZF1 and NOTCH1 co-factor 
ZMIZ1 (Pinnell, Yan et al. 2015). This is not an unexpected finding as activating NOTCH1 
mutations occur in over 50% of human T-ALLs. However, it is a highly significant finding in 
the context of the origin of the leukaemia in the SBxTie2-Cre mice. In Chapter 4, in vitro 
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analysis of the leukaemic cells in the bone marrow implicated haemogenic endothelium as 
originating cells for the leukaemia and it was speculated that post-natal haemogenic 
endothelium may reside in the CD31-expressing H vessels in the bone marrow. Endothelial 
activation of Notch signalling in these vessels leads to expansion of HSC niches (Kusumbe, 
Ramasamy et al. 2016). Therefore, activating Notch1 mutations directed to the haemogenic 
endothelium by Tie2-Cre in the SBxTie2-Cre mice may drive uncontrolled haematopoiesis 
leading to the leukemogenesis identified in these mice. In several mice, this pathway to 
leukemogenesis was augmented or substituted by RUNX1 mutations. RUNX1 is critical for the 
generation of HSCs from the haemogenic endothelium. Without RUNX1, the haemogenic 
endothelium accumulates but there is no expansion of HSC niches (Lancrin, Sroczynska et al. 
2009). This is consistent with the discovery that RUNX1 expression is required in Tie2+ or 
VE-cadherin+ ECs for haematopoietic development (Li, Chen et al. 2006, Chen, Yokomizo et 
al. 2009, Liakhovitskaia, Gribi et al. 2009). Interestingly, one of the most striking findings 
between the 3 previously described SB-induced lymphoma models (Vav-Cre, Lck-Cre and 
CD4-Cre) was the significant enrichment of Notch1 mutations in the Vav-Cre model, which 
was reduced in Lck-Cre mice and absent in CD4-Cre mice. The SBxTie2-Cre model follows 
closely to the Vav-Cre model suggesting that Notch1 is lost at the HSC commitment phase 
(Berquam-Vrieze, Nannapaneni et al. 2011). In support of this expression of Ikzf2 increases 
and Notch1 falls significantly between HECs and HSCs (Kartalaei, Yamada-Inagawa et al. 
2015). 
 
The finding of mutations in Notch1, Runx1 and other Notch signalling pathway genes in this 
endothelium-targeted model of SB-induced leukaemia is both revealing and enticing in terms 
of elucidating the contribution of haemogenic endothelium to leukemogenesis. However, 
these mutations have been identified in other SB-directed models of leukaemia. Both Notch1 
and Runx1 activating mutations (as well as Erg and Rasgrp1 mutations) were found in the 
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first germline model of SB that used the same T2/Onc2 transposon and SB11 transposase as 
in this model (Dupuy, Akagi et al. 2005). The majority of these mice were diagnosed with T-
cell lymphomas. Mutations in these same genes were also found in an SBxVav-Cre directed 
model of T cell lymphoma but not when Cre was activated later in haematopoiesis by Lck-
Cre or CD4-Cre, in which the mutational profiles changed significantly (Berquam-Vrieze, 
Nannapaneni et al. 2011). Notch1 and Ikzf1 mutations were much less frequent and Runx1, 
Zmiz1, Rasgrp1, Erg and Ets mutations were not found. Using a different Vav-Cre in 
combination with a predisposing JAK2 mutation changed the phenotype to predominantly 
erythroleukaemia with some mice also having a lymphoid leukaemia. However, while Vav-
Cre is considered to be HSC-specific, it is also active in the endothelium (Georgiades, Ogilvy 
et al. 2002, Croker, Metcalf et al. 2004). The similarities in both phenotype and mutational 
profile between the endothelial-targeted (Tie2-Cre) and endothelial / HSC-targeted (Vav-Cre) 
models may confound the interpretation of results from Vav-Cre mice regarding the origin of 
leukaemia. It is possible that the cell of origin in the Vav-Cre mice was similarly endothelial 
and that the lymphoma in the germline model also arose from the haemogenic endothelium.  
 
Although mouse models have not wholly represented human disease, the discovery of 
mutated genes in SBxTie2-Cre mice verifies human leukaemia in the current mouse model 
and is therefore suggestive of human disease (Table 5.2). Although mutation data from Table 
5.2 were analysed with expression data from The Cell Line Encyclopedia, the expression of 
these genes is unknown in the SBxTie2-Cre mice and the mutational status of some of these 
genes was unclear in human disease. Expression does not necessarily reflect mutational 
status; therefore, while beyond the scope of this project, more analyses must be performed to 
understand the expression levels and consequences of the mutations of the gene lists from 
Table 5.2.  
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It is interesting to note that the SBxTie2-Cre mice did not develop any forms of 
erythroleukaemia but developed leukaemia of lymphoid and myeloid lineages. Wnt signalling 
has been proven to stimulate primitive erythropoiesis, while activation of the Notch pathway 
obstructs this developmental platform (Lancrin, Sroczynska et al. 2010). These two signalling 
pathways oppose each other, as erythropoiesis requires expression of Notch inhibitors 
whereas activation of Notch signalling gives rise to an influx of Wnt pathway inhibitors 
thereby obstructing erythropoiesis (Cheng, Huber et al. 2008).  
 
Acute forms of leukaemia are highly aggressive heterogenous malignant diseases, which are 
classified by frequent genetic abnormalities that define subgroups of diverse biological and 
clinical characteristics. The SB system of insertional mutagenesis is a suitable model for the 
different subtypes of leukaemia as it is non-biased and is completely random. The SB model 
described herein provides a new platform for therapeutic development to address a previously 
unrecognised basis of acute leukaemia.  
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6.1 Summary 
The SB mutagenesis system, under the direction of the Tie2-Cre reporter was chosen as the 
model to examine the outcome of mutating the endothelial genome. The SBxTie2-Cre mice 
became moribund between 5 and 52 weeks of age. Analysis of tissues (heart, thymus, lungs, 
kidneys, spleen and liver) identified acute forms of leukaemia (ALL, AML and MPAL). This 
model identified a novel role for ECs in leukaemogenesis (by proliferation and 
transdifferentiation into early precursors of the leukocytic lineage) although it does not rule 
out alterations in EC-derived growth factors that may accelerate HSC differentiation. 
 
In vitro assays (CFU assays) were performed to identify the source of the malignancy. CD45-
/CD31+ endothelial cells gave rise to lymphoid and myeloid population Moreover, these EC 
populations were significantly enriched for HECs (CD45-/CD31+/CD144+/CD73-), which 
supports haemogenic endothelium as the origin of the leukaemia in the SBxTie2-Cre mice. 
These outcomes provide new evidence that the haemogenic endothelium continues to function 
post-natally. Furthermore, it provides rationale for why anti-angiogenic agents may be viable 
options for the treatment of acute leukaemias.   
 
Targeted deep sequencing of leukaemic tissues from SBxTie2-Cre mice identified changes to 
known mediators in haematological lineage specification and leukaemogenesis, validating this 
model as a having high fidelity to human disease. Novel genes, previously undocumented in 
human leukaemia, were also discovered. These genes may be useful in distinguishing acute 
leukaemias of endothelial origin from those with other origins. The finding of mutations in 
known leukaemia-associated genes further substantiates that the basis of acute leukaemia has 
an endothelial origin and provides direction to refine anti-angiogenic therapies for greater 
effectiveness in the treatment of leukaemia.   
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6.2 Previous Literature vs Current Study 
The prevailing dogma is that leukaemias arise from HSCs at diverse phases of their 
maturation and differentiation. An integral part of this view is that the leukaemogenic 
immature HSCs undergo self-renewal, whereas less aggressive forms of leukaemia (such as 
chronic leukaemias) arise from the more mature, committed HSCs (Dong, Han et al. 2007). 
 
Angiogenesis was originally considered insignificant in haematological malignancies due to 
the “soft” nature of these malignancies, but reports identify that increased bone marrow 
vascularity in ALL patients (Perez-Atayde, Sallan et al. 1997) may have a pathogenic role in 
leukaemia. Although first suggested in solid tumours, the presence of the angiogenic switch 
was thus applied to haematological malignancies (Hanahan and Folkman 1996). In leukaemia 
the angiogenic switch is characterised by elevated neovascularisation of the bone marrow, 
increased expression of pro-angiogenic factors and reduced expression of endogenous 
angiogenesis inhibitors (Dong, Han et al. 2007, Frater, Kay et al. 2008). Indeed, the urine and 
peripheral blood samples from ALL patients exhibit of high levels of pro-angiogenic factors 
(such as bFGF and VEGF), which correlated with the extent of bone marrow angiogenesis 
(Yetgin, Yenicesu et al. 2001). Therefore, the level of angiogenesis in the bone marrow is 
often associated with disease burden, prognosis, and treatment outcome. 
 
A major discovery of the present study is that targeting the endothelial genome using SB-
mediated insertional mutagenesis resulted in acute leukaemia, distinguishing it from previous 
models and providing insight into dual roles for the endothelium in haematopoiesis. This 
finding questions the current assumptions on the origins of leukaemia and provides a different 
perspective on the role of ECs in haematological malignancies. This study collectively 
supports the notion that ECs (particularly the haemogenic endothelium), and not HSCs, are 
drivers of the acute leukaemia that develops in the SBxTie2-Cre mouse model. The bone 
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marrow was a source of initiation of acute leukaemia (as observed from the CFU assays) and 
therefore this present study suggests that the haemogenic endothelium is present in the adult 
bone marrow niche. One correlate of the current study was the use of the Tie-2 promoter to 
drive Cre expression.  Tie-2 expression, and activation of this promoter, has previously been 
reported in hematopoietic cells in Tg mice.  The CFU assays with CD31+ cells have ruled out 
the activation of the promoter in HSCs as the source of this leukemia; however, to re-inforce 
these conclusions the studies should be performed in a Cre-Tg strain which has little 
activation in the HSC population. VECad-Cre-ERT2 mice are Cre-Tg with endothelial-specific 
activation similar in pattern to that of Tie-2 Cre mice; however, the VECad-Cre-ERT2 mice 
have almost no activation of expression in hematopoietic populations (Monvoisin et al., 2006; 
Appendix 6) if induction occurs after E11.5 and would be a good choice in which to confirm 
the endothelial-specific nature of the origins of leukaemia in the SB mouse model. 
 
Of all the proposed mechanisms to explain the origins of cancer there are two (cancer stem 
cells and genomic instability) that may be applicable to the haemogenic endothelium and its 
role in leukaemia. In the progression of tumour development, a subset of tumour cells with 
stem cell-like properties has been distinguished. These cancer stem cells generate tumours 
through the stem cell processes of self-renewal and differentiation into multiple cell types. As 
such, cancer stem cells can give rise to expanding tumour cell populations and all components 
of the tumour stroma (Lagasse 2008). Genomic instability refers to the tendency for 
alterations in the genome to accumulate over time (Shen 2011).  Such alterations include extra 
copies, translocations and inversions of chromosomes, chromosome deletions, single- and 
double-strand breaks in DNA, point mutations and intercalation of foreign substances into 
DNA that cause the loss or expression of genes (Shen 2011). Genomic instability is a 
“hallmark” of tumour cells and is a major driving force for tumorigenesis (Shen 2011).  
Combining these two theories, a novel model for the origins of leukaemia was derived. The 
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haemogenic endothelium is more stem-like, and arguably more genetically unstable, than the 
normal endothelium. The current study proposes that this population would accumulate 
mutations and/or chromosomal anomalies at a greater rate than non-haemogenic ECs (due to 
the higher proliferative rates mandatory on self-renewing populations) and ultimately become 
malignant. These data fit with the first report of cancer stem cells (which happened to be in 
AML) where a CD34+/CD38− subpopulation was capable of initiating tumours in naïve mice 
(Bonnet and Dick 1997). The authors suggested these were derived from HSCs; however, 
their final recommendation was that “normal primitive cells, rather than committed progenitor 
cells, are the targets for leukemic transformation” (Bonnet and Dick 1997). The haemogenic 
endothelium fit all these characteristics of leukaemic cancer stem cells and expansion of the 
haemogenic endothelium in the H-vessels of the bone marrow would also promote formation 
of new HSC niches for expanded haematopoietic cell production. This study therefore 
challenges the current notion that all endothelium is genetically stable and suggests that by 
targeting this unstable EC population, therapies can be improved for acute forms of 
leukaemia. 
 
 
6.3 Future Directions 
The new findings in the present study open new lines of investigation for subsequent studies.  
Some of these have been outlined below: 
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6.3.1 Analyse Vessel Density And Localisation of the Haemogenic 
Endothelium in Leukaemic Tissues of SBxTie2-Cre Mice. 
Patients with acute leukaemias exhibit enhanced neovascularisation of bone marrow, which 
correlates with disease progression (Perez-Atayde, Sallan et al. 1997, Hussong, Rodgers et 
al. 2000). The present study has yet to document whether this is a feature of the SBxTie2-
Cre mice. Changes in rates of angiogenesis (vessel density and lymphangiogenesis) can be 
measured by staining sections of mouse spleen, liver, thymus and bone marrow with 
markers for blood vessels (CD31) and lymphatics (LYVE-1). One of the restrictions of the 
present study was the use of bone marrow samples for flow cytometry and CFU analyses 
precluding such assessment.  
 
Documenting CD31 and LYVE1 staining will allow the identification of altered 
lymphangiogenesis in leukaemic tissues and confirm if the level of angiogenesis is a critical 
part of the pathogenesis of leukaemia in these mice. Some of the mice may have altered 
vessel density, which may explain different models of disease in the SBxTie2-Cre mice (e.g. 
retinal angiogenesis). Moreover, dual staining with CD31 (stains all endothelium) and CD73 
(stains only non-haemogenic endothelium) will allow us to determine the location of the 
haemogenic endothelium in the bone marrow and whether it co-localises with the “H” vessels 
as hypothesised in Chapter 4. Whether the “H” vessels also proliferate during leukaemia is yet 
to be studied although expansion of “H” vessels in response to Notch stimulation promotes 
haematopoiesis and is therefore likely in leukaemia. Confirmation of the location of the “H” 
vessels may allow for new imaging modalities (based on their high expression of endomucin) 
to determine the responsiveness of patients to anti-angiogenic therapies which is one of the 
“holy grails” of clinical implementation of anti-angiogenic therapy. 
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6.3.2 Determine if HECs Cells from SBxTie2-Cre Mice can Precipitate 
Leukaemia in Naïve Mice. 
The present study was limited in its ability to define the proportion of endothelial cells with a 
stem like potential. The sorting strategy used in Chapter 4 to identify HECs left the possibility 
that a CD45-/CD31+/Sca1+ pool of endothelial cells might exist and this may further define 
the haemogenic endothelium. The CD31 positive cell fraction from the bone marrow of 
SBxTie2-Cre mice could be sorted into Sca1 positive and negative by flow cytometry and 
assessed for the remaining markers (CD144+/CD73-) to determine whether HECs are indeed 
Sca1 positive as previously suggested (Kartalaei, Yamada-Inagawa et al. 2015). Once 
isolated, these cells could be used to define the leukaemogenic potential of the haemogenic 
endothelium. 
 
 
Another limitation of this study was that it did not include in vivo experiments to measure the 
potential for HECs from symptomatic mice to “transfer” leukaemic phenotype to naïve mice. 
This is an essential test for a disease-causing agent in leukaemia and has been previously used 
to implicate cellular subsets in the pathogenesis of disease (Mullen 2004). To assess this, bone 
marrow could be isolated from symptomatic SBxTie2-Cre mice and haemogenic ECs (CD45-
/CD31+/CD144+/CD73-) selected. These cells can be placed subcutaneously into C57Bl/6 
mice in biopolymer Matrigel (a self-hardening 3D matrix from the engelbroth-holm-swarm 
mouse sarcoma). Placed into the flank of mice, the HECs are free to form HSCs (Poulos, 
Crowley et al. 2015), which can be subsequently validated using histological techniques. 
Alternatively the plugs can be de-polymerised and analysis performed by flow cytometry. 
 
If the initial transplantation experiments show promise then the HECs can be transferred to 
irradiated mice (900 Rad). Such “adoptive transfer” experiments, wherein bone marrow cells 
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from SBxTie2-Cre mice are transplanted into irradiated WT mice and vice versa (cells from 
normal WT mice are transplanted into irradiated SBxTie2-Cre mice) would be a seminal 
result in supporting our contention that the basis of leukaemia was endothelial in nature.  
Irradiated mice will die unless cells capable of reconstituting haematopoiesis repopulate their 
bone marrow. If HECs increase survival then they will be known to have repopulated the 
bone marrow successfully thus indicating their ability to sustain post-natal haematopoiesis. If 
HECs produce a leukaemic phenotype then they will have demonstrated their pathogenic role 
and validated the current study’s claims of an endothelial cell basis for acute leukaemias. 
 
6.3.3 Validate the Known Tumour Suppressor and Oncogenes Discovered 
and Determine the Relevance to the Leukaemia Phenotype of Novel 
Genes Identified  
A limitation of the CIS analysis is that it is known which genes are targeted by SB-mediated 
mutagenesis; however, whether the changes inhibit or promote expression and have functional 
effects are yet to be determined. Frozen spleen and thymus samples are available for all the 
mice that underwent targeted deep sequencing. RNA can be extracted from these and control 
tissues and transcript levels assessed by qPCR for the most highly mutated genes identified in 
Chapter 5. A widespread assessment of the genes discovered in the present study must be 
performed to enable the identification of the functional role of these genes in human disease 
(Kool and Berns 2009). Functional studies (including RT-PCR and next-generation 
sequencing) must be performed on the genes discovered in the present study to identify if the 
genes have a differential expression (Elso, Chu et al. 2015). Therefore, this would indicate if 
these genes had a causal role in tumorigenesis. These analyses would also demonstrate 
whether the observed changes segregate with the leukaemic phenotypes as suggested by the 
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CIS analysis (Chapter 5) and their degree of utility as potential discriminating biomarkers for 
the different sub-types of acute leukaemias documented. 
 
Further work should also include assessing the expression and function of mutated genes in 
human leukaemia cell lines. Leukaemia cell lines are available for this purpose in the Bill 
Walsh Translational Cancer Research Laboratory If the gene expression signature for each 
leukaemic subtype identified in Chapter 5 was substantiated by the analysis of the SBxTie2-
Cre tissues then the same gene panels could be examined in the human ALL and AML cell 
lines. B-ALL, CML and erythroleukaemia cell lines can be used as controls. Validation of co-
expressed genes in pathways that could be used as new diagnostics and therapeutics will be a 
unique find. Assessment of functional studies following knockdown or re-expression of novel 
genes in human leukaemia cell lines must be performed in order to determine their relevance 
to leukaemia. Explorations of the pathways that are identified may offer novel therapeutic 
advantages. 
 
One gene of particular interest from both Chapters 4 and 5 is Notch1. Chapter 4 indicated that 
H vessels are responsive to Notch signalling, and enhanced endothelial cell Notch activation 
promoted haematopoiesis (Kusumbe, Ramasamy et al. 2016). Chapter 5 identified Notch1 as 
a core gene targeted in SBxTie2-Cre mice with acute lymphoblastic leukaemias. As NOTCH1 
mutations are present in human T-ALL (Weng, Ferrando et al. 2004, Ferrando 2009), the 
present study suggests that the haemogenic endothelium may have a role in human T-ALL. 
Notch signalling has profound effects of cell fate decisions and differentiation, specifically in 
endothelial and blood cells, and mounting evidence supports its association with haemogenic 
specification (Artavanis-Tsakonas, Rand et al. 1999, Kim, Albacker et al. 2013, Lee, 
Werbowetski-Ogilvie et al. 2013). Notch1 is expressed in the ventral wall of the dorsal aorta 
at a point in development when the haemogenic endothelium emerges and is thought to 
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regulate HEC specification and function (Jang, Lu et al. 2015). With these analyses in mind, 
inhibition of Notch1 is an attractive approach to treat acute forms of leukaemia. Indeed, small 
molecule gamma secretase inhibitors can effectively inhibit oncogenic NOTCH1 and are in 
clinical testing for the treatment of T-ALL (Weng, Ferrando et al. 2004, Palomero, Barnes et 
al. 2006, Palomero, Lim et al. 2006). 
 
6.3.4 Assess Different Anti-Angiogenic Agents in Leukaemic SBxTie2-Cre 
Mice 
This study is a back-translational study as anti-angiogenic agents are already in clinical trials 
for acute leukaemias; however, the underlying mechanism is unspecified. At publication of 
this thesis, receptor tyrosine kinase inhibitors (Vatalanib, Semaxinib, Sorafenib, Sunitinib, 
PKC-412, Cediranib), anti-VEGF antibodies (Bevacizumab) and immunomodulatory agents 
(Thalidomide, Lenalidomide) are being trialled in all forms of acute and chronic leukaemia 
(https://clinicaltrials.gov/). However, according to the author’s knowledge, it is uncertain 
what the most effective anti-angiogenic agent is as there is no assay for judging the 
effectiveness of therapies other than remission of disease. As such, the SBxTie2-Cre mice 
could serve as a robust pre-clinical model for the development of new agents.  Once the 
SBxTie2-Cre mice start showing signs of ailment, they can be phenotyped (ALL, AML and 
MPAL) and selected anti-angiogenic agents administered to validate the most effective 
compound for that form of leukaemia. This is important for rare leukaemias like MPAL 
where the pathogenesis and best treatment strategies are undefined. The outcomes of such 
studies are entirely unclear. Will the anti-angiogenic agents ablate the leukaemic cells or 
indeed all haematopoiesis? Alternately, will they normalise the endothelium and the 
neovascularisation of the bone marrow? These are key questions in the development of better 
therapeutics that remain unanswered. 
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Another mechanism to study is the combination of anti-angiogenic agents with current 
leukaemic therapy (chemotherapy). Questions arising from this include: Does the 
combination reduce chemotherapy-induced bone marrow toxicity? Does the combination 
increase survival rates compared to anti-angiogenic agents alone? What are the molecular 
targets of anti-angiogenic agents in combinatorial settings? Could anti-angiogenic agents 
regulate the effectiveness of chemotherapy or vice versa? What is the ideal order of 
administration of combinatorial drugs? Which is better: sequential treatment regimen of anti-
angiogenic agents followed by chemotherapeutic drugs or simultaneous administration of the 
two drugs? To date, these essential and clinically significant concerns remain unclear. 
 
 
6.3.5 Regenerate HSCs from the Haemogenic Endothelium 
Chapter 4 described the use of CFU assays to generate HSCs, ECs and HECs. The inter-
relationships and degree of plasticity between these lineages remains largely unexplored 
although early work seems to indicate that transition between HECs and HSCs is more 
unidirectional than that between HECs and ECs (Lancrin, Sroczynska et al. 2010). It would be 
useful for leukaemic settings to regenerate HSCs from HECs.  Current therapy utilises 
radiation and/or chemotherapy, which diminish majority of the bone marrow cells and 
subsequently, patients frequently rely on allogeneic bone marrow transplants to regenerate the 
complete balance of blood constituents (Sills and Hirschi 2011). These treatments also ablate 
the HEC component of bone marrow, or at least render the endogenous HECs non-functional. 
Therefore, reprograming the adult endothelium to a haemogenic phenotype, or isolation and 
expansion of HECs from patient marrow prior to radiotherapy, could be used to produce new 
adult-type definitive HSCs in vivo. Re-administration of these cells to patients may avoid the 
need for bone marrow matching and relieve the burden on donor registries and stored marrow 
for transfusions. The SBxTie2-Cre mice could be used as a model to develop such approaches 
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and simultaneously assess the inherent risks of such a procedure (like graft vs host disease, 
graft rejection and other risk factors associated with bone marrow transplantation).  
 
6.3.6 Examine The Angiogenic Potential of the SBxTie2-Cre Mice 
A significant finding in Chapter 3 was that the hearts of SBxTie2-Cre mice had greater 
content of blood and lymphatic vessels than those of WT mice. This was despite the hearts 
being histopathologically normal and of approximately equivalent weight (no signs of heart 
failure) (Chapter 3, Figure 3.8). These data confirm the changed relationship between 
metabolic need and vascular density in these tissues. This type of change is often associated 
with the angiogenic switch and is a precursor to tumour onset. These changes were 
documented in asymptomatic mice without evidence of leukaemia so the two phenotypes are 
not linked. The CIS in these cardiac ECs are unknown but would reveal the genomic changes 
that are producing these effects. Further, it is not known whether the production of circulating 
or tissue resident angiogenic regulators is altered in these mice. Such information would help 
to illucidate which factors are driving this response. The gDNA needs to be isolated from 
these mice and the CIS determined.   
 
The information is of vital importance as it may hold clues to the reformulation of pro-
angiogenic therapy for greater effectiveness. Pro-angiogenic therapy was first proposed in 
1996 (Isner, Pieczek et al. 1996) for the revascularisation of ischaemic and diabetic tissues to 
preserve tissue viability and reduce tissue damage. The unmet medical need for such a 
therapy is considerable as even therapies meeting today's highest standard of medical care are 
unable to stop the advancement of ischaemic heart disease to chronic heart failure, adding to 
its growing incidence (Velagaleti, Pencina et al. 2008). Even in patients who have undergone 
coronary artery bypass grafting or percutaneous coronary intervention commonly require 
secondary revascularisation after many years due to reappearance of symptoms (Velagaleti, 
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Pencina et al. 2008). Angiogenesis treatments delivering pro-angiogenic factors to promote 
myocardial perfusion in ischaemic heart disease have attracted attention  in preclinical and 
clinical studies (Zhang, van Olden et al. 2014). However, the trials of pro-angiogenic therapy 
suffered from poor effect size and diminishing benefit in the long term despite good short-
term outcomes and success in pre-clinical models. The major challenges in therapeutic 
angiogenesis are the lack of stability of native angiogenic proteins and mechanisms for 
providing sustained delivery of biologically active proteins at ischemic sites (Zhang, van 
Olden et al. 2014). The CIS from the hearts of SBxTie2-Cre mice may contain the answers to 
many of these questions and potentially hold the key to unlocking the reformulation of pro-
angiogenic therapy for clinical implementation. 
 
6.3.7 Utilise the SB Model for Other Diseases 
At the outset, Chapter 3 hypothesised that there may be development of altered vascular 
structure, haemangiosarcomas or spontaneous solid tumours in SBxTie2-Cre mice. Whilst 
these did not manifest, a significant unanswered question is: do random somatic mutations in 
the endothelial cell genome of the mouse alter the angiogenic properties of the host? The only 
tissue in which vessel density was investigated was the heart. Whilst morphologic assessment 
of other organs (bone marrow, kidney, lungs, liver, etc.) was performed, CD31 or LYVE1 
staining was not documented in these organs. As such, it is unknown whether vessel density is 
increased in all organs or just the heart. The other organs should be stained with antibodies 
against CD31 and LYVE1 to determine whether the enhanced vascular density is a ubiquitous 
finding or specific to the coronary vascular bed. Other studies have reported increased bone 
marrow vascular density in patients with ALL and AML, indicating that acute leukaemias 
may be angiogenesis dependent and thus raising the possibility for a role of anti-angiogenic 
therapy in the treatment of AML and ALL (Perez-Atayde, Sallan et al. 1997, Padro, Ruiz et 
al. 2000). 
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To further the investigation of the altered angiogenic potential in the SBxTie2-Cre mice, in 
vivo and ex vivo assays should be initiated to directly examine the neovascularisation 
response. The Matrigel plug angiogenesis assay is a simple and rapid in vivo method to 
determine the angiogenic potential (growth of blood vessels) of compounds (Auerbach, Lewis 
et al. 2003). Matrigel has a composition is comparable to the basement membrane of vessels 
and its main constituents are structural proteins (such as laminin, elastin, and collagen) 
(Auerbach, Lewis et al. 2003). Subcutaneous implantation of Matrigel supplemented with 
pro-angiogenic factors (such as FGF-2 or VEGF-A165) elicits a robust angiogenic response, 
which would be expected to be higher in SBxTie2-Cre mice. A more physiological model 
could employ sub-cutaneous implantation of a C57Bl/6 tumour allograft (such as B16-F10 
melanoma cells or Eo771 breast cancer cells). Both models are excised after 14 days and the 
tissues fixed with formalin overnight, embedded in paraffin, and sectioned onto slides for 
histological analysis. Tissue sections are stained to enhance the visibility of blood vessels 
(CD31) and lymphatics (LYVE1) determine the lymphangiogenic response as determined in 
Chapter 3. Analysis of the tissues using thick sections and whole mount staining will also thus 
enable determination of the morphology and complexity of the resulting vascular networks 
and also the potential for identifying the genes responsible for normalisation of tumour 
vasculature (which is another elusive goal of anti-angiogenic therapy). Moreover, failure of 
the vessel density in tumours (angiogenesis) and hearts (angiogenesis) to correlate may allow 
for the identification of genes (using CIS analysis) that specifically regulate pathological 
versus physiological angiogenesis and provide avenues for new drug development for anti-
angiogenic therapy that are without the significant side effects (e.g. hypertension, bleeding, 
etc.) that plague current therapeutics. 
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Another method to assess angiogenesis in mice is through organ culture. The aortic ring assay 
is a widely utilised method of choice where the isolated aorta is cut into segments and placed 
in culture (usually in a matrix-containing setting) (Auerbach, Lewis et al. 2003). With the 
addition of test elements, the explants can be examined over 7-14 days for the outgrowth of 
endothelial cells as well as other cell types. Quantification can be accomplished by assessing 
the length and number of vessel-like expansions from the explant (Auerbach, Lewis et al. 
2003). Counterstaining with endothelium-selective reagents (such as fluorescein-labelled 
BSL-1) or staining for support cells (such as pericytes and vascular smooth muscle cells) can 
be utilised to examine vascular stabilisation and mural cell-EC interactions in the formation of 
new vessels (Plendl, Hartwell et al. 1993). These assays would be capable of determining 
whether mutation of the endothelial genome favours enhanced formation or decreased 
regression of vascular beds and provide mechanistic insight into the altered physiological 
regulation of neovascularisation of the coronary vasculature in SBxTie2-Cre mice.   
 
6.4 Conclusions  
In the present study, random mutation of the endothelial genome was used to generate a 
unique model of disease. The novel mouse model developed for this project provides an 
innovative and potentially powerful platform for assessing the endothelium as a modifier of 
leukaemia. Cell type specific activation of the SB transgene has allowed the present study, for 
the first time, to identify a novel role of the endothelium in leukaemia. Furthermore, these 
data for the first time provide a rational basis for the use of anti-angiogenic agents in the 
treatment of acute leukaemias. This mouse model provides not only a powerful system to 
discover disease causing genes, but also a new platform for therapeutic development to 
address a previously unrecognised basis of acute leukaemia. These data further the 
understanding of endothelial cells and leukaemia by examining the expression profiles of 
known and new genes identified in this mouse model.  
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Appendix 1: Raw data of percentage body weight for heart and vessel densities in WT 
and SBxTie2-Cre mice. 
 
Table A1: Raw data for WT percentage (%) body weight (BW) for heart and CD31 and 
LYVE-1 vessel densities (VD). 
Block ID Mouse ID 
% BW for 
HW 
CD31 VD Pixels 
per Field 
LYVE-1 VD Pixels 
per Field 
11-0201-28 81 0.34 N/A 27016 
11-0201-34 82 0.50 118091 35414 
11-0201-58 104 0.40 188585 35246 
11-0201-70 106 0.33 215386 59601 
11-0201-76 107 0.33 209293 67354 
11-0214-180 165 0.49 121494 47211 
11-0214-186 166 0.43 189329 54061 
11-0214-192 167 0.42 71125 65273 
11-0214-222 201 0.42 107690 44811 
11-0214-228 202 0.34 47101 55134 
11-0214-234 204 0.38 163090 37378 
11-0228-294 241 0.40 70303 30751 
11-0228-300 242 0.40 93368 37558 
11-0228-312 244 0.42 70573 30376 
11-0228-331 258 0.60 62482 32649 
11-0228-357 259 0.40 66776 26997 
11-0228-343 260 0.52 57644 31383 
11-0325-4 279 0.36 42970 N/A 
11-0325-16 282 0.43 31190 N/A 
11-0325-22 284 0.33 12441 N/A 
11-0325-78 309 0.40 48366 N/A 
11-0325-97 318 0.37 43525 N/A 
11-0325-103 319 0.33 48008 N/A 
 
 
 
 
Appendices 
 5 
 
Table A2: Raw data for SBxTie2-Cre percentage (%) body weight (BW) for heart and 
CD31 and LYVE-1 vessel densities (VD). 
Block ID Mouse ID 
% BW 
forHW 
CD31 VD Pixels 
per Field 
LYVE-1 VD Pixels 
per Field 
11-0201-4 76 0.33 305991 56413 
11-0201-10 77 0.52 N/A 37963 
11-0201-16 79 0.26 92920 N/A 
11-0201-22 80 0.41 288300 56491 
11-0201-40 85 0.55 85246 39735 
11-0201-46 87 0.35 127142 N/A 
11-0201-52 92 0.37 N/A 73080 
11-0201-64 105 0.40 325873 31196 
11-0201-88 123 0.42 274582 60942 
11-0201-94 125 0.46 201032 34049 
11-0201-100 128 0.34 159098 32540 
11-0201-106 130 0.38 88233 27480 
11-0201-117 135 0.35 90185 32165 
11-0201-123 139 0.48 54720 33124 
11-0201-134 145 0.40 97643 37963 
11-0201-140 152 0.40 136978 49773 
11-0214-198 176 0.40 108021 32249 
11-0214-204 189 0.46 156895 48338 
11-0214-210 194 0.43 202902 99376 
11-0214-216 195 0.52 367430 27716 
11-0228-255 228 0.41 66451 51410 
11-0228-261 230 0.33 146568 47704 
11-0228-269 231 0.43 239347 58951 
11-0228-275 234 0.59 121736 52339 
11-0228-281 237 0.39 79707 32829 
11-0228-287 238 0.49 122350 27534 
11-0228-306 243 0.46 74579 21681 
11-0228-318 253 0.46 41729 24797 
11-0228-324 257 0.50 106226 27716 
11-0228-348 261 0.43 91013 31196 
11-0325-10 281 0.44 34146 N/A 
11-0325-28 286 0.34 110372 N/A 
11-0325-35 287 0.31 86274 N/A 
11-0325-41 288 0.40 309817 N/A 
11-0325-48 289 0.43 435276 N/A 
11-0325-54 291 0.38 623702 N/A 
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11-0325-60 292 0.38 378533 N/A 
11-0325-66 297 0.42 66810 N/A 
11-0325-72 301 0.37 193379 N/A 
11-0325-84 310 0.46 65884 N/A 
11-0325-90 312 0.37 145652 N/A 
 
N/A = not available. 
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Appendix 2: Raw data of all organs in WT and SBxTie2-Cre mice. 
 
Table A3: Organ weights of WT mice. 
 
WT 
Mouse ID BW (g) Spleen %BW Liver %BW Thymus %BW Lungs %BW Heart %BW K1 %BW K2 %BW 
Total 
%BW (K) 
2521 26.4 0.13 0.51 1.16 4.40 0.03 0.13 0.19 0.71 0.11 0.43 0.17 0.63 0.15 0.56 1.19 
2515 30.7 0.10 0.32 1.21 3.95 0.10 0.34 0.21 0.67 0.12 0.39 0.17 0.54 0.19 0.62 1.16 
2516 29.8 0.09 0.32 1.19 4.00 0.02 0.08 0.16 0.54 0.11 0.38 0.20 0.68 0.16 0.54 1.23 
2404 32.3 0.17 0.54 1.15 3.57 0.05 0.16 0.28 0.88 0.15 0.46 0.24 0.76 0.26 0.80 1.56 
2405 33.2 0.15 0.45 1.36 4.11 0.03 0.08 0.26 0.79 0.14 0.43 0.21 0.63 0.20 0.60 1.23 
2642 29.1 0.11 0.37 1.05 3.60 0.02 0.05 0.21 0.74 0.10 0.36 0.21 0.72 0.19 0.66 1.37 
2624 32.4 0.13 0.39 1.29 3.99 0.01 0.03 0.17 0.53 0.18 0.57 0.15 0.46 0.18 0.55 1.01 
2640 31.9 0.13 0.42 1.13 3.55 0.05 0.16 0.21 0.65 0.13 0.39 0.21 0.65 0.22 0.68 1.33 
3128 22.2 0.11 0.50 0.90 4.03 0.02 0.11 0.11 0.49 0.12 0.55 0.12 0.52 0.11 0.48 1.00 
3133 21.3 0.11 0.51 0.86 4.02 NA NA 0.16 0.75 0.14 0.64 0.14 0.64 0.13 0.59 1.23 
3129 24.8 0.05 0.19 0.77 3.09 0.04 0.16 0.23 0.93 0.14 0.57 0.14 0.57 0.14 0.57 1.14 
3130 21.8 0.05 0.21 0.71 3.23 0.03 0.16 0.17 0.76 0.09 0.39 0.13 0.60 0.13 0.59 1.19 
3131 24.6 0.09 0.36 0.71 2.88 0.04 0.14 0.21 0.85 0.11 0.44 0.18 0.72 0.12 0.49 1.21 
2683 35.2 0.05 0.15 1.51 4.29 0.02 0.04 0.29 0.82 0.16 0.46 0.22 0.62 0.16 0.45 1.07 
2614 35.5 0.15 0.42 1.16 3.26 0.01 0.04 0.24 0.67 0.15 0.42 0.20 0.56 0.21 0.59 1.14 
2760 37.7 0.14 0.37 1.30 3.44 0.05 0.13 0.20 0.53 0.11 0.30 0.16 0.43 0.16 0.41 0.84 
2762 35.3 0.14 0.39 2.15 6.09 0.08 0.24 0.56 1.59 0.11 0.32 0.19 0.55 0.20 0.58 1.13 
2775 37.1 0.15 0.40 1.40 3.78 0.06 0.17 0.19 0.52 0.13 0.36 0.17 0.46 0.19 0.51 0.97 
2676 33.7 0.15 0.45 1.46 4.33 0.05 0.14 0.30 0.90 0.15 0.45 0.25 0.74 0.23 0.67 1.41 
2782 34.2 0.08 0.24 1.29 3.77 0.03 0.09 0.22 0.64 0.15 0.43 0.24 0.71 0.26 0.77 1.48 
2783 34.9 0.08 0.23 1.29 3.70 0.01 0.02 0.22 0.63 0.17 0.49 0.27 0.78 0.23 0.67 1.45 
2377 24.9 0.18 0.74 1.21 4.85 0.03 0.12 0.12 0.49 0.09 0.35 0.14 0.54 0.15 0.60 1.15 
2384 23.1 0.15 0.65 1.06 4.58 0.05 0.22 0.26 1.10 0.08 0.35 0.14 0.63 0.13 0.55 1.18 
2369 23.2 0.16 0.68 1.05 4.51 0.03 0.14 0.22 0.94 0.09 0.41 0.15 0.63 0.14 0.62 1.24 
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2595 23.5 0.14 0.58 0.85 3.60 0.02 0.08 0.15 0.64 0.11 0.46 0.17 0.73 0.13 0.54 1.27 
2592 23 0.14 0.59 0.96 4.18 0.02 0.08 0.27 1.16 0.12 0.52 0.13 0.55 0.13 0.57 1.11 
2662 27.8 0.06 0.22 0.92 3.31 0.02 0.07 0.18 0.64 0.10 0.38 0.16 0.59 0.15 0.55 1.14 
2664 25.3 0.04 0.14 0.85 3.36 0.02 0.06 0.29 1.14 0.10 0.41 0.14 0.57 0.16 0.62 1.19 
2665 32 0.17 0.53 1.33 4.15 0.04 0.11 0.21 0.66 0.14 0.43 0.17 0.53 0.18 0.57 1.10 
2647 25 0.16 0.62 1.00 4.00 0.04 0.15 0.19 0.76 0.10 0.42 0.14 0.55 0.14 0.56 1.11 
2648 24.2 0.15 0.61 0.93 3.82 0.03 0.11 0.16 0.67 0.09 0.38 0.13 0.54 0.14 0.59 1.13 
2785 31.3 0.08 0.26 1.13 3.62 0.05 0.17 0.30 0.96 0.10 0.31 0.16 0.52 0.17 0.55 1.07 
 
Red = female; blue = male; %BW = percentage body weight NA = not available (for thymus – too small to remove). 
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Table A4: Age of death and organ weights of SBxTie2-Cre mice. 
 
SB Mouse 
ID 
Age at 
death 
(Days) BW (g)  Spleen %BW Liver %BW Thymus %BW Lungs %BW Heart %BW K1 %BW K2 %BW 
Total 
%BW 
(K) 
132 77 19 0.07 0.36 1.06 5.59 NA NA 0.20 1.07 0.11 0.57 0.18 0.96 0.17 0.91 1.87 
143 77 19.26 0.20 1.03 0.51 2.65 NA NA 0.11 0.56 0.08 0.42 0.18 0.91 0.17 0.90 1.81 
158 77 21.43 1.74 8.12 4.44 20.70 NA NA 0.20 0.94 0.10 0.47 0.14 0.64 0.06 0.30 0.94 
179 77 18.55 0.71 3.84 0.18 0.95 NA NA 0.16 0.87 0.11 0.58 0.13 0.71 0.09 0.50 1.21 
184 77 18.55 0.86 4.65 2.19 11.81 NA NA 0.17 0.91 0.12 0.65 0.12 0.66 0.10 0.56 1.23 
197 77 17.98 0.64 3.57 2.99 16.64 NA NA 0.26 1.44 0.12 0.69 0.26 1.42 0.22 1.23 2.65 
198 77 19.61 0.89 4.52 3.82 19.50 NA NA 0.16 0.82 0.10 0.51 0.15 0.76 0.09 0.48 1.24 
203 77 17.98 0.67 3.71 1.13 6.28 NA NA 0.11 0.60 0.13 0.74 0.30 1.67 NA 0.00 1.67 
245 77 17.6 0.50 2.87 0.64 3.65 NA NA 0.20 1.11 0.07 0.40 0.09 0.49 0.08 0.45 0.93 
247 77 20 0.44 2.18 0.94 4.71 NA NA 0.05 0.24 0.08 0.40 0.93 4.63 0.07 0.33 4.96 
256 77 21.4 0.07 0.33 0.69 3.24 NA NA 0.13 0.59 0.10 0.48 0.13 0.61 0.11 0.50 1.10 
296 77 21.2 0.27 1.26 0.82 3.88 NA NA 0.17 0.78 0.09 0.45 0.10 0.46 0.12 0.56 1.02 
315 77 14.89 0.04 0.26 0.51 3.46 NA NA 0.15 1.00 0.07 0.49 0.07 0.49 0.08 0.51 1.00 
2334 75 21.60 0.57 2.62 2.12 9.80 0.66 3.08 0.37 1.69 0.08 0.38 0.13 0.61 0.20 0.92 1.53 
2340 71 18.40 0.74 4.00 1.72 9.35 0.18 1.00 0.25 1.34 0.07 0.39 0.10 0.52 0.11 0.60 1.12 
2345 279 20.00 1.04 5.21 2.49 12.44 NA NA 0.51 2.54 0.13 0.64 0.17 0.87 0.17 0.87 1.74 
2354 79 26.00 0.91 3.51 2.15 8.28 NA NA 0.13 0.51 0.13 0.49 0.21 0.82 0.13 0.49 1.31 
2389 91 22.00 0.23 1.04 0.76 3.43 0.07 0.31 0.18 0.81 0.09 0.42 0.12 0.54 0.09 0.40 0.94 
2393 76 20.80 0.14 0.69 0.87 4.16 0.90 4.33 0.36 1.74 0.10 0.47 0.09 0.41 0.11 0.54 0.95 
2395 93 17.50 0.11 0.60 0.55 3.16 0.45 2.60 0.29 1.68 0.07 0.37 0.10 0.58 0.11 0.64 1.21 
2396 132 22.90 1.12 4.91 3.12 13.63 0.79 3.45 0.10 0.42 0.10 0.44 0.12 0.51 0.12 0.50 1.01 
2399 56 22.00 0.87 3.97 1.34 6.08 NA NA 0.14 0.63 0.10 0.44 0.13 0.60 0.12 0.57 1.16 
2401 64 22.70 0.94 4.15 1.88 8.29 0.27 1.19 0.33 1.45 0.10 0.44 0.17 0.74 0.13 0.57 1.31 
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2402 62 18.20 1.20 6.61 2.19 12.02 0.05 0.27 0.16 0.87 0.09 0.51 0.12 0.66 0.10 0.55 1.21 
2403 64 22.30 0.90 4.03 1.59 7.12 0.02 0.09 0.15 0.69 0.09 0.41 0.16 0.70 0.18 0.82 1.52 
2406 89 18.10 0.20 1.11 0.81 4.45 0.78 4.30 0.10 0.56 0.06 0.32 0.09 0.49 0.07 0.40 0.89 
2517 38 16.60 0.33 2.00 0.82 4.93 0.07 0.40 0.12 0.73 0.06 0.37 0.09 0.54 0.07 0.45 0.98 
2518 83 16.70 0.64 3.82 2.11 12.65 0.01 0.04 0.23 1.41 0.08 0.49 0.09 0.54 0.11 0.68 1.22 
2519 59 19.70 0.37 1.87 1.03 5.22 0.89 4.53 0.18 0.92 0.10 0.53 0.16 0.81 0.15 0.76 1.57 
2520 55 18.60 0.45 2.43 0.93 4.98 0.12 0.62 0.14 0.73 0.08 0.44 0.09 0.46 0.10 0.53 0.99 
2522 42 15.40 0.85 5.51 1.39 9.00 0.11 0.69 0.21 1.34 0.06 0.38 0.08 0.50 0.07 0.49 0.99 
2523 71 21.30 0.99 4.62 1.58 7.43 0.01 0.03 0.28 1.33 0.11 0.51 0.11 0.52 0.09 0.44 0.96 
2524 104 19.30 0.75 3.88 1.48 7.66 0.11 0.56 0.18 0.96 0.08 0.40 0.10 0.54 0.11 0.57 1.11 
2525 89 19.00 0.66 3.48 1.96 10.33 0.01 0.06 0.16 0.82 0.10 0.52 0.08 0.44 0.10 0.52 0.96 
2526 73 18.00 0.16 0.88 0.61 3.42 0.66 3.65 0.05 0.27 0.06 0.36 0.06 0.32 0.10 0.54 0.86 
2357 58 15.30 0.83 5.43 2.08 13.58 0.85 5.57 0.24 1.58 0.07 0.43 0.09 0.56 0.09 0.57 1.12 
2361 48 14.00 1.19 8.51 2.08 14.87 0.02 0.15 0.18 1.31 0.06 0.46 0.09 0.61 0.09 0.62 1.23 
2362 86 17.50 2.17 12.37 2.89 16.51 0.12 0.68 0.30 1.72 0.09 0.49 0.09 0.53 0.10 0.57 1.10 
2364 99 17.30 0.20 1.16 0.94 5.42 1.07 6.16 0.27 1.58 0.07 0.39 0.23 1.32 0.13 0.75 2.07 
2365 79 18.00 1.52 8.45 2.70 14.98 0.10 0.57 0.50 2.76 0.06 0.36 0.10 0.56 0.08 0.45 1.02 
2366 84 18.50 0.60 3.26 4.08 22.05 0.24 1.28 0.45 2.44 0.06 0.34 0.19 1.05 0.30 1.61 2.66 
2367 68 12.60 0.85 6.77 1.03 8.16 0.05 0.37 0.31 2.46 0.06 0.46 0.08 0.62 0.10 0.81 1.43 
2368 79 16.60 0.96 5.80 2.19 13.22 0.21 1.29 0.35 2.09 0.08 0.47 0.07 0.45 0.10 0.62 1.07 
2372 34 13.10 0.28 2.12 0.62 4.72 0.04 0.30 0.10 0.78 0.07 0.53 0.05 0.35 0.07 0.50 0.85 
2374 96 16.90 0.84 4.95 2.68 15.87 0.01 0.04 0.19 1.10 0.07 0.43 0.07 0.39 0.10 0.61 1.00 
2376 92 17.90 0.90 5.05 1.50 8.36 0.61 3.43 0.29 1.64 0.09 0.48 0.09 0.48 0.09 0.48 0.96 
2378 90 14.70 0.44 3.01 0.74 5.03 NA NA 0.14 0.97 0.06 0.43 0.06 0.44 0.06 0.43 0.87 
2379 70 16.20 0.66 4.06 1.84 11.38 0.10 0.59 0.22 1.39 0.09 0.53 0.11 0.66 0.10 0.59 1.26 
2383 91 17.40 0.67 3.84 1.66 9.54 0.18 1.03 0.22 1.28 0.08 0.48 0.08 0.45 0.07 0.40 0.85 
2386 93 13.50 0.47 3.48 1.27 9.41 0.26 1.96 0.19 1.41 0.05 0.39 0.10 0.72 0.10 0.73 1.45 
2387 97 15.30 0.64 4.20 1.30 8.51 0.02 0.16 0.17 1.12 0.09 0.60 0.08 0.53 0.08 0.53 1.06 
2420 75 14.00 0.18 1.28 0.87 6.22 0.58 4.13 0.21 1.53 0.07 0.49 0.07 0.52 0.07 0.51 1.03 
2421 47 13.50 0.82 6.09 1.44 10.67 0.02 0.11 0.14 1.03 0.09 0.64 0.09 0.64 0.08 0.61 1.25 
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2422 79 17.40 0.79 4.55 2.72 15.61 0.61 3.51 0.25 1.46 0.09 0.53 0.07 0.43 0.10 0.59 1.01 
2424 58 15.90 0.17 1.06 0.53 3.32 0.06 0.36 0.21 1.34 0.06 0.36 0.08 0.49 0.08 0.48 0.97 
2425 82 17.10 0.66 3.84 1.88 11.01 0.16 0.96 0.13 0.78 0.08 0.49 0.08 0.48 0.09 0.52 1.01 
2427 77 18.50 0.42 2.29 0.99 5.35 0.30 1.62 0.21 1.11 0.08 0.42 0.11 0.58 0.07 0.40 0.98 
 
Red = female; blue = male; %BW = percentage body weight NA = not available (for thymus – too small to remove and measure weight; for kidney – 
missing organ). 
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Appendix 3: Statistical analyses of organ vs organ in WT and SBxTie2-Cre mice. 
 
Table A5: Statistical analyses for Figure 3.26. 
 
 
Number of 
XY Pairs Spearman r 
95% confidence 
interval 
P value (two-
tailed) 
P value 
summary 
Exact or Approximate P 
value? 
Correlation 
significant? 
(alpha=0.05) 
WT Spleen vs. Liver 55 0.2552 -0.01890 to 0.4937 0.06 ns Gaussian Approximation No 
WT Spleen vs. Liver F 11 0.8636 0.5327 to 0.9655 0.0012 ** Exact Yes 
WT Spleen vs. Liver M 44 0.02192 -0.2852 to 0.3249 0.8877 ns Gaussian Approximation No 
SB Spleen vs. Liver 101 0.8018 0.7162 to 0.8636 < 0.0001 *** Gaussian Approximation Yes 
SB Spleen vs. Liver F 22 0.6501 0.3026 to 0.8450 0.0011 ** Gaussian Approximate Yes 
SB Spleen vs. Liver M 79 0.7242 0.5948 to 0.8171 < 0.0001 *** Gaussian Approximation Yes 
WT Spleen vs. Thymus 31 0.1834 -0.1934 to 0.5131 0.3233 ns Exact No 
WT Spleen vs. Thymus F 11 0.6027 -0.01616 to 0.8877 0.0497 * Exact Yes 
WT Spleen vs. Thymus M 20 0.1144 -0.3581 to 0.5402 0.6312 ns Exact No 
SB Spleen vs. Thymus 40 -0.3543 -0.6057 to -0.03848 0.0249 * Exact Yes 
SB Spleen vs. Thymus F 21 -0.3228 -0.6699 to 0.1400 0.1535 ns Exact No 
SB Spleen vs. Thymus M 19 -0.4561 -0.7603 to 0.01217 0.0497 * Exact Yes 
WT Spleen vs. Lungs 55 -0.008264 -0.2804 to 0.2651 0.9523 ns Gaussian Approximation No 
WT Spleen vs. Lungs F 11 -0.1595 -0.7036 to 0.5026 0.6396 ns Exact No 
WT Spleen vs. Lungs M 44 -0.02136 -0.3244 to 0.2857 0.8905 ns Gaussian Approximation No 
SB Spleen vs. Lungs 101 0.4676 0.2941 to 0.6112 < 0.0001 *** Gaussian Approximation Yes 
SB Spleen vs. Lungs F 22 0.3614 -0.08436 to 0.6866 0.0984 ns Exact No 
SB Spleen vs. Lungs M 79 0.298 0.07563 to 0.4921 0.0077 ** Gaussian Approximation Yes 
WT Spleen vs. Heart 55 0.2686 -0.004496 to 0.5045 0.0473 * Gaussian Approximation Yes 
WT Spleen vs. Heart F 11 -0.1373 -0.6920 to 0.5193 0.6873 ns Exact No 
WT Spleen vs. Heart M 44 0.3977 0.1053 to 0.6268 0.0075 ** Gaussian Approximation Yes 
SB Spleen vs. Heart 101 0.3216 0.1288 to 0.4909 0.001 ** Gaussian Approximation Yes 
SB Spleen vs. Heart F 22 0.2267 -0.2283 to 0.6004 0.3104 ns Exact No 
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SB Spleen vs. Heart M 79 0.2633 0.03814 to 0.4631 0.019 * Gaussian Approximation Yes 
WT Spleen vs. Kidneys 55 0.1145 -0.1634 to 0.3756 0.4051 ns Gaussian Approximation No 
WT Spleen vs. Kidneys F 11 0.2443 -0.4336 to 0.7456 0.4692 ns Exact No 
WT Spleen vs. Kidneys M 44 0.2757 -0.03215 to 0.5358 0.07 ns Gaussian Approximation No 
SB Spleen vs. Kidneys 101 -0.09146 -0.2873 to 0.1117 0.363 ns Gaussian Approximation No 
SB Spleen vs. Kidneys F 22 0.2441 -0.2107 to 0.6121 0.2735 ns Exact No 
SB Spleen vs. Kidneys M 79 -0.08813 -0.3094 to 0.1422 0.4399 ns Gaussian Approximation No 
 
SB = SBxTie2-Cre; F = female; M = male; ns = not significant; *,**,*** = significance of P value (low, moderate and high respectively). 
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Table A6: Statistical analyses for Figure 3.27. 
 
 
Number of 
XY Pairs 
Spearman r 95% confidence 
interval 
P value (two-
tailed) 
P value 
summary 
Exact or Approximate P 
value? 
Correlation 
significant? 
(alpha=0.05) 
WT Liver vs. Thymus 31 0.1018 -0.2723 to 0.4491 0.586 ns Gaussian Approximate No 
WT Liver vs. Thymus F 11 0.5982 -0.02330 to 0.8862 0.0562 ns Exact No 
WT Liver vs. Thymus M 20 -0.0907 -0.5230 to 0.3787 0.7037 ns Gaussian Approximate No 
SB Liver vs. Thymus 40 -0.1684 -0.4636 to 0.1604 0.2989 ns Gaussian Approximate No 
SB Liver vs. Thymus F 21 -0.1 -0.5198 to 0.3587 0.6663 ns Gaussian Approximate No 
SB Liver vs. Thymus M 19 -0.3456 -0.6989 to 0.1432 0.1472 ns Gaussian Approximate No 
WT Liver vs. Lungs 55 0.07034 -0.2064 to 0.3367 0.6098 ns Gaussian Approximation No 
WT Liver vs. Lungs F 11 0.06378 -0.5715 to 0.6513 0.8603 ns Exact No 
WT Liver vs. Lungs M 79 0.2875 0.06426 to 0.4834 0.0102 * Gaussian Approximation Yes 
SB Liver vs. Lungs 101 0.4548 0.2792 to 0.6010 < 0.0001 *** Gaussian Approximation Yes 
SB Liver vs. Lungs F 22 0.3621 -0.08350 to 0.6871 0.0977 ns Gaussian Approximation No 
SB Liver vs. Lungs M 44 0.03587 -0.2723 to 0.3374 0.8172 ns Gaussian Approximation No 
WT Liver vs. Heart 55 0.03555 -0.2396 to 0.3054 0.7966 ns Gaussian Approximation No 
WT Liver vs. Heart F 11 -0.1098 -0.6772 to 0.5394 0.7545 ns Exact No 
WT Liver vs. Heart M 44 0.06514 -0.2449 to 0.3631 0.6744 ns Gaussian Approximation No 
SB Liver vs. Heart 101 0.2835 0.08735 to 0.4585 0.0041 ** Gaussian Approximation Yes 
SB Liver vs. Heart F 22 0.01134 -0.4233 to 0.4417 0.96 ns Gaussian Approximate No 
SB Liver vs. Heart M 79 0.2395 0.01276 to 0.4429 0.0335 * Gaussian Approximation Yes 
WT Liver vs. Kidneys 55 -0.06566 -0.3325 to 0.2109 0.6339 ns Gaussian Approximation No 
WT Liver vs. Kidneys F 11 0.3134 -0.3708 to 0.7771 0.3415 ns Exact No 
WT Liver vs. Kidneys M 44 -0.04525 -0.3457 to 0.2636 0.7705 ns Gaussian Approximation No 
SB Liver vs. Kidneys 101 0.04218 -0.1603 to 0.2412 0.6754 ns Gaussian Approximation No 
SB Liver vs. Kidneys F 22 0.3672 -0.07768 to 0.6902 0.0927 ns Gaussian Approximation No 
SB Liver vs. Kidneys M 79 0.04649 -0.1829 to 0.2711 0.6842 ns Gaussian Approximation No 
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Table A7: Statistical analyses for Figure 3.28. 
 
 
Number of 
XY Pairs 
Spearman r 95% confidence interval 
P value (two-
tailed) 
P value 
summary 
Exact or Approximate P 
value? 
Correlation 
significant? 
(alpha=0.05) 
WT Thymus vs. Lungs 31 0.3096 -0.06129 to 0.6053 0.0901 ns Gaussian Approximation No 
WT Thymus vs. Lungs F 11 0.1076 -0.5411 to 0.6759 0.7545 ns Exact No 
WT Thymus vs. Lungs M 20 0.3162 -0.1607 to 0.6734 0.1744 ns Gaussian Approximation No 
SB Thymus vs. Lungs 40 0.2207 -0.1070 to 0.5052 0.1712 ns Gaussian Approximation No 
SB Thymus vs. Lungs F 21 0.4128 -0.03679 to 0.7234 0.0629 ns Gaussian Approximation No 
SB Thymus vs. Lungs M 19 0.06253 -0.4153 to 0.5133 0.7993 ns Gaussian Approximation No 
WT Thymus vs. Heart 31 -0.385 -0.6569 to -0.02448 0.0325 * Gaussian Approximation Yes 
WT Thymus vs. Heart F 11 -0.4943 -0.8498 to 0.1703 0.1217 ns Exact No 
WT Thymus vs. Heart M 20 -0.3457 -0.6911 to 0.1282 0.1354 ns Gaussian Approximation No 
SB Thymus vs. Heart 40 -0.2884 -0.5571 to 0.03499 0.0711 ns Gaussian Approximation No 
SB Thymus vs. Heart F 21 -0.2535 -0.6261 to 0.2133 0.2675 ns Gaussian Approximation No 
SB Thymus vs. Heart M 19 -0.2767 -0.6577 to 0.2170 0.2515 ns Gaussian Approximation No 
WT Thymus vs. Kidneys 31 0.02808 -0.3393 to 0.3881 0.8808 ns Gaussian Approximation No 
WT Thymus vs. Kidneys F 11 -0.1713 -0.7097 to 0.4934 0.6147 ns Exact No 
WT Thymus vs. Kidneys M 20 0.1025 -0.3685 to 0.5316 0.6672 ns Gaussian Approximation No 
SB Thymus vs. Kidneys 40 0.06419 -0.2613 to 0.3766 0.6939 ns Gaussian Approximation No 
SB Thymus vs. Kidneys F 21 0.08496 -0.3719 to 0.5087 0.7142 ns Gaussian Approximation No 
SB Thymus vs. Kidneys M 19 -0.003084 -0.4681 to 0.4633 0.99 ns Gaussian Approximation No 
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Table A8: Statistical analyses for Figure 3.29. 
 
 
Number of 
XY Pairs 
Spearman r 95% confidence 
interval 
P value (two-
tailed) 
P value 
summary 
Exact or Approximate P 
value? 
Correlation 
significant? 
(alpha=0.05) 
WT Lungs vs. Heart 55 0.1751 -0.1027 to 0.4275 0.2011 ns Gaussian Approximation No 
WT Lungs vs. Heart F 11 0.1032 -0.5442 to 0.6735 0.7545 ns Exact No 
WT Lungs vs. Heart M 44 0.2649 -0.04380 to 0.5275 0.0822 ns Gaussian Approximation No 
SB Lungs vs. Heart 101 0.1523 -0.05034 to 0.3429 0.1284 ns Gaussian Approximation No 
SB Lungs vs. Heart F 22 -0.3698 -0.6917 to 0.07478 0.0903 ns Gaussian Approximation No 
SB Lungs vs. Heart M 79 0.1747 -0.05498 to 0.3868 0.1236 ns Gaussian Approximation No 
WT Lungs vs. Kidneys 55 0.1546 -0.1234 to 0.4101 0.2597 ns Gaussian Approximation No 
WT Lungs vs. Kidneys F 11 0.1848 -0.4829 to 0.7166 0.5765 ns Exact No 
WT Lungs vs. Kidneys M 44 0.2459 -0.06408 to 0.5126 0.1076 ns Gaussian Approximation No 
SB Lungs vs. Kidneys 101 0.08277 -0.1203 to 0.2792 0.4106 ns Gaussian Approximation No 
SB Lungs vs. Kidneys F 22 0.4862 0.06785 to 0.7591 0.0218 * Gaussian Approximation Yes 
SB Lungs vs. Kidneys M 79 0.09063 -0.1397 to 0.3117 0.427 ns Gaussian Approximation No 
WT Heart vs. Kidneys 55 0.3607 0.09746 to 0.5767 0.0068 ** Gaussian Approximation Yes 
WT Heart vs. Kidneys F 11 0.02784 -0.5953 to 0.6300 0.9462 ns Exact No 
WT Heart vs. Kidneys M 44 0.3731 0.07668 to 0.6090 0.0126 * Gaussian Approximation Yes 
SB Heart vs. Kidneys 101 0.2139 0.01339 to 0.3979 0.0317 * Gaussian Approximation Yes 
SB Heart vs. Kidneys F 22 -0.1564 -0.5516 to 0.2962 0.4871 ns Gaussian Approximation No 
SB Heart vs. Kidneys M 79 0.3588 0.1430 to 0.5421 0.0012 ** Gaussian Approximation Yes 
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Appendix 4: Statistical analyses of each organ in WT and SBxTie2-Cre mice. 
 
 
Figure A1: Frequency distribution histograms of body weights (g) in WT (A) and 
SBxTie2-Cre (B) mice and also with both groups of mice together (C). 
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Figure A2: Frequency distribution histograms of % body weight of heart in WT 
(A) and SBxTie2-Cre (B) mice and also with both groups of mice together (C). 
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Figure A3: Frequency distribution histograms of % body weight of spleen in WT 
(A) and SBxTie2-Cre (B) mice and also with both groups of mice together (C). 
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Figure A4: Frequency distribution histograms of % body weight of liver in WT 
(A) and SBxTie2-Cre (B) mice and also with both groups of mice together (C). 
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Figure A5: Frequency distribution histograms of % body weight of thymus in 
WT (A) and SBxTie2-Cre (B) mice and also with both groups of mice together 
(C). 
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Figure A6: Frequency distribution histograms of % body weight of lungs in WT 
(A) and SBxTie2-Cre (B) mice and also with both groups of mice together (C). 
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Figure A7: Frequency distribution histograms of % body weight of kidneys in 
WT (A) and SBxTie2-Cre (B) mice and also with both groups of mice together 
(C). 
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Appendix 5: Mutation analyses of SBxTie2-Cre mice. 
 
Table A9:  Sample IDs (CIS Howell) of SBxTie2-Cre spleen (S) and thymus (Y) for 
mutation analyses. Shaded areas = spleen 
 
CIS Howell ID Sample ID CIS Howell ID Sample ID 
1 2334S 35 2396S 
2 2334Y 36 2396Y 
3 2340S 37 2399S 
4 2340Y 38 2401S 
5 2345S 39 2401Y 
6 2354S 40 2403S 
7 2357S 41 2406S 
8 2357Y 42 2406Y 
9 2361S 43 2420S 
10 2362S 44 2420Y 
11 2362Y 45 2421S 
12 2364S 46 2422S 
13 2364Y 47 2422Y 
14 2365S 48 2523S 
15 2365Y 49 2424S 
16 2366S 50 2424Y 
17 2366Y 51 2425S 
18 2367S 52 2425Y 
19 2368S 53 2427S 
20 2368Y 54 2427Y 
21 2372S 55 2517S 
22 2374S 56 2517Y 
23 2376S 57 2518S 
24 2376Y 58 2519S 
25 2378S 59 2519Y 
26 2383S 60 2520S 
27 2383Y 61 2520Y 
28 2386S 62 2522Y 
29 2386Y 63 2524S 
30 2389S 64 2524Y 
31 2389Y 65 2525S 
32 2393Y 66 2526Y 
33 2395S 
34 2395Y 
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Table A10: Compiled gCIS of SBxTie2-Cre spleens and thymii. 
 
Gene 
Symbol 
Chi-
squared D.F. P-value Q-value 
# of 
Tumours Reads per tumour 
Tumours with insertions 
(Howell ID #) 
Erg 
2285.2
59 1 0 0 29 
88.929;33.599;15.312;5.445;87.821;43.338;15.788;17.
821;19.409;23.418;85.991;13.802;50;42.577;5.375;45.
667;50;8.318;7.117;47.555;21.317;50;38.219;49.836;
34;49.704;52.032;42.81;24.904 
 10; 12; 14; 15; 16; 19; 2; 20; 
23; 24; 27; 28; 30; 32; 34; 36; 
39; 4; 40; 44; 46; 48; 5; 52; 6; 
62; 63; 7; 9 
Notch1 
6413.4
32 1 0 0 23 
50.25;56.427;71.869;13.72;44.832;36.9;27.141;12.92
2;35.617;30.47;33.334;9.838;50;45.439;50.006;14.69
3;30.642;35.39;12.5;27.685;61.367;33.628;36.037 
 11; 16; 2; 20; 22; 23; 27; 28; 
3; 32; 35; 36; 38; 39; 4; 40; 45; 
52; 54; 58; 61; 66; 9 
Ets1 
2656.2
2 1 0 0 20 
20.51;19.819;51.591;13.632;31.433;57.085;54.237;3
4.822;40.373;7.58;46.599;50;41.142;51.552;27.518;5
0;25;37.994;79.281;81.763 
 10; 14; 15; 23; 24; 26; 30; 31; 
33; 35; 38; 41; 43; 46; 51; 53; 
54; 57; 63; 65 
Ncoa2 
508.57
9 1 0 0 17 
50;50;33.496;20;44.495;43.081;21.65;43.877;5.36;40
.343;14.084;35.319;39.474;55.136;50.261;79.785;10.
528 
 1; 11; 18; 21; 27; 30; 33; 34; 
37; 39; 45; 49; 57; 63; 65; 66; 
9 
Sos1 
855.78
9 1 0 0 15 
48.243;8.896;42.894;37.29;50;5.63;33.355;28.113;50
;25.101;41.218;30.025;19.945;30.072;63.928 
 1; 11; 21; 24; 3; 31; 34; 36; 
37; 4; 46; 49; 6; 60; 61 
Zmiz1 
692.16
2 1 0 0 15 
17.209;41.216;15.966;48.673;20;36.992;35.461;40.8
27;16.672;5.497;26.984;18.858;38.651;23.11;14.951 
 10; 11; 15; 20; 21; 22; 23; 32; 
35; 36; 44; 46; 47; 51; 58 
Erbb4 35.858 1 2.12E-09 1.55E-07 14 
5.633;11.134;33.39;14.586;27.109;10;15.339;8.203;6
.085;12.838;40.788;33.049;28.015;31.59 
 12; 18; 19; 2; 20; 21; 24; 31; 
38; 45; 55; 56; 6; 9 
Pard3b 49.453 1 2.03E-12 1.89E-10 14 
6.438;8.941;10.912;10.005;33.09;27.154;16.666;5.63
9;8.323;35.636;11.381;8.784;13.454;36.968 
 12; 15; 20; 21; 22; 23; 35; 4; 
44; 5; 51; 55; 56; 58 
Rasgrp1 1169.8 1 0 0 14 14.794;32.648;18.403;26.797;38.298;29.734;19.848;  11; 19; 22; 23; 28; 31; 32; 35; 
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79 16.669;13.36;6.118;14.688;50;33.837;21.205 36; 41; 43; 51; 58; 6 
Stat5b 
1255.6
65 1 0 0 14 
5.411;5.204;38.077;59.779;20.16;9.563;37.68;25.143
;37.748;18.863;10.54;13.947;12.5;29.009 
 10; 24; 25; 26; 31; 32; 36; 38; 
4; 43; 44; 46; 54; 60 
Tmeff2 
232.28
9 1 1.89E-52 8.79E-50 14 
10.269;7.075;6.087;25.413;7.667;39.453;5.168;32.41
3;10.229;49.961;8.334;7.734;8.84;25.011 
 14; 19; 2; 21; 30; 34; 36; 4; 
43; 46; 48; 49; 56; 66 
Bcl2 
268.80
8 1 2.06E-60 1.14E-57 11 
23.961;16.498;8.979;13.855;6.524;50;28.678;35.461;
35.839;15.835;8.005 
 10; 14; 15; 21; 24; 31; 33; 43; 
46; 62; 65 
Kcnq5 57.848 1 2.83E-14 3.00E-12 11 
6.285;9.539;50.278;36.275;7.035;5.454;33.78;8.235;
5.627;9.026;15.986 
 10; 24; 25; 3; 31; 33; 34; 37; 
40; 46; 63 
Spag16 29.002 1 7.23E-08 4.46E-06 11 
30.46;11.09;12.727;10.851;10;7.216;6.089;12.355;16
.443;6.146;29.878 
 10; 15; 19; 2; 21; 36; 38; 45; 
51; 55; 63 
Ghr 
119.09
5 1 9.98E-28 2.40E-25 10 
42.422;10.612;54.424;10;44.843;33.439;35.717;7.03
8;50;45.976 
 12; 14; 16; 21; 27; 28; 4; 40; 
48; 52 
Smap1 394.97 1 6.85E-88 4.98E-85 10 
20.89;8.653;23.715;11.426;13.295;15.644;8.334;22.8
67;34.839;30.843 
 16; 2; 24; 25; 27; 45; 48; 52; 
63; 9 
Dis3l2 79.126 1 5.83E-19 8.75E-17 9 
7.006;10;44.9;22.707;25.648;40.758;28.369;35.528;3
6.394  2; 21; 22; 3; 38; 39; 4; 40; 49 
Ikzf1 
356.95
9 1 1.29E-79 8.60E-77 9 
32.026;44.271;7.902;42.843;44.288;11.459;41.666;4
9.889;11.498 
 12; 16; 24; 27; 28; 3; 48; 52; 
60 
Ptpn4 129.88 1 4.35E-30 1.25E-27 9 
8.911;36.807;14.039;9.618;11.281;15.191;27.043;10.
438;17.395  1; 10; 3; 31; 37; 39; 4; 43; 53 
Runx1 178.85 1 8.64E-41 3.30E-38 9 
30.357;7.247;31.767;29.057;24.961;16.911;8.519;52.
799;31.924  1; 10; 2; 31; 32; 33; 36; 45; 9 
Aff3 46.508 1 9.12E-12 8.20E-10 8 37.065;5.28;15.155;30.568;50;21.584;26.302;6.079  18; 20; 23; 27; 30; 39; 49; 58 
Agfg1 
334.40
1 1 1.06E-74 6.65E-72 8 7.242;14.566;10;25.93;34.056;49.1;24.928;9.344  10; 14; 21; 22; 28; 4; 40; 46 
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Akt2 608.12 1 0 0 8 
33.424;8.98;38.326;20.003;8.171;33.033;28.875;41.3
58  32; 33; 34; 36; 4; 43; 44; 7 
Ankrd44 80.698 1 2.63E-19 4.03E-17 8 26.28;61.565;10.893;36.385;6.443;11.297;50;5.006  11; 14; 2; 21; 24; 26; 35; 46 
Myo1b 
145.95
8 1 1.33E-33 4.47E-31 8 
5.526;12.039;17.729;43.557;28.078;34.717;8.044;7.7
66  10; 14; 2; 21; 28; 3; 36; 4 
Rasgrf1 
218.50
9 1 1.91E-49 8.40E-47 8 
31.731;46.266;49.072;5.325;32.653;33.422;31.008;8
3.248  18; 2; 3; 36; 38; 39; 54; 66 
Rpe 
705.61
6 1 0 0 8 
32.157;35.44;39.267;40.444;16.666;39.758;12.508;3
5.877  16; 2; 27; 45; 48; 52; 54; 9 
Sik3 
129.53
7 1 5.17E-30 1.47E-27 8 6.758;50;5.707;24.886;36.43;50;8.354;33.403  2; 22; 39; 4; 40; 43; 49; 7 
Srgap2 86.075 1 1.73E-20 2.94E-18 8 
11.903;22.567;10;11.046;26.188;28.945;28.678;36.2
73  15; 2; 21; 30; 36; 4; 45; 9 
Trip12 
159.42
8 1 1.51E-36 5.57E-34 8 50;15.75;33.017;7.21;43.819;50;8.334;38.427  10; 12; 2; 33; 45; 46; 48; 9 
2310035
C23Rik 135.66 1 2.37E-31 7.45E-29 7 34.224;37.367;7.48;47.469;44.721;45.849;25.151  12; 2; 21; 45; 48; 57; 9 
Atp8a2 40.198 1 2.29E-10 1.85E-08 7 31.852;8.995;9.57;34.498;16.666;50;12.992  16; 22; 23; 27; 48; 52; 58 
Braf 
118.76
3 1 1.18E-27 2.80E-25 7 43.29;25.776;31.294;36.209;34.639;6;25.215  22; 4; 40; 43; 44; 46; 7 
Col19a1 41.785 1 1.02E-10 8.38E-09 7 9.536;7.238;7.739;17.031;5.718;36.335;9.46  10; 18; 19; 20; 36; 53; 9 
Col4a3 
124.81
7 1 5.58E-29 1.49E-26 7 8.007;16.904;5.825;9.366;17.783;5.319;7.189  1; 22; 26; 37; 40; 45; 9 
Crebbp 
130.40
6 1 3.34E-30 9.72E-28 7 32.09;6.098;41.957;16.666;48.778;48.627;28.582  12; 14; 32; 35; 44; 48; 6 
Cyp27a1 603.72 1 0 0 7 9.685;5.88;33.537;11.054;16.948;44.442;65.82  18; 19; 20; 54; 55; 56; 61 
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Dyrk1a 
139.77
7 1 2.98E-32 9.76E-30 7 14.869;7.501;8.056;27.31;8.962;10.612;20.384  10; 3; 31; 35; 43; 46; 57 
Hecw2 37.867 1 7.57E-10 5.93E-08 7 18.474;5.055;11.046;17.059;12.094;8.768;13.086  10; 24; 31; 32; 43; 5; 9 
Sdccag8 83.496 1 6.39E-20 1.05E-17 7 6.625;13.866;10.569;32.922;50;80.388;28.005  15; 24; 25; 43; 44; 65; 7 
Stat5a 
767.90
5 1 0 0 7 38.077;12.832;20.16;9.563;18.863;10.54;12.5  25; 26; 31; 32; 43; 44; 54 
Trerf1 
109.81
8 1 1.07E-25 2.36E-23 7 5.307;10;22.912;36.216;16.666;50;16.23  16; 21; 22; 23; 35; 36; 58 
6030407
O03Rik 54.097 1 1.91E-13 1.90E-11 6 5.088;10;5.902;13.159;10.666;7.638  2; 21; 3; 38; 39; 51 
Atf3 
748.46
5 1 0 0 6 37.774;10.04;42.885;50;41.666;43.042  16; 21; 27; 36; 48; 52 
Dennd1b 48.712 1 2.96E-12 2.73E-10 6 20.636;29.925;10;20.364;7.362;13.473  14; 18; 21; 44; 49; 54 
Fam71a 
1267.7
34 1 0 0 6 37.774;10.04;42.885;50;41.666;43.042  16; 21; 27; 36; 48; 52 
Gigyf1 
1086.0
48 1 0 0 6 28.059;6.474;15.739;8.964;18.052;5.994  10; 26; 28; 38; 40; 57 
Gigyf2 86.378 1 1.49E-20 2.56E-18 6 19.534;7.936;41.286;29.409;31.105;5.464  2; 28; 3; 38; 39; 57 
Gls 
132.87
3 1 9.64E-31 2.95E-28 6 29.802;5.569;6.033;7.804;39.858;12.602  1; 3; 34; 46; 55; 7 
Gm13476 1106.37 1 0 0 6 17.692;33.108;18.438;22.563;32.239;15.21  1; 3; 31; 37; 4; 43 
Ikzf2 67.933 1 1.69E-16 2.10E-14 6 33.627;10;14.199;36.894;6.121;38.231  2; 21; 24; 45; 57; 9 
Il1r1 
147.09
2 1 7.49E-34 2.56E-31 6 34.423;10;22.64;6.399;34.532;43.761  18; 21; 3; 37; 39; 54 
Kras 276.99 1 3.39E-62 1.97E-59 6 8.305;5.153;5.802;7.465;10.004;16.16  10; 25; 26; 31; 46; 53 
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Lmbrd1 126.79 1 2.06E-29 5.72E-27 6 18.294;27.786;30.65;21.068;45.023;27.95  19; 20; 3; 53; 55; 56 
Nfkbiz 
380.94
2 1 7.76E-85 5.47E-82 6 10;33.956;27.544;16.672;50;40.359  21; 22; 23; 35; 36; 58 
Phlpp1 50.235 1 1.36E-12 1.28E-10 6 44.173;10;8.819;10.818;36.305;17.195  15; 21; 28; 44; 51; 63 
Pik3c2b 
263.46
7 1 3.01E-59 1.63E-56 6 25.285;16.666;31.887;50;16.666;36.017  32; 35; 44; 47; 48; 5 
Plag1 
250.01
8 1 2.57E-56 1.25E-53 6 50;13.066;16.987;16.666;18.116;6.749  12; 15; 19; 35; 48; 55 
Pop7 
1368.2
32 1 0 0 6 28.059;6.474;15.739;8.964;18.052;5.994  10; 26; 28; 38; 40; 57 
Satb2 68.548 1 1.24E-16 1.56E-14 6 41.495;11.366;12.809;43.396;5.42;9.055  18; 31; 43; 54; 57; 6 
St18 24.062 1 9.33E-07 4.73E-05 6 27.764;7.455;12.617;10.453;8.977;36.191  24; 32; 41; 5; 6; 60 
Zeb2 95.367 1 1.58E-22 3.04E-20 6 43.133;33.108;18.438;44.135;32.239;15.21  1; 3; 31; 37; 4; 43 
1700123
O12Rik 24.934 1 5.93E-07 3.12E-05 5 9.778;10;32.597;50;38.745  20; 21; 32; 35; 44 
Akt1 
604.59
9 1 0 0 5 24.759;17.096;13.191;10.88;12.751  32; 41; 47; 5; 6 
Bmi1 
411.20
5 1 0 0 5 19.76;50;42.996;50;34.063  19; 20; 25; 56; 6 
C1qtnf6 928.403 1 0 0 5 21.115;12.524;23.779;11.084;16.524  26; 36; 38; 46; 65 
Dock10 27.556 1 1.53E-07 8.88E-06 5 5.727;8.758;31.897;12.455;5.138  10; 19; 28; 46; 54 
Eed 
231.75
3 1 2.47E-52 1.13E-49 5 22.026;21.522;14.835;26.142;14.305  12; 14; 2; 35; 38 
Elovl6 89.995 1 2.39E-21 4.34E-19 5 8.358;11.105;16.666;37.437;11.76  22; 23; 35; 5; 58 
Evl 76.184 1 2.58E-18 3.56E-16 5 38.481;24.401;30.89;50.013;38.616  41; 49; 5; 55; 6 
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Fli1 92.387 1 7.13E-22 1.33E-19 5 24.176;24.376;50;42.002;17.032  10; 19; 25; 37; 46 
Gulp1 25.332 1 4.83E-07 2.58E-05 5 5.728;8.033;6.51;9.706;11.745  1; 2; 37; 45; 49 
Il2rb 
546.08
9 1 0 0 5 12.932;36.923;8.334;14.863;21.384  14; 41; 48; 5; 6 
Mir30c-
2 554.5 1 0 0 5 19.944;8.537;10;23.355;5.983  15; 18; 21; 51; 54 
Nfyc 
109.38
8 1 1.33E-25 2.88E-23 5 20.504;31.312;6.888;6.328;12.5  28; 40; 44; 5; 54 
Otop3 
654.45
7 1 0 0 5 38.947;9.116;34.831;28.488;37.187  12; 2; 3; 38; 39 
Pcbd2 202.42 1 6.19E-46 2.57E-43 5 12.844;10;36.98;8.334;44.645  16; 21; 27; 48; 52 
Pms1 68.393 1 1.34E-16 1.68E-14 5 24.433;26.317;5.006;13.816;11.506  24; 34; 46; 60; 62 
Rnf149 252.99 1 5.79E-57 2.93E-54 5 47.636;16.187;23.415;19.788;35.069  11; 31; 33; 43; 45 
9330151
L19Rik 
399.91
3 1 5.75E-89 4.32E-86 4 28.61;20.556;16.666;46.425  22; 23; 35; 58 
9430016
H08Rik 
238.15
5 1 9.93E-54 4.72E-51 4 26.076;31.349;15.578;8.145  22; 4; 40; 63 
A33002
3F24Rik 
186.38
3 1 1.96E-42 7.60E-40 4 8.582;6.351;17.039;20.881  15; 25; 49; 63 
Arfgef1 45.108 1 1.87E-11 1.60E-09 4 14.255;7.195;23.47;5.782  10; 4; 46; 60 
B3gat2 62.276 1 2.99E-15 3.41E-13 4 20.89;13.295;8.334;22.867  16; 27; 48; 52 
Btaf1 50.878 1 9.83E-13 9.37E-11 4 47.972;5.414;5.386;50  22; 26; 4; 40 
Cited1 
466.56
6 1 0 0 4 31.444;36.251;7.843;26.206  2; 45; 57; 9 
Clec1a 
147.59
4 1 5.82E-34 2.02E-31 4 20.532;30.456;25.413;50  2; 3; 38; 39 
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Cnot1 56.697 1 5.08E-14 5.31E-12 4 6.941;6.761;8.992;9.451  28; 32; 40; 44 
Col5a2 29.594 1 5.33E-08 3.38E-06 4 7.987;10.176;5.713;21.421  16; 2; 27; 3 
Csf3r 
254.51
9 1 2.69E-57 1.39E-54 4 32.019;39.88;34.418;43.522  12; 23; 30; 7 
Cspp1 46.193 1 1.07E-11 9.55E-10 4 28.843;33.809;15.055;7.591  43; 44; 6; 7 
Cxcr4 
496.65
8 1 0 0 4 32.903;23.973;31.349;40.719  2; 35; 45; 9 
Dnaaf2 
269.05
5 1 1.82E-60 1.04E-57 4 28.61;20.556;16.666;46.425  22; 23; 35; 58 
Dock11 22.844 1 1.76E-06 8.33E-05 4 10;7.198;6.327;19.553  21; 22; 23; 58 
Epor 
549.71
1 1 0 0 4 8.194;16.887;6.848;8.409  10; 15; 28; 46 
Fam117
b 69.762 1 6.69E-17 8.65E-15 4 5.139;40.852;43.012;48.038  18; 43; 44; 7 
Fam78b 74.418 1 6.32E-18 8.55E-16 4 24.23;50;33.334;50  22; 23; 35; 58 
Flt3 86.178 1 1.64E-20 2.81E-18 4 6.507;14.847;17.735;26.251  25; 49; 53; 63 
Gm1670
1 
202.63
4 1 5.56E-46 2.35E-43 4 24.23;50;33.334;50  22; 23; 35; 58 
Gpatch2 38.353 1 5.90E-10 4.64E-08 4 7.046;46.708;16.049;18.302  14; 33; 45; 62 
Hadha 
121.27
4 1 3.33E-28 8.33E-26 4 50;34.578;12.094;30.43  2; 3; 38; 39 
Hadhb 
130.87
4 1 2.64E-30 7.77E-28 4 50;34.578;12.094;30.43  2; 3; 38; 39 
Irf2 53.705 1 2.33E-13 2.31E-11 4 15.329;6.223;5.459;5.78  24; 33; 49; 58 
Jak1 49.108 1 2.42E-12 2.24E-10 4 31.599;11.857;16.666;14.267  25; 32; 35; 44 
Kcnj13 230.64 1 4.30E-52 1.93E-49 4 19.534;41.286;29.409;31.105  2; 3; 38; 39 
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Mff 
132.09
1 1 1.43E-30 4.32E-28 4 8.007;9.366;5.319;7.189  1; 37; 45; 9 
Mir1960 
374.50
8 1 1.95E-83 1.34E-80 4 50;34.578;12.094;30.43  2; 3; 38; 39 
Mreg 
113.84
1 1 1.41E-26 3.22E-24 4 6.59;18.837;5.164;39.616  3; 34; 39; 46 
Myc 
431.61
7 1 0 0 4 9.255;13.107;40.209;11.962  28; 33; 34; 40 
Nipbl 23.863 1 1.03E-06 5.18E-05 4 6.974;12.985;18.191;37.669  26; 28; 40; 5 
Nprl3 
158.07
6 1 2.98E-36 1.08E-33 4 10;44.654;43.95;46.27  21; 43; 44; 7 
Phip 33.463 1 7.26E-09 5.06E-07 4 36.959;31.56;27.032;41.388  36; 41; 5; 6 
Pign 28.897 1 7.63E-08 4.68E-06 4 16.765;9.713;21.764;45.849  10; 2; 46; 57 
Prdm14 
294.36
7 1 5.56E-66 3.32E-63 4 10;5.36;7.149;35.319  21; 37; 46; 49 
Ptpn14 52.337 1 4.68E-13 4.53E-11 4 7.062;29.155;23.845;34.375  2; 3; 38; 39 
Rpl36al 435.702 1 0 0 4 28.61;20.556;16.666;46.425  22; 23; 35; 58 
Scmh1 36.409 1 1.60E-09 1.21E-07 4 24.166;9.213;11.229;25  30; 31; 43; 54 
Shfm1 
151.21
1 1 9.43E-35 3.32E-32 4 16.629;46.32;18.122;35.798  2; 3; 38; 39 
Slc39a10 86.734 1 1.24E-20 2.16E-18 4 10;8.334;7.196;5.05  21; 48; 49; 57 
Slc9a2 63.252 1 1.82E-15 2.11E-13 4 7.226;9.142;9.109;16.41  21; 23; 36; 6 
Stat4 49.168 1 2.35E-12 2.18E-10 4 29.256;7.814;39.072;9.066  18; 19; 55; 57 
Tyw5 
168.83
7 1 1.33E-38 4.98E-36 4 26.076;31.349;15.578;8.145  22; 4; 40; 63 
Appendices 
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Ubac2 43.56 1 4.11E-11 3.48E-09 4 39.464;38.066;25;39.109  16; 27; 48; 52 
Zbtb42 
775.51
6 1 0 0 4 24.759;17.096;10.88;12.751  32; 41; 5; 6 
Zfp423 25.378 1 4.71E-07 2.53E-05 4 8.877;19.951;17.313;5.16  10; 31; 43; 46 
1700063
A18Rik 57.402 1 3.55E-14 3.72E-12 3 15.284;14.415;14.807  2; 45; 9 
1810046
K07Rik 66.616 1 3.30E-16 4.04E-14 3 29.58;10;20.412  15; 21; 51 
2010300
C02Rik 34.669 1 3.91E-09 2.81E-07 3 28.367;24.936;38.072  41; 5; 6 
4933427
D14Rik 57.934 1 2.71E-14 2.88E-12 3 29.584;33.13;39.312  2; 45; 9 
5430435
G22Rik 
116.21
7 1 4.26E-27 9.82E-25 3 30.241;50;24.587  2; 45; 9 
9230112
J17Rik 
117.08
5 1 2.75E-27 6.40E-25 3 50;31.534;42.811  41; 5; 6 
A830060
N17 78.667 1 7.35E-19 1.07E-16 3 7.636;33.334;5.635  32; 35; 44 
Abcb5 25.148 1 5.31E-07 2.82E-05 3 5.4;6.474;5.532  28; 40; 43 
Acsl3 54.154 1 1.85E-13 1.85E-11 3 6.838;14.019;89.203  25; 55; 66 
BC0265
85 91.549 1 1.09E-21 2.01E-19 3 12.575;9.566;11.908  2; 45; 9 
Bcor 35.869 1 2.11E-09 1.55E-07 3 6.236;10.729;6.173  31; 41; 43 
Bend5 66.379 1 3.72E-16 4.53E-14 3 23.534;21.05;21.399  12; 26; 38 
Brsk2 80.504 1 2.90E-19 4.41E-17 3 5.513;5.846;100  34; 46; 47 
Cab39 45.977 1 1.20E-11 1.06E-09 3 20.564;12.818;20.994  14; 26; 32 
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Cacna2d
4 36.38 1 1.62E-09 1.22E-07 3 35.272;8.334;8.411  4; 48; 54 
Casp8ap
2 62.111 1 3.25E-15 3.69E-13 3 5.672;14.604;7.38  10; 14; 46 
Ccdc6 39.178 1 3.87E-10 3.07E-08 3 43.392;33.334;47.794  32; 35; 44 
Cd200r3 61.978 1 3.47E-15 3.92E-13 3 6.367;8.893;6.439  28; 40; 57 
Cep170 27.415 1 1.64E-07 9.50E-06 3 32.922;50;28.005  43; 44; 7 
Chek1 92.981 1 5.28E-22 9.91E-20 3 20.401;10;23.513  15; 21; 51 
Clca1 76.821 1 1.87E-18 2.64E-16 3 42.305;16.666;21.244  32; 35; 44 
Cnnm1 56.049 1 7.07E-14 7.28E-12 3 6.62;13.307;6.86  22; 23; 58 
Creb1 33.329 1 7.78E-09 5.36E-07 3 24.21;6.493;10.425  35; 49; 6 
Cyp20a1 56.557 1 5.46E-14 5.65E-12 3 11.797;7.354;20.715  10; 46; 53 
D63002
3F18Rik 
131.15
6 1 2.29E-30 6.83E-28 3 34.655;33.475;28.386  43; 44; 7 
D930028
M14Rik 
348.17
8 1 1.06E-77 6.83E-75 3 13.464;11.984;46.026  11; 36; 47 
Dlst 
105.69
1 1 8.62E-25 1.79E-22 3 44.953;40.37;37.885  43; 44; 7 
Efhd1 78.726 1 7.14E-19 1.04E-16 3 43.06;9.787;10.328  14; 2; 24 
Eras 
252.12
3 1 8.95E-57 4.43E-54 3 7.803;44.15;16.905  20; 6; 62 
Erlec1 74.812 1 5.18E-18 7.04E-16 3 10;11.73;13.752  21; 33; 45 
Fam126
b 33.708 1 6.40E-09 4.48E-07 3 30.875;9.445;22.195  35; 53; 55 
Fam135
a 25.257 1 5.02E-07 2.68E-05 3 21.71;5.259;30.869  55; 60; 63 
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Fkbp15 46.783 1 7.93E-12 7.15E-10 3 34.355;16.666;46.362  32; 35; 44 
Fra10ac
1 59.007 1 1.57E-14 1.69E-12 3 16.682;29.38;29.076  22; 23; 58 
G53001
1O06Rik 
319.99
4 1 1.45E-71 8.90E-69 3 40.441;50;37.972  41; 5; 6 
Gart 
104.62
1 1 1.48E-24 2.99E-22 3 37.044;38.481;50.011  2; 45; 9 
Gm1160
2 60.549 1 7.18E-15 7.88E-13 3 9.866;7.399;12.568  2; 38; 55 
Gm1544
1 
212.08
8 1 4.81E-48 2.07E-45 3 35.111;33.784;28.92  2; 45; 9 
Gm4956 
126.21
7 1 2.76E-29 7.46E-27 3 32.132;39.608;5.12  2; 45; 57 
Gng12 23.659 1 1.15E-06 5.70E-05 3 26.213;26.59;34.114  22; 23; 58 
Greb1 27.061 1 1.97E-07 1.13E-05 3 13.56;22.287;23.376  2; 45; 9 
Hat1 45.67 1 1.40E-11 1.22E-09 3 34.028;34.781;36.427  2; 45; 9 
Hmg20a 34.542 1 4.17E-09 2.99E-07 3 17.777;8.804;18.218  11; 24; 47 
Hs6st1 99.476 1 1.99E-23 3.95E-21 3 31.133;9.217;40.816  43; 44; 7 
Iars2 70.687 1 4.19E-17 5.47E-15 3 11.53;6.867;10.661  24; 60; 62 
Il3 255.19 1 1.92E-57 1.01E-54 3 17.312;44.673;13.85  1; 3; 37 
Jph1 25.105 1 5.43E-07 2.88E-05 3 11.539;6.83;19.902  24; 7; 9 
Kcne3 187.96 1 8.87E-43 3.50E-40 3 6.553;6.124;7.343  2; 45; 9 
Kpna3 32.599 1 1.13E-08 7.69E-07 3 22.082;23.509;31.076  41; 5; 6 
Lias 
126.57
8 1 2.30E-29 6.29E-27 3 6.527;28.247;33.334  16; 27; 48 
Lin9 52.22 1 4.96E-13 4.77E-11 3 14.896;14.733;5.748  31; 43; 49 
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Mir181a
-1 
197.93
2 1 5.90E-45 2.37E-42 3 19.205;18.201;71.279  10; 14; 63 
Mir181b
-1 
197.93
2 1 5.90E-45 2.41E-42 3 19.205;18.201;71.279  10; 14; 63 
Nck2 24.585 1 7.11E-07 3.66E-05 3 12.672;15.017;29.776  33; 45; 5 
Ndufs1 69.404 1 8.02E-17 1.03E-14 3 9.866;7.399;12.568  2; 38; 55 
Nmu 76.624 1 2.07E-18 2.88E-16 3 30.877;37.983;48.53  41; 5; 6 
Pcmtd1 28.346 1 1.01E-07 6.05E-06 3 7.334;8.196;5.443  10; 18; 46 
Pdxk 
137.83
3 1 7.93E-32 2.53E-29 3 30.038;25.933;25.752  2; 45; 9 
Phf3 39.445 1 3.37E-10 2.70E-08 3 30.679;19.351;33.172  27; 31; 39 
Pias2 26.808 1 2.25E-07 1.27E-05 3 22.733;5.92;21.276  16; 27; 52 
Pla2g4c 69.218 1 8.82E-17 1.12E-14 3 35.572;9.731;30.627  16; 19; 55 
Prox2 124.367 1 7.00E-29 1.83E-26 3 44.953;40.37;37.885  43; 44; 7 
Ptpn12 33.448 1 7.32E-09 5.08E-07 3 38.801;28.857;34.407  41; 5; 6 
Rasa3 38.452 1 5.61E-10 4.43E-08 3 26.883;31.366;33.512  21; 32; 44 
Rcn2 
104.87
4 1 1.30E-24 2.68E-22 3 16.569;11.11;8.334  31; 43; 48 
Rfwd3 88.586 1 4.87E-21 8.71E-19 3 24.636;28.494;35.043  41; 5; 6 
Rlf 55.132 1 1.13E-13 1.15E-11 3 5.332;5.221;8.701  28; 38; 40 
Satb1 27.197 1 1.84E-07 1.05E-05 3 10;9.098;10.024  21; 24; 60 
Scnn1g 82.714 1 9.48E-20 1.53E-17 3 34.804;35.145;40.368  43; 44; 7 
Serbp1 82.456 1 1.08E-19 1.72E-17 3 37.873;34.658;20.102  22; 4; 40 
Sgk3 26.24 1 3.01E-07 1.67E-05 3 6.867;47.941;22.778  1; 16; 30 
Slc31a1 77.504 1 1.32E-18 1.91E-16 3 34.355;16.666;46.362  32; 35; 44 
Son 76.878 1 1.82E-18 2.58E-16 3 37.044;38.481;50.011  2; 45; 9 
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Stat1 71.051 1 3.48E-17 4.58E-15 3 19.271;15.704;6.12  26; 38; 63 
Stk17b 64.781 1 8.37E-16 9.99E-14 3 50;9.115;5.256  15; 19; 26 
Tab2 46.298 1 1.02E-11 9.09E-10 3 26.32;16.666;30.203  32; 35; 44 
Tfap2d 40.467 1 2.00E-10 1.62E-08 3 10.896;6.921;6.204  15; 19; 57 
Tram2 45.378 1 1.62E-11 1.41E-09 3 32.846;37.508;38.37  18; 24; 25 
Vcpip1 78.844 1 6.72E-19 9.90E-17 3 10.492;5.213;16.201  10; 26; 46 
Wdr64 22.865 1 1.74E-06 8.27E-05 3 5.441;6.671;6.171  1; 15; 24 
Zfp451 48.232 1 3.79E-12 3.46E-10 3 7.434;5.72;9.089  24; 40; 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 38 
Table A11: Compiled CIS of SBxTie2-Cre spleens and thymii. All hits are included in this table. 
 
 
Chr Start (bp) Stop (bp) 
# of 
Tumours UCSC address Gene Symbol(s) Tumours with insertion 
chr1 49501420 51271443 42 chr1:49501420-51271443 Tmeff2 
 1; 11; 14; 16; 18; 19; 2; 20; 21; 23; 24; 25; 26; 
27; 3; 30; 31; 32; 34; 35; 36; 39; 4; 43; 44; 45; 
46; 47; 48; 49; 53; 54; 55; 56; 58; 6; 60; 61; 63; 
66; 7; 9 
chr1 51527122 52635702 32 chr1:51527122-52635702 
Gls, Myo1b, Nab1, 
Obfc2a, Stat1, Stat4 
 1; 10; 11; 12; 14; 15; 18; 19; 2; 20; 21; 24; 25; 
26; 27; 28; 3; 30; 34; 36; 38; 39; 4; 46; 47; 49; 
55; 57; 61; 63; 65; 7 
chr16 95611774 95755807 29 chr16:95611774-95755807 Erg 
 10; 12; 14; 15; 16; 19; 2; 20; 23; 24; 27; 28; 
30; 32; 34; 36; 39; 4; 40; 44; 46; 48; 5; 52; 6; 
62; 63; 7; 9 
chr9 32304491 32535270 26 chr9:32304491-32535270 Ets1, Fli1 
 10; 11; 14; 15; 16; 19; 23; 24; 25; 26; 30; 31; 
33; 35; 37; 38; 41; 43; 46; 47; 51; 53; 54; 57; 
63; 65 
chr9 32342870 32657263 26 chr9:32342870-32657263 Ets1, Fli1 
 10; 11; 14; 15; 16; 23; 24; 25; 26; 30; 31; 33; 
35; 37; 38; 4; 41; 43; 46; 47; 51; 53; 54; 57; 63; 
65 
chr1 13016362 13626749 23 chr1:13016362-13626749 
Lactb2, Ncoa2, 
Prdm14, Tram1 
 1; 11; 14; 18; 19; 2; 21; 27; 30; 33; 34; 37; 39; 
45; 46; 49; 53; 55; 57; 63; 65; 66; 9 
chr2 26321391 26327912 23 chr2:26321391-26327912 Notch1 
 11; 16; 2; 20; 22; 23; 27; 28; 3; 32; 35; 36; 38; 
39; 4; 40; 45; 52; 54; 58; 61; 66; 9 
chr1 46879414 47581967 20 chr1:46879414-47581967 Slc39a10  1; 16; 20; 21; 24; 26; 27; 3; 30; 36; 37; 38; 40; 
Appendices 
 39 
48; 49; 53; 54; 57; 65; 66 
chr1 56581018 57065822 18 chr1:56581018-57065822 
9130024F11Rik, 
Hsfy2, Satb2 
 15; 18; 2; 21; 24; 30; 31; 34; 38; 43; 46; 5; 51; 
53; 54; 57; 6; 61 
chr1 71626495 72069085 17 chr1:71626495-72069085 Fn1, Gm8883 
 10; 15; 16; 21; 25; 27; 31; 32; 33; 36; 45; 46; 
48; 49; 52; 57; 61 
chr1 82561733 82893588 16 chr1:82561733-82893588 
Agfg1, Col4a3, 
Col4a4, Mff, 
Tm4sf20 
1; 10; 12; 14; 16; 21; 22; 26; 28; 33; 37; 4; 40; 
45; 46; 9 
chr17 80783196 80850558 16 chr17:80783196-80850558 Arhgef33, Sos1 
 1; 11; 21; 24; 3; 31; 34; 36; 37; 4; 46; 49; 54; 
6; 60; 61 
chr1 130318661 130556142 15 chr1:130318661-130556142 Cxcr4 
 1; 18; 2; 22; 25; 31; 35; 37; 38; 4; 43; 45; 54; 
61; 9 
chr1 139782491 139980540 15 chr1:139782491-139980540 
Mir181a-1, 
Mir181b-1, Ptprc 
 1; 10; 14; 15; 27; 3; 32; 37; 39; 4; 48; 53; 55; 
63; 65 
chr11 100666413 100769751 15 
chr11:100666413-
100769751 Stat3, Stat5a, Stat5b 
 10; 20; 24; 25; 26; 31; 32; 36; 38; 4; 43; 44; 
46; 54; 60 
chr14 26303394 26424815 15 chr14:26303394-26424815 
4931406H21Rik, 
Zmiz1 
 10; 11; 15; 20; 21; 22; 23; 32; 35; 36; 44; 46; 
47; 51; 58 
chr2 117082196 117182880 15 chr2:117082196-117182880 Fam98b, Rasgrp1 
 11; 19; 22; 23; 28; 31; 32; 35; 36; 41; 43; 49; 
51; 58; 6 
chr3 29950417 30266649 15 chr3:29950417-30266649 Mecom 
 15; 2; 22; 24; 25; 26; 3; 31; 32; 38; 39; 53; 58; 
60; 63 
chr1 62277149 62702688 13 chr1:62277149-62702688 Pard3b  12; 20; 21; 22; 23; 35; 36; 4; 44; 5; 55; 56; 58 
chr1 23190102 23368361 12 chr1:23190102-23368361 Mir30a, Mir30c-2  1; 15; 18; 20; 21; 24; 37; 51; 53; 54; 57; 6 
chr1 66742538 66838703 11 chr1:66742538-66838703 
1110028C15Rik, 
Rpe, Unc80  16; 2; 24; 27; 33; 38; 45; 48; 52; 54; 9 
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chr1 94125292 94372454 11 chr1:94125292-94372454 Ndufa10  12; 16; 22; 27; 36; 4; 40; 48; 51; 52; 53 
chr1 108499030 108562223 11 chr1:108499030-108562223 Bcl2  10; 14; 15; 21; 24; 31; 33; 43; 46; 62; 65 
chr11 11596850 11686731 11 chr11:11596850-11686731 Ikzf1  12; 16; 24; 27; 28; 3; 38; 39; 48; 52; 60 
chr15 78322994 78366919 11 chr15:78322994-78366919 C1qtnf6, Il2rb  14; 24; 26; 36; 38; 41; 46; 48; 5; 6; 65 
chr1 23852541 23915910 10 chr1:23852541-23915910 B3gat2, Smap1  16; 2; 24; 25; 27; 45; 48; 52; 63; 9 
chr1 43119545 43386802 10 chr1:43119545-43386802 
AI597479, Fhl2, 
Tgfbrap1  22; 24; 30; 41; 5; 55; 56; 6; 63; 7 
chr1 53796913 54105436 10 chr1:53796913-54105436 Hecw2, Stk17b  10; 15; 19; 24; 26; 31; 32; 43; 5; 9 
chr1 84659227 84827997 10 chr1:84659227-84827997 Dner, Trip12  10; 12; 2; 28; 33; 4; 45; 46; 48; 9 
chr1 121534614 121663909 10 chr1:121534614-121663909 Epb4.1l5, Ptpn4  1; 10; 3; 31; 37; 39; 4; 43; 53; 6 
chr1 196702271 196936745 10 chr1:196702271-196936745 
A330023F24Rik, 
C030002c11rik, 
Cd34, Cd46, Cr1l, 
Mir29b-2, Mir29c  1; 14; 15; 22; 25; 27; 3; 39; 49; 63 
chr15 3410009 3531298 10 chr15:3410009-3531298 Ghr  12; 14; 16; 21; 27; 28; 4; 40; 48; 52 
chr1 6687696 6897453 9 chr1:6687696-6897453 St18  20; 21; 24; 32; 41; 5; 56; 6; 60 
chr1 9655155 9879112 9 chr1:9655155-9879112 
Mybl1, Sgk3, 
Vcpip1  1; 10; 16; 19; 26; 30; 35; 36; 46 
chr1 59856826 60036531 9 chr1:59856826-60036531 Bmpr2, Fam117b  18; 2; 21; 32; 43; 44; 45; 7; 9 
chr1 88941858 89343100 9 chr1:88941858-89343100 
Akp3, Alpi, Alppl2, 
Chrnd, Chrng, 
Dis3l2, Ecel1, 
Efhd1, Eif4e2, 
Gigyf2, Kcnj13  14; 2; 24; 28; 3; 36; 38; 39; 57 
chr1 133122172 133386724 9 chr1:133122172-133386724 
Ikbke, Rassf5, 
Srgap2  15; 2; 21; 25; 30; 36; 4; 45; 9 
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chr16 92702204 92790733 9 chr16:92702204-92790733 Runx1  1; 10; 2; 31; 32; 33; 36; 45; 9 
chr8 47808152 47975435 9 chr8:47808152-47975435 Irf2  2; 24; 33; 34; 45; 47; 49; 58; 9 
chr9 89729174 89867949 9 chr9:89729174-89867949 Rasgrf1  18; 2; 3; 36; 38; 39; 48; 54; 66 
chr1 10093074 10213680 8 chr1:10093074-10213680 Arfgef1, Cspp1  10; 4; 43; 44; 46; 6; 60; 7 
chr1 24237199 24386110 8 chr1:24237199-24386110 Col19a1, Col9a1  10; 18; 19; 20; 21; 36; 53; 9 
chr1 54765562 54876623 8 chr1:54765562-54876623 Ankrd44  11; 14; 2; 21; 24; 26; 35; 46 
chr1 72681921 72837728 8 chr1:72681921-72837728 
Ankar, Rpl37a, 
Smarcal1  1; 10; 26; 33; 37; 45; 55; 62 
chr1 74644692 74772184 8 chr1:74644692-74772184 
Cyp27a1, Rnf25, 
Stk36, Ttll4  18; 19; 20; 53; 54; 55; 56; 61 
chr1 80652197 80836493 8 chr1:80652197-80836493 Dock10  10; 19; 2; 28; 45; 46; 48; 9 
chr1 81142937 81284702 8 chr1:81142937-81284702 9430031J16Rik  20; 21; 22; 33; 34; 37; 4; 40 
chr1 107478773 107738666 8 chr1:107478773-107738666 
2310035C23Rik, 
Pign, Tnfrsf11a  12; 2; 21; 37; 45; 48; 57; 9 
chr16 4119868 4307929 8 chr16:4119868-4307929 
Adcy9, Crebbp, 
Gm5766  12; 14; 32; 35; 44; 48; 54; 6 
chr4 125678557 125703664 8 chr4:125678557-125703664 Csf3r  12; 23; 30; 32; 35; 44; 54; 7 
chr7 28372976 28390962 8 chr7:28372976-28390962 Akt2  32; 33; 34; 36; 4; 43; 44; 7 
chr9 45937955 46000300 8 chr9:45937955-46000300 Sik3  2; 22; 39; 4; 40; 43; 49; 7 
chr1 38337310 38501006 7 chr1:38337310-38501006 Aff3  20; 23; 27; 30; 39; 49; 58 
chr1 39489159 39625613 7 chr1:39489159-39625613 
D1Bwg0212e, 
Rnf149, Snord89, 
Tbc1d8  11; 21; 31; 33; 34; 43; 45 
chr1 52519559 52731708 7 chr1:52519559-52731708 
Mfsd6, Nab1, 
Tmem194b  11; 24; 25; 26; 3; 47; 65 
chr1 69537183 69663209 7 chr1:69537183-69663209 Ikzf2  2; 21; 24; 45; 53; 57; 9 
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chr1 89584282 89754433 7 chr1:89584282-89754433 
Atg16l1, Dgkd, 
Inpp5d, Sag, 
Scarna6  25; 30; 36; 43; 53; 57; 63 
chr1 92017290 92238549 7 chr1:92017290-92238549 Cxcr7, Iqca  10; 14; 21; 36; 46; 49; 54 
chr1 99454539 99614905 7 chr1:99454539-99614905 
D1Ertd622e, 
Ppip5k2  14; 24; 25; 33; 34; 4; 46 
chr1 192855716 193001851 7 chr1:192855716-193001851 
1700022P22Rik, 
Atf3, Batf3, Fam71a, 
Nsl1, Tatdn3  16; 21; 27; 36; 48; 52; 53 
chr14 60349949 60465267 7 chr14:60349949-60465267 Atp8a2  16; 22; 23; 27; 48; 52; 58 
chr16 55813696 55900435 7 chr16:55813696-55900435 
Cep97, Fam55c, 
Nfkbiz  21; 22; 23; 35; 36; 4; 58 
chr16 94799158 94858187 7 chr16:94799158-94858187 Dyrk1a  10; 3; 31; 35; 43; 46; 57 
chr17 47360888 47458131 7 chr17:47360888-47458131 Trerf1  16; 21; 22; 23; 35; 36; 58 
chr5 137929086 137956698 7 chr5:137929086-137956698 Pop7  10; 26; 28; 38; 40; 57; 62 
chr6 39558080 39597495 7 chr6:39558080-39597495 Braf  22; 4; 40; 43; 44; 46; 7 
chr6 145191949 145226186 7 chr6:145191949-145226186 Kras  10; 25; 26; 31; 46; 53; 63 
chr1 19069980 19188546 6 chr1:19069980-19188546 Tcfap2d  11; 15; 19; 34; 35; 57 
chr1 21282917 21409535 6 chr1:21282917-21409535 
Gm4956, Kcnq5, 
Khdc1a, Khdc1b, 
Khdc1c  2; 24; 33; 34; 45; 57 
chr1 24678531 24748105 6 chr1:24678531-24748105 Lmbrd1  19; 20; 3; 53; 55; 56 
chr1 40321096 40328231 6 chr1:40321096-40328231 Il1r1  18; 21; 3; 37; 39; 54 
chr1 65051902 65212508 6 chr1:65051902-65212508 
4921521F21Rik, 
Cryga, Crygb, 
Crygc, Crygd,  10; 43; 44; 6; 63; 7 
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Cryge, 
D630023F18Rik, 
Idh1 
chr1 73387526 73537293 6 chr1:73387526-73537293 Pinc  19; 2; 24; 31; 43; 61 
chr1 88604330 88732982 6 chr1:88604330-88732982 Dis3l2  21; 22; 38; 4; 40; 49 
chr1 90857200 91006328 6 chr1:90857200-91006328 Sh3bp4  10; 2; 25; 37; 62; 7 
chr1 108093340 108224644 6 chr1:108093340-108224644 Phlpp1  15; 21; 28; 44; 51; 63 
chr1 127326489 127491298 6 chr1:127326489-127491298 Actr3, Slc35f5  10; 18; 31; 35; 43; 54 
chr1 134930338 134991004 6 chr1:134930338-134991004 Pik3c2b  32; 35; 44; 47; 48; 5 
chr1 140917093 140999608 6 chr1:140917093-140999608 Dennd1b  14; 18; 21; 44; 49; 54 
chr1 178739708 178842316 6 chr1:178739708-178842316 Sdccag8  15; 24; 25; 43; 44; 7 
chr1 185785085 185946212 6 chr1:185785085-185946212 
1700056E22Rik, 
Dusp10  1; 15; 21; 32; 35; 51 
chr11 80198561 80334522 6 chr11:80198561-80334522 
Cdk5r1, Myo1d, 
Psmd11, Zfp207  10; 2; 3; 38; 39; 46 
chr11 115198214 115287899 6 
chr11:115198214-
115287899 
Atp5h, 
C630004H02Rik, 
Cdr2l, Ict1, Kctd2, 
Otop3  12; 2; 3; 38; 39; 63 
chr2 44956992 44961087 6 chr2:44956992-44961087 Zeb2  1; 3; 31; 37; 4; 43 
chr3 129274018 129409764 6 chr3:129274018-129409764 Egf, Elovl6  22; 23; 35; 5; 57; 58 
chr4 3869242 3878121 6 chr4:3869242-3878121 Chchd7  12; 15; 19; 35; 48; 55 
chr9 56264424 56366820 6 chr9:56264424-56366820 
C230081A13Rik, 
Hmg20a  11; 14; 21; 24; 47; 49 
chr1 7099504 7187269 5 chr1:7099504-7187269 Pcmtd1  10; 11; 18; 46; 47 
chr1 14224278 14338359 5 chr1:14224278-14338359 Eya1  10; 27; 32; 37; 52 
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chr1 20861471 20971181 5 chr1:20861471-20971181 Efhc1, Paqr8  11; 25; 26; 47; 61 
chr1 53264291 53363877 5 chr1:53264291-53363877 Ormdl1, Pms1  24; 34; 46; 60; 62 
chr1 57452637 57483450 5 chr1:57452637-57483450 
1110034B05Rik, 
9430016H08Rik  22; 25; 4; 40; 63 
chr1 64617791 64717988 5 chr1:64617791-64717988 Creb1, Fam119a  21; 35; 49; 58; 6 
chr1 68396070 68514993 5 chr1:68396070-68514993 Erbb4  18; 2; 31; 45; 9 
chr1 128217548 128248499 5 chr1:128217548-128248499 Nckap5  1; 14; 21; 24; 37 
chr1 164111355 164220109 5 chr1:164111355-164220109 
Dnm3, Dnm3os, 
Mir199a-2, Mir214  24; 41; 5; 6; 63 
chr1 168879305 168935796 5 chr1:168879305-168935796 Fam78b  22; 23; 35; 58; 7 
chr1 190562647 190569770 5 chr1:190562647-190569770 Ush2a  22; 23; 25; 37; 58 
chr10 50509948 50572690 5 chr10:50509948-50572690 Ascc3  2; 25; 3; 32; 39 
chr12 70295414 70337190 5 chr12:70295414-70337190 
1110034A24Rik, 
9330151L19Rik, 
Pole2  22; 23; 35; 53; 58 
chr12 109821681 109830435 5 
chr12:109821681-
109830435 Evl  41; 49; 5; 55; 6 
chr12 113914506 113925373 5 
chr12:113914506-
113925373 Zbtb42  32; 41; 47; 5; 6 
chr13 55847496 55847496 5 chr13:55847496-55847496 Pcbd2  16; 21; 27; 48; 52 
chr17 8583390 8647749 5 chr17:8583390-8647749 T, T2  2; 27; 3; 38; 39 
chr2 18600311 18601417 5 chr2:18600311-18601417 Bmi1  19; 20; 25; 56; 6 
chr4 100879214 100977260 5 chr4:100879214-100977260 Jak1  25; 32; 35; 40; 44 
chr4 120442704 120503694 5 chr4:120442704-120503694 Mir30e, Nfyc  28; 40; 44; 5; 54 
chr5 32252709 32252709 5 chr5:32252709-32252709 Bre  4; 40; 41; 5; 6 
chr6 129333617 129388985 5 chr6:129333617-129388985 Clec12b, Clec1a,  2; 3; 38; 39; 49 
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Clec1b, Clec9a 
chr7 97105945 97112590 5 chr7:97105945-97112590 Eed  12; 14; 2; 35; 38 
chr9 55300686 55410249 5 chr9:55300686-55410249 Etfa, Isl2, Scaper  2; 35; 45; 57; 9 
chr1 36151517 36180299 4 chr1:36151517-36180299 Hs6st1  23; 43; 44; 7 
chr1 40725300 40743255 4 chr1:40725300-40743255 Slc9a2  21; 23; 36; 6 
chr1 44140550 44163293 4 chr1:44140550-44163293 1700029F09Rik  19; 21; 53; 57 
chr1 45446062 45458658 4 chr1:45446062-45458658 Col5a2  16; 2; 27; 3 
chr1 69127804 69151364 4 chr1:69127804-69151364 Erbb4  20; 55; 56; 6 
chr1 72219295 72253036 4 chr1:72219295-72253036 Mreg  3; 34; 39; 46 
chr1 92470841 92506529 4 chr1:92470841-92506529 Cops8  18; 26; 34; 54 
chr1 97465824 97509398 4 chr1:97465824-97509398 St8sia4  15; 25; 51; 54 
chr1 129354248 129366240 4 chr1:129354248-129366240 Mgat5  15; 21; 25; 51 
chr1 191659294 191659294 4 chr1:191659294-191659294 Ptpn14  2; 3; 38; 39 
chr11 32140903 32152864 4 chr11:32140903-32152864 Nprl3  21; 43; 44; 7 
chr11 54063709 54086315 4 chr11:54063709-54086315 Il3  1; 3; 37; 38 
chr14 122280599 122280599 4 
chr14:122280599-
122280599 Ubac2  16; 27; 48; 52 
chr19 37046914 37059829 4 chr19:37046914-37059829 Btaf1  22; 26; 4; 40 
chr3 86548432 86548432 4 chr3:86548432-86548432 Lrba  16; 27; 48; 52 
chr5 30489596 30489596 4 chr5:30489596-30489596 Hadhb  2; 3; 38; 39 
chr5 148175103 148177358 4 chr5:148175103-148177358 Flt3  25; 49; 53; 63 
chr6 6513367 6513367 4 chr6:6513367-6513367 Shfm1  2; 3; 38; 39 
chr7 25914401 25938682 4 chr7:25914401-25938682 Pou2f2  11; 20; 36; 47 
chr8 98298690 98334916 4 chr8:98298690-98334916 
4930513N10Rik, 
Cnot1  28; 32; 40; 44 
chr9 3552258 3596166 4 chr9:3552258-3596166 Gucy1a2  2; 3; 38; 55 
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chr9 55410249 55432732 4 chr9:55410249-55432732 Scaper  2; 35; 45; 9 
chr9 82774207 82815621 4 chr9:82774207-82815621 Phip  36; 41; 5; 6 
chr9 96416715 96464358 4 chr9:96416715-96464358 Rasa2  16; 2; 27; 52 
chr9 106906023 106929030 4 chr9:106906023-106929030 Dock3  10; 31; 43; 46 
chrX 33570660 33570660 4 chrX:33570660-33570660 Dock11  21; 22; 23; 58 
chr1 33864396 33867093 3 chr1:33864396-33867093 Zfp451  24; 40; 60 
chr1 37771545 37771545 3 chr1:37771545-37771545 2010300C02Rik  41; 5; 6 
chr1 69877010 69881209 3 chr1:69877010-69881209 Spag16  15; 21; 51 
chr1 70717645 70724605 3 chr1:70717645-70724605 Spag16  2; 38; 45 
chr1 159414028 159414028 3 chr1:159414028-159414028 BC026585  2; 45; 9 
chr1 161498621 161498621 3 chr1:161498621-161498621 Tnr  43; 44; 7 
chr10 7664960 7665060 3 chr10:7664960-7665060 Tab2  32; 35; 44 
chr10 66647766 66647766 3 chr10:66647766-66647766 Jmjd1c  2; 3; 39 
chr10 69588342 69588442 3 chr10:69588342-69588442 Ccdc6  32; 35; 44 
chr10 109181170 109181170 3 
chr10:109181170-
109181170 Nav3  22; 23; 58 
chr11 71977139 71977139 3 chr11:71977139-71977139 4933427D14Rik  2; 45; 9 
chr12 16746987 16746987 3 chr12:16746987-16746987 Greb1  2; 45; 9 
chr12 86440908 86440908 3 chr12:86440908-86440908 Prox2  43; 44; 7 
chr14 62040932 62040932 3 chr14:62040932-62040932 Kpna3  41; 5; 6 
chr15 8355677 8364047 3 chr15:8355677-8364047 Nipbl  28; 40; 5 
chr15 35339299 35346519 3 chr15:35339299-35346519 Vps13b  2; 31; 43 
chr15 37387672 37387672 3 chr15:37387672-37387672 Ncald  2; 3; 39 
chr16 89867202 89867202 3 chr16:89867202-89867202 Tiam1  2; 45; 9 
chr16 91653282 91653282 3 chr16:91653282-91653282 Son  2; 45; 9 
chr18 77367369 77367369 3 chr18:77367369-77367369 Pias2  16; 27; 52 
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chr19 38297768 38297768 3 chr19:38297768-38297768 5730455O13Rik  22; 23; 58 
chr19 43516590 43516590 3 chr19:43516590-43516590 Cnnm1  22; 23; 58 
chr2 49760363 49760363 3 chr2:49760363-49760363 Lypd6b  2; 45; 9 
chr2 68170807 68172213 3 chr2:68170807-68172213 Stk39  21; 44; 47 
chr2 71247751 71247751 3 chr2:71247751-71247751 Hat1  2; 45; 9 
chr3 53373081 53373181 3 chr3:53373081-53373181 Frem2  31; 43; 48 
chr3 144399009 144399109 3 chr3:144399009-144399109 Clca1  32; 35; 44 
chr4 62019033 62019133 3 chr4:62019033-62019133 Fkbp15  32; 35; 44 
chr4 84639709 84640504 3 chr4:84639709-84640504 Cntln  32; 35; 44 
chr4 102129263 102129363 3 chr4:102129263-102129363 Pde4b  32; 35; 44 
chr4 117682276 117682276 3 chr4:117682276-117682276 St3gal3  22; 23; 58 
chr4 120079186 120081385 3 chr4:120079186-120081385 Scmh1  31; 43; 54 
chr4 150486879 150486979 3 chr4:150486879-150486979 Camta1  32; 35; 44 
chr5 33212490 33218554 3 chr5:33212490-33218554 Depdc5  25; 32; 44 
chr6 66883482 66883482 3 chr6:66883482-66883482 Gng12  22; 23; 58 
chr6 67224953 67224953 3 chr6:67224953-67224953 Serbp1  22; 4; 40 
chr7 128895872 128895872 3 chr7:128895872-128895872 Scnn1g  43; 44; 7 
chr7 149152363 149152463 3 chr7:149152363-149152463 Brsk2  34; 46; 47 
chr8 24852579 24852579 3 chr8:24852579-24852579 Zmat4  16; 27; 52 
chr9 9853827 9854037 3 chr9:9853827-9854037 Cntn5  2; 3; 38 
chr9 36525046 36525046 3 chr9:36525046-36525046 Chek1  15; 21; 51 
chr9 55895147 55895247 3 chr9:55895147-55895247 Rcn2  31; 43; 48 
chr9 82858959 82858959 3 chr9:82858959-82858959 Phip  41; 5; 6 
chrX 7502932 7505112 3 chrX:7502932-7505112 Eras  20; 6; 62 
chrX 11627465 11631689 3 chrX:11627465-11631689 Bcor  31; 41; 43 
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Appendix 6: Characteristics of endothelial-targeting inducible promoters in 
transgenic mice 
In addition to the constitutive promoters outlined in Section 3.1.2 there have been a 
number of inducible promoters developed for targeting the endothelium in a temporal 
manner.  These promoters are based around 2 key systems, namely the TetO-rtTa and 
ERT2 systems which are induced by tetracycline and tamoxifen, respectively.  They 
have also primarily used the VE-Cadherin/Cadherin 5 promoter as the driver 
capitalising on the ubiquitous and specific nature of this promoter (specified in Table 
3.1).  All three systems (upon induction) show recombination throughout the 
vasculature with whole mount staining of treated mice highlighting the vasculature of 
the head, yolk sac, limbs, skin, muscle, liver, kidney, lungs, spleen and heart in both 
12.5 and 16.5 day embryos (all staining assessed 48 h after maternal administration of 
tamoxifen)(Monvoisin et al., 2006; Sun et al. 2005; Sorensen et al. 2009).  The dosage 
of tamoxifen does change levels of recombination with shorter protocols (1x 1 mg, 
intraperitoneally to the mother) resulting in 37% recombination by E11.5 increasing 
to 50% by 18.5 (Monvoisin et al., 2006).  The percentage recombination increased if 
to 62% by E14.5 if 2 doses were administered (E10.5 and 11.5) and further again if 
injections were given at E10.5, E12.5, and E14.5 (95% excision by E18.5) 
(Monvoisin et al., 2006).  In adult mice, IP injection with 0.5 mg tamoxifen for 5 
consecutive days yielded ~70% recombination 1 week after the last injection which 
was stable for 6 weeks (2 mg/day achieved higher results [but not significantly so] 
whilst 0.05 mg/day was without effect).  Thus, limited Cre activation in these models 
provides lasting and effective targeting of the endothelium in multiple organ systems 
(both in development and adulthood) making inducible systems a powerful tool for 
genetic manipulation of endothelial cell behaviour. 
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Table A12: Characteristics of endothelial-targeting inducible promoters in 
transgenic mice. 
 
Gene Reporter 
Gene 
Expression 
in ECs 
Expression in Non-
ECs 
Reference 
VE-Cadherin 
CreERT2  Tamoxifen Yes 
< 0.3% HSC  for 
induction post-
E11.5 
(Monvoisin, 
Alva et al. 
2006) 
VE-
Cadherin: 
tTa-Cre 
Tetracycline Yes In embryos, detects HSCs 
(Sun, Phung 
et al. 2005) 
Cdh5(PAC)- 
CreERT2 
Tamoxifen Yes 0.4% of cells in bone marrow  
(Sorensen, 
Adams et al. 
2009) 
 
The VE-Caherin-Cre (Table 3.1, Alva et al., 2006) with the VECad-Cre-ERT2 show 
similar profiles with respect to activation/specificity in the endothelial lineages; 
however, the downfall of many endothelial-specific promoters has been the co-
regulation in the hematopoietic system (see section 3.1.2).  In this respect the VECad-
Cre-ERT2 is far superior to other promoters.  Indeed, a simultaneous comparison of 
the bone marrow of mice crossed against the ROSA-26 Lac z-Tg showed that bone 
marrow evaluated 3 weeks after tamoxifen induction (2 mg intraperitoneally for 5 
consecutive days) contained only a small population of E-gal positive cells compared 
to the majority of cells from the VE-Cadherin-Cre mice (Monvoisin et al., 2006).  
Flow cytometry for these populations revealed that 0.4% of all bone marrow cells in 
tamoxifen treated VECad-Cre-ERT2 mice were LacZ positive while the bone marrow 
from VE-Cadherin-Cre mice was 63% positive (Monvoisin et al., 2006).  This small 
positive population persisted even after whole bone marrow transplantation into WT 
mice suggesting that the population is real; however, this is promoter system remains 
the most high fidelity system available for genetic targeting of endothelial cells in 
vivo (Monvoisin et al., 2006). 
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Appendix 7: Information about CD Markers 
 
Table A13: Mouse CD Markers 
 
CD = cluster of differentiation; ECs = endothelial cells; NK = natural killer; TCR = 
T-cell receptor and MHC = major histocompatibility complex. 
  
Cell Marker 
(Mouse) 
Description/Function Reference 
CD14 Expressed on the surface of macrophages 
 
eBioscience 
CD144 (VE-
Cadherin) 
Facilitates homophilic adhesion between 
neighbouring ECs and is confined within 
specialised structures at cell-cell contacts 
(adherens junctions). It is expressed throughout 
the vasculature 
eBioscience 
CD19 Expressed by follicular dendritic cells and B 
cells during all phases of development 
excluding the terminally differentiated plasma 
cells 
eBioscience 
CD3 Largely expressed on T cells, NK-T cells, and 
at different levels on thymocytes during T cell 
differentiation. Plays a vial function in TCR 
signal transduction, T cell activation, and 
antigen recognition by binding the 
peptide/MHC antigen complex 
BioLegend 
CD4 Mainly expressed on most thymocytes, a subset 
of T cells, and faintly on macrophages and 
dendritic cells 
BioLegend 
CD45 Expressed on all cells of haematopoietic origin 
except erythrocytes and platelets 
Miltenyi 
Biotech 
CD73 Expressed in subsets of myeloid cells, T cells 
and thymic epithelial cells. 
Miltenyi 
Biotech 
CD8 Expressed on the surface of most thymocytes 
and a subset of mature TCR α/β T cells 
BioLegend 
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Appendix 8: SBxTie2-Cre Mouse Kidney Quantification 
 
Table A14: Leukocyte infiltration in SBxTie2-Cre mouse kidneys. 
 
  1+ 2+ 3+ 4+ 
2362 ✔ 
   
2365 
 
✔ 
  
2366 
   
✔ 
2367 ✔    
2368 ✔ 
   
2376   ✔  
2379 ✔ 
   
2383 
 
✔ 
  
2386   
✔ 
 
2420 
  
✔ 
 
2422 ✔    
2334 
   
✔ 
2524 
 
✔ 
  
2361 ✔ 
   
2374 
  
✔ 
 
2387  ✔   
2425 ✔ 
   
2424 ✔ 
   
2364 
   
✔ 
2427 
  
✔ 
 
197    ✔ 
2518 
 
✔ 
  
2523 ✔    
2340 
  
✔ 
 
2396 
  
✔ 
 
2401  
✔ 
  
2522 
 
✔ 
  
2519    ✔ 
2517 
 
✔ 
  
2421 ✔ 
   
158 ✔ 
   
184 ✔ 
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198 ✔ 
   
203    ✔ 
2345 
 
✔ 
  
2354 
 
✔ 
  
2402 
  
✔ 
 
2403 ✔ 
   
2525 ✔    
2406 
  
✔ 
 
2520  ✔   
2526 ✔ 
   
245 ✔ 
   
247 ✔    
2399 
 
✔ 
  
2393   ✔  
2372 ✔ 
   
2378 ✔ 
   
143 
   
✔ 
179 ✔ 
   
296 ✔    
2389 ✔ 
   
2395 
 
✔ 
  
132 
 
✔ 
  
256 ✔ 
   
315 ✔    
Blue = male (n=35) and red = female (n=22). Level = amount of leukcoyte infiltration 
(indicated by the tick), 1+ = similar to WT (no infiltration of leukocytes); 2+ = little 
infiltration of leukocytes, 3+ = medium infiltration of leukocytes and 4+ = heavy 
infiltration of leukocytes.  
 
Table A15: Summary of leukocyte infiltration in SBxTie2-Cre mouse kidneys. 
Level Number Percentage 
1+ 25 44.5 
2+ 14 25 
3+ 10 18 
4+ 7 12.5 
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Appendix 9: SBxTie2-Cre Mouse Albumin Quantification 
To determine the impact of Cre-mediated SB activation on the endothelial phenotype, 
including permeability, we challenged SBxTie2-Cre and WT mice with an allograft of 
B16F10 melanoma cells (1x106 cells).  Mice were euthanised after 10 and 14 days to 
determine the effect on tumour and heart tissues (Figure A8). The tumour and heart 
growth data from SBxTie2-Cre mice and WT littermates was expressed as the fold 
change in tumour and heart weight to account for inter-experimental variability of 
age.  Tumour growth in SBxTie2-Cre mice was more variable with 20% of tumours 
greater or less than 2SD from the mean tumour weight of WT mice (Figure A8.A). 
These results indicated that the angiogenic potential of some of the mice was 
significantly different from that of WT mice and that mutations to the endothelial 
genome were altering tumour growth. 
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Figure A8: Tumour and heart growth data in WT and SBxTie2-Cre mice. The 
tumour and heart growth data from SBxTie2-Cre mice were expressed as the fold 
change in tumour and heart weight relative to the WT group to normalise for inter-
experimental variability. The mean (black line) and +/-2SD (green lines) of WT mice 
are shown. (A) Normalised tumour weight; WT (n=85) and SBxTie2-Cre (n=42) 
mice. (B) Normalised heart weight; WT (n=23) and SBxTie2-Cre (n=42) mice. T-test 
(Mann-Whitney). Mean + 2SD.  
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Plasma leakage in tumours is an indicator of physical defects in vessel walls resulting 
from the abnormal environment within tumours. Solid tumours commonly retain an 
immature, highly permeable vasculature sustained by vascular permeability-
enhancing factors (e.g. VEGF-A). Enhanced permeability is often exacerbated by a 
disorganised lymphatic network, which compromises drainage of interstitial fluid 
resulting in increased intratumoural pressure and accumulation of plasma 
macromolecules (>40 kDa) such as albumin(Peters 1996). To assess the permeability 
of the tumour vessels, albumin immunostaining was performed on tumour sections 
from WT and SBxTie2-Cre mice (Figure A9). The albumin antibody (NB600-41532, 
Novus Biologicals), which is a goat-polyclonal anti-mouse species, was utilised at 2 
μg/mL (1:400 concentration) with the Envision+ System HRP Labelled Polymer 
Anti-Rabbit solution at pH9 overnight in 4qC. 
The scoring criteria for extracellular vascular permeability were as follows (brown 
staining): 
1+ = diffuse aggregate  
2+ = 20-100 microns (aggregate)  
3+ = 100-250 microns (aggregate)  
4+ = >250 microns (aggregate) 
No significant differences were seen globally between WT and SBxTie2-Cre mice 
(Tables A15-16) with an average score of 2.73 for WT and 2.69 for SBxTie2-Cre 
mice. Therefore, mutating the endothelium in SBxTie2-Cre mice did not affect 
vascular permeability. 
Vascular permeability occurs via trans-cellular (across the endothelium) and peri-
cellular routes (around the endothelium) (Feng, Wang et al. 2002). The trans-cellular 
route is mediated primarily through vacuole formation in the caveolae of the 
Appendices 
 56 
membrane. Conversely, intercellular tight and adhesions junctions control peri-
cellular permeability. The lack of effect of SB-mediated mutagenesis on vascular 
permeability in the heart (Figure 3.21) or in tumours (Figure A9, Tables A15-A16) 
suggest that expression of junctional proteins (such as zonula occudens -1 (ZO-1), 
VE-cadherin or the claudins) or constituents of caveolae (such as the scaffold proteins 
canvolin 1 or 2) are equivalent in SBxTie2-Cre and WT mice; however, this remains 
to be empirically determined.  The perturbation of the relationship between tumour 
size and vascularity, such as observed in the small tumours that have enhanced 
vascularity in the SBxTie2-Cre cohort, demonstrates differences in the endothelium in 
SB mice of currently undisclosed nature.   
 
Figure A9: Albumin immunostained tumours in WT (B) and SBxTie2-Cre mice 
(C) with isotype control (IgG) (A). Scale bar = 200 μm for panel (A) and scale bar = 
1000 μm for panels (B-C). Arrows represent some pockets of albumin staining. 
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Table A16: Scoring of albumin staining in 10 WT mouse tumour. 
Block ID Mouse No# 1 2 3 4 5 6 7 8 9 10 Average 
11-0201-25 81 2 4 2 3 2 4 3 1 4 3 2.8 
11-0201-55 104 4 2 3 3 2 3 3 3 4 2 2.9 
11-0201-67 106 1 2 3 1 3 4 4 1 1 1 2.1 
11-0201-73 107 4 3 3 2 3 1 2 2 1 2 2.3 
11-0214-189 167 2 2 2 1 2 1 3 1 1 1 1.6 
11-0214-225 202 2 1 1 1 2 2 2 2 4 3 2 
11-0214-231 204 4 3 3 2 2 1 2 1 3 2 2.3 
11-0214-297 242 4 4 3 2 3 2 4 3 2 3 3 
11-0228-309 244 2 2 3 2 3 2 2 4 4 4 2.8 
11-0228-334 259 4 4 4 3 3 3 3 3 3 3 3.3 
11-0325-1 279 4 4 3 4 3 2 4 3 3 2 3.2 
11-0325-13 282 1 1 2 1 1 1 2 3 4 2 1.8 
11-0325-19 284 2 4 3 4 4 3 3 4 4 4 3.5 
11-0325-75 309 4 4 4 4 4 3 4 4 4 4 3.9 
11-0325-94 318 2 3 3 3 4 3 4 4 3 3 3.2 
11-0325-100 319 4 4 4 3 2 2 4 2 2 3 3 
 
Table A17: Scoring of albumin staining in 10 SBxTie2-Cre mouse tumour. 
Block ID Mouse No# 1 2 3 4 5 6 7 8 9 10 Average 
11-0201-13 79 1 1 2 4 1 1 1 4 3 4 2.2 
11-0201-37 85 4 3 4 4 4 4 3 1 3 4 3.4 
11-0201-43 87 2 4 4 3 4 4 3 4 4 4 3.6 
11-0201-49 92 2 3 1 1 4 4 4 4 4 4 3.1 
11-0201-61 105 2 2 3 2 3 2 3 3 3 3 2.6 
11-0201-79 114 4 4 4 4 4 4 4 4 4 4 4 
11-0201-91 125 3 3 3 4 4 4 2 3 2 2 3 
11-0201-97 128 1 1 1 2 1 2 3 1 1 2 1.5 
11-0201-103 130 1 2 2 2 2 2 2 2 2 2 1.9 
11-0201-114 135 2 2 2 4 2 1 1 1 1 2 1.8 
11-0201-120 139 1 3 3 1 2 1 2 2 4 3 2.2 
11-0201-131 145 3 2 2 3 3 3 2 2 3 2 2.5 
11-0201-137 152 1 3 3 3 3 1 1 2 2 2 2.1 
11-0214-195 176 4 4 4 4 4 4 4 4 4 4 4 
11-0214-201 189 1 2 2 2 2 2 2 2 1 2 1.8 
11-0214-207 194 2 2 1 1 1 2 3 1 3 1 1.7 
11-0228-252 228 3 4 3 3 4 4 4 4 2 3 3.4 
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11-0228-258 230 4 4 4 3 3 3 4 2 2 2 3.1 
11-0228-266 231 3 4 4 3 4 3 2 3 4 3 3.3 
11-0228-272 234 3 3 4 4 4 4 4 3 4 3 3.6 
11-0228-284 238 2 1 1 1 1 2 3 4 2 3 2 
11-0228-303 243 1 1 1 1 2 2 2 1 1 2 1.4 
11-0228-315 253 1 2 3 2 3 3 3 4 4 4 2.9 
11-0228-321 257 3 2 3 2 3 4 2 2 2 3 2.6 
11-0325-7 281 2 3 1 2 2 2 2 3 4 4 2.5 
11-0325-25 286 2 3 3 3 3 3 3 3 2 3 2.8 
11-0325-81 310 3 2 2 4 2 3 3 4 1 2 2.6 
11-0325-87 312 4 4 4 4 3 3 4 4 4 3 3.7 
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